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W4a
Genetic background of carbapenem and
metronidazole resistance: detection of genes and
mechanisms of expression
M.E. Hedberg (Stockholm, S)
Antimicrobial resistance is increasingly common among anaer-
obic Gram-negative bacteria, especially for the Bacteroides
fragilis group. At present resistance has been described in
this group of bacteria to almost all of the regularly used anti-
anaerobic agents. Carbapenems and 5-nitroimidazoles are two
of the most active antimicrobial agents against the B. fragilis
group, but isolates resistant to these drugs seem to appear
more frequently, although they still are quite rare. Metroni-
dazole is often used as empiric therapy for anaerobic infections
and susceptibility testing is not always routinely performed.
Strains resistant to carbapenems have been found to produce
metallo-beta-lactamase, an enzyme that hydrolyses various
beta-lactam antibiotics and exhibits resistance to beta-lactamase
inhibitors. B. fragilis metallo-beta-lactamase is encoded by the
cﬁA gene. Several diverse types of insertion sequence (IS)
elements in the upstream region of cﬁA in carbapenem-
resistant B. fragilis strains have been found. The IS elements
most likely provide a promoter to express the cﬁA. It has been
reported that about 2–4% of the B. fragilis strains carry the cﬁA
gene regardless of whether they express it. Also an IS-less
activation mechanism of cﬁA in B. fragilis strains has been
detected. The 5-nitroimidazole molecule is a prodrug whose
activation depends up on the reduction of the nitro group in
the absence of oxygen. Decreased uptake and/or alteration in
reduction are believed to be responsible for metronidazole
resistance. Five nim genes (A–E) have been described in the B.
fragilis group that confer reduced susceptibility to 5-nitroimi-
dazole compounds. nim-Positive strains have been shown to be
more prone to induction than nim-negative isolates. A nimF
gene has been detected in a metronidazole susceptible strain.
Isolates lacking nim genes but still highly resistant to metroni-
dazole have also been demonstrated which probably means
that other resistance mechanisms are involved. Studies of
protein expression patterns in metronidazole susceptible and
metronidazole resistant B. fragilis strains have revealed a
complex shift in the resistant strain resulting in both down-
and up-regulation of proteins with different molecular weight
and isoelectric points. This might be part of a broader
programme of genetic control that alters the physiology to
protect and prevent metronidazole activation. Such alterations
may also increase the virulence.
W4b
Unexpected resistance mechanisms behind
known antibiotic resistance in anaerobic
pathogen and their detection
L. Dubreuil, J. Behra, L. Calvet (Lille, F)
Despite resistance to all b-lactams (including imipenem) by
production of a carbapenemase (cﬁA gene), Bacteroides fragilis
group strains may be resistant to the combination of b-lactams
with b-lactamase inhibitor among imipenem susceptible
strains. If a silent carbapenemase could be involved, in other
cases the lack of porin in combination with the production of
the chromosomal cephalosporinase (cep A gene) is responsible
for the resistance to co-amoxiclav among B. fragilis (lack of the
45 kDa Outer Membrane Protein) or in B. thetaiotaomicron (lack
of the 67 kDa OMP). In the last two years we were able to
isolate metronidazole-resistant strains of B. fragilis (MIC from
16 to 256 mg/L). Their detection could be easily done using a
disk-diffusion test if the incubation is prolonged for at least
48 hours. For one of these trains, the high-level metronidazole
resistance was associated with the presence of two copies of
the nim A gene on the chromosome (Marchandin H. et al.).
Decreased susceptibility to metronidazole (MIC 8 and 16 mg/
L) is still increasing in France and UK (Brazier et al.) as
demonstrated by antibiotic surveys. With exception of the
reference agar dilution method (NCCLS M11 A6), the detection
remains problematic. Detection by disk-diffusion method is
very difﬁcult using 4 lg metronidazole disks and should be
improved by using a 10 lg potency disk, Rosco disks or the E
test method. Resistance to metronidazole is widespread as nim
genes are nowadays found in Prevotella and Veillonella species.
Intrinsic unknown resistance could be presumed from pub-
lished studies such as low-level resistance to vancomycin,
linezolid and ramoplanin for C. ramosum, to vancomycin
and daptomycin for C. innocuum and to teicoplanin and
ramoplanin for C. clostridioforme, respectively. With exception
of C. innocuum (Leclercq et al.) most mechanisms had not been
investigated.
History of medical microbiology in Denmark
S8
Danish medical microbiologists in the 19th
century: Panum, Salomonsen & Gram
H.J. Kolmos (Odense, DK)
Three persons played a key role in the development of medical
microbiology in Denmark in the second half of the 19th century:
The physiologist and epidemiologist Peter Panum (1820–85), the
bacteriologist Carl Salomonsen (1847–1927), and his assistant
Christian Gram (1853–1938). Panum has gained international
reputation for his epidemiological description of the measles
epidemic in the Faroe Islands in 1846, but he alsomade signiﬁcant
experimental contributions to microbiology. In 1855–56, during
his appointment as professor at the University of Kiel, he
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performed a series of laboratory experiments with dogs, in order
to characterize the so-called ‘putrescent poison’, a substance
claimed to be the causative agent of blood-poisoning. The dogs
were given i.v. infusions of rotten meat juice in different
modiﬁcations, and observed for symptoms and signs. His
observations on the biological effects of putrescent poison bear
striking similarities with present-day endotoxins, e.g. the char-
acteristic symptoms and signs, the delay in onset of symptoms,
and the preserved biological activity after long-term boiling.
Panum at ﬁrst rejected the possibility that the putrescent poison
could be of bacterial origin, but later changed his opinion. From
1864 Panum served as professor of physiology at the University
of Copenhagen, and in his institute he established the ﬁrst
laboratory facilities for bacteriological studies in Denmark.
Salomonsen was the ﬁrst to perform microbiological examina-
tions on an infected patient. They took place in 1873 at the
Municipality Hospital in Copenhagen, where he treated a patient
with pyaemia. In pus aspirated from an inﬂamed knee joint he
was able to demonstrate streptococci, andhe could also isolate the
streptococci from a rabbit that had been inoculatedwith pus from
the patient. In his thesis, which he wrote under the supervision of
Panum from 1876–77, he described one of the earliestmethods for
making pure cultures of bacteria, using capillary glass tubes.
From 1883, Salomonsen held Europe’s ﬁrst chair in bacteriology
at the University of Copenhagen, and he played a leading role in
the foundation the State Serum Institute in 1902. Salomonsens
assistant, Gram, invented the Gram-stain during a short visit to
Friedla¨nder’s laboratory in Berlin in 1884.He is probably themost
famous of all Danish microbiologists, which is somewhat para-
doxical, since he left microbiology immediately after his inven-
tion, and never worked with Gram staining afterwards.
S9
Serum treatment of diphtheria: a controlled
clinical trial performed in Copenhagen in 1898
A. Hro´bjartsson (Copenhagen, DK)
In 1898, the Danish Nobel laureate Johannes Fibiger published a
controlled trial of the effect of serum treatment on diphtheria.
Fibiger was one of the ﬁrst to discuss random allocation as a
method to avoid bias in clinical trials. He stated: ‘A ﬁrm
conclusion can in many cases only be reached when a large
number of randomly selected patients are treated with a new
remedy and an equally large number of randomly selected
patients at the same time are treated as usual.’ Fibiger’s trial
included as many as 484 patients that were allocated depending
on day of admittance: serum treatment was used every second
day and standard treatment every second day. Furthermore, the
ﬂow of patients, and other methodological and clinical aspects
of the trial, were reported precisely. Thus, the trial is a
pioneering investigation in the history of clinical trials.
S11
Production of penicillin in Denmark during
World War II. An early warning against
development of antibiotic resistance
K. Jensen (Karlshamn, S)
It is well known to most people that penicillin was discovered
in 1928 by Alexander Fleming in his laboratory at St. Mary’s
Hospital. It was extremely difﬁcult to produce and to purify
penicillin in sufﬁcient amounts to be used to treat humans. It
was not until 1938 that Florey, Abraham and Chain succeeded
in isolating and purifying Penicillin in pure and stable form
thus allowing further studies of its unique activity, extremely
low toxicity, and high clinical efﬁciency. It was found that
penicillin was a true wonder drug in treating infected
wounds. The production in large scale was attempted in
England, but in 1941 It became necessary to move the entire
project to USA to avoid the harassment caused by the German
air raids. In USA the production of penicillin was considered
of millitary importance The War Production Board in cooper-
ation with 22 medical companies united in the efforts to
produce penicillin in sufﬁcient amounts for use by the allied
millitary forces and for civil use. All informations about the
production and puriﬁcation processes were considered as war
secrets, and the penicillium strains used for production were
kept under strict custody. However, today it may not be
widely known, that Denmark was the only place outside
England and USA where the production of penicillin was
taken up during World War II. This fact is even more
remarkable because it took place during the German occupa-
tion of Denmark, when exchange of information with the free
world was practically impossible, and resources of nearly
every kind became increasingly scarce. The attempts to
produce penicillin in Denmark were started during the
spring of 1943 at the University Institute of General Pathol-
ogy, and as early as September 1944 the ﬁrst patient was
treated with Danish penicillin. This remarkable achievement
was made by the head of the institute professor K. A. Jensen.
He came from the Danish Statens Serum Institute where he
worked as a world-known scientist within the ﬁeld of
tuberculosis. He had experiences in standardization of biolo-
gical products and production of tuberculin and BCG vaccine,
and he was deeply engaged in research on antituberculous
chemotherapy. He was thus well equipped to start the
research on penicillin when he in 1941 took over the chair
in general pathology. The late owner of the Leo Pharmaceu-
tical Industry: Knud Abildgaard Elling initiated this research
by providing him with a reprint obtained from Sweden of
Florey, Abraham and Chain’s article about penicillin. K. A.
Jensen started the search for a penicillin producing mould,
found it, and developed his own methods of production,
puriﬁcation, standardization and clinical trials of Penicillin.
He succeeded so well, that the further development and
production of penicillin in large scale was taken over by the
Leo Pharmaceutical Industry. After the end of World War II
\"Leo\" was able to take up the international competition,
and succeeded so well that within a few years they supplied a
substantial part of penicillin to the world market. K. A. Jensen
was asked by the Danish Board of Health to distribute and
control the clinical use, not only of penicillin, but of all the
other new antibiotics which were introduced during the
postwar period. This gave him a unique opportunity to
develop the new ﬁeld of clinical microbiology to warn against
development of resistance and restrict the misuse of antibiot-
ics in Denmark. As son of K.A. Jensen, the author had the
opportunity to follow the above mentioned development as a
personal witness. He will describe some of the exiting features
of this pioneering work, and some of the perils of the work
with penicillin in Denmark during wartime and German
occupation.
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Update on toxoplasmosis (Symposium arranged with ESGT)
S13
‘Virulence’ of Toxoplasma gondii in humans
M.-L. Darde´ on behalf of the CRB ToxoBS group
The majority of Toxoplasma gondii strains have been grouped into
3 main genotypes, called type I, II, and III. Recently, multilocus
studies revealed the existence of atypical and recombinant
genotypes. The relationship between isolate genotype and
virulence is well described in the mouse model, but is more
difﬁcult to approach in humans due to the opportunistic
behaviour of this parasite. For instance, in France, where the
isolates are systematically collected and typed (Biological
Resource Centre, ToxoBS group), the vast majority of congenital
toxoplasmoses are due to type II, whatever the clinical outcome
(foetal death, neurological involvement, chorioretinitis, or sub-
clinical toxoplasmosis), the main prognosis factor remaining the
stage of pregnancy at the time of infection. Whether this
predominance of type II in congenital toxoplasmosis is due to
its predominance in humans and animals in France or to a
higher tendency to cross the placental barrier remains to be
determined. The very few type I or atypical strains isolated from
congenital toxoplasmosis are found in severe disease, notably
disseminated toxoplasmosis, suggesting a role for the strain
genotype in the pathogenesis of these forms. In immunocom-
petent patients, the ‘serotyping’ method has never been applied
to large series of asymptomatic patients, so the strains respon-
sible for about 80% of toxoplasmic infections in humans are still
unknown. The classical lymphadenopathies seem to be due to
type II strains, but more severe acquired toxoplasmosis or ocular
toxoplasmosis are associated with atypical or type I strains. In
immunodeﬁcient patients, the 3 main types, principally type II,
but also atypical or recombinant strains, were detected. These
studies were performed mainly in some European countries and
U.S.A. and the situation might well be different in other
continents as suggested by the higher genetic diversity – and
pathogenicity – of isolates in French Guiana or Brazil, or by the
frequency of recombinant genotypes detected in African
patients. Physiopathological and immunological aspects of the
behaviour of the different Toxoplasma genotypes in humans are
totally ignored. All our hypothesis (widespread parasite dis-
semination in organs for type I strains, cyst formation and
reactivation with type II strains) are derived from mouse
experimental toxoplasmosis and studies are needed to better
understand the inﬂuence of strain genotype on human toxo-
plasmosis.
S14
Congenital toxoplasmosis in Europe
E. Petersen (Aarhus, DK)
The policies for controlling and treating congenital toxoplas-
mosis differ between countries in Europe and include
systematic monthly or three monthly screening during preg-
nancy, neonatal screening, widespread haphazard prenatal
screening and a deﬁnite decision not to do anything. Treat-
ment of newborns range from 3 months to 24 months with
pyrimethamine and sulfadiazine or sulfadoxine. The diversity
of policies is due to different perception of the size of the
problem and a lack of good studies, which can be used for
decision making. Several studies have shown that the risk of
infection with Toxoplasma gondii has been declining over the
past four decades and studies based on data collected more
than two decades ago can therefore not be used to estimate
the risk of infection in to days pregnant mothers. To address
these problems European centres have over the past thirteen
years performed a range of studies on congenital toxoplas-
mosis starting with the performance of diagnostics assays,
standardization of antibody- and nucleic acid diagnosis and
case deﬁnitions. In 1997 the European Multi-centre Study on
Congenital Toxoplasmosis, EMSCOT, was started as a large,
multi-centre, prospective cohort study to provide solid evi-
dence of the beneﬁt of prenatal and neonatal screening. The
study included fourteen European centres and when recruit-
ment stopped in 2002, more than 1300 women with proven
Toxoplasma gondii infection during pregnancy were enrolled
giving birth to more than 250 infected children. This and
other studies performed on other European cohorts showed
clearly that prenatal screening and treatment to the pregnant
mother failed to prevent transmission of Toxoplasma gondii
from the mother to the child. The EMSCOT study is still being
analysed and data on treatment effect on signs and symptoms
in children with congenital toxoplasmosis will be presented.
Two on-going studies building on the EMSCOT results are
still on-going: SYROCOT, Systematic Review of Congenital
Toxoplasmosis, aim at performing a meta-analysis of data
from several cohorts including more than 2500 infected
pregnant women; and EUROTOXO aim at critically reviewing
existing data to provide a new platform for designing rational
studies of prevention and treatment of congenital toxoplas-
mosis. Key data from the different European studies will be
presented.
European guidelines for diagnosis of tick borne diseases
(Symposium arranged with ESCAR)
S16
Guidelines for the diagnosis of Lyme borreliosis
B. Wilske (Munich, D)
In Europe Lyme borreliosis is caused by at least 3 species,
B. burgdorferi sensu stricto, B. afzelii and B. garinii. Thus micro-
biological diagnosis in European patients must consider the
heterogeneity of Lyme disease borreliae for development of
diagnostic tools such as PCR primers and antigens. According to
guidelines of the German Society of Hygiene and Microbiology
the serological diagnosis should follow the principle of a two
step procedure (a strategy also recommended by the CDC). A
sensitive ELISA (preferentially such differentiating IgM and IgG)
is recommended as the ﬁrst step. In case the ELISA is reactive, it
is followed by immunoblots (IgM and IgG) as the second step.
The reactive bands should be clearly identiﬁed, which is easy if
recombinant antigens are used. The sensitivity and standardiza-
tion of immunoblots has been considerably enhanced by use of
recombinant antigens instead of whole cell lysates. Improved
sensitivity resulted from use of recombinant proteins that are
expressed primarily in vivo (e.g. VlsE) and combination of
homologous proteins from different strains of borreliae
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(e.g. DbpA). It also appears promising to use recombinant
proteins or synthetic peptides as ELISA antigens. At present,
detection rates for serum antibodies are 20–50% in stage I
(erythema migrans), 70–90% in stage II (i.e. acute neuroborrel-
iosis) , and nearly 100% in stage III Lyme disease (i.e. acroder-
matitis and arthritis). The main goals for the future are to
improve speciﬁcity in general and sensitivity for diagnosis of
early manifestations (stage I and II). Detection of the etiological
agent by culture or PCR should be conﬁned to speciﬁc indications
and specialized laboratories. Recommended specimens are skin
biopsy specimens, CSF and synovial ﬂuid. The best results are
obtained from skin biopsies with culture or PCR (50–70%) and
synovial tissue or ﬂuid (50–70% with PCR). CSF yields positive
results in only 10–30% of patients. Methods which are not
recommended for diagnostic purposes are antigen tests in body
ﬂuids, PCR of urine and serum, and lymphocyte transformation
tests. Interpretation of test results must always be done in context
with clinical data. Here case deﬁnitions are helpful (1). The low
predictive value of positive serology in case of nonspeciﬁc
symptoms need to be considered. 1. Wilske, B. et al. MIQ 12
Lyme-Borreliose. Urban & Fischer, Mu¨nchen Jena; 2000 (English
version: http://www.dghm.org/red/index.html?cname=MIQ).
Vancomycin- and methicillin-resistant Staphylococcus aureus
(VMRSA): how to cope with it in the hospital setting? (Symposium
arranged with ESGNI)
S17
European epidemiology of vancomycin-resistant
and intermediate resistant S. aureus: need for an
ESGNI surveillance study?
B. Cookson (London, UK)
Thus far there have only been three known cases of vancomy-
cin transposon A positive methicillin resistant S. aureus
(MRSA) reported, all in the USA. Fortunately these strains
were all susceptible to many other antibiotics and screening
failed to detect any spread to other patients. Two of the cases
were seen in patients with diabetic related leg ulcers and were
co-colonised with glycopeptide-resistant enterococci. Other less
vancomycin-resistant S. aureus isolates have been encountered
(VISAs and hetero-resistant VISAs). In some instances there
have been isolates that are only resistant to another glycopep-
tide teicoplanin (TISAs e.g. some isolates of EMRSA-17 in the
UK). A case-controlled study has been performed on these.
Interestingly there have been relatively few cases of infections
reported world-wide of GISA infections; Japan, for example,
where the ﬁrst isolates were described has failed to see the
epidemic that was predicted. Isolates have often proved to be
unstable in their resistance when stored in the laboratory or
when cross infecting other patients who have not received
vancomycin treatment. We will describe the current situation
with types of MRSA that are commonly seen in Europe and the
reports of the types of GISAs that have been encountered in
the world. We will also discuss a possible ESCMID Study
Group on Nosocomial Infection (ESGNI) study looking at
GISAs and other important aspects of MRSA in the EU that
would complement other European and previous ESGNI
studies.
Management of relapses and outbreaks of Clostridium difﬁcile
(Symposium arranged with ESGCD)
S19
Clincal management of relapsing Clostridium
difﬁcile diarrhoea
J.T. van Dissel (Leiden, NL)
C. difﬁcile is a leading cause of nosocomial infectious diarrhoea.
The condition typically affects the elderly patient with severe
underlying disease who has received broad spectrum antimi-
crobial therapy during an extended stay in the hospital. These
factors disrupt the endogenous bowel ﬂora and are associated
with acquisition and/or outgrowth of C. difﬁcile. By conse-
quence, individual cases of C. difﬁcile- pseudo-membranous
colitis occur, and these patients create a reservoir from which
the bacterium may transmit to susceptible individuals and give
rise to large hospital-associated outbreaks of diarrhoea. The
infection may add signiﬁcant costs to patient care. C. difﬁcile-
diarrhoea relapses in about 10 to 20% of cases. Treatment of
C. difﬁcile-diarrhoea optimally consists of the discontinuation of
antibiotics to end disruption of endogenous bowel ﬂora. All but
mild cases receive therapy with metronidazole and/or vanco-
mycin. Unfortunately, such additional cycles of antimicrobial
therapy may trigger new recurrences. In relapsing diarrhoea,
alternative treatments have been tried to reduce C. difﬁcile bowel
colonization and stop or neutralize toxin production, including
toxin-binding resins, antimicrobial combinations comprising of,
for instance, vancomycin and rifampin or bacitracin, probiotics
like Saccharomyces boulardii, Lactobacillus GG, and even stools
from healthy human relatives by tube or enema. Many of these
treatments, however, appear to be only modestly effective.
Recent developments to aid in the prevention of relapsing
C. difﬁcile-diarrhoea include, among other interventions, poly-
clonal antibody-enriched immune whey, intravenous antibod-
ies, and vaccinations.
S20
Antibiotic-resistant toxin A-negative toxin
B-positive Clostridium difﬁcile in Dublin, Ireland
D. Drudy, N. Harnedy, S. Fanning, R. O’Mahony,
L. Kyne (Dublin, IRL)
C. difﬁcile is a major cause of infectious diarrhoea in hospitalised
patients. Clinically important toxin A-negative, toxin B-positive
strains ofC. difﬁcile that cause diarrhoea and pseudomembranous
colitis in humans have recently been isolated worldwide. The
aims of this study were to investigate a C. difﬁcile outbreak in one
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university-afﬁliated hospital in Dublin, Ireland and to determine
the prevalence of toxin A-negative, toxin B-positive C. difﬁcile in
other care institutions in the greater Dublin area. For the outbreak
investigation, we prospectively studied all consecutive patients
with nosocomial C. difﬁcile diarrhoea between August 2003 and
January 2004. . For the prevalence study, toxin positive faecal
samples (n = 123) were collected between February and August
2004 from a twelve different institutions in Dublin Ireland.
C. difﬁcile was cultured from faecal specimens. Toxin-speciﬁc
enzyme immunoassays, IMR-90 cytotoxicity assay and PCRwere
used to analyse C. difﬁcile isolates. Antibiotic sensitivities were
determined using E-tests. Seventy-three cases of C. difﬁcile
diarrhoea were identiﬁed during the outbreak study period.
Studies examining in vitro production of toxin A and B showed
that ninety-ﬁve % of isolates tested negative for production
of toxin A but were positive when investigated using the
cell culture cytotoxicity assay. These toxin A-negative, toxin
B-positive C. difﬁcile isolates had a 1.7 kb deletion in the tcdA
gene. PCR ribotyping determined that these isolates were clonal.
The clonal outbreak isolates were resistant to all ﬂuoroquinolo-
nes (MIC’s of >32 lg ml)1) and MLS antibiotics tested (MIC’s of
>256 lg ml)1). In the prevalence study, 52 of 123 C. difﬁcile
isolates, (42%) were toxin A-negative, toxin B-positive. Preval-
ence rates per institution varied from 0–62%. In the three
University teaching hospitals the prevalence rates were 18%,
40%, and 59% respectively. Using PCR, these toxin A-negative,
toxin B-positive strains had the same deletion described for the
outbreak study (toxinotype VIII strains e.g., C. difﬁcile serotype F,
1470). Toxin A-negative, toxin B-positive C. difﬁcile appears to be
prevalent in hospitals in the greater Dublin area and caused at
least one hospital outbreak. This report adds to the expanding
body of literature reporting the increasing incidence and wide-
spread geographical distribution of clinically important toxin-
variant C. difﬁcile strains.
Antibiotics for lower respiratory tract infections in primary care
(Symposium arranged with ESPRIT)
S21
A randomised controlled factorial trial of
antibiotic prescribing strategies and an
information leaﬂet about natural history for acute
lower respiratory tract infection
P. Little, K. Rumsby, J. Kelly, L. Watson, I. Williamson,
M.Moore,G.Warner,T.Fahey (Southampton,Romsey,Dundee,UK)
Background: Acute LRTI is the most common condition
managed in primary care. The systematic reviews of
antibiotics are small and come to different conclusions, and
many physicians still prescribe antibiotics.
Methods: 807 patients with acute LRTI were randomised to
three prescribing strategies – immediate antibiotics, delayed
prescription, and no offer of antibiotics. Half of each of these
groups received an information leaﬂet.
Results: Cough rated at least ‘a slight problem’ lasted on
average 11.7 days (25% lasted 17+days). An information leaﬂet
had no effect on the main outcomes. Compared with no offer of
antibiotics, other strategies did not alter cough duration
(delayed +0.75 days, 95% conﬁdence intervals )0.37 to 1.88;
immediate +0.11 days, )1.01 to 1.24) nor other primary
outcomes. Antibiotics reduced duration of ‘moderately bad’
symptoms, a secondary outcome, by one day ()1.08; )2.1 to
)0.09). Compared with the antibiotic group slightly fewer
patients were ‘very satisﬁed’ in the delayed and control
groups (respectively 86%, 77%, 72%, p < 0.005), fewer used
antibiotics (96%, 20%,16%, p < 0.001) and fewer believed in the
effectiveness of antibiotics (75%, 40%, 47%, p < 0.001). There
was lower re-attendance for cough within a month with delayed
and immediate prescribing (mean attendances: no antibiotics
0.19, delayed 0.12, immediate 0.11, Kruskal Wallis p = 0.03).
Conclusion: For most patients with acute uncomplicated
LRTI, no offer or a delayed offer of antibiotics was
acceptable, associated with little difference in symptom
resolution, and considerably reduced antibiotic use and
beliefs in antibiotics. Delayed prescribing may have some
advantages to not prescribing since fewer patients
reconsulted.
S22
Cross-sectional study on antibiotics for lower
respiratory tract infections: clinical determinants
of under- and overtreatment in primary care
A.E. Akkerman, M.M. Kuyvenhoven, J.C. van der Wouden,
T.J.M. Verheij (Utrecht, Rotterdam, NL)
Objectives: To assess the appropriateness of antibiotic
treatment in acute lower respiratory tract infections (LRTIs) in
primary care and to assess clinical patient characteristics that
cause under- or overprescribing of antibiotics.
Methods: During four weeks in winter (2002–2003), 146 Dutch
general practitioners (GPs) from the middle region of the
Netherlands included all patients with lower respiratory tract
complaints. They registered patient demographics (age and
gender), clinical presentation (signs and symptoms, like
duration of complaints, cough, fever and dyspnoe), severity of
illness, whether they thought patients expected antibiotic
treatment, diagnosis and management. Using the current
guidelines of the Dutch College of General Practitioners on
LRTIs, we assessed the appropriateness of antibiotic prescribing
in cases of LRTIs. The association between clinical patient
characteristics and under-/overtreatment was assessed by
means of GEE (SAS) with odds ratios (ORs) (with 95%
conﬁdence intervals).
Results: In more than 60% of LRTI-consultations antibiotic
treatment was according to national guidelines. In three out of
each ten LRTI-consultations antibiotics were not indicated but
prescribed.High severity of illness, fever, purulent sputum and if
the GP thought the patient expected an antibiotic, were
independent predictors of this overtreatment with antibiotics
(ORs between 1.6 and 10.0). In about one of each twenty LRTI-
consultations antibiotics were indicated but not prescribed
(undertreatment). In these cases mostly symptomatic treatment,
like analgesics and cough suppressants, were prescribed.
Conclusion: Incorrect interpretation of clinical patient
characteristics and perceived expectation of patients were
associated with overprescribing of antibiotics in cases of LRTIs
in primary care. Overtreatment farly outweighs undertreatment.
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Antibiotic use and policies: an in-depth look at ARPAC results
(Symposium arranged with ESGAP)
S23
Patterns of antibiotic use in European hospitals
F.M. MacKenzie (Aberdeen, UK)
Aggregated hospital antibiotic use data from 2001, collected
from 140 European ARPAC hospitals are presented. This work
was carried out under the auspices of the ESCMID Study Group
on Antibiotic Policies.
Methods: Antibiotic use was measured in DDD/100 occupied
bed-days (BD), using DDDs described by the WHO (2004). Data
are described for individual antibiotics as well as the ATC J01
classes. Data were analysed by various demographic
characteristics. Relationships between antibiotic use and
resistance were also explored.
Results: For all hospitals, the antibiotic use range was 5–129
DDD/100 BD (median = 55, IQR 40, 73). For all hospitals, J01C
(penicillin B-lactams) were used most often, followed by J01D
(non-penicillin B-lactams) and quinolones with median values
of 22, 10 and 6 DDD/100 BD. Total and class antibiotic use
varied signiﬁcantly by geographical region. It did not vary
signiﬁcantly by hospital size, teaching status or case mix.
Median total antibiotic use for the north, south-east, south,
west and centre/east (regions 1–5 respectively) was 48, 45, 81, 63
and 37 DDD/100 BD respectively. Median use of J01C for
regions 1–5 was 25, 13, 24, 29 and 12 DDD/100 BD. The most
used sub-class were the B-lactamase inhibitor combinations
(J01CR) making up 1, 27, 79, 67 and 48% of J01C for regions 1–5
respectively. There was a signiﬁcant relationship between the
number of individual antibiotics listed per hospital (maximum
n = 80) and total antibiotic use; the higher the number of
antibiotic available, the higher the total use. The North of
Europe had the highest number of antibiotics listed but had
relatively low total use; which may indicate better control.
A large proportion of total antibiotic use was accounted for by a
minority number of individual antibiotics; on average, the
top 10 most frequently used antibiotics accounted for 75% of
total use. The most frequently used individual antibiotics were
amoxicillin + enzyme inhibitor (oral), amoxicillin + enzyme
inhibitor (parenteral), ciproﬂoxacin (oral), cefuroxime
(parenteral) and amoxicillin (oral). Of 7 groups of antibiotics
tested, total antibiotic use (both including and excluding
glycopeptide use) as well as use of 3rd generation
cephalosporins showed a signiﬁcant, positive correlation with
MRSA prevalence (unadjusted, unweighted tests). After
removal of variation in MRSA due to demographic factors, a
strong statistically signiﬁcant partial correlation was found
between MRSA prevalence and macrolide use.
S24
The inﬂuence of antibiotic policies on antibiotic
use patterns: ARPAC data
J. Bruce, J. Mollison, F.M. MacKenzie, I.M. Gould on behalf of the
ARPAC Steering Group
Aim: One aim of the ARPAC study was to explore antibiotic
policies and prescribing practices associated with antibiotic
consumption.
Methods: Postal questionnaires and electronic spreadsheets
were used for retrospective collation of hospital antibiotic
policy and consumption data from European hospitals for 2001.
A total of 170 hospitals provided policy data; 140 antibiotic
consumption data and 124 hospitals provided both. Respondents
provided data on antibiotic availability, formularies, policies,
education, audit and the role of pharmacy and laboratory.
Thirteen key questions were identiﬁed as indicators of good
antibiotic policies and practice. Antibiotic consumption was
measured using DDD per 100 bed-days (WHO, 2004). Data were
analysed by hospital demographic characteristics, geographical
region (N, W, S, SE, CE) and associations between policies and
antibiotic consumption were explored.
Results: There was geographical variation in antibiotic policy
factors, with hospitals from North and Western Europe more
likely than those from other regions to have written antibiotic
policies (N 79%, W 72%, CE 54%, S 46%, SE 25%; P < 0.01),
written antibiotic formularies (W 94%, N 84%, CE 85%, S 59%,
SE 42%; P < 0.01) and to have drugs and therapeutics
committees in 2001 (N 100%, W 98%, CE 88%, SE 69%, S 68%;
P < 0.01). Hospitals from the North were less likely than other
regions to include a restricted list of antibiotics within
formularies (N 39%, W 71%, S 78%, SE 78%, CE 82%;
P < 0.01). However, for other policy indicators, no statistically
signiﬁcant differences were found in practice across
geographical region or by hospital case-mix. There was no
consistent pattern of reduced antibiotic consumption (total and
other major sub-classes) by policy factor e.g. employment of
an antibiotic utilisation co-ordinator, computerised prescribing,
education of staff on antibiotic consumption and consequences
of resistance. Issues relating to the measurement of antibiotic
consumption and indicators of good antibiotic stewardship will
be discussed.
Is the commensal anaerobic microﬂora involved in spreading
antibiotic resistance? (Symposium arranged with ESGARAB)
S25
Antibiotics promote colonisation by resistant
anaerobic bacteria
E. Nagy (Szeged, HUN)
The use and even more the overuse of antibiotics in some
instances act not only on the pathogens, but also on the normal
gut ﬂora of the patients dominated by anaerobes, causing
disturbance in the composition of it. This may lead to
overgrowth of pathogens causing sever diarrhoea, the most
well known side effect of antibiotic treatment. Disturbance in the
composition of the normal ﬂora however, can occur on all
mucosal surfaces. During antibiotic usage not only the changes
in the composition of the normal ﬂora can be observed, but the
increase of resistance to the antibiotics among the bacteria
present. The consequences of the overuse of tetracycline,
erythromycin and clindamycin in acne patients can be well
followed by the increasing number of resistant Propionibacter
acnes isolates among acne patients and their close contacts.
Carbapenem resistant (or still susceptible, but cﬁA positive)
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Bacteroides strains emerged not only among clinical isolates, but
also among normal faecal ﬂora isolates during the past 10 years,
parallel with the increased use of this antibiotics in the clinical
practice. The Helicobacter pylori eradication programmes may not
only cause an increase in the amoxicillin or clarythromycin
resistance of the aerobes and anaerobes in the normal ﬂora, but
the selection of the metronidazole resistant Bacteroides fragilis
and related species. The increase of the antibiotic resistance
among the indigenous anaerobic ﬂora of the different body sites
may cause the potential danger of the development of infections
due to antibiotic resistant or multiresistant anaerobes. The
impact of the antibiotic usage in the clinical practice is extremely
high not only on the composition of the normal ﬂora dominated
by anaerobes, but also on the emergence and selection of
resistance in these bacteria.
Malaria control – what is in the pipeline?
S37
Malaria in the developing and industrialised
world
A. Schapira (Geneva, CH)
Malaria remains one of the main global communicable disease
problems of our time. It is estimated that the malaria incidence in
2004 in 111 countries affected by malaria was 350–450 million
cases. The disease is responsible for over 1 million deaths in the
world per year, mainly in tropical Africa, where it is a principal
cause of nearly 20%of all young child deaths;malariamortality in
eastern and southernAfrica almost doubledover the period 1992–
1998 compared with 1982–1989 possibly as a result of increasing
resistance to chloroquine; in addition, malaria is an important
indirect cause of death for example through malaria-related
maternal anaemia in pregnancy and lowbirthweight. Thedisease
impedes economic growth in tropical developing countries not
only as a result of the mortality and morbidity burden and the
expenditures for prevention and treatment but also because it is a
powerful deterrent to foreign investment. For industrialized
countries, malaria is mainly a problem in travelers, who suffer a
total of about 10,000 acute disease episodes per year. Despite
small outbreaks in industrialized countries around the world,
there is no evidence that the disease is returning to temperate
regions as a result of global warming or other factors. Effective
tools for prevention, control and treatment are now available.
Among the most important are long-lasting insecticidal nets,
intermittent preventive treatment in pregnancy, artemisinin-
based combination therapy, artemisinin-based suppositories,
and rapid diagnostic tests. International transfers for malaria
control have greatly increased since the establishment of the
Global Fund to Fight AIDS, Tuberculosis and Malaria and have
now reached a level of about USD 400 million per year. The key
challenge to developing countries is now to improve health
systems and to recruit and maintain the health workforce, which
is needed at all levels of the system for cost-effective use of
resources and tools and documentation of results. The main
challenge to the scientiﬁc community and industry is to develop
new antimalarial treatments, new insecticides and methods for
vector control, better diagnostics and, possibly, effective vaccines.
S40
Treatment of malaria: the present status and
update on new antimalarials
S. Looareesuwan, P. Wilairatana, N. Tangpukdee,
S. Krudsood (Bangkok, TH)
New antimalarial drugs that have been investigated at the
Hospital for Tropical Diseases, Faculty of Tropical Medicine,
Mahidol University, in recent years are as follows. atovaquone, a
hydroxynaphthoquinone, was evaluated and it was found that
atovaquone alone proved safe and effective. All patients treated
had clinical cure, however, one third of patients had late
recrudescence (RI). When it was combined with proguanil, the
cure rate increased to 100%. This combination has now been
developed into a ﬁxed drug named Malarone. Artemisinine
derivatives such as artesunate, artemether, arteether and dihyd-
roartemisinin are also tested at the Bangkok Hospital for
Tropical Diseases. Artesunate and artemether alone at a total
dose of 600 to 750 mg. given over 5–7 days produced cure rates
of 80 to 95%. Artesunate or dihydroartemisinin suppositories at
a dose of 10 mg/kg/day have been proved successful for the
treatment of severe malaria. The artemisinin derivatives, (4 mg/
kg/day) when used in combination with meﬂoquine (8 mg/kg/
day) given once a day for 3 days gave improved cure rates, up
to 95–100%. Dihydroartemisinin alone with a total dose of
480 mg given over 5 days gave a cure rate of 90%. Arteether, a
WHO/TDR supported drug, has been evaluated in the Hospital
and now has been registered for use (the same dose of
artemether) in severe malaria under the name Artemotil.
Other combinations (artemisinin derivatives combined with
tetracycline or doxycycline and meﬂoquine combined with tet-
racycline or doxycycline) have also been evaluated with
improvement in cure rates. Recently, a ﬁxed drug (artemether
plus lumefantrine) named Coartem (six doses given over 72
hours) proved to be a safe and effective drug (cure rate over
95%) for the treatment of falciparum malaria and it has been
registered for use in many western countries. At present, studies
with combinations of artemisinin derivatives plus meﬂoquine
(in various doses and durations of treatment) are being
investigated. Recently we have ﬁnished the double-blind,
randomized, comparative study of 200 patients (adults and
children) with falciparum malaria treated by a pre-packed
blister approach (4 mg/kg/day artesunate and 8 mg/kg/day
given once a day for 3 days) and found that this approach
proved safe and effective and this approach could translate
clinically into a better patient compliance. Other ﬁx-combina-
tions (Artecom, Artekin) proved safe and efﬁcious (cure rate
over 98%) and could be an alternative antimalarial drugs. In
general, artemisinin derivatives (12 mg/kg total dose given in
3 days) combined with meﬂoquine (25 mg/kg total dose given
in 3 days) have been a standard regimen for the treatment of
multidrug resistant falciparum malaria in Thailand. Until
proven otherwise, drug combinations are still recommended
for all adult patients suffering from acute uncomplicated
falciparum malaria contracted in multidrug resistant areas.
The treatment for uncomplicated malaria is aimed at producing
a radical cure using the combination of either (1) artesunate
(4 mg/kg/day) plus meﬂoquine (8 mg/kg/day) for 3 days; (2)
a ﬁxed dose of artemether and lumefantrine (20/120 mg tablet)
named Coartem (4 tablets twice a day for three days for adults
weighing more than 35 kg); (3) quinine 10 mg/kg 8-hourly plus
tetracycline 250 mg 6-hourly for 7 days (or doxycycline 200 mg
once a day for 7 days as an alternative to tetracycline) in patients
aged 8 years and over; and (4) a combination of atovaquone and
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proguanil called Malarone (in adult, 4 tablets given daily
3 days). In treating severe malaria, early diagnosis and early
treatment with a potent antimalarial drug is recommended to
save the patient’s life. The antimalarial drugs of choice are:
intravenous quinine or a parenteral form of an artemisinin
derivative (artesunate i.v./i.m. 2.4 mg/kg followed by 1.2 mg/
kg injection at 12 and 24 hr and then daily for 5 days; artemether
i.m. 3.2 mg/kg injection followed by 1.6 mg/kg at 12 and 24 hrs
and then daily for 5 days; artemether i.m. (Artemotil ) with the
same dose of artemether; artesunate suppository (5 mg/kg)
given rectally 12 hourly for 3 days). Oral artemisinin derivatives
(artesunate, artemether, dihydroartemisinin with the dose
4 mg/kg/day should replace parenteral forms when patients
can tolerate oral medication. Oral meﬂoquine (25 mg/kg divi-
ded into two doses 8 hrs apart) should be given at the end of the
artemisinin treatment course to reduce recrudescence. The
treatment of vivax malaria in Thailand is still using chloroquine
and primaquine. However with the ineffective to primaquine
(15 mg/kg/day for 14 days with relapse rate of 15%) the higher
dose (30 mg/kg/day for 14 days) is recommended. The efﬁcacy
studies of primaquine in various regimen given together with
Sulfadoxin/Pyrimethamine or artemisinin derivatives are in
progress. Tefenoquine phase III study in the planning stage for
clinical trial in our setting in Thailand is in progress.
Pseudomonas aeruginosa: a rogue bacterium in the intensive care unit
(Symposium arranged with ESICM)
S43
Role of efﬂux pumps in multiresistance of
Pseudomonas aeruginosa
J. Vila (Barcelona, E)
Pseudomonas aeruginosa are an important cause of opportunistic
nosocomial infections. A major feature of this microorganism is
the increasing resistance to multiple antimicrobial agents.
Three main factors contribute to this multiresistance: i. The
intrinsic resistance; ii. Facility to acquire resistance and iii.
Ability to survive in moist environments. Intrinsic multiresis-
tance can be due to the interplay between the low permeability
of the outer membrane which, for some antibiotics, is 10 to
100-fold less than that of Escherichia coli and the constitutive
expression of some efﬂux pump(s). Currently, at least ﬁve
main efﬂux pumps associated with the resistance to multiple
antimicrobial agents have been shown (MexAB-OprM,
MexCD-OprJ, MexXY-OprM, MexEF-OprN and MexVW-
OprM). These efﬂux pumps have different substrate speciﬁci-
ties. The constitutive expression of MexAB-OprM seems to
play an important role in intrinsic multiresistance since
mutations that prevent expression of this efﬂux pump result
in hypersusceptibility to quinolones, tetracyclines, chloram-
phenicol, trimethoprim and some b-lactam antibiotics. On the
other hand, MexXY-OprM may have a primary role in intrinsic
resistance to aminoglycosides and erythromycin. However, the
greatest therapeutic problems occur when these multi-drug
efﬂux pumps are overproduced, generating a high level of
multiresistance. This scenario can also be observed during the
course of treatment of an infection caused by P. aeruginosa.
Unfortunately, the emergence of resistance during therapy is
not a rare event in this microorganism. An in depth study
analysing the prevalence of the overproduction of each of the
abovementioned efﬂux pumps in clinical strains of P. aerugi-
nosa has not been performed. However, efﬂux pump-overpro-
ducing P. aeruginosa mutants selected during the treatment of
infections may range from 50 to 80%. The acquisition of
resistance during therapy is normally associated with speciﬁc
mutations. Hypermutability is an important factor which,
together with a high inoculum in the infection site and the
ability of P. aeruginosa to produce bioﬁlm, may contribute to
therapeutic failures. Knowledge of the prevalence of efﬂux
pumps in the acquisition of multiresistance in P. aeruginosa
clinical isolates and the ability of the different antimicrobial
agents to select resistant mutants would help in the selection of
the appropriate therapy.
Tuberculosis: persistence and resistance
S48
Treatment in the modern era of resistance
F. Drobniewski (London, UK)
Drug resistant, and particularly multiple-drug resistant tuber-
culosis (MDRTB) is increasing globally particularly in Eastern
Europe, but the actual incidence is unknown. Countries with
effective TB programmes see low rates of MDRTB amongst new
cases annually. Hot spots with high rates such as countries of
the former Soviet Union exist and modelling of existing data
suggest that between 250–500 000 new MDRTB cases occur
globally. MDRTB is particularly difﬁcult to treat, particularly
when co-existing with HIV infection, and carries a high
mortality compared to drug sensitive disease. Although
modern rifampicin-based short course treatments are effective
against drug sensitive and mono-resistant disease (apart from
rifampicin resistance), MDRTB therapy is difﬁcult and pro-
longed. Survival requires therapy with at least three agents to
which the bacteria are susceptible. New research has produced
many rapid and novel methods to diagnose drug resistance
earlier which may confer some survival or public health
advantage as may other processes that reduce diagnostic delay
including the reduction of stigma. In high income countries,
individualised therapy forms the gold standard of treatment but
the substantial laboratory costs associated with this approach
have led to studies of standardised treatment in middle/low
income countries. Studies in Peru examined both approaches
with comparable success. Nevertheless even standardized
treatment requires an accurate survey of drug resistance and
an understanding and correction of the initial causes of high
rates of MDRTB. Few new drugs are available for treatment and
the individual and health system costs of treating drug resistant
cases are high emphasising the critical importance of curing
drug sensitive tuberculosis at ﬁrst presentation. The presenta-
tion will discuss some of the management options available for
the treatment of resistant disease.
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Clinical microbiology: what’s new in conventional and molecular
diagnostics? (Symposium arranged with ESGMD)
S49
The role of conventional diagnostic techniques in
the diagnosis of respiratory tract infections
M. Ieven (Edegem, B)
In view of the increasing development of bacterial antibiotic
resistance, proper and rapid diagnostic tests may result in better
patient management with appropriate therapy or reduction of
unnecessary antibiotic therapy. Therefore, a number of recent
evidence based guidelines for the management of patients with
respiratory tract infections also include guidelines on microbio-
logical diagnosis, including both conventional and new tech-
niques. Competition between traditional and new techniques are
conditioned by: rapidity and quality of results, need for special
infrastructure and trained personnel, possibility to deliver results
24/24 hours 7/7 days and cost. In pneumonia blood and pleural
exsudateculturesarepositive inonly4–18%andupto40%ofcases
respectively. However, as they offer a highly speciﬁc diagnosis,
blood cultures should be performed in hospitalised patients with
CAP and thoracentesis when signiﬁcant pleural ﬂuid is present.
Quantitative bacterial cultures may be important for the assess-
ment of BAL and PSB ﬂuid: advantages and limitations will be
discussed. The most frequently submitted specimen is sputum.
Criteria forgoodquality sputumarenowuniversallyacceptedbut
there are still great controversies about the value of sputumGram
stain and culture. Gram strain of a valuable sputum showing a
predominant morphotype correlates well with the results of
boodcultures, is a rapid and low cost technique allowing a
presumptive etiological diagnosis of pneumonia in many cases,
allows correct interpretation of sputum culture results and
therefore is recommended. Urine antigen detection is recom-
mended for the diagnosis of L. pneumophila infections but for
S. pneumoniae more studies are needed. Serological tests usually
produce late results particularly for the ‘atypicals’, while the
multitude of procedures for C. pneumoniae and M. pneumoniae
produce divergent results. Some recent studies on the improved
detection of these agents bymolecular tests illustrate the often low
predictive value of serology showing the limited application in the
routine management of the individual patient. Based on recent
studies and guidelines, indications for the use of a number of
conventional diagnostic techniques in different clinical situations
will be discussed.A compromisemust often be foundbetween the
value of the test, feasibility turnaround time and cost.
S50
Urinary antigen testing for respiratory infections:
for which pathogens and when to use them?
J.A. Domı´nguez (Barcelona, E)
Community-acquired pneumonia (CAP) is a frequently occur-
ring disease with high morbidity and mortality, which causes
numerous hospitalizations. Despite of advances in the devel-
opment of vaccines and of the appearance of new antibiotics,
the incidence of pneumonia does not decrease. This is
probably due to the ageing of the population, an increase in
the number of immunodepressed persons, and an increase in
the prevalence of chronic diseases. Knowing the etiology of
pneumonia is of great signiﬁcance because it permits an
empirical antibiotic therapy to be converted into a speciﬁc
one, which contributes to optimizing costs and probably helps
conserve bacterial ecology. The etiological diagnosis of CAP in
the majority of cases remains uncertain. An adequate sputum
specimen is often difﬁcult to obtain, and even then, the
specimen is frequently contaminated with oropharyngeal
bacteria. The blood culture is positive in less of a 20% of
cases. Serological tests requires to be performed preferably in
paired serum samples, providing a retrospective diagnostic.
Various recent studies from distinct geographical areas coin-
cide in that the etiological yield is lower than 60% with
conventional microbiological diagnostic techniques. The most
frequent aetiological agents are Streptococcus pneumoniae, Hae-
mophilus inﬂuenzae, Legionella pneumophila, Chlamydophila pneu-
moniae and Mycoplasma pneumoniae. In the severe cases of
pneumonia the ﬁrst 3 etiologies should always be considered.
Techniques for antigen detection of L. pneumophila and
S. pneumoniae in urine samples have, in the last few years,
been demonstrated to be rapid, sensitive and speciﬁc. In
addition, the use of urine samples concentrated by selective
ultraﬁltration procedure improves the sensitivity signiﬁcantly.
In our experience, these techniques have proven to be useful
in the diagnosis of CAP. Given the large number of diagnos-
tics, even when the patient has received prior treatment with
antibiotics, the use of these techniques is highly recommend-
able as having the etiological diagnosis available allows
antibiotic treatment to be adjusted, the importance of which
it is not necessary to point out.
Antibiotic usage: practices and policy interventions
O53
Self-medication with antibiotics in Europe
L. Grigoryan, F.M. Haaijer-Ruskamp, D. Monnet, R. Mechtler,
A. Tambic Andrasevic, A. Alkerwi, E.A. Scicluna, C. Stalsby
Lundborg, J. Birkin, A. Di Matteo, R. Cunney, H. Edelstein,
R. Valinteliene, R. Deschepper, R. Andrajati, P. Grzesiowski,
J. Campos, C. Bara, T. Tesar, M. Cizman (Groningen, NL;
Copenhagen, DK; Linz, A; Zagreb, HR; Luxembourg, LUX;
Guardamangia, MT; Stockholm, S; Nottingham, UK;Maria Imbaro, I;
Dublin, IRL; Afula, IL; Vilnius, LT; Brussels, B; Hradec Kralove, CZ;
Warsaw,PL;Madrid,E;Craiova,RO;Bratislava,SVK;Ljubljana,SVN)
Objectives: To assess the prevalence of self-medication with
antibiotics in 19 European countries, including actual use in the
last 12 months and ‘at risk’ self-medication, i.e. intended use
without contacting a doctor, storage of antibiotics at home; to
explore sources of obtaining antibiotics, the reasons for self-
medication and the relation between persons characteristics,
prescribed use of antibiotics and self-medication.
Methods: A population survey conducted in each country
(Austria, Netherlands, Sweden, UK, Ireland, Denmark , Italy,
Malta, Luxembourg, Belgium, Spain, Israel, Romania, Czech rep,
Slovakia, Lithuania, Slovenia, Croatia, Poland), with a self-
administered postal questionnaire using a two-stage stratiﬁed
sampling design. Study population in each country included a
random sample of 1000–3000 adults equally distributed in urban
and rural areas. Logistic regression was used to analyse the
determinants of self-medication use.
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Results: The overall response rate was 40% (ranging 18–70%
between the countries). The rates of actual and ‘at risk’ self-
medication as well as prescribed use of antibiotics tend to be
high in southern and eastern European countries and low in
western and northern countries (table 1). The main sources of
self-medication were directly from pharmacy without
prescription (58% of all self-medication courses), leftovers
(32%) and friends/relatives (8%). The most common reasons
for self-medication use reported by the respondents were
throat symptom (20% of self-medication courses), teeth/gum
symptom (15%), acute bronchitis (9%), inﬂuenza (7%), urinary
tract infection (7%) upper respiratory infection (6%).
Penicillins (J01C) was the most frequently used antibiotic
group for self-medication (ﬁgure 1). Younger age, country,
presence of chronic diseases and prescribed use of antibiotics
were related to self-medication use. Gender and location
(urban/rural) were not associated with actual self-medication
with antibiotics.
Conclusions: Self-medication with antibiotics is a problem in
all European countries in varying degrees, with low levels in
North and West and high levels in South and East. This
consistency underlines the relevance of health care system and
cultural factors for antibiotic use. Broad spectrum penicillins
tend to be used for self-medication more frequently in South
and East.
O54
Antibiotic use in 2003 in Europe
M. Ferech, S. Coenen, E. Hendrickx, K. Dvorakova, H. Goossens
and ESAC Project Group
Objectives: ESAC, European Surveillance of Antimicrobial
Consumption, granted by DG/SANCO of the European
Commission, is an international network of surveillance
systems, aiming to collect comparable and reliable data on
antibiotic consumption in Europe. Thirty-four countries have
joined the second phase of the ESAC project (2004–2007),
including all 25 EU countries and 4 current applicant countries.
Methods: Outpatient and hospital antibiotic use for 2003 were
collected, using the ATC/DDD methodology, version 2004.
Results were expressed as DDD per 1000 inhabitants per day
(DID). Detailed information on the sources of antibiotic use data
can be found at the ESAC website (www.ua.ac.be/ESAC). Of
the 34 participating countries 21,19 and 2 were able to deliver
outpatient, hospital and total data, resp., for 2003. In view of the
expected change of DDD for parenteral co-amoxicillin, a pilot
study on the pattern of consumption of antibiotics with multiple
DDDs was conducted, based on data subdivided by route of
administration.
Results: Outpatient antibiotic use varied with a factor of 3.2
between the countries with the lowest and highest consumption,
c.q. still the Netherlands (9.8 DID) and for the ﬁrst time Greece
(31.4 DID). Consumption in France decreased by 7.1% the year
after their ﬁrst national campaign. A similar reduction was seen
in Belgium ()7.6%) after the ﬁrst Belgian campaign. Hospital
antibiotic use ranged between 1.4 DID in Norway and 3.6 DID in
France. Nine substances with multiple DDDs were identiﬁed
within the J01 ATC group: amoxicillin and enzyme inhibitor,
cefuroxime, ciproﬂoxacin, clarithromycin, clindamycin, fosfo-
mycin are available in oral and parenteral form, tobramycin in
inhalatory and parenteral form, while DDDs for erythromycin
and methenamine differ according to their chemical salts.
Speciﬁcally consumption of parenteral co-amoxicillin was
substantial in 4 out of 10 countries, which were able to deliver
detailed data.
Conclusion: ESAC data underpin the success of two national
campaigns on antibiotic prescribing (Belgium and France). An
introduction or change of DDD for a speciﬁc form of any
antibiotic can substantially inﬂuence the proﬁle of antibiotic
consumption in some countries. Thus the ESAC data collection
protocol shall be adjusted to allow us to control for these
changes retrospectively, by collecting data at a product
presentation level.
055
Changing antibiotic prescribing for respiratory
infections in primary care: systematic review
I. Welschen, M.M. Kuyvenhoven, T.J.M. Verheij, A.W. Hoes on
behalf of ESPRIT
Objective: Almost 80% of outpatient used antibiotics are
prescribed by general practitioners with up to 75% of these
prescriptions being for acute RTIs. There is an international
trend to prescribe more new and broad spectrum antibiotics,
Table 1. Actual use of systemic antibiotics in the last 12 months
and ‘‘at risk’’ self-medication in 19 European countries
Rates per 1000 respondents (95% CI)
Self-
medication
Prescribed
use
Intended
self
medication Storage
North
Sweden 4 (0.09–0.2) 135 (109–161) 118 (94–143) 14 (2–26)
Denmark 7 (4.12) 172 (154–189) 132 (116–147) 42 (33–52)
West
Netherlands 1 (0.2)2) 152 (134–170) 85 (11–101) 10 (6–17)
Austria 9 (2.25) 159 (134–145) 73 (49–105) 32 (14–55)
Belgium
(Flanders)
9 (5.15) 222 (201–242) 80 (67–95) 1 (19–84)
Luxemburg 9 (3.19) 288 (212–324) 83 (62–107) 90 (69–114)
UK 12 (5–23) 121 (109–254) 156 (137–295) 33 (21–49)
Ireland 14 (7–25) 353 (330–306) 150 (125–276) 29 (19–43)
South
Israel 15 (6–31) 330 (287–374) 137 (150–223) 120 (91–140)
Malta 55 (38–79) 422 (380–462) 228 (152–354) 156 (125–136)
Italy 62 (33–103) 512 (444–580) 243 (185–301) 379 (314–445)
Spain 152 (103–201) 315 (251–379) 314 (249–380) 260 (200–320)
East
Czech
Republic
7 (3–13) 253 (238–279) 179 (156–201) 45 (33–58)
Slovenia 17 (10–26) 293 (266–320) 230 (253–307) 119 (100–137)
Croatia 31 (19–48) 239 (399–478) 205 (172–237) 130 (103–156)
Poland 33 (33–47) 199 (172–225) 115 (94–136) 69 (53–87)
Slovakia 43 (38–54) 369 (537–512) 324 (284–365) 192 (159–225)
Romania 190 (160–235) 307 (263–351) 431 (303–470) 200 (162–230)
Lithuania 210 (181–230) 275 (243–308) 119 (412–486) 147 (142 –201)
Fig. 1. Use of major groups of antibiotics for self-medication in
17 countries.
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also in countries with relatively low prescribing rates such as
the Netherlands. Several methods (clinical guidelines,
postgraduate educational courses and prescribing feedback)
have been used to reduce and optimise antibiotic treatment of
acute RTI’s, but changing towards a more frugal and rational
prescribing behaviour seems to be difﬁcult. However, there are
no reviews available on the effectiveness of educational
interventions aimed at optimising prescribing antibiotics for
acute RTI’s in primary care. That is why the purpose of this
study was to evaluate the effectiveness of educational
interventions aimed at changing professional behaviour:
reducing prescribing antibiotics or increasing prescribing of
ﬁrst choice antibiotics for acute RTI’s in primary care by
systematically reviewing available randomised controlled trials
(RCT’s).
Methods: Data sources. Medline (1966–October 2003), Embase
(1980–October 2003) and Cochrane Library (October 2003).
Study selection. In the ﬁrst phase, studies describing effects of
interventions on changing prescribing antibiotics in primary
care were included by screening titles, keywords and abstracts.
In the second stage, the full text was retrieved using the
following inclusion criteria: (1) involving an intervention aimed
at improving and reducing prescribing antibiotics for RTI’s, (2)
control group in which no intervention relating to RTI’s was
present, (3) RCT with before and after measurements, (4)
outcome measures: ‘antibiotic prescription rates’ for acute
RTI’s or ‘percentage of ﬁrst choice antibiotics’. Data extraction.
Reviewers independently extracted data. Methodological
quality was assessed relating to selection procedure, the
intervention, outcomes and statistics.
Results: Eight trials (12 interventions) were included. Mean
quality was relatively low (56% of the maximum). Antibiotic
prescription rates reducedby6%(95%CI: 4 to 7),while proportion
of ﬁrst choice antibiotics increased by 12% (95% CI: 10 to 14).
Conclusions: Most interventions aimed at optimising
prescribing antibiotics for acute RTI’s were effective. However,
changing to prescribing more ﬁrst choice antibiotics seemed
easier than reducing the number of prescriptions.
056
Differences in incidence and prescribing
antibiotics in upper respiratory tract infections in
Dutch general practice between 1987–2001: did
publication of national guidelines make a
difference?
T.J.M. Verheij, M. Kuyvenhoven, G.A. van Essen, F.G. Schellevis
on behalf of ESPRIT
Objective: Most antibiotic prescriptions are prescribed in
primary care with respiratory tract infections (RTI’s) being the
most common indication. Although Dutch antibiotic rates are
low, even in the Netherlands up to 50% of antibiotic
prescriptions for RTI’s are assumed to be unnecessary. Over-
prescribing unnecessarily exposes patients to risk of side
effects, encourages re-consulting for similar problems and
enhances antimicrobial resistance. In the nineties the Dutch
College of General Practitioners has published guidelines for
management of upper RTI’s with clear indications for
antimicrobial treatment. It is unknown whether these
guidelines have yielded a reduction in prescribing antibiotics.
This study is aimed to assess differences in antibiotic
prescribing and incidence rates of upper RTI’s in Dutch
General Practice between 1987 and 2001, before and after
publication of Guidelines.
Methods: Data were collected in 96 general practices in 1987
(First Dutch National Survey of General Practice; practice
population n = 344,449 patients) and in 90 general practices in
2001 (Second Dutch National Survey of General Practice;
practice population n = 358,008 patients). Outcome measures:
(1) percentage of contacts for AOM, common cold, sinusitis and
acute tonsillitis in which an antibiotic was prescribed (=
antibiotic prescription rate); (2) number of antibiotic
prescriptions per 1000 patients per year; (3) incidence rates of
urti’s per 1000 patients per year.
Results: Antibiotic prescribing rates in AOM and common cold
were increased in 2001 compared to 1987 (from 27% to 48% and
from 17% to 23% respectively), while the rates for sinusitis and
tonsillitis were the same. The number of antibiotic prescriptions
per 1000 patients decreased except for AOM. Incidence rates of
all upper rti’s were lower in 2001 as compared to 1987.
Conclusion: Antibiotic prescribing rates have not declined
several years after publication of urti-guidelines. The total
volume of antibiotic prescriptions per 1000 patients/per year for
common cold, sinusitis and tonsillitis has decreased mainly
because of a reduction of incidences. The question arises
whether patients’ reduced inclination to present illness to their
GPs is an indirect consequence of a more selective use of
antibiotics by their GPs or a concurrent trend among patients in
community. Long term trends studies in antibiotic prescribing
rates should include information about incidences in outcome
measurement.
O57
Trends in penicillin-resistance rates among
pneumococcal carriage strains in children’s
day-care centres in France: 1999–2004
M. Roussel-Delvallez, C. Laurans, H. Carsenti-Dellamonica,
P. Dellamonica, M. Pecking, E. Bonnet, B. Dunais, S. Maurin,
C. Pradier (Lille, Nice, Neuilly-sur-Seine, Paris, F)
Objectives: To monitor penicillin resistance trends among
nasopharyngeal (NP) carriage strains of S pneumoniae (SP) in
children’s day-care centres (DCC)in the wake of interventions
promoting prudent antibiotic use in France.
Methods: Cross-sectional surveys were conducted on a random
sample of children attending DCCs in 2 areas of France, Alpes
Maritimes (AM) and Nord (N), in January–March 1999, 2002
and 2004. Penicillin-susceptibility and serotype of SP isolates
were tested on NP aspirates. An intervention programme began
in AM in October 2000 to reduce unnecessary pediatric ATB
prescriptions. A large scale national campaign was launched in
2002. Pneumococcal conjugate vaccine (PCV) is reimbursed
since December 2002.
Results: Samples were obtained from 250, 240 and 233 children
in N and 298, 294 and 334 in AM in 1999, 2002 and 2004,
respectively. In N, SP carriage rates (CR) remained stable from
1999 to 2002 (47% vs 49%, respectively) and decreased between
2002 and 2004 (49% vs 36%, respectively; p < 0.01). In AM, CR
remained unchanged (54%, 58% and 51% in 1999, 2002 and 2004,
respectively). Among SP carriers, the proportion of PDSP
increased in N between 1999 and 2002 (72% vs 85%,
respectively; p = 0.01) but remained stable in AM (63% and
64%, respectively). This proportion declined in both areas
between 2002 and 2004 (85% vs. 60% in N, p < 10–3, and 64%
vs. 43% in AM, p < 10–3, respectively). In 1999, prevalence rates
of PDSP among SP carriers were similar in N (72%) and AM
(63%). In 2004, this rate was lower in AM (43%) than in N (60%)
(p < 0.01). In AM, there was a decrease in proportion of
serotypes 23F (31% in 1999, 17% in 2002 and 9% in 2004;
p < 10–3), 6B (20% in 2002 vs. 12% in 2004; p = 0.04) and 14 (15%
in 2002 vs. 7% in 2004; p = 0.01) and an increase of serotype 6A
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(6% in 2002 vs. 15% in 2004, p < 0.01). In N, serotype 23F
decreased (27% in 2002 vs. 8% in 2004; p < 0.01), and serotype
6A increased (1% in 2002 vs. 14% in 2004; p < 0.01). In 2004, at
least 28% of children in N and in 36% in AM had received PCV.
SP and PDSP carriage was signiﬁcantly lower among vaccinees
in AM (43% vs. 56% for SP; p = 0.03; and 14% vs 26% for PDSP;
p = 0.01) but not in N.
Conclusion: A 30% decrease in proportion of PDSP among SP
carriage strains from children attending DCCs has occurred
since the implementation of local and national campaigns
promoting judicious antibiotic use in France. Serotype
distribution has shifted signiﬁcantly with fewer carriers of
PCV strains.
O58
Prospective observational study on the empirical
use of antibiotics and on the adjustment of
antibiotic therapies in a university hospital
J. Mettler, M. Simcock, P. Sendi, A. Widmer, M. Battegay,
U. Flu¨ckiger, S. Bassetti (Basel, CH)
Objectives: To study the adequacy of empirical antibiotic
therapies and of adjusted antibiotic therapies, as well as the
use of microbiological investigations at a Swiss university
hospital where no restrictive measures regarding antibiotic use
were in place.
Methods: A prospective study was conducted on alternating
weeks over an 8½-month period. All patients admitted
through the emergency department who received therapeutic
antibiotic therapy (AT) within 24 hours of admission were
included. Data on demographic characteristics, diagnoses,
comorbidities, SIRS-parameters, microbiological investigations
and antibiotic(s) used were prospectively collected. The ﬁrst
AT received by the patient and, if applicable, the adjusted AT
were analysed. AT was considered adequate if the spectrum
of activity, the dose and the duration of AT were appropriate,
according to local recommendations and/or published
guidelines.
Results: 2943 admitted patients were evaluated. Of these, 539
(18.3%) received an AT within the ﬁrst 24 h and were analyzed.
Most patients had respiratory tract (169 pts., 31%), urinary tract
(109, 20%) and gastrointestinal (88, 16%) infections. 716
microbiological investigations were performed. Blood cultures
were taken from 62% of pts. The 2 most frequently isolated
pathogenic bacteria were E. coli (12% of pts.) and S. aureus (5%).
431 pts. (80%) received a monotherapy, 108 (20%) a combination
therapy for empirical antibiotic therapy (EAT). The 3 most
commonly used antibiotics for EAT were amoxicillin/
clavulanate (279 pts., 52%), ciproﬂoxacin (88, 16%) and
piperacillin/tazobactam (62, 11%). EAT was inadequate in 121
pts. (22%). 168 of the 539 pts. (31%) received an adjusted
antibiotic therapy (AAT). AAT was inadequate in 27% of cases.
The main reason for inadequacy of AT was the use of antibiotics
with unnecessarily broad spectrums (24% of inadequate EAT
and 53% of inadequate AAT). In 27% of pts. with inadequate
AAT identiﬁed pathogens were resistant to the administered
antibiotics, or antibiotics with the same spectrum were
unnecessarily combined.
Conclusion: Despite the absence of a restrictive antibiotic
policy, the rate of inadequate AT was similar to the rates
reported from other institutions. Surprisingly, AAT were more
frequently inappropriate than EAT. Interventions aiming at
improving antibiotic prescribing should focus on streamlining
and adjustment of AT once microbiological results become
available.
O59
A simulation model of the cost of treatment
failure in patients hospitalised with community-
acquired pneumonia in the US
N. Neil, D. Lamm, K. Ogden, L. Noe, L. Peterson,
R. Mallick (Highland Park, Evanston, Philadelphia, USA)
Objective: Managing patients hospitalized with community-
acquired pneumonia (CAP) in the US is costly, particularly for
those failing IV antibiotic therapy. We developed a simulation
model to estimate the cost of treatment failure in this
population.
Methods: The simulation is based on American Thoracic
Society (ATS) treatment guidelines, published literature and
expert opinion. The model simulates initial, empiric IV therapy
through as many as three subsequent courses of therapy.
Patients requiring third-line therapy are assumed to either
achieve cure or expire. Base-case analyses include the most
common pathogens, resistance patterns and treatment regimens,
and consider immune-competent Usual Care, Penicillin-allergic,
and PORT Class V subpopulations. The model considers only
CAP-related costs. Therapeutic decisions are simulated on the
basis of ATS guidelines and prioritized to minimize the use of
ﬂuoroquinolones early in treatment, minimize drug cost and
maximize drug efﬁcacy. Resource use is estimated from the
payer perspective in 2002 US dollars; component costs include
diagnostics, antibiotics, monitoring, ICU and non-ICU care,
respiratory support and complications. At each line of therapy,
our analysis focused on the subsequent costs of only those
patients who failed therapy. We varied key parameters in
sensitivity analyses.
Results: Each patient failing initial, empiric therapy generated
an average of $5,393 in additional care costs before achieving
cure or expiring. Average per patient cost of failure at ﬁrst- and
second-line treatment was $6,028 and $6,113, respectively. Our
estimates were most sensitive to assumptions about case mix,
bed costs and mortality.
Conclusions: Our ﬁndings indicate that failing initial, empiric
therapy adds $5,393 per patient to the cost of care. On average,
patients requiring three lines of antibiotic therapy before
achieving therapeutic success cost about $11,830 more to treat
than those cured with the initial, empiric regimen.
O60
Antibiotic cycling for control of extended-
spectrum beta-lactamases – experience in an
Indian intensive care unit
U. Sekar, V. Hemalatha, P. Sireesha, V. Kamat (Chennai, IND)
Objectives: To study the impact of antibiotic cycling on the
prevalence of Extended spectrum beta lactamases [ESBL]
producing enterobacteriaceae and the MIC levels of third
generation cephalosporins [3GC] and betalactam inhibitor
combination drugs of ESBL isolates.
Methods: A prospective study was done in a multidisciplinary
ICU of a tertiary care centre in 2 phases. Phase 1 was before
antibiotic cycling [Jan 2003–May 2003] and phase 2 was after
antibiotic cycling [Jun 2004–Oct 2004]. The antibiotic cycling
included use of quinolones, cefoperazone sulbactam and
piperacillin tazobactam with restricted use of ceftazidime and
cefotaxime. ESBL production was screened and conﬁrmed by
standard NCCLS protocols. MIC of cefotaxime, ceftazidime,
cefoperazone sulbactam and piperacillin tazobactam for a total
of 60 isolates in both phases was done by agar dilution method
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according to NCCLS guidelines. The usage of these drugs in
grams/100 patient days and the cross-resistance pattern to
ﬂuroquinolones and aminoglycosides were determined.
Results: The prevalence of ESBL producing enterobactericeae
decreased from 45.01% in phase 1 to 30.7% in phase 2[p < 0.001].
The usage of cefotaxime, ceftazidime, cefoperazone sulbactam
and piperacillin tazobactam in grams/100 patient days was 742,
153, 184 and 113 in phase 1 and 620, 28, 256 and 350 in phase 2
respectively. All the isolates both in phase 1 and phase 2 had
MIC levels to 3GC above the breakpoints. The percentage of
isolates with MIC levels >64 lg/ml of cefotaxime and
ceftazidime was 83.3% and 96.6% in phase1 and 56.6% and
80% in phase 2[p < 0.05] respectively. The percentage
susceptibility to cefoperazone sulbactam and piperacillin
tazobactam in phase 1 was 71.6% and 41.6% which changed to
53.35 and 70% in phase 2 [p < 0.05] respectively. The cross-
resistance to quinolones and aminoglycosides was high in both
phases.
Conclusion: Antibiotic cycling is an effective method to contain
high ESBL prevalence. The period of cycling has to be more than
a year for effective control. Strict infection control policies
should be adhered to for ESBL eradication.
O61
Impact of an antibiotic restriction policy on
antibiotic usage and cost
F. Jover, J. Cuadrado, V. Ortiz de la Tabla, C. Martin, V. Sanchez,
M. Gonzalez, T. Aznar (Alicante, E)
Objective: To assess the impact of a programme to evaluate the
quality of an antibiotic restriction policy at a University hospital.
Methods: A multidisciplinary antimicrobial management team
(AMT) composed by Infectious Diseases (ID),Microbiology and
Pharmacy members daily evaluated restricted antibiotic
prescriptions. We designed a prospective study with two
periods:observational (Oct 1st 2003–March 14th 2004) and
interventional (March 15th–Sept 1st 2004). A speciﬁc
prescription formulary aiming to evaluate the usage of broad
spectrum antibiotics was introduced. Revision criteria were
according to ID Committee guidelines and the Sanford Guide
to Antimicrobial Therapy. Clinical, microbiological and
pharmaceutical data were collected from each patient.
Antibiotic therapy appropriateness, restricted therapy
eligibility and economic outcomes were evaluated. During
interventional period, antibiotic recommendation prescriptions
were formulated. Statistical analysis with non-parametric tests
were performed. A p value of <0.05 was accepted as signiﬁcant.
Results: 480 patients were evaluated (54.3% observational and
45.7% interventional period). Overall, restricted agents
prescribed were ceftazidime (27.9%), imipenem (24.8%),
amikacin (14.6%), piperacilin-tazobactam (12.1%), vancomicin
(6.5%) and cefepime (5%). Most frequent diagnostic groups were
sepsis (40.3%), gastrointestinal (20.4%), respiratory (13.1%), soft-
tissue and bone infections (12.9%) and prophylaxis (7.9%).
Antibiotic therapy was not indicated in 7.1% of cases and the
restricted antibiotherapy was suitable in 29.8%. Comparing both
periods of study, we found several statistical signiﬁcant
features: a decrease of usage of ceftazime, amikacin,
teicoplanin and piperacilin-tazobactam; however, imipenem
and vancomicin usage increased. Adequate prescription of
antibiotherapy increased from 81.7% to 96.8%. Restricted
antibiotic prescription signiﬁcantly improved from 58.5% to
86.3%, while concordance to AMT prescription increased from
53.3% to 78.5%. Economic outcomes were signiﬁcantly reduced
comparing both study periods. In the interventional period,
recommendations were formulated in 38% of cases, while 70.2%
of them were accepted.
Conclusions: The development of prophylactic and
therapeutics local guidelines reached by consensus, and the
evaluation and interventional policy by an AMT group have
signiﬁcantly improved the quality and economical costs of
restricted antibiotic prescription in our hospital.
O62
Appropriateness of IV antibiotic therapy: impact
of counselling based on standardised decisional
algorithms 72 hours after prescription
O. Manuel, R. Kammerlander, B. Burnand, M. Vansantvoet,
T. Swinnen, P. Francioli, G. Zanetti (Lausanne, CH)
Objectives: To estimate the impact of a therapeutic counselling
intervention based on a standardized decisional approach aimed
at fostering and guiding reassessment of antibiotic therapy 3
days after initial prescription on the appropriateness of IV
antibiotic therapy in hospitalised patients.
Methods: Interim analysis of an ongoing prospective crossover
cohort study in 2 similar internal medicine wards in a 850-bed
university hospital. Predeﬁned, standardized decisional
algorithms based on chart review were used in the
intervention group to evaluate 5 steps in IV antibiotic therapy:
indication, choice of antibiotic, administration route, dose, and
duration of therapy. Physicians in charge of included patients
received a standardized, itemized evaluation form that included
proposals if applicable. The present interim analysis included
only patients hospitalised in the ﬁrst intervention ward during
the 6-month period before crossover. We compared
appropriateness of IV antibiotic therapy 3 days after
prescription during the ﬁrst and the second trimesters of the
intervention.
Results: 109 IV antibiotic therapies were evaluated, 43 in the
ﬁrst trimester and 66 in the second trimester. The proportion of
fully appropriate antibiotic therapies was higher during the
second trimester: 41/66 (62%) vs. 14/43 (33%, p < 0.01, Fisher
exact test). For all speciﬁc items of the evaluation there was a
trend towards better antibiotics use in the second trimester:
appropriate indication (94% vs. 83%, p = 0.10), appropriate
antibiotic choice (88% vs. 79%, p = 0.28), and appropriate
administration route (80% vs. 63%, p = 0.05). Total antibiotic
consumption was higher during the second trimester, however:
352 vs. 299 prescribed daily doses/1,000 patients-days (of which
68% vs. 62% were given by IV route, and 19% vs. 18% were
broad-spectrum antibiotics). Since antibiotics were used more
appropriately during the second trimester, this higher antibiotic
consumption may reﬂect a higher burden of infection.
Conclusion: Although more deﬁnite results are expected
after study completion, this interim analysis showed a
promising potential of a counselling intervention based on
standardized decisional algorithms to improve the use of IV
antibiotics.
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Hepatitis virus
O64
Hepatitis C virus-speciﬁc CD8+ T cell response
and their phenotypic characteristics in chronic
patients treated with interferon-alpha and
ribavirin
J. Caetano, A. Paiva, A. Martinho, B. Pais, C. Valente,
F. Regateiro, C. Luxo (Coimbra, P)
Objectives: Hepatitis C virus (HCV) shows a high propensity to
establish chronic infection. Interferon-alpha in combination with
ribavirin is standard therapy for hepatitis C. However, this
treatment is still limited by a high non-response rate. As CD8+
cytotoxic T lymphocytes are thought to play a crucial role in the
course of HCV infection, we evaluated the magnitude of
HCV-speciﬁc CD8+-T cell response during therapy, and its
effect on the dynamics of CD8+-T cell subsets: CD45RA+/
CCR7+ (naive), CD45RA+/CCR7) (effector), CD45RA-/CCR7+
(central memory) and CD45RA-/CCR7) (memory/effector).
Methods: We studied 5 HLA-A2+ healthy controls and 11
HLA-A2+ patients chronically infected with HCV. Patients were
treated with IFN-alpha and ribavirin, during 48 weeks for
genotype 1, and 24 weeks for genotypes 2 and 3. Peripheral
blood mononuclear cells were collected before treatment, and
one, three and six months after the end of treatment. They were
analyzed at speciﬁc time points by four-colour ﬂow cytometry
using HLA-A2 HCV-peptide speciﬁc tetramers, together with a
panel of phenotypic markers of homing and differentiation:
CCR7 and CD45RA, respectively.
Results: Patients infected with HCV displayed an increase in
the percentage of HCV-speciﬁc CD8+T cells, when compared
with healthy controls. Our results pointed to a more pronounced
increase of HCV-speciﬁc CD8+T cells in patients who responded
to treatment. The phenotypic pattern of the CD8+T-cell subsets
studied was altered in therapy responders, when compared
with healthy controls. The more signiﬁcant differences were a
decrease in the percentage of CD45RA+/CCR7- cells and an
increase in CD45RA+/CCR7+ cells in therapy responders. In
contrast, non-responder patients seemed to present a similar
pattern for all CD8+-T cell subsets, as control individuals.
Conclusions: Our results seem to indicate that the success of
treatment for hepatitis C is related to a signiﬁcant increase in
HCV-speciﬁc CD8+T cells. Moreover, the relative proportions of
the CD8+ T cell subsets studied appear to be important for a
successful outcome of response. The decrease in CD45RA+/
CCR7- subset of HCV-speciﬁc CD8+-T cell observed in
peripheral blood of responder patients could be explained
with their massive recruitment to the liver, which leads to a
relative increase in CD45RA+/CCR7+ cells. Further prospective
large studies are needed to conﬁrm these observations.
Work partially supported by Roche Pharma Portugal.
O65
Treatment of acute C hepatitis in HIV infected
patients
S. Audagnotto, F.G. De Rosa, O. Bargiacchi, S. Garazzino,
L. Veronese, G. Cariti, G. Di Perri (Turin, I)
Objective: ChronicChepatitis is an important causeofmorbidity
andmortality in patients with HIV infection. Although treatment
with pegylated interferon (PEG-IFN) and ribavirin has
signiﬁcantly improved the outcome, HCV co-infection remains
a major threat for HIV patients. Recent ﬁndings suggest that
treatment of HCV infection in its acute phase may be very
successful, but no data are available on acute infection in HIV-
positive patients.We report fourHIV-positive patientswith acute
C hepatitis treated with PEG-IFN alpha-2b for 12 weeks.
Methods: Inclusion criteria were documented seroconversion,
positive HCV-RNA and elevated ALT levels with a known risk
factor in the preceding 6 month in patients with HIV infection,
naı¨ve for antiretroviral therapy, with the CD4 cell count >400/
mm3. Patients received PEG-IFN alpha-2b ranging from 1.1 to
1.5 lg/Kg once weekly for 12 weeks. ALT, CD4 cell count,
HCV-RNA and HIV-RNA measurements were made at week
0, 1, 2, 3, 4, 8, 12, and 24 weeks after the end of treatment. The
primary endpoint was the sustained viral response (SVR).
Monitoring of critical HIV immuno-virological parameters was
also performed.
Results: Two patients had HCV genotype 1. Risk factors for
HIV and HCV transmission were intravenous drug use (50%)
and sexual exposure (50%). At baseline, median HCV-RNA level
was 1.478.000 copies/mL (range: 3.200–7.600.000); the median
HIV-RNA level was 50.000 copies/mL (range: 20.000–2.600.000).
Treatment was given within 120 days (range: 30–120) of the ALT
level peak. At week 4 HCV-RNA was undetectable in all
patients but one, who never had a negative HCV-RNA. SVR was
achieved in three patients. The non responder patient received a
lower interferon dosage. At week 1 there was a mean decrease of
HIV-RNA of 0.6 log10, which did not change until the end of
therapy. No signiﬁcant decrease of CD4 cell count was observed.
Conclusions: Treatment with PEG-IFN administered for 12
weeks is effective, well tolerated and is not associated with any
signiﬁcant change of HIV infection parameters. As also seen in
other settings, higher PEG-IFN dosage may be associated with
SVR. According to recent studies the treatment of acute C
hepatitis can provide a unique opportunity for a sustained
control of HCV infection in HIV patients.
O66
High diversity in the interferon sensitivity
determining region of HCV genome in HCV/
HIV-coinfected patients
A. Pen˜a, N. Martinez, J. Casado, J. Parra-Ruiz, B. Valero,
F. Lozano, P. Mun˜oz de Rueda, J. Salmero´n,
J. Herna´ndez-Quero, F. Garcı´a (Granada, Seville, E)
Background: Mutations in the Interferon Sensitivity
Determining Region (ISDR) in the NS5a of HCV genome have
been related in some studies with an increased response to
Interferon+ribavirin (IFN+RBV) therapy. Little information on
PegIFN plus RBV therapy has been developed and, to our
knowledge, none on HCV/HIV-coinfected patients undergoing
combination therapy.
Aim: To investigate the differences between HCV/HIV-
coinfected and HCV-monoinfected patients in terms of ISDR
variability and its predictability over response to PegIFN plus
RBV treatment.
Patients and Methods: ISDR was investigated by means of an
in house protocol: RNA was extracted with Quiamp Viral RNA
Kit (Quiagen), and subjected to an RT-PCR with ‘ONE STEP RT-
PCR System’ (Roche), subsequently, a nested-PCR was
performed. Speciﬁc primers were used for genotypes 1a, 1b
and 3. ISDR sequences were obtained using the Open Gene
System (Bayer). The study included 69 patients: 47 were HCV/
HIV-coinfected and 22 were HCV-monoinfected. Baseline
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characteristics were similar amongst groups, except for sex
(male 83% in coinfected, against 54% in HIV negative patients)
and HCV genotype: for HCV/HIV-coinfected patients, 23 were
genotype 3a and 24 were genotype 1 (8 1b and 16 1a). All HCV-
monoinfected patients were by genotype 1 (17 1b and 5 1a).
Results: For the genotype 1 population, ISDR mutations were
statistically more prevalent for HCV-monoinfected patients than
for HIV-coinfected patients: only 2/24 (8%) coinfected patients
harboured wild-type viruses while 9/22 (41%) of the
monoinfected patients were wild type in the ISDR (p = 0.01).
According to ISDR scorage (intermediate: 1–3 mutations;
mutant > 3 mutations), no mutant ISDR strains were recorded
for the monoinfected group while 2/24 (8%) from the coinfected
group were mutant strains (p = 0.02). Sustained viral response
(SVR) is available so far for 16 coinfected and for all the
monoinfected patients: the number of mutations in the ISDR
was statistically related to SVR only in the monoinfected group
(p = 0.023). For genotype 3a coinfected patients, ISDR mutations
were as follows: 15 wt, 4 intermediate and 4 were mutants; no
relationship between ISDR mutations and a SVR was observed
for these patients.
Conclusions: ISDR in HCV1a and HCV1b from HIV-coinfected
patients shows a higher variability than HCV-monoinfected
patients. SVR was associated with higher number of mutations
in ISDR region only in HIV negative patients.
O67
Mortality in a cohort of hepatitis C patients
S.E. Ramsay, K.R. Neal on behalf of the Trent Hepatitis C Study
Group
Objectives: Hepatitis C infection forms a signiﬁcant burden of
mortality as a result of severe liver disease and liver cancer. The
aim of this study was to describe the pattern of mortality in a
cohort of hepatitis C patients.
Methods: The cohort comprised of hepatitis C patients of the
Trent region of UK and has been followed up since 1991.
Subjects were recruited through secondary care referrals such as
from general practice clinics, drug and alcohol clinics, and
prisons. As of 1st January 2004, information on mortality for
1345 patients was available from death certiﬁcates sent by the
National Health Service Central Register. Descriptive statistics
and survival analysis were used to describe the mortality
patterns.
Results: 8.3% of the cohort died during the follow-up period of
13 years. The approximate probability of surviving after 6 years
of follow-up was 93% and after 10 years was 89%. The mean
survival time was 6.47 years (standard deviation 2.73). The
mean age at death was 50.95 years (standard deviation
15.68 years). The causes of death in the cohort were grouped
into three categories – HCV related from liver disease, HCV
unrelated from other medical problems such as cardiac diseases,
and lifestyle factors like drug overdose, suicide and murder.
Most subjects (40%) had died from HCV related liver disease
while 37% died from unrelated medical causes. 22% of deaths
were attributable to lifestyle factors such as injecting drug
overdose, suicide and murder. The highest percentage (42%) of
death was in the younger age group 36–50 years. Younger
subjects (under 50 years) died mostly due to lifestyle related
causes while maximum HCV related deaths were in 51–65 year
olds (p < 0.001). Deaths unrelated to HCV infection occurred
mostly in those over 65 years old.
Conclusions: There are two striking ﬁndings of this study on
mortality in a highly representative sample of HCV patients.
Firstly, majority of deaths occurred in the 36–50 years age group
and not in older subjects. Secondly, many young people died as
a result of drug overdose and suicide. This higher mortality in
younger subjects could be explained by the confounding effect
of injecting drug use which was the main route of infection in
these subjects. Thus, deaths in HCV patients could thus result
not only from liver disease but also from factors related to their
lifestyle.
O68
Arthritis associated with chronic hepatitis C virus
infection
J.A. Bernal, M.A. Escobar, A.A. Garcia-Egido, F.J. Fernandez,
S.P. Romero, D. Garcia-Gil, P. Ruiz, A. Michan, F. Bricen˜o,
F. Gomez (Cadiz, E)
Introduction: Arthritis is one of the numerous manifestations of
hepatitis C virus infection (HCV).
Objectives: To determine the prevalence of HCV in patients
presenting with chronic peripheral inﬂammatory arthritis
(CPIA) and, the clinical forms of CPIAs associated with HCV
in a 425 beds teaching hospital reference of the Bay of Cadiz
(over 250,000 inhabitants).
Methods: Prospective case-control study in 1687 patients
presenting with CPIA as their predominant symptom
(excluding cristal induced and degenerative arthritis), mean
age (±SD) 47.6 ± 17.3 years, 64% of them women (n = 1080).
Control groups: 643 consecutive patients with non-inﬂammatory
chronic arthritis (NICA), and 4315 consecutive ﬁrst time blood
donors (BD) matched for age and sex. HCV status was
determined (3rd generation ELISA conﬁrmation by RT-PCR,
and HCV genotype).
Results: The prevalence of HCV antibodies (5.6%) in patients
with CPIA was higher than that in patients with NICA (2.6%) or
BD (0.88%) (p < 0.01 in both cases). The prevalence of chronic
HCV infectionwas higher in patientswithCPIA (4.3%) than in BD
(0.88%). The prevalence of chronic HCV infection by ﬁnal
diagnosis as compared to BD was: 3.1% for Rheumatoid arthritis
(RA) (p < 0.01), 6.4% for seronegative RA (p < 0.005), 11.9% for
intermitent mono-oligoarthritis (p < 0.001), 6.0% for Sjo¨gren’s
syndrome (p < 0.005), and9.8% for systemic lupuserythematosus
(p < 0.001). The prevalence of chronic HCV infection in psoriasic
arthritis, seronegative spondyloarthropathies, and other ﬁnal
diagnosis was not different than that in BD. CPIA associated to
HCV infection was non erosive/non deforming in 76% of the
patients. Type II cryoglobulins and, decreased levels of C4/C3
were detected in 37% and 48%/22% of the patients with CPIA
associated to HCV infection, respectively.
Conclusions: An increased prevalence of HCV infection exists
in patients presenting with chronic peripheral inﬂammatory
arthritis. HCV antibodies (3rd generation ELISA) overestimates
the prevalence of HCV infection in those patients. A search for
HCV infection should be performed in the diagnostic
process of both inﬂammatory arthritis and collagen vascular
diseases.
O69
A LightCycler Real Time PCR protocol for
accurate quantiﬁcation of HCV viraemia followed
by sequencing of different genotypes
L. Tagliaferro, P. Menegazzi, M.A. De Donno, J.L. McDermott,
O.E. Varnier (Lecce, Genoa, I)
Objectives: The main objectives of this project were the
development of a rapid LightCycler Real Time PCR (RTiPCR)
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protocol for accurate quantiﬁcation of HCV viraemia, its use in
the testing of a large number of clinical samples and its cost-
effective integration in the genotyping protocol.
Methods: Serial ten-fold dilutions of two HCV RNA positive
controls (Accurun, BBI), 170,000 and 910,000 IU/ml,
respectively, were ampliﬁed and the data from the resulting
calibration curve were stored in the LightCycler database for the
quantiﬁcation of plasma HCV RNA. Clinical samples were
tested in a rapid single-tube RTiPCR reaction and cost-effective
HCV RNA quantiﬁcation was determined using one reference
standard during each assay. The quantiﬁcation obtained for the
single reference standard was validated in a comparative
analysis with the stored calibration curve followed by
interpolation of the amount of HCV RNA in the clinical
samples. HCV sequencing was directly performed using 10 ll
of puriﬁed real time PCR amplicons.
Results: A total of 2,470 plasma samples were tested from
Oct 2002 to Sept 2004. HCV RNA was quantiﬁed in 1,226
samples with a dynamic range of 57 to 2.5 · 10.9 IU/ml and
the theoretical threshold was 53 IU/ml. The standard
deviation (SD) and the coefﬁcient of variation (CV) of the
HCV RNA levels were 1.08 and 3.55% for the 170,000 IU/ml
standard and 1.34 and 4.78% for the 910,000 IU/ml standard.
In 266 samples the amplicons were puriﬁed and sequenced
for HCV genotyping (Bayer Diagnostics). Thirty ﬁve
different HCV strains were typed: the majority were
genotype 1b (36%) and 2 (30%), but genotypes 4 and 5 were
also identiﬁed.
Conclusions: Our study shows that this HCV RTiPCR
protocol, which has been used for 2 years to test over 2,000
samples with minimal SD and CV values, allows accurate
quantitation of HCV RNA in clinical samples. The
characteristics of rapidity and accuracy have been extended
to include cost-effectiveness due to subsequent use of the
amplicons for sequencing.
O70
Revaccination of non-responder infants born
from HBsAg positive mothers
M.R. Hasanjani Roushan, Y. Zahed Pasha, R. Saghebi,
F. Kohi (Babol, IR)
Objectives: Infants born from HBsAg positive mothers
who are not responding to primary vaccination schedule are
likely to develop HBV infection. The purpose of this study was
to evaluate anti-HBs response following administration of two
doses of hepatitis B vaccine in this group of infants.
Methods: From April 1998 to September 2004,Thirty-four non-
responder infants born from HBsAg positive mothers received
two additional doses of hepatitis B vaccine one month apart at
15 months of age. Anti-HBs levels in these infants were
evaluated two months after the later dose.
Results: Eighteen girls and 16 boys were evaluated in this
study. The mothers of 4 infants (11.8%) were HBe Ag positive
and in 30 infants (88.2%)were HBe Ag negative. HBs Ab
production was seen in 32 (94%) cases of vaccine recipients
(96.6%infants of anti HBe Ag positive and 75%infants of HBe Ag
positive mothers) (p = 0.225). Mean HBsAb level in girls and
boys was 232 and 215 IU/L, respectively (p = 0.142).
Conclusion: With administration of additional two doses of
hepatitis B vaccine, protective levels of anti-HBs developed in
94% of non-responder infants.
O71
Vaccination against hepatitis B in patients with
chronic renal failure – 16 year follow-up
L. Roznovsky, I. Orsagova, A. Kloudova, I. Lochman,
L. Kabieszova (Ostrava, CZ)
Objectives: Hepatitis B virus infection is an important cause of
liver disease among patients with chronic renal failure. The
vaccination against hepatitis B can considerably decrease
number of these infections. The vaccination against hepatitis B
was performed in 769 patients with chronic renal failure from 4
dialysis units. Anti-HBs antibodies response after immunisation
and breakthrough infections were investigated in these patients.
Methods: Active immunisation against hepatitis B was
commenced in 1988. The number of immunised patients
gradually increased and the group included 769 patients in
November 2004. Of these patients, 328 died during
investigation. The vaccination schedule was 0, 1, 6 months for
pre-dialysis patients and 0, 1, 2 months for dialysis patients and
patients with renal transplantation. Plasma-derived or since
1990 recombinant vaccines were administered intramuscularly,
each vaccine contained 40 lg of HBsAg, but for pre-dialysis
patients only 20 lg till 1998. The immunisation schedules were
completed in 622 patients. Blood samples were obtained 6 weeks
after third or next dose of vaccine and biannual thereafter.
Samples were tested by ELISA for HBsAg, anti-HBs and anti-
HBc. The patients without protective anti-HBs level after basic
vaccination were once or twice re-vaccinated. The patients with
vanishing of anti-HBs antibodies were also re-vaccinated.
Results: Anti-HBs antibodies after vaccination were
investigated in 488 patients. Protective anti-HBs levels were
proved in 241 of 488 patients (47%) after basic immunisation and
in 309 (63%) or 347 (71%) patients after fourth or ﬁfth dose of
vaccine. The new HBsAg positive status was proved in 28
dialysis patients, most of them suffered from acute hepatitis B.
These breakthrough infections were more frequent after
initiation of vaccination programme, 27 of them in period
1988–1994, the latest breakthrough infection was proved in 2000.
Asymptomatic infections with new appearance of anti-HBc
antibodies were observed in 11 patients. Anamnestic response
(double or higher increase of anti-HBs without revaccination)
was observed in 42 patients.
Conclusion: Vaccination against hepatitis B in 769 patients with
chronic renal failure was not quite satisfactory. Only 71% of
them developed protective anti-HBs level after 5 doses of
vaccine, but long-term vaccination considerably reduced
hepatitis B incidence in our patients.
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From mild to severe respiratory tract infection: what’s new with
azalides? (Symposium arranged by PLIVA)
S79
Single-dose treatment of respiratory tract
infections
G.W. Amsden (Cooperstown, USA)
Several pharmacokinetic studies have demonstrated that when
the same total dose of azithromycin is administered over shorter
regimens a patient’s exposure to azithromycin is actually higher
than if the dose was administered over a longer period of time.
As such, even though the 1.5 g regimen has been marketed as
both a 5-day and 3-day course patients actually have a higher
exposure to azithromycin when it is taken over 3 days. If
administered as a single 1.5 g dose, patient exposure to
azithromycin is even higher; exceeding that experienced with
either the 3- or 5-day regimens. Not only would single dose
administration of azithromycin potentially lead to more favora-
ble outcomes due to higher systemic exposures but it also has
the potential to achieve as close to perfect patient compliance as
is possible. Single-dose azithromycin was approved for the
treatment of childhood otitis media in 2003 after studies
demonstrated equal safety and efﬁcacy versus standard com-
parators such as amoxicillin/clavulanate and ceftriaxone. In
these studies, single-dose azithromycin was found to be asso-
ciated with signiﬁcantly higher compliance (vs amoxicillin/
clavulanate) and to have a clinical cure rate higher than if the
same azithromycin dose was split over 3 days or compared to
ceftriaxone. When the same concept has been applied to adults
with community-acquired pneumonia, two studies to date have
demonstrated equivalent safety and efﬁcacy of a single 1.5 g
dose vs the dose spread over 3-days or a comparable compa-
rator such as 10 days of clarithromycin. The single-dose has also
been shown to be efﬁcacious in a small study of adults with
uncomplicated tonsillitis. Based on these results, it appears that
administering single oral doses of azithromycin is a safe and
effective option for a variety of adult and pediatric respiratory
tract infections, though further study of the concept is warran-
ted. Expansion of these studies to the use of single intravenous
azithromycin doses for the treatment of hospitalised patients
with community-acquired respiratory infections should also be
considered.
S80
Treatment of CAP in ICU – an intensivist
perspective
B. Barsˇic (Zagreb, HR)
Severe pneumonia treated in intensive care units (ICU) repre-
sents a great therapeutic challenge. Usual defervescence of fever
does not occur as in other patients, particularly not in mechan-
ically ventilated patients. We evaluated 30 consecutive patients
with community acquired pneumonia admitted in the ICU.
Initial therapy was azithromycin intravenously for seven days
plus beta-lactams (ceftriaxon or penicillin). Switch to oral
treatment was possible after defervescence of fever. Treatment
was ﬁnished as planned in 25 patients. In ﬁve patients it was
stopped because of early therapeutic failure, isolation of resist-
ant pathogens or adverse drug event. However, in 10/25
patients which completed planned treatment additional antibi-
otics were added despite improvement of pneumonia because of
suspected or conﬁrmed nosocomial infection. Treatment
beta-lactams plus azithromycin was successful in 21 patients.
Analysis of duration of fever in survivors showed that only in
one patient defervescence of fever occurred after three days of
treatment. Our results suggest that randomized clinical studies
do not show exact clinical efﬁcacy of antibiotics, as observational
studies do, due to the selection of patients, even with severe
pneumonia. Evaluation of treatment effect should be based
more on meticulous estimation of respiratory function than on
parameters representing systemic inﬂammatory response or
x-ray ﬁndings.
S81
PK/PD modelling of antibiotics: the way of
maximising clinical outcome
I. Francetic (Zagreb, HR)
Optimal dosing of antibiotics depends on pharmacokinetic and
pharmacodynamic features of antimicrobials. Better under-
standing of pathophysiology of infection has brought up
interest in pharmacokinetics of antimicrobials and relationship
between PK and clinical outcome. As opposed to previous
standpoint today antimicrobials are divided in two different
cathegories, namely, concentrations dependent and time
dependent killing. However, this division into two groups
seems not to apply in total since certain groups of antimicro-
bials such as azithromycin, tetracyclines are somewhere in
between. Time over the minimal inhibitory concentration with
azithromycin and doxycycline has to be disregarded or
minimized since the persistent effects are better represented
by AUC24/MIC. This is especially relevant for intracellular
microorganisms. Cellular pharmacokinetics of azithromycin
makes the time over the MIC irrelevant since accumulation of
the azithromycin intracellulary provides concentration well
above MIC for period much longer than 24 hours. However,
this is not the case with other macrolides. In deﬁning
relationship between PK and outcome one has to take into
account the type of infection. In infections caused by intracel-
lular microorganisms cellular PK of antimicrobial is essential,
while in blood stream infections extracellular PK is important
and deﬁnes the outcome of infection providing that activity
against the causative agent is present. However, increasing the
dosing of azithromycin is likely to enhance the microbiologic
outcome especially in infections like acute otitis media (OAM)
caused by extracellular microorganisms such as non-typeable
Haemophylus inﬂuenzae (NTHI). Results from in vivo infec-
tion models and clinical trials indicate that for azithromycin
24 hour AUC/MIC ratio of 25 is associated with treatment
efﬁcacy.
S82
Additional beneﬁts of macrolides in the
treatment of community-acquired pneumonia
T.M. File (Rootstown, USA)
CAP is a common disorder that is potentially life threatening.
Optimal management of these infections requires appropriate
use of antimicrobials. Decisions concerning proper antimicrobial
therapy are guided by several considerations such as spectrum
of activity, pharmacokinetics (PK), efﬁcacy in clinical trials,
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safety proﬁle, and cost effectiveness. Because the azithromycin
is active against the key pathogens of CAP, it is particularly
useful to treat patients-either as monotherapy for mild infections
or as part of combination therapy with a beta-lactam for serious
infections. While numerous randomized clinical trials have
documented the efﬁcacy of azithromycin for the treatment of
CAP from the standpoint of clinical and bacteriological end-
points, studies have also demonstrated ‘other’ beneﬁts of this
antimicrobial. Such beneﬁts include: shorter dosing duration;
excellent safety proﬁle; decreased length of stay in the hospital;
and cost-effectiveness. The unique PK properties of azithromy-
cin, which include prolonged T1/2 and excellent respiratory
tract penetration, allow for the reduced dosing regimens. This
has several advantages that include better compliance, reduced
adverse events, quicker change from IV to po therapy in
hospitalized patients, and reduced costs. Several studies have
demonstrated an advantage of azithromycin, when used as
monotherapy in selected patients, as compared to other
antimicrobials concerning the length of stay within the hospital.
In a pharmacoeconomic study, Paladino et al. found that
azithromycin was more cost-effective as empiric therapy for
low-risk patients hospitalized with CAP compared to cefurox-
ime with or without erythromycin. In addition, several studies
have found that use of a macrolide, such as azithromycin, which
is part of an initial combination therapy for patients hospitalised
with CAP is associated with decreased mortality or shorter
hospital stay than with a cephalosporin alone. The speciﬁc
aetiology of infection was not determined in these studies,
however it is possible that the added coverage for ‘atypical’
pathogens may in part explain this observation. Additional
retrospective studies suggest the beneﬁt of this combination
therapy applies not only to CAP in general but also to CAP
speciﬁcally associated with S. pneumoniae bacteraemia. The
possible coexistence of atypical pathogens or the immunomod-
ulating effect of the macrolides may in part be responsible for
this ﬁnding.
Emerging viral infections
O88
In vitro studies on interferon-inducing capacity
and sensitivity to IFN of human severe acute
respiratory syndrome coronavirus
C. Scagnolari, G. De Vito, F. Bellomi, E. Riva, G. Cappiello,
A. Spano`, M. Clementi, F. Dianzani, G. Antonelli
(Rome, Milan, I)
Objectives: No fully effective antiviral treatment are currently
available against severe acute respiratory syndrome coronavirus
(SCOV) infection. In this study, we investigated whether
interferons (IFNs), used alone and in combination, exhibit in
vitro anti-SCOV activity. In parallel experiments we examined
the capacity of SCOV to induce human IFN alpha from
peripheral blood mononuclear cells (PBMC) of healthy donors.
Methods: Anti-SCOV (Hsr1 strain) or anti-EMC/VSV/NDV
activities of IFN alpha, beta and gamma were determined by
using CPE inhibition test in epithelial kidney monkey Vero cell
culture. Synergistic, additive or antagonistic interactions
between IFNs were evaluated using the combination index
analysis method developed by Chou & Talalay. Analysis of
transcript levels for a series of IFN alpha (1, 2, 5, 6, 8, 10, 13, 17,
21) genes were determined by Real Time PCR. Antiviral activity
of IFN secreted from PBMCs after incubation of SCOV were
determined by an EMC assay performed in A549 cell line.
Results: All the tested IFNs showed anti-SARS virus activities
on Vero cell culture but at different extent. Speciﬁcally the
results showed that, compared to EMC/VSV/NDV, SCOV
grown in Vero cell can be only moderately inhibited by
pretreatment with IFN beta. IFN alpha and above all IFN
gamma, by contrast, were less effective. We have however found
that IFN gamma synergizes with the innate IFNs (IFN alpha and
beta) to potently inhibit SCOV replication in vitro. Interestingly
incubation of PBMCs with SCOV leads to early and strong IFN
alpha mRNA synthesis. IFNs secreted from PBMCs after SCOV
stimulation possesses antiviral activity in vitro.
Conclusions: The data document the synergistic antiviral
activity of innate IFNs and IFN gamma to an extent that may
be compatible with clinical use for SARS prevention and
therapy. Moreover since IFNs are normally produced in the
ﬁrst phase of viral infections, it could be important to
understand whether and to what extent the relative low
sensitivity of SCOV to IFNs associated to its ability to induce
the production of IFN alpha may have any relevance in
determining the course of infection.
O89
A novel coronavirus, HKU1, from patients with
pneumonia
P.C.Y. Woo, S.K.P. Lau, C.-M. Chu, K.-H. Chan, H.-W. Tsoi,
Y. Huang, B.H.L. Wong, R.W.S. Poon, J.J. Cai, W.-K. Luk,
L.L.M. Poon, Y. Guan, S.S.Y. Wong, J.S.M. Peiris,
K.-Y. Yuen (Hong Kong, HK)
Objectives: To characterize and analyze the complete genome
of a novel coronavirus, coronavirus HKU1 (CoV-HKU1), from
patients with pneumonia.
Methods: We ampliﬁed a 440-bp fragment of the RNA-
dependent RNA polymerase (pol)gene of coronaviruses by
RT-PCR, using coronavirus conserved primers, from RNA
extracted from the nasopharyngeal aspirate (NPA) of a 71-year
old Chinese man with pneumonia. The complete genome of the
coronavirus (CoV-HKU1) was ampliﬁed and sequenced using
RNA extracted from the NPA as template and degenerate
primers designed by multiple alignment of the genomes of other
group 2 coronaviruses. Real-time quantitative RT-PCR was
performed to quantify the amount of virus in the NPA obtained
in the ﬁrst to the ﬁfth week of the illness. Speciﬁc antibody was
detected by Western blot assay and ELISA using recombinant
nucleocapsid of CoV-HKU1. Screening for CoVHKU1 on NPA
obtained during the SARS period was carried out by RT-PCR.
Results: RT-PCR and sequencing of the 440-bp fragment of the
pol gene showed that there were 89–91% amino acid identity
between the sequence of the fragment and those of other group 2
coronaviruses. The genome of CoV-HKU1 is a 29926-nucleotide,
polyadenylated RNA. The G + C content is 32%, the lowest
among all known coronaviruses with available genome
sequence. Phylogenetic analysis reveals that CoVHKU1 is a
new group 2 coronavirus. Quantitative RT-PCR showed that the
amount of CoV-HKU1 RNA were 8.5 to 9.6 · 106 copies per ml
in his NPA during the ﬁrst week of the illness and dropped
progressively to undetectable levels in subsequent weeks.
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He developed increasing serum levels of speciﬁc antibodies
against the recombinant nucleocapsid protein of CoV-HKU1
with IgM titres of 1:20, 1:40 and 1:80 and IgG titres of <1:1000,
1:2000 and 1:8000 in the ﬁrst, second and fourth weeks of the
illness respectively. Cultural, antigenic, RNA, or serological
detection of other microbial pathogens were negative. Screening
of 400 NPA collected during the SARS period identiﬁed the
presence of CoV-HKU1 RNA in one specimen, with a viral load
of 1.13 · 106 copies per ml, from a 35-year old woman with
pneumonia.
Conclusion: Our data support the existence of a novel group 2
coronavirus in the NPA of patients with pneumonia. Resolution
of the illness in the index patient was associated with the
disappearance of the viral RNA and the development of speciﬁc
IgG and IgM antibody response against the virus.
O90
Crimean-Congo haemorrhagic fever in the central
Anatolian region of Turkey: a report of 92 cases
N. Elaldi, M. Bakir, I. Dokmetas, M. Sencan (Sivas, TR)
Objectives: Crimean-Congo haemorrhagic fever virus
(CCHFV) belongs to the genus Nairovirus in the Bunyaviridae
family and causes a potentially fatal disease, Crimean-Congo
haemorrhagic fever (CCHF) is characterised by hemorrhage and
fever. Previously, CCHF cases have been reported in Turkey. An
outbreak of CCHF occurred in the Central Anatolian region of
Turkey during April and October 2004. We report herein 92
cases who diagnosed as CCHF during the outbreak.
Methods: Patients with acute febrile syndrome characterized by
malaise, bleeding, leukopenia, and thrombocytopenia were
admitted to our hospital (Cumhuriyet University Hospital, an
800-bed teaching hospital in Sivas city, located in the Central
Anatolian region of Turkey) during the spring and summer of
2004. Patients who had IgM antibodies or polymerase chain
reaction (PCR) results positive for CCHFV in serum samples
were included. Obtained serum samples from all patients both
acute- and convalescent-phase of the illness were sent to the
World Health Organisation (WHO) reference laboratories in
Lyon, France, and London, England to test for the presence of
CCHF virus.
Results: Ninety-two patients had immunoglobulin M
antibodies and/or PCR results positive for CCHFV in serum
samples during the outbreak. Forty-three (47%) were female and
49 (53%) were male. The mean age was 45.7 ± 2.2 (range 5–92
years). Malaise (94%), fever (91%) and muscle ache (90%) were
the most common presenting symptoms, rash (57%) and
conjunctival injection (50%) were the most common initial
clinical ﬁndings among the patients. Forty-two per cent of
patients had history of tick bite, and 80% of handling
livestock. Complete blood counts at admittance showed
thrombocytopenia in all patients leukopenia in 69 (75%),
anaemia in 11 (12%) of 92 patients. Elevated serum aspartate
aminotransferase (AST) levels were determined in 84 (91.3%),
alanine aminotransferase (ALT) in 73 (79%), and lactate
dehydrogenase (LDH) in 91 (98.9%) of 92 patients. Eighty-
seven (95%) patients were treated with oral ribavirin. Six
patients, died during the outbreak, 3 of them died because of
bleeding. The overall mortality was 6.5%.
Conclusion: Herein we report an outbreak of CCHF in the
central Anatolian of Turkey. Our CCHF cases had lower
mortality rate. It could be explained by early deﬁning of the
disease during the outbreak, supportive therapy and ribavirin
treatment.
O91
Complete L segment coding-region sequence
determination of a Russian Crimean-Congo
haemorrhagic fever virus
J. Meissner, S. Seregin, N. Yakimenko, O. Vyshemirskii,
S. Netesov, V. Petrov (New Mexico, USA; Koltsovo, RUS)
Crimean-Congo haemorrhagic fever virus is the type species of
the genus Nairovirus, family Bunyaviridae. CCHF virus is a
spherical, enveloped virus with a single-stranded, tripartite
RNA genome of negative polarity.
Objectives: The goal of this work was to establish L segment
sequences of CCHF virus laboratory isolates representative of
strains circulating in European Russia and Asia, and to compare
these sequences with partial or full-length CCHF virus L
segment sequences from Nigeria, Pakistan, and Iraq.
Materials and methods: Two laboratory-adapted CCHF virus
strains were used in this work. After total RNA extraction using
the RNeasy MiniKit (QIAGENE, Germany) RT-PCR was
performed using the Access RT-PCR kit (-Dromega, USA). The
goal of primer selection and design was to produce overlapping
amplicons of 350–700 nucleotides spanning the entire L
segment. Fragments were puriﬁed from 1% agarose gel using
the Q-Biogene GeneClean extraction kit and directly sequenced
using CEQ 2000 DTCS kit run on the CEQ 2000XL DNA
Analysis System.
Results: The large (L) segment CCHF virus strain ASTR/
TI30908 was ampliﬁed and sequenced. After removal of the 5’
and 3’ primer-generated ends, this L segment sequence is 12112
nucleotides long, and is 97% identical at the translated amino
acid level to partial or full-length CCHF virus L segment
sequences currently published or available in GenBank A
complete L segment coding-region sequence for CCHF virus
strain TADJ/HU8966 was also determined. The 30908 RdRp
ORF shares 90% nt identity with IbAr10200 and 87% nt identity
with Matin. In RdRp ORF we identiﬁed a variable region,
approximately 50-aa, corresponding to nt positions 2346–2513 in
30908, which is ﬂanked by well-conserved regions.
Discussion: This variable region serves a very useful practical
purpose for both diagnostics and phylogenetic analysis, in that
the ﬂanking conserved regions could be used for to design
ampliﬁcation primers useful for any CCHF virus, while the
internal variable region sequence, provided it is variable
enough, can be used for classiﬁcation and molecular
epidemiology.
O92
Analysis of the mortality among the patients with
Crimean Congo haemorrhagic fever virus
infection
A. Celikbas, O¨. Ergonul, N. Baykam, S. Eren, H. Esener,
B. Dokuzoguz (Ankara, TR)
Objective: To determine the causes and predictors of mortality
among Crimean Congo Haemorrhagic Fever (CCHF) virus
infected patients.
Method: Fifty-four patients with Crimean-Congo
haemorrhagic fever (CCHF) were analysed for the causes of
mortality. Forty-one patients had positive results of IgM, and/
or IgG, and/or PCR results for CCHF virus in blood or tissue.
Thirteen patients are highly suspected cases, and their
conﬁrmation is pending.
Results: Fifty-four patients were included, and 4 died. The
overall case fatality rate (CFR) was 7.4%. Forty-eight per cent
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of the patients were male. The age, gender, and days from
symptoms to admission were similar between survived and
died patients (p > 0.05). Among the clinical ﬁndings,
hematemesis (p = 0.009), melena (p = 0.001), and somnolence
(p = 0.022) were signiﬁcantly more common among died
patients. The rate of the other symptoms and signs such as
nausea-vomiting, diarrhoea, and maculopapular rash were
similar in both groups. Among died cases, the median
platelet count was signiﬁcantly lower (10 600/ml versus 20
000/ml, p = 0.038), mean prothrombin time (27 sec vs 16 sec,
p = 0.002), and mean activated partial thromboplastin time
were longer (73 sec vs 44 sec, p < 0.001), and the mean ALT
(1125 vs 331, p £ 0.001), and mean AST (3118 vs 913, p = 0.004)
were higher. Serum IgM and IgG positivity against CCHF
virus was detected in 33% and 0% of died cases, whereas 93%
and 68% of survived cases, respectively. PCR positivity was
detected in 100% of died cases. Twenty-ﬁve patients (46%)
were intended to be given per oral ribavirin, but 3 among these
couldn’t get the drug because of gastrointestinal bleeding and
somnolence. These three patients and the one who did not get
ribavirin died.
Conclusion: The lack of antibody production against CCHF
virus infection was observed as a strong indicator of mortality.
Gastrointestinal bleeding and somnolence could be the reason
for the ineffectiveness of oral ribavirin. Intravenous ribavirin
should be given to the severe cases.
Advances in febrile neutropenia
O93
Inﬂuence of Mannan binding lectin serum levels
on the risk of infection during chemotherapy-
induced neutropenia in adult haematological
cancer patients
M. Vekemans, A. Georgala, C. Heymans, F. Muanza,
M. Paesmans, J. Klastersky, M. Barette, N. Meuleman, F. Huet,
O.J. Robinson, O. Marchetti, T. Calandra, S. Costantini,
A. Ferrant, K. Petersen, M. Axelsen, M. Aoun (Brussels, B;
Lausanne, CH; Copenhagen, DK)
Background: Mannan Binding Lectin (MBL) is a C-type serum
lectin produced by the liver and involved in innate immune
response. Low level serum MBL concentration constitutes a risk
factor for infection in pts receiving myelo-suppressive
chemotherapy. Substitutive therapy methods are under
development and will be tested in the future.
Methods: We conducted a prospective observational study
focusing on assessment of MBL as a risk factor for infection.
All pts with haematological malignancy hospitalized for
administration of at least one chemotherapy cycle, between
December 2001 through December 2003 were eligible for the
study. Serum MBL concentration was measured by a Time
Resolved Immune Fluoro-Metric Assay method. Deﬁciency was
deﬁned using serumMBL levels or MBL genotypes according to
a pre-deﬁned algorithm. Outcomes considered included the
occurrence of febrile (N), severe infection (sepsis, pneumonia,
bacteraemia or invasive fungal infection), bacteraemia, and the
time to ﬁrst development of one of these outcomes, from
enrollment and across the cumulative cycles for each patient. We
used logistic regression models for analyzing binary outcomes
(and Fisher exact tests); Kaplan-Meier estimates and logrank
tests for analyzing time to event variables
Results: 255 pts who received 569 cycles of chemotherapy were
analyzed with a median number of received chemotherapy
cycles of 1. Median number of days of (N) per cycle was 7 days
(inter-quartile range 0–13).62 pts (24%) were considered as MBL
deﬁcient. 200 pts developed, at least once, febrile (N). No
difference in the occurrence of febrile (N) per cycle or per pt
between deﬁcient and non deﬁcient pts was observed. On
pt-based analysis, there was a rate of severe infections in MBL
deﬁcient pts (1.96 per 100 days versus 1.34 per 100 days,
p = 0.008) on the overall group of pts; this impact was even
increased on the subgroup obtained by excluding acute
leukaemic pts. On cycle-based analysis, MBL deﬁciency was
associated with a trend to a higher rate of severe infection (13/72
(18%) vs 20/194 (10%); OR 1.92 [95%CI 0.90–4.09]; p = 0.09),
excluding pts with acute leukemia’s and BMT pts. On that
subgroup, MBL deﬁciency was also associated with a greater
rate of bacteraemia (14% versus 5%, p = 0.01).
Conclusion: These results show that MBL deﬁciency is
associated with earlier and more severe infections in adult
haematological cancer pts with chemotherapy-induced(N). The
association was strengthened when acute leukaemic pts were
excluded from the analysis
O94
Resurgent Gram-negative infections are not
associated with increased morbidity and
mortality in high-risk neutropenic inpatients
with haematological malignancies not receiving
ﬂuoroquinolone prophylaxis
O.J. Robinson, T. Calandra, F. Bally, O. Marchetti (Lausanne, CH)
Background: Since the late 1980s, ﬂuoroquinolone (FQ)
prophylaxis is often used to reduce the incidence of
G- infections in neutropenic cancer patients. However, while it
is unclear whether it reduces morbidity and mortality,
FQ prophylaxis has been associated with the emergence of
FQ-resistant G-. Therefore this preventive measure was
promptly discontinued in our hospital. Yet, investigators have
argued about the appropriateness of stopping prophylaxis in
light of recent reports of high mortality of G- infection among
patients not receiving FQ (ICAAC 2004 Abstract K-1436).
Objectives: To assess the morbidity and mortality of
G- infections in high-risk neutropenic inpatients with
haematological malignancies not receiving FQ prophylaxis.
Methods: Prospective observational study of all consecutive
adult neutropenic inpatients undergoing intensive
chemotherapy +/) autologous stem cell transplantation for
haematological malignancies between April 2002 and August
2003. Patient management according to IDSA guidelines
(Hughes, CID, 2002). Febrile episodes (FE) were classiﬁed as
microbiologically (MDI) or clinically (CDI) documented
infections and fever of unknown origin (FUO) (ICHS, JID,
1990). Severe sepsis/septic shock were deﬁned according to
ACCP-SCCM (Bone, Chest, 1992).
Results: 208 FE occurred during 134 episodes of neutropenia in
96 patients with acute leukemia (53), lymphoma (20), and
myeloma (23). Median days of neutropenia: 16 (3–114). MDI
with and w/o bacteraemia occurred in 49 (24%) and in 20 (9%),
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respectively, CDI in 74 (36%), and FUO in 65 (31%) of the FE.
Among 56 bacterial bloodstream isolates, 29 (52%) were
G- (E.coli 10, Klebsiella 9, Pseudomonas 1, other 9) and 27
(48%) G+ (CNS 14, streptococci 7, other 6). Empirical
antibacterial treatment was appropriate according to sus-
ceptibility testing in 26/29 (90%) G- (3 E. coli ESBL) and in
17/27 (63%) G+. Severe sepsis occurred in 5/208 (2%) FE
(1 E.coli ESBL bacteraemia, 3 CDI, 1 FUO), and septic shock was
not observed. Overall in-hospital mortality in the entire study
population was 0%.
Conclusion: Gram-negative bacteria accounted for 50% of
bloodstream infections in high-risk febrile neutropenic patients
not receiving ﬂuoroquinolone prophylaxis. However Gram-
negative infections were associated with low morbidity and zero
mortality arguing against the need for prophylaxis in high-risk
hospitalized patients with haematological malignancies.
O95
Haematological malignancies and bacteraemia.
The impact of malignancy type and microbial
agent on 30-day mortality
M. Nørgaard, H. Larsson, G. Pedersen, H.C. Schønheyder,
H.T. Sørensen (Aalborg, A˚rhus, DK)
Objectives: To examine the variation in mortality of
bacteraemia in patients with different haematological
malignancies and examine the prognostic impact of the
different types of bacteraemia.
Methods: We conducted a population-based cohort study and
included all patients >14 years living in North Jutland County,
Denmark with a new diagnosis of a haematological malignancy
registered in both the Hospital Discharge Registry and the
Danish Cancer Registry from 1992–2002. The patients with
bacteraemia were identiﬁed in the Bacteremia Research
Database. Mortality within 30 days was determined through
the Central Population Registry. Cox proportional hazard
regression analysis was used to compare mortality rates
between the major groups of haematological malignancies
using acute myeloid leukemia as reference and between Gram-
positive (reference group), Gram-negative, and polymicrobial
bacteraemia or fungaemia. We adjusted for age, gender,
comorbidity, calendar time, and whether or not the empiric
antibiotic therapy was appropriate.
Results: In total 1666 patients were registered with a new
haematological malignancy and 358 (21%) of these had a
successive episode of bacteraemia yielding an incidence rate on
96 bacteremias per 1000 person years. Overall 30-days
cumulative mortality rate was 0.32 (95% conﬁdence interval
(CI): 0.27–0.37). Compared with acute myeloid leukemia the
adjusted mortality rate ratios (MRR) for 30 days of follow-up
were for Hodgkin’s disease 1.3 (95% CI: 0.3–4.2), for multiple
myeloma 1.0 (95% CI: 0.5–1.9), and for non-Hodgkin
lymphoma or chronic lymphocytic leukemia 0.7 (95% CI: 0.4–
1.1). Gram-positive organisms caused 35% and Gram-negative
organisms 50% of the bacteremias. Fifteen % were
polymicrobial or caused by yeasts. Gram-negative
bacteremias did not have a substantially increased risk
compared with Gram positive bacteremias (adjusted MRR 1.1
(95% CI: 0.7–1.6)). Adjusted MRR for polymicrobial
bacteremias or fungaemias compared with Gram-positive
bacteremias was 2.4 (95% CI: 1.3–4.1).
Conclusion: The 30-day mortality of bacteraemia showed little
variation according to the underlying type of haematological
malignancy. Polymicrobial bacteremias and fungaemias had the
poorest prognosis whereas Gram-positive and Gram-negative
bacteremias had similar impact on mortality.
O96
Antibiotic prophylaxis of bacterial infections in
afebrile neutropenic patients following
chemotherapy. Systematic review and
meta-analysis
A. Gafter-Gvili, A. Fraser, M. Paul, L. Leibovici (Petah Tikva, IL)
Background: Bacterial infections are major causes of morbidity
and mortality among neutropenic cancer patients. Antibiotic
prophylaxis has been shown to reduce bacterial infections but
not overall mortality, thus current guidelines do not advise its
use.
Methods: Systematic compilation of all randomised trials
comparing antibiotic prophylaxis vs. no prophylaxis; and
different types of prophylaxis. The search included Medline,
Embase, The Cochrane Library, conference proceedings and all
references. No date, language, age or publication limits were
imposed. Data were extracted independently by two reviewers.
Meta-analyses were performed for each comparison. Relative
risks with 95% conﬁdence intervals were calculated using the
ﬁxed effect model.
Results: Comparing prophylaxis to no prophylaxis (51 studies
4379 patients), a highly signiﬁcant reduction in overall
mortality with prophylaxis was found, RR0.67 (0.55–0.81).
Prophylaxis also signiﬁcantly decreased infection-related
mortality, RR0.58 (0.45–0.74); the occurrence of fever, RR0.79
(0.75–0.82); clinically documented infections, RR0.64 (0.59–
0.71); microbiologically documented infections, RR0.54 (0.49–
0.60); and bacteraemia, RR0.52 (0.46–0.59). Development of
resistance to intervention drug was signiﬁcantly more frequent
in the intervention arm with trimethoprim-sulfamethoxazole
(TMP-SMZ), RR2.42 (1.35–4.36), but not with quinolones,
RR1.69 (0.73–3.92). Comparing different types of prophylaxis
(44 studies 5023 patients), systemic antibiotics were superior to
nonabsorbables, quinolones were superior to TMP-SMZ, and
additional antibiotics directed against gram-positive bacteria
(GP) did not enhance efﬁcacy of quinolones alone (table). In
trials in which quinolones were compared to TMP-SMZ, less
resistance developed to quinolones in the quinolone arm than
to TMP-SMZ in the TMP-SMZ arm, RR0.45 (0.27–0.74).
Quinolone efﬁcacy was not associated with study years. Most
trials included adults with haematological malignancies (64
trials were restricted to haematological cancer patients). Nine
trials included >80% patients with solid tumors. Prophylaxis
was given for up to 6 weeks.
Conclusions: Compilation of an extensive amount of evidence
derived from randomised trials convincingly demonstrates that
antibiotic prophylaxis reduces overall mortality within the
timeframe of one chemotherapy course. In light of the present
ﬁndings systemic prophylaxis should be considered for routine
use in neutropenic patients.
All cause mortality Febrile episodes
Clinically documented
infections Adverse events
Comparison RR
(95 % Cl)
Studies
(patients)
RR
(95 % Cl)
Studies
(patients)
RR
(95 % Cl)
Studies
(patients)
RR
(95 % Cl)
Studies
(patients)
Quinolones vs.
TMP - SMZ
1.07
(0.66–0.72)
10 (917) 0.95
(0.86–1.04)
10 (931) 1.33
(1.06–1.66)
10 (931) 0.74
(0.63–0.87)
10 (1027)
Quinolones
plus GP vs.
quinolones
1.23
(0.66–2.30)
9 (1232) 1.05
(0.98–1.12)
8 (1133) 1.01
(0.79–1.30)
7 (1093) 1.94
(1.28–2.94)
6 (516)
Non-absorbable
vs. systemic
1.06
(0.74–1.50)
8 (813) 1.06
(1.00–1.13)
8 (808) 1.11
(0.95–1.31)
10 (862) 1.23
(1.01–1.50)
10 (934)
Systemic plus
non-absorbable
vs. systemic
0.9
(0.34–2.38)
2 (83) 0.93
(0.72–1.20)
2 (103) 0.54
(0.25–1.15)
1 (63) 1.75
(1.02–3.00)
3 (146)
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Antibiotic monotherapy for the empirical
treatment of febrile neutropenia. Systematic
review and meta-analysis
M. Paul, D. Yahav, A. Fraser, L. Vidal, L. Leibovici
(Petah Tikva, IL)
Background: Broad-spectrum antibiotic monotherapy has
become standard empirical treatment for febrile neutropenia.
Several monotherapy options are recommended differing
possibly in antibacterial spectrum, resistance induction, and
adverse events. We conducted a systematic review of trials
comparing these monotherapies.
Methods: We included randomised controlled trials comparing
different beta-lactams (BLs) for febrile neutropenia.
Combination with a glycopeptide (GP) in both arms was
permitted. We searched the Cochrane Library, Medline,
Embase, Lilacs, FDA and pharmaceutical company documents,
conference proceedings and all references. No date, language,
age or publication limits were imposed. Two reviewers
extracted data supplemented by contact with authors
independently. Outcomes for ﬁrst episode by intention to treat
were extracted. Relative risks and 95% conﬁdence intervals are
reported.
Results: Cefepime was compared to other antibiotics in 17 trials
including 3144 patients. Overall 30-day mortality was
signiﬁcantly higher with cefepime than with comparator drugs
RR1.58 (1.09–2.31, ﬁgure). Ceftazidime was the comparator in
most trials. We did not ﬁnd a disadvantage to cefepime with
regard to infection-related mortality, treatment failure or
modiﬁcations, microbiological failure and adverse events.
Bacterial super-infections were more frequent in the cefepime
arm RR1.70 (0.94–3.09). Comparing carbapenems to other BLs
(19 trials, 4600 patients) the advantage to carbapenems in overall
mortality was not signiﬁcant RR0.86 (0.58–1.28), as for other
efﬁcacy outcomes. GPs were added more frequently to
comparators, RR0.83 (0.70–0.99), while anti-fungals were
added more frequently to the carbapenem arm, RR1.14 (0.94–
1.38). Adverse events were signiﬁcantly more frequent with
imipenem (500 mg qid), including seizures, RR3.21 (1.04–9.88).
Piperacillin-tazobactam (PT) was assessed in 5 trials, 973
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patients. Success without modiﬁcation was more frequent when
compared to cefepime RR0.88 (0.77–1.00). Other outcome
comparisons were small and differences were non-signiﬁcant.
Conclusions: We found that overall mortality is signiﬁcantly
higher with cefepime when compared to other monotherapies.
Recommendations for its use should be reconsidered and this
ﬁnding investigated further. Mortality may have been due to
increased super-infection rates. No advantage justifying
empirical use of carbapenems over ceftazidime or PT was
found. Data for PT are limited.
The impact of beta-lactamases on clinical practice
S101
The impact of beta-lactamases on the
management of community-acquired infections
R. Canto´n (Madrid, E)
During the last decade extended spectrum beta-lactamase
(ESBL) producing isolates were epidemiologically linked to
nosocomial outbreaks whereas few isolates were encountered
in the community setting. These isolates were recognized to
produce ESBLs belonging to TEM or SHV families and they
were mainly identiﬁed in Klebsiella pneumoniae and to a lesser
extent in Escherichia coli isolates. Risk factors for the acquisition
of infections due to these isolates included admission to
intensive care units, recent surgery, urinary catheterization,
prolonged hospitalization and previous beta-lactam and/or
aminoglycoside exposure. Nowadays, an outburst of ESBL
producing isolates, mainly E. coli with different CTX-M
variants, has been recognized in the community. Complex
population structures have been identiﬁed in different coun-
tries with high clonal variability and coexistence with the
spread of speciﬁc clones. In these isolates, co-resistance with
ﬂuoroquinolones is a general feature rather than exception.
This fact has been suggested to play an important role in the
dispersion of these isolates in the community. On the other
hand the insertion of blaCTX-M genes in different genetic
environments (ISEcp1, In60 like structures) participating in
horizontal gene transfer processes may has also facilitated the
spread of these genes and these enzymes producing isolates.
Recent recognition of frequent fecal carriage of healthy volun-
teers and out-patients with ESBL producing isolates depicts
future increase of these isolates in the community. Moreover
the accumulation of different blaESBL-genes in bacterial pop-
ulations, co-existence with other beta-lactamases, including
cephamycinases, the recognition of extended-spectrum beta-
lactamase variants with carbapenemase activity, and the
association of certain blaESBL genes with new recognized
resistance genes like qnr represents new threats in the antimi-
crobial resistance scenario. Intervention strategies to control the
spread of these isolates in the community are limited for the
frequent exhibited multirresistance phenotype and the absence
of efﬁcient oral alternatives for the management of infections
due to ESBL producing isolates.
The year in HIV medicine
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The year in HIV medicine
J. Lundgren (Hvidovre, DK)
This session will focus on a discussion on recent publications
related to the management of HIV. The following topics will be
included: 1. Virology: Evolutionary pathways and how antiret-
roviral therapy (ART) affects this. Response to ART according to
which of the viral subtypes the patient is infected with. 2. Effect
of ART: New strategies, newer generation of drugs from the
three main drug classes and new drug classes to manage
patients harbouring HIV fully susceptible to all types of ART
and patients harbouring HIV that has varying degrees of
diminished susceptibility. When using ART, setting altered
aims than complete viral suppression for patients harbouring
HIV with widespread decreased susceptibility. 3. Adverse
effects of ART: Emerging knowledge on metabolic toxicities
associated with the use of ART. What are the mechanism of
actions. Which drugs and drug classes are responsible? Indi-
vidual patient management. 4. Use of ART in patients
co-infected with hepatitis viruses. What is the extend of the
problem? Can the hepatitis virus infection be cured? 5.
Epidemiology: Assessing the risk of turning a fully drug
susceptible HIV epidemic to a multi-drug resistant epidemic
from widespread introduction of ART within a population. How
effective can the introduction of ART within a population expect
to attenuate the risk of transmission. 6. Vaccine development.
How effective is the prime-boost approach to enhance anti-HIV
cytotoxic T-lymphocyte (CTL) response. Which level of CTL
response is required for clinical protection?. A listing of the
publications to be reviewed will be available at the start of the
session.
Coping with the severe acute respiratory syndrome
S107
The SARS Accelerated Vaccine Initiative (SAVI)
and the search for a SARS vaccine
R.C. Brunham, B. Finlay on behalf of the SAVI research team
Canada was the most affected nation outside of Asia following
the worldwide spread of SARS in 2003. Over 42% of the 251
cases occurred in healthcare workers and the rapid development
of a vaccine was deemed an urgent public health priority for
Canada. A novel research management structure called SAVI
was developed in May 2003 and was predicated on accelerating
vaccine research by parallel processing of multiple science
projects. During 18 months of operations SAVI developed and
evaluated 3 key vaccine strategies including whole killed virus
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(WKV), recombinant spike protein and viral vectored vaccines
for SARS CoV. Two vaccines (WKV and adenovirus vectored)
were compared head to head in two animal models (B129 mice
and outbred ferrets). Overall WKV vaccine with or without
alum adjuvant generated substantial neutralizing antibody titres
and reduced viral shedding in the upper and lower respiratory
tract of SARS CoV challenged experimental animals. WKV
vaccine appeared more efﬁcacious than adenovirus vector
vaccines expressing the S and N genes. Nonetheless, inﬂamma-
tory pathology occurred in the lungs of experimental animals
following challenge despite favorable serological and virological
response to vaccine.
Conclusion: The results suggest that human trials with WKV
vaccine should proceed with caution.
Supported by: A grant in aid to the Michael Smith Foundation
for Health Research from the government of British Columbia
and by the CIHR.
Advances in foreign body infections
S108
Improved methods for detection of
microorganisms in bioﬁlms
A. Trampuz (Basel, CH)
Background: Implant-associated infections are typically caused
by attached microorganisms growing in bioﬁlms. These
microbes are enclosed in an extracellular matrix and are
organized in complex communities with structural and
functional heterogeneity, resembling multicellular organisms.
Existence within a bioﬁlm represents a basic survival
mechanism by which microbes resist against external
(antimicrobial agents) and internal environmental factors (host
immune system).
Challenge: Depletion of metabolic substances or waste product
accumulation in bioﬁlms causes microbes to enter a slow- or
nongrowing (stationary) state, in which they are less susceptible
to growth-dependent antimicrobial agents. These characteristics
make bioﬁlm microbes not only more resistant to antimicrobial
killing as compared to planktonic bacteria, but also more
difﬁcult to detect. As a consequence, implant-associated
infections are often difﬁcult to diagnose with routine
microbiological methods.
Routine diagnostic methods: Increased synovial ﬂuid cell
count and presence of acute inﬂammation in periprosthetic
tissue correlate well with infection, however, the causing
microorganism cannot be identiﬁed with this method. Gram
staining has usually a low sensitivity. Periprosthetic tissue and
synovial ﬂuid cultures are frequently used as the reference
standard for diagnosing infection, however, they do not have an
ideal sensitivity and speciﬁcity. New diagnostic methods
directed to identify microbes in bioﬁlms are needed.
Potential new methods: By dispersing adherent bacteria from
the surface and disrupting their multicellular structure, the
recovery efﬁciency of diagnostic assays may be increased.
Various potential strategies to dislodge microbial bioﬁlms
from surfaces have been used in research setting, including
mechanical (sonication, vortexing, shock waves), biochemical
(enzyme treatment), and electrical approaches. To date, mostly
ultrasound has been studied for improvement of recovery of
bioﬁlm microbes. In addition, cultures may be false-negative
because of prior antimicrobial exposure, a low number of
organisms, inappropriate culture media, or fastidious or atypical
organisms. Therefore, molecular (culture-independent) methods
may be used to improve the diagnosis of infection, for example
broad-range 16S rDNA PCR.
S109
Foreign body infections: when can we save the
implant?
A. Widmer (Basel, CH)
Foreign body infections continue to challenge current diagnostic
and therapeutic options. Orthopedic device related infections
(ODRI) such as hip prostheses or ﬁxation devices poorly
respond to antimicrobial therapy and frequently require
removal to cure the infection. Routine susceptibility testing do
not predict cure. However, susceptibility testing against station-
ary-phase and adherent bacteria correlated well with the
outcome in the ODRI guinea-pig animal model (Widmer AF.
JID 1990). Representative pathogens have been tested from
patients suffering from ODRI, and were treated according to a
standard regimen (Zimmerli W. NEJM 2004). Data from patients
were generated by full chart review from patients hospitalized
between 1994–2003. Strains were tested with standard MIC,
MBCs against bacteria in logarithmic and stationary phase of
growth. Early ODRIs deﬁned as signs and/or symptoms of
infection not longer than 1–3 months can be cured without
removal of the device, given the antibiotic is active against the
pathogen even in these sophisticated tests, an appropriate
debridement is performed and treatment duration is prolonged
to 3–6 months. Multiresistant pathogens in ODRIs are a new
challenge: Their treatment regimens remains poorly deﬁned,
and removal of the device is deemed necessary because
sufﬁcient evidence by in-vitro and in-vivo tests are still lacking.
Paediatric infections
O110
Borna disease virus infection in early childhood,
a potential risk for developing brains
L. Bode, T. Scholbach, A.M. Patti, M. Vetterlein,
H. Ludwig (Berlin, Leipzig, D; Rome, I)
Objectives: For the ﬁrst time, the infection prevalence of children
with Borna disease virus (BDV), an unusual neurotropic virus of
humans and animals, has been addressed in Germany (D) and
Italy (I) monitoring 2000 children of all ages.
Methods: BDV infection is detectable in blood. Plasma samples
were investigated for BDV-speciﬁc immune complexes (BDV-
CIC) by novel ELISA tests which use two monoclonal antibodies
against the major antigens (proteins N and P). BDV-CIC are
formed after periods of virus activity with antigenaemia and
subsequent antibody formation.
Results: BDV is an unique negative stranded RNA virus
targeting the limbic system of the brain. Its broad host spectrum
covers humans and companion animals. In animals, behavioural
and developmental brain disorders are conﬁrmed. Aworld-wide
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impact of BDV on humanmental health has been suggested in the
mid 1990s, when psychiatric patients’ infections were conﬁrmed
by RNA /proteins in blood cells. New infection markers, namely
BDV-CIC, estimated a fairly high BDV prevalence in healthy
adults (20–30%) vs. 90% in depressed subjects. This multi-centre
study for the ﬁrst time unravels the prevalence of BDV-CIC
through randomised cohorts of children in two European
countries. German cohorts included healthy and diseased
children (various diagnosis) (n = 770; 0–18 years) in Saxony,
Italian cohorts focused on healthy children only (n = 1224;
0–15 years), but covered eight regions of residence. In both
countries, an unexpectedly high but congruent mean prevalence
of 60% was found, double as high as shown in healthy adults.
More intriguingly, the age-dependent frequencies were congru-
ently peaking in early childhood (D:1–3 and I:1–5 years), reaching
85% (one region, D) and 75% (mean of regions, Italy). In addition,
the Italian cohorts revealed dramatic regional differences.
Conclusion: This multi-centre cross-sectional study on 2000
children provides ﬁrst evidence that BDV infects children
unnoticed very early in life, suggesting vertical transmission
as a main route. Given the high impact of BDV for behavioural
disorders in mammals, the high mean prevalence together with
accumulating frequencies in young children suggests so far
unconsidered age-dependent mental-health risks during brain
development. The results point to the need for appropriate
world-wide risk-assessment studies on BDV in children.
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Pertussis cases detected by active surveillance in
Catalonia, Spain
M. Romero, N. Carden˜osa, G. Carmona, M.R. Sala, I. Barrabeig,
M. Company, C. Planas, S. Minguell, P. Godoy, J. Cayla,
G. Codina, A. Dominguez on behalf of the Catalonian Pertussis
Working Group; Communicable Diseases Group of RCESP
Objectives: To know if distribution of cases of pertussis,
detected from reported cases’ contact study is related to age.
Methods: From May 2003 to May 2004, pertussis-suspect-cases
were reported from voluntary health care centres all over
Catalonia (6.3 million inhabitants); patients were sampled by
nasopharinx aspirate or swabs. Possible related caseswere sought
by telephone and home interview and swab sampling of suspect
household contacts. We included in the study cases that matched
the Program’s case deﬁnition: cough lasting at least 2 weeks or
cough lasting at least 1weekwith paroxysmal cough, post-tussive
vomiting, whooping or apnoea. We evaluated data from epide-
miological interviews, from epidemiological and clinical reports
and fromB. pertussis PCR and culture tests. Data were compared
using Chi-square test or Fisher’s exact test, as convenient.
Results: 160 reported cases (RC) leaded to identiﬁcation of 42
new detected cases (DC). 34 (21.25%) RC and 4 (9.52%) DC were
conﬁrmed by laboratory tests; overall, 38 (18.81%) cases were
conﬁrmed. DC were 3.4%(2) of all children under 1 year and
5.6% (1) of lab conﬁrmed; in 1–13 years, 12.5% (14) and 5.9% (1);
in 1–3 y, 13.8% (4) and 0; in 4–13 y 12% (10) and 8.3% (1); under
14y 9.4% (16) and 5.7% (2); in 14 and more years, 81.3% (26) and
66.7% (2); RC were 20.8% of all cases and 10.5% of conﬁrmed
cases. We found no statistically signiﬁcant differences by case
type (reported or detected) between age groups under 14 years;
there was signiﬁcant difference in RC and DC between under
14 years and 14 years and over age groups in the total of cases
(P < 0.0001; OR: 41.71; CI: 13.65–134.46) and also in the
conﬁrmed cases (P = 0.0246; OR: 33; CI: 4.03–270.5).
Conclusions: Although reported cases of petussis in 14 years
old and older group are few (15.8%), the proportion of cases
detected investigating household contacts is higher in this group
than in children under 14 (81.3% vs. 9.4% for the total of cases).
In order to improve the knowledge of pertussis epidemiology
and its control, its important to perform case ﬁnding in
household contacts when a case is reported.
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Epidemiology of pneumococcal carriage among
Warao children in the Delta Amacuro in
Venezuela
I. Rivera, T. Bello, B. del Nogal, M. Sluijter, D. Bogaert,
P. Hermans, J. de Waard (Caracas, VE; Rotterdam, NL)
Objectives: To determine the prevalence of nasopharyngeal
carriage and the distribution of serotypes of Streptococcus
pneumoniae in Warao children and to obtain insight in the
transmission of pneumococci in 4 distinct geographically
isolated communities.
Methods: A single nasopharyngeal swab was cultured from 202
children aged 3–60 months living in Murako(n = 40), Guayo
(n = 53), Pedernales (n = 69) and Nabasanuka (n = 40) between
March and June 2004. S. pneumoniae isolates were serotyped and
their susceptibility for penicillin assessed by disk diffusion
and E-test. The isolates were genotyped by restriction fragment
end labeling (RFEL) analysis and the data were compared with
the 26 RFEL types represented by the Pneumococcal
Epidemiology Network and approximately 1000 RFEL
genotypes present in the Dutch RFEL data library.
Results: In total, 114 pneumococcal isolates were collected.
The overall nasopharyngeal carriage rate for S. pneumoniae was
56%. All isolates were susceptible to penicillin. The most
important capsular serotypes were 23F (20.2%), 6A (18.4%). 15B
(11.4%), 6B (8.7%) and 19F (7.0%). The theoretical coverage by
the 7-valent pneumococcal conjugate vaccine was 45% when
combining the four communities (See Table 1). When including
the cross-reactive serotypes 6A and 19A the theoretical vaccine
coverage increased to 66%. The 114 isolates represented 53
different genotypes, and 71% of these isolates belonged to 20
distinct genetic clusters. The most important cluster
represented 15 isolates of serotype 23F. These isolates, which
were invariably found in Pedernales, were genetically identical
to the RFEL type 4 that was present in the Dutch RFEL data
library. Two genetically closely related RFEL clusters
representing 18 serotype 6A isolates were found in all the
communities studied. The latter two genotypes were not
present in the reference data libraries.
Table 1. Distribution of pneumococcal serotypes in 4 Warao
communities, Delta Amacuro, Venezuela
Serotypes (%)
Murako
(n = 26)
Guayo
(n = 17)
Nabasanuka
(n = 22)
Pedernales
(n = 49)
Total
(n = 114)
23F 23.1 9.1 30.6 20.2
6A 34.6 11.8 31.8 6.1 18.4
15B 7.7 23.5 9.1 10.2 11.4
6B 5.9 9.1 14.3 8.8
19F 5.9 18.2 6.1 7.0
14 7.7 5.9 6.1 5.3
11 7.7 17.7 4.1 6.1
18C 3.9 5.9 1.8
9V 11.8 1.8
10 8.2 3.5
19A 7.7 4.5 2.6
Others 7.7 12.5 18.1 14.3 12.3
VCN7-v*
(4.9 V, 14, 19F,
23F, 18Cy 68)
34.7 35.2 36.4 57.1 44.7
VCN7-v
(including 6A)
77.0 47.0 72.7 63.3 65.8
*VCN7-V 7 valent pneumococcal conjugate vaccine
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Conclusions: The prevalence of pneumococcal colonization in
the pediatric population was found to be relatively high being
56%. No resistance to penicillin was observed. Coverage by the
7-valent pneumococcal conjugate vaccine is low. The presence of
two genetically closely related clusters of serotype 6A isolates in
all the communities studied is remarkable, since these
communities are geographically very isolated, only reachable
by boat and hardly any contact between their inhabitants. The
remaining clusters were restricted to single communities,
suggesting limited, local spread of these genotypes.
O113
Clonal diversity of invasive Streptococcus
pneumoniae from Portuguese children
I. Serrano, J. Carric¸o, S. Aguiar, J. Melo-Cristino,
M. Ramirez (Lisbon, Oeiras, P)
Objective: To identify the clones responsible for invasive
disease among Portuguese children.
Methods: A recent (1999–2002) collection of 82 invasive isolates
recovered from children <6 years old in Portugal was
characterized using a combination of macrorestriction
proﬁling, using SmaI and pulsed ﬁeld gel electrophoresis
(PFGE), and multi-locus sequence typing (MLST). The
Bionumerics software was used to make UPGMA (unweighed
pair group method with arithmetic mean) dendrograms of PFGE
fragment patterns. The dice similarity coefﬁcient was used with
optimization and position tolerance settings of 1.0 and 1.5%.
Among the 18 serotypes detected, serotypes 14 (25.6%), 23F
(17.1%), 1 (12.2%), and 6B (9.8%) were the most prevalent.
Results: We found 42 sequence types (ST), including 12 novel
STs, corresponding to 27 different lineages by e-BURST analysis.
By combining the PFGE and MLST data we were able to infer
the genetic lineages of the majority of the isolates. Among
serotype 14, most isolates (16/21) were clustered with the
Spain9V-3 clone, including representatives of ST156, 557, and
the new ST790. Another cluster with 4 strains included ST15,
related to the England14-9 clone, and ST409. Among serotype
23F the majority of the isolates (12/14) were grouped into a
single cluster that included ST338, the same ST as the
Colombia23F-26 clone, and the new ST1371. Serotype 1 was
clustered into two main lineages, one including representatives
of ST306 and 228 (7/10), and the other ST304 and 350 (3/10). In
serotype 6B most isolates (5/8) were included in a cluster with
ST273 the same ST of the Greece6B-22 clone, and the new
ST1224. The other strain was ST887 related to Poland6B-20.
Among penicillin non-susceptible strains 80.5% were related to
two lineages, Spain9V-3 expressing serotypes 14 and 9V (18/36)
and Colombia23F-26 (11/36), and the remaining isolates
belonged to other internationally disseminated clones -
Spain23F-1, Greece6B-22, and Poland6B-20.
Conclusions: Representatives of 6 internationally disseminated
clones were found among invasive isolates recovered from
children <6 years old, accounting for 91.6% of the penicillin non-
susceptible isolates. The most frequent lineages were related to
Spain9V-3 (23.2%) and Colombia23F-26 (14.6%). This study
provides a baseline for detecting potential effects of the use of
the 7-valent conjugated vaccine on the distribution of individual
genetic lineages within this population.
O114
Attempt to rationalise antibiotic use in a
paediatric intensive care unit
N. Goldman, D. Biarent, C. Fonteyne, F. Otte,
A. Vergison (Brussels, B)
Objectives: To evaluate the impact of antibiotics policies in the
Intensive Care Unit (ICU) of a 170-beds pediatric teaching
hospital between 2001 & 2003. The ICU is a 16-beds medical and
surgical unit (8 intensive and 8 medium care). Antibiotic
guidelines in the ICU aimed at (1) decrease the share of broad-
spectrum antibiotics, (2) switch to narrow spectrum antibiotics
whenever possible (3) reduce the empirical treatment durations
and (4) reduce amikacin and vancomycin consumption.
Methods: Starting in march 2002, regular information was
provided on local epidemiology and antibiotic resistance
(MRSA, ESBL,) during seminars (3/year) and bedside
discussions were performed on a regular basis (minimum
twice a week) with the infectious disease specialist. Antibiotics
consumption were analyzed through pharmacy billing data.
Data were expressed in DDD/100 patient-days (PD). Broad
spectrum antibiotics included Amoxicillin-Clavulanate (AC),
Ceftriaxone, Ceftazidime, Cefotaxime, Cefepime and
Meropenem. Narrow spectrum drugs used were ﬂucloxacillin,
amoxicillin, ampicillin and penicillin.
Results: Broad spectrum antibiotics decreased from 33 to 26
DDD/100PD between 2001 and 2003. Amoxicillin-clavulanate
reduction was the most important (11 to 5 DDD/100PD).
Narrow spectrum drugs increased from 8 to 12 DDD/100PD.
Amikacin decreased from 4.2 to 1.8 DDD/100PD and
vancomycin from 8.65 to 6 DDD/100 PD. Cefuroxime
increased from 2.83 to 9.05 DDD/100PD and oral ciproﬂoxacin
from 0.7 to 1.95 DDD/100PD. Total AB consumption in the ICU
remained stable (57 DDD/100PD.
Conclusions: Antibiotic use analysis for ICU showed: (1) a
decrease in broad spectrum antibiotics together with an increase
in Narrow spectrum drug use, (2) a reduction of Amikacin and
Vancomycin use, (3) The data obtained represent encouraging
information feedback for physicians in the ICU and emphasize
the need for collaboration between ICU physicians and
infectious disease specialist.
New typing approaches for MRSA control
O115
An automated DNA sequence-based early-
warning system for detection of MRSA-outbreaks
in hospitals
A. Mellmann, A.W. Friedrich, N. Rosenko¨tter, R. Reintjes,
W. Witte, D. Harmsen (Munster, Hamburg, Wernigerode, D)
Objectives: Isolation of methicillin resistant Staphylococcus
aureus (MRSA) in hospitals often implies rigorous
infection-control measures. The use of rapid and accurate
typing is required to monitor nosocomial spread. Prompt
identiﬁcation of epidemic MRSA is crucial to control an
outbreak, in order to avoid unnecessary interventions for
patients and staff unrelated to an outbreak. In this study we
evaluated different early-warning algorithms for MRSA-
outbreak detection in hospitals.
Methods: Between 1998 and 2003, 557 non-replicate MRSA-
strains were collected from staff and patients admitted to
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Mu¨nster University Hospital (1480 beds), Germany. Of these
strains, the DNA sequence of the repeat-region of the S. aureus
protein A gene (spa) was analyzed by the Ridom StaphType
software v2.0 beta. Different early-warning algorithms
(frequency and clonal alerts, infection control professionals
[ICP], Z-score) were evaluated for the year 2003 using spa
typing results and epidemiological data. Outbreaks were
detected on the level of minimally two MRSA-colonized or -
infected patients or staff on the same or related nursing units
exhibiting the same spa type within a two-week time window.
Results: 549 of 557 MRSAs were typeable by spa sequencing. In
total, 79 different spa types were identiﬁed. Retrospectively
analyzed, 42 of the overall 175 MRSA isolates formed 13
signiﬁcant clonal outbreaks in 2003 (scantest, 5% signiﬁcance
level). These outbreaks were used as gold standard to evaluate
the different algorithms in a prospective simulation. 100%
sensitivity and 95.2% speciﬁcity for outbreak detection were
reached using the combination of spa typing and
epidemiological data (place and time). All other methods were
less sensitive or less speciﬁc: using solely epidemiological data
(frequency alert) resulted in 100% sensitivity and 47.3%
speciﬁcity, whereas investigations of the ICP resulted in 62.1%
sensitivity and 97.3% speciﬁcity, respectively.
Conclusion: A surveillance method based on both
epidemiological and spa typing data gives infection-control
professionals opportunities to intervene before limited clusters
of preventable MRSA transmissions become expansive
outbreaks. This innovative combined use of medical
informatics and molecular laboratory technique provides a
vision for future innovations that can expand our capacity to
detect and treat clusters of infectious diseases, thus limiting their
spread and improving the patients’ safety.
O116
Sequence-based typing of methicillin-resistant
Staphylococcus aureus for real-time infection
control
M. Christensen, K. Boye, A.R. Larsen, R. Skov,
H. Westh (Hvidovre, Copenhagen, DK)
Objectives: After an epidemic in the late 1960’s, Denmark has
been almost free of MRSA. In 2003, however, a signiﬁcant
increase in the number of MRSA patients in Denmark was
observed (from 100 in 2002 to 240 in 2003). At Hvidovre
hospital, the number of patients with MRSA has increased
from 33 in 2003 to an expected 118 in 2004. A rise in MRSA
can lead to serious treatment difﬁculties since the MRSAs are
resistant to all betalactam antibiotics and often also to other
groups of antibiotics. Furthermore, patients with MRSA
need to be isolated during hospitalization. In order to study
the epidemiological relatedness of the MRSA isolates
and potentially discover routes of transmission we selected
a number of genes for typing by PCR and/or DNA
sequencing.
Methods: 115 MRSA isolates from 2003 and 2004 were
analyzed. The genes or gene clusters chosen for analysis were
the following: the variable repeat region of the staphylococcus
protein A gene (spa typing), the Staphylococcal Chromosomal
Cassette (SCCmec typing), the Panton-Valentine leukocidin
(PVL) genes, and multilocus sequence typing (MLST) of all
novel spa types.
Results: One dominant spa type, t024 (SCCmecIV, PVL-, ST8),
was found in 50 of the MRSA isolates (43 %) and was clearly
associated with nursing homes. This spa type was also
predominant during the MRSA outbreaks in Denmark in the
1960’s. 15 isolates (13 %) were t019 (SCCmecIV, PVL+, ST30).
ST30 is known as the CA-MRSA from Oceania, and all of
these patients came from or had a connection to the same
Asian country. spa type t044 (SCCmecIV, PVL+, ST80) was
found in 9 isolates. ST80 is the most common CA-MRSA in
Europe. spa type t008 (SCCmecIV, PVL+, ST8) was found in 7
and t002 (ST5) in 5 isolates. Of the remaining 28 patients with
sporadic MRSA clones, 12 had acquired the MRSA in a
foreign country.
Conclusions: MRSA is spreading in Denmark, primarily in the
community, but these patients are often hospitalized with the
risk of nosocomial spread. Most isolates carry the SCCmecIV. A
clear connection to other countries can be found for several
minor or sporadic clones. However, the most dominant MRSA
clone, spa type t024, seems to be related to the archaic clone
common in Denmark in the 1960’s and 1970’s.
O117
Rapid, reliable sub-typing of methicillin-resistant
Staphylococcus aureus by denaturing high
pressure liquid chromatography and DNA
sequence analysis
F. Jury, M. Al-Mahrous, A. Fox, W. Ollier,
M. Upton (Manchester, UK)
Objectives: Methicillin resistant Staphylococcus aureus (MRSA)
is a signiﬁcant cause of hospital and community acquired
disease. Epidemic MRSA (EMRSA)strains are particularly
successful pathogens able to spread rapidly. Detection and
sub-typing of EMRSA can require a week of investigation. To be
of true use, methods for identiﬁcation of cross-infection events
and outbreaks need to be highly discriminatory and easy to
perform. The current methods for this purpose have numerous
disadvantages including expense and a lack of standardisation
and rapidity. Characterisation of the X region of the spaA gene
provides a rapid, unambiguous, discriminatory sub-typing
method that can inform outbreak investigation. Denaturing
high-performance liquid chromatography (DHPLC) is a
powerful technique for separation and quantitation of nucleic
acids. We have used DHPLC to detect DNA sequence variation
within the spaA gene of 32 samples to fully investigate the
application of DHPLC approaches as a possible rapid and cheap
alternative to spa typing by conventional methods.
Methods: Genomic DNA was extracted from cultured isolates
and used as template in PCR to amplify the X region of the spaA
gene. DHPLC was carried out by Transgenomic WAVETM DNA
fragment analysis. PCR products were screened for size
variation by running 5 ll of each PCR sample through a linear
acetonitrile gradient. The samples were run blindly so no prior
assumptions could be made of the EMRSA type. Retention times
were collected for each sample and comparisons to a size
standard (pUC18 Haelll digest) were made. The number of
repeat units for each sample was calculated. Sequence data were
also obtained for each of the samples.
Results: Sequence data indicated a predominance of strains
with 15 (n = 13; group A) or 16 (n = 8; group B) repeat units in
the spaA X region. With the exception of a repeat unit that was
inserted as the sixth unit in group B isolates, the succession of
repeat units in group A strains was identical to that seen in those
of group B. The number of repeat units in each sample matched
exactly those predicted by WAVETM analysis.
Conclusion: DHPLC methods can rapidly detect repeat unit
number with a very high correlation to sequence data. This
indicates the ability of the WAVE to rapidly sub-type strains of
MRSA, which differ by a single repeat unit. Expansion of the
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predominant repeat unit succession, by insertion of a new repeat
unit, suggests possible local evolution of the spaA X region.
O118
Comparison of random ampliﬁcation of
polymorphic DNA with pulsed-ﬁeld gel
electrophoresis for the molecular typing of
methicillin-resistant Staphylococcus aureus in an
infection control setting
J.M. Caddick, A.C. Hilton, P.A. Lambert, T. Worthington,
T.S.J. Elliott (Birmingham, UK)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA)
is a signiﬁcant cause of nosocomial morbidity and mortality
with increasing reports of multiple-resistant (MR) hospital
acquired (HA) strains and an emerging problem of
community acquired (CA) infections. The objective of this
study was to compare random ampliﬁcation of polymorphic
DNA (RAPD) with pulsed-ﬁeld gel electrophoresis (PFGE) for
the characterisation of MRSA and to assess the suitability of
RAPD as a typing technique in an infection control setting.
Methods: A total of 129 MRSA isolates were typed: 28 MR-
MRSA isolates (only sensitive to vancomycin, tetracycline and
rifampicin), 66 HA-MRSA isolates from the University Hospital
Birmingham NHS Trust, UK, (UHB) and 35 CA-MRSA isolates
sent to the UHB by general practitioners in the Birmingham
area. The RAPD reaction consisted of two separate reactions for
which two arbitrary 10mer primers (designated s and l) were
used and was optimised and tested for reproducibility,
typability and discrimination. PFGE was performed following
SmaI macrorestriction. Proﬁle relatedness was calculated by the
Dice coefﬁcient and a dendrogram was constructed using
UPGMA clustering.
Results: PFGE analysis revealed 30 proﬁles, type B (26 isolates)
and type J (2 isolates) representing two MR-MRSA strains and
type A (31 isolates) and type C (17 isolates) representing strains
that shared the same genotype as the EMRSA-15 and EMRSA-16
respectively. All CA-MRSA strains shared the same genotype
with 1 or more of the HA-MRSA strains excluding 9 CA-MRSA
strains,which had unique PFGEproﬁles. RAPDanalysis revealed
ten proﬁles, type B(sl) (45 isolates) representing strains that
shared the same genotype as EMRSA-16 and the MR-MRSA
strains and typeA(sl) (74 isolates) representing strains that shared
the same genotype as EMRSA-15. The B(sl) type was associated
with a higher resistance phenotype than the A(sl) type. The
discriminatory capacities of PFGE and RAPD as determined by
Simpson’s Index of Diversity were 88% and 58% respectively.
Conclusion: This study indicates that RAPD has a limited
discriminatory capacity compared to PFGE for typing of MRSA,
however, RAPD was able to elicit results within a single
working day and grouped all the MRSA isolates associated
with a higher resistance phenotype. Such timely information is
invaluable in directing appropriate infection control which is
especially important in the management of MR-MRSA
outbreaks.
O119
Staphylococcal cassette chromosome in
methicillin-resistant Staphylococcus aureus:
different methods resulting in different types
K. Becker, M. Schulte, B. Schuhen, G. Peters,
C. von Eiff (Munster, D)
Background: Methicillin-resistant Staphylococcus aureus (MRSA)
strains possess the mecA gene, which is carried by a unique
mobile genetic element, Staphylococcal cassette chromosome
(SCCmec), integrated into the S. aureus chromosome. A full
characterization of MRSA strains requires structure
determination of the complex SCCmec element. In addition to
the SCCmec types I–V, several subtypes have been described.
Most recently, a progressive replacement of type II SCCmec-
bearing isolates with type IV SCCmec-bearing isolates, which
coincided with >4-fold increase in methicillin resistance was
reported.
Methods: In order to analyze the SCCmec (sub)types of 130
MRSA isolates recovered from patients admitted to our
Hospital, two different multiplex PCR typing strategies
reported by Oliveira & Lencastre (A) and by Okuma et al. (B)
were used. For conﬁrmation of the SCCmec type, the method of
Branger et al. was used. The presence of the pls gene - described
to be associated with type I - was also determined. Only one
MRSA isolate per patient was included.
Results: Concordant results based on all methods used were
found in only 59% of the isolates tested comprising MRSA
strains exhibiting type I (n = 40, 52%), type II (n = 10, 13%), type
III (n = 2, 3%), type IV (n = 20, 26%) and 5 nontypeable strains.
All isolates tested positive for pls were shown to be type I.
Regarding type I (A: n = 64, 49% [incl. type IA] versus B: n = 30,
23%) and type IV (A: n = 24, 18% versus B: n = 58, 45%) major
discrepancies were detected. Using approach A, 13 (10%) and 3
(2%) MRSA strains showed type II and III (incl. IIIA),
respectively, whereas method B yielded 15 (12%) and 7 (5%)
type II and III, respectively, results. 26 isolates were not typeable
using method A as were 30 isolates applying method B (no PCR
bands or uncharacteristic band patterns).
Conclusions: The application of different approaches to
determine the SCCmec type showed major discrepancies, in
particular regarding types I and IV. As both methods failed in
typing of some MRSA isolates, the structure of SCCmec may be
more heterogenous than assumed so far.
Pharmacokinetics and pharmacodynamics of antibiotics
O120
Pharmacological comparison of antibiotics
against intracellular S. aureus
M. Barcia-Macay, M.P. Mingeot-Leclercq, P.M. Tulkens,
F. Van Bambeke (Brussels, B)
Objectives: The parameters governing the intracellular activity
of antibiotics are still poorly understood. In this study, we have
compared the concentration-effect relationships at 24 h of 4
antibiotics against extracellular and intracellular forms of
S. aureus.
Methods: Infection of THP-1 human macrophages by S.aureus
ATCC25923 and assessment of antibiotic activity was performed
following the general procedure described in Seral et al. (AAC
47:2283–92) with minor adaptations for cells in suspension.
Antibiotics were used at concentrations ranging from 0.05 X
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MIC to 1000 X MIC. Antibiotic content in cell lysates was
measured by microbiological (OXA, GEN), ﬂuorimetric (MXF)
or radiochemical (ORI) assay.
Results: The table shows the parameters calculated from a
sigmoidal regression of the concentration-effects relationships,
with concentrations expressed in X MIC and the effect, as the
change in CFU over 24 h, as compared to the initial inoculum (all
R2 > 0.9). Extracellularly, all antibiotics reached a static effect
and EC50 at a conc. close to their MIC and were highly cidal (4–5
log decrease) upon exposure to high conc. Intracellularly, OXA
andMXF showed a static effect and EC50 at extracell. conc. 3–4 X
those observed for extracellular bacteria, whereas conc. of
approx. 10 X higher were needed for GEN and ORI. The
intracellular max. effect was lower than the extracellular one for
all drugs, but a cidal effect (2 log decrease) could still be achieved
at clinically relevant conc. for OXA, MXF and ORI.
Conclusions: The model shows that the intracellular milieu
weakens the overall effects of antibiotics while also increasing
the concentration needed to reach a given effect, irrespective of
the capacity of the drug to accumulate or not in cells.
O121
In vivo pharmacodynamic activity of
gemiﬂoxacin against multiple strains of
Streptococcus pneumoniae
W.A. Craig, D. Andes (Madison, USA)
Background: The 24-hr AUC/MIC for free drug is the PK/PD
parameter that best correlates with in-vivo activity of
ﬂuoroquinolones. We used the neutropenic murine thigh-
infection models to determine the magnitude of the AUC/MIC
needed for efﬁcacy of gemiﬂoxacin (GEM) against 61 strains of
SP with varing ﬂuoroquinolone susceptibility.
Methods: Mice had 10 to the 5.728.3 cfu/thigh when treated for
24 hrs with 0.073–1200 mg/kg of GEM every 12 hrs. Serial
dilutions of thigh homogenate were plated for CFU
determinations. A sigmoid dose-response model was used to
estimate the dose (mg/kg/24 hr) required to achieve a net
bacteriostatic effect over 24 hrs. The AUC for the static dose was
estimated from serum levels following doses of 18.8, 75 and
300 mg/kg determined by microbiologic assay. Protein binding
was determined by ultraﬁltration.
Results: PK studies exhibited AUC/dose values of 0.12–0.18
and half-lives of 0.7–1.6 hrs; protein binding was 66%. MICs
ranged from 0.008–2.0 mg/L and some strains had single or
multiple parC, parE and gyrA mutations. Five strains had efﬂux
(conﬁrmed by 4- to 16-fold lower MIC with reserpine); the free
drug 24-hr AUC/MIC values for the static dose for these strains
were 2.1–5.7. For the 56 other stains, the static dose varied 275-
fold (1.7–468 mg/kg q12h), while the free drug 24-hr AUC/MIC
values for the static dose varied only 5-fold (16–82) and the
mean AUC/MIC was similar at different MIC values.
Conclusions: The magnitude of the 24-hr AUC/MIC of free
GEM required for in vivo bacteriostasis was similar for most
strains of SP with and without gyrA, parC and parE mutations.
However, for strains with higher MICs due to efﬂux, GEM was
much more active than the MIC predicted. This suggests that
efﬂux might be down-regulated in vivo.
O122
Comparison of pharmacodynamic target
attainment calculated by Monte Carlo simulation
with microbiological response for two
carbapenems in the treatment of complicated skin
and skin structure infections
J. Kuti, C. Ong, M. Lo, D. Melnick, N. Soto, D. Nicolau (Hartford,
Wilmington, USA)
Objectives: Monte Carlo simulation (MCS) is commonly used to
predict pharmacodynamic target attainment (TA) of antibiotics
against speciﬁc bacteria. The relevance of these predictions to
outcomes in humans, however, has not been well studied. This
study aimed at determining the probability of attaining
pharmacodynamic exposures for meropenem (MEM) 500 mg
every 8 hours and imipenem (IMI) 500 mg every 8 hours against
pathogens isolated from complicated skin and skin structure
infections (cSSSI) during a randomized, multicentre, clinical trial
and comparing TA with microbiological response (MR).
Methods: A subset of the clinically evaluable study population
who had bacteria isolated and MICs performed for their
respective randomized treatment was extracted. The MICs of
these bacteria were treated as a single MIC distribution for each
carbapenem. Free drug exposures for 5000 subjects were
simulated using a one-compartment infusion model. Mean
pharmacokinetic data and variability, including blister ﬂuid
penetration, was derived from published studies in healthy
volunteers and incorporated using MCS. TA at 40%, 50%, 60%,
and 70% time above the MIC (T > MIC) in both serum and
blister ﬂuid was calculated for each carbapenem and compared
with its MR at the end of treatment.
Results: Of 548 clinically evaluable patients, 210 had bacteria
with MICs reported and were included (MEM, n = 98; IMI,
n = 112).MRforMEMand IMIagainst thesepathogenswas87.8%
(95%CI: 79.8–92.9) and91.1%(95%CI: 84.3–95.1), respectively. For
MEM, bactericidal TA (40%T > MIC)were 90.4 and 89.9 in serum
and blister ﬂuid and did not differ from MR. TA at all other
T > MICexposuresalso agreedwithMR. In contrast, TA for IMI at
40% T > MIC in either matrix was not predictive of MR. Instead,
onlyTAin serumat 60%and70%T > MIC, andblisterﬂuidat 50%
and 60% T > MIC were similar to MR.
Conclusions: For these carbapenems in the treatment of cSSSI,
an association between TA calculated by MCS and MR does
exist, although the exposures needed for a successful response
appear to be different between MEM and IMI.
O123
Overestimation of vancomycin therapeutic drug
monitoring levels in haemodialysis patients
F. Fitzpatrick, T. McGaley, L. Rajan, R. Crowley, M. Turley,
H. Humphreys, E. Smyth (Dublin, IRL)
Patients on haemodialysis are one of the largest populations in
whom vancomycin therapeutic drug monitoring (TDM) is
performed in our institution. Concern has been expressed in
Antibiotics
Extracellularly Intracellularly
Static
conca ECa50
Max
effectb
Static
conca ECa50
Max
effectb
Antibiotic
celllular
accumulation
OXA 0.52 1.22 )3.70 2.09 1.85 -1.58 4.0
MXF 0.29 0.79 )4.29 0.63 0.81 -2.77 7.6
GEN 0.30 0.88 )5.76 2.09 7.73 -2.54 4.4
ORI 0.20 1.00 )5.55 4.79 13.8 -3.16 148.0
aIn multiples of the MIC
bIn difference of log CFU as compared to time 0 h
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the past about the accuracy of polyclonal antibody-based
ﬂuorescence polarization immunoassays (pFPIA) for the
detection of vancomycin serum concentrations in these patients.
However, most laboratories in the Republic of Ireland and in the
UK still use the Abbott TDx, which is based on pFPIA, for
vancomycin TDM.
Methods: We evaluated the accuracy of our routine procedure
for vancomycin TDM, on the Abbott TDx system, with a
monoclonal antibody-based FPIA on the Abbott AxSYM system,
in 62 serum samples from 19 haemodialysis patients over a one-
month period.
Results: Compared with the Abbott AxSYM, the Abbott TDx
consistently overestimated vancomycin TDM (from 15–59%)
with the majority (23/62 samples, 37%) between 26–30%
overestimation. Therapeutic decisions based on falsely
elevated vancomycin concentrations in 17 samples (27%) from
nine (47%) patients may have resulted in inadequately treated
infections and potential therapeutic failure.
Conclusion: Our data suggests that there is a clinically
signiﬁcant impact of end stage renal disease on the
determination of vancomycin serum concentrations using the
Abbott TDx. We therefore recommend that the mFPIA assay on
the Abbott AXSYM be used in patients with ESRD.
O124
Pharmacokinetics of linezolid in bone tissue
investigated by in situ microdialysis
L. Stolle, N. Plock, M. Arpi, M. Mueller, C. Joukhadar,
C. Buerger, P. Riegels-Nielsen, C. Kloft (Aarhus, DK; Berlin, D;
Herlev, DK; Vienna, A; Esbjerg, DK)
Objective: Knowledge concerning the distribution of
antimicrobial agents in bone tissue is valuable for
pharmacokinetic characterisation and clinical use.
Unfortunately, appropriate techniques are difﬁcult to apply.
The aim of this investigation was to introduce microdialysis to
corticocancellous bone tissue for pharmacokinetic investigations
of the novel antiinfective linezolid.
Methods: 10 healthy pigs (weight: range 38–43 kg) were
included into the study. Two microdialysis catheters were
inserted in cancellous bone of the right tibia and calibration was
performed according to the retrodialysis principle. After this
each animal received 600 mg of linezolid as a 20 min. iv.
infusion. Bone samples were harvested from the left and
microdialysate samples (lateral catheter, lc, and medial
catheter, mc) were obtained from the right tibia over a period
of 6 hours. In addition, samples of serum and bone marrow
were collected and drug concentrations were measured. All data
presented are geometric mean ± geometric SD.
Results: Maximum serum and bone marrow concentrations of
26.14 ± 9.98 lg/mL and 21.90 ± 8.84 lg/mL were reached at a
median tmax of 30 minutes respectively. Bone microdialysate
yielded mean Cmax values of 13.15 ± 8.39 lg/mL (mc) and
11.81 ± 6.69 lg/mL (lc), while Cmax values for bone specimen
were 5.87 ± 1.34 lg/g.
Conclusions: To achieve concentrations higher than the MIC
for susceptible organisms (>4 mg/L) the chosen dose of
linezolid was sufﬁcient for bone, bone marrow and serum. It
is not surprising that the observed bone concentrations are
lower than bone microdialysate concentrations because bone
concentrations are given in lg/g. With the use of microdialysis
we here present the ﬁrst results for linezolid bone penetration
that are directly comparable to unbound concentrations in other
matrices such as serum or bone marrow. From this we conclude
that linezolid has an excellent penetration into bone tissue.
Genetic typing for important viral infections: recent technological
and conceptual developments (Symposium arranged with ESGEM)
S126
Molecular diversity of new and emerging viruses
B. Mahy (Atlanta, USA)
During the past 15 years, at least 60 new viruses infecting
humans have been recognized. In some cases the viruses have
been infecting humans for many years, but have only recently
been recognized (e.g. Sin Nombre and related viruses causing
hantavirus pulmonary syndrome) but in other cases the virus
has not previously entered the human population either because
it recently emerged from a reservoir host (e.g. Nipah virus or the
SARS coronavirus) or was newly introduced from a different
geographic location (e.g. West Nile virus in the USA). In the case
of the SARS coronavirus, sequence analysis of isolates from
several different locations (Vietnam, Germany and Canada)
revealed almost no sequence diversity, which is not surprising
since these outbreaks could all be traced back to a single infected
person in Hong Kong. Similarly, there has been little molecular
variation noted in West Nile viruses isolated in the US following
the single introduction from Israel to New York in 1999.
However, some signiﬁcant variation has recently been reported
following sequencing of isolates from Mexico. It is of interest
that the epidemic of haemorrhagic fever caused by Ebola virus
in Kikwit, Zaire in 1995, some 19 years after a previous epidemic
had occurred there, was caused by a virus with almost identical
sequence. This may indicate that Ebola virus had emerged from
a reservoir in which the virus is quite stable, with no pressure
for sequence change.
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Figure 1. illustrates the mean tissue concentration-time proﬁles
obtained from microdialysates and bone samples.
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Modifying the ribosome as a mechanism of resistance
(Joint symposium arranged with ICAAC)
S129
Distinctive ketolide interaction and resistance
mechanisms
S. Douthwaite, C. Toft Madsen, J. Poehlsgaard,
L. Jakobsen (Odense, DK)
Macrolide antibiotics and their latest generation of derivatives,
the ketolides, bind within the peptide tunnel of the bacterial 50S
ribosomal subunit. Here, the drugs exert an effective blockade
against the growing peptide chain to prevent the synthesis of
new bacterial proteins. For inhibition to be effective it is essential
that macrolides and ketolides attach securely to their binding
site within the tunnel. The primary attachment site of all these
drugs is at adenosine 2058 (A2058) in domain V of 23S rRNA.
An additional interaction with domain II of the rRNA at around
nucleotide A752 is made via the synthetic carbamate-alkyl-aryl
substituent in the ketolide telithromycin, and contributes to
telithromycin’s improved activity. As a consequence of its
stronger interaction, there are fewer bacterial isolates that are
resistant to telithromycin compared to those resistant to the
parent macrolide compound, erythromycin. However, telithro-
mycin resistance has been noted in some strains of Streptococcus
pyogenes and members of the Mycobacterium tuberculosis com-
plex. We have analysed the rRNA of these strains to determine
the molecular mechanisms of telithromycin resistance. In this
presentation, these resistance mechanisms will be compared to
those found in other strains of the same genera, which are
resistant to macrolides while remaining susceptible to telithro-
mycin.
S130
Resistance mechanisms and the site of action of
oxazolidinone antibiotics in the ribosome
A.S. Mankin (Chicago, USA)
Linezolid, a ﬁrst clinically useful representative of oxazolidi-
none antibiotics, was introduced in medical practice in 2001. It
represented the ﬁrst principally new class of antibiotics devel-
oped in the last 25 years. The site and mode of oxazolidinone
action, the nature of side effects and mechanisms of resistance
are only starting to be unraveled. Oxazolidinones bind to the
ribosome and inhibit protein synthesis in sensitive bacteria.
Though oxazolidinones inhibit cell-free translation they bind
only weakly to isolated ribosomes, which complicated identiﬁ-
cation of the site of their action. Therefore, the majority of our
knowledge about the site and mechanism of action of oxazolid-
inones comes from in vivo studies. Crosslinking of photo-
reactive oxazolidinones to their target in living bacteria revealed
the ribosomal peptidyl transferase centre as the main site of
oxazolidinone action. The use of various photoreactive deriva-
tives allowed for the accurate modelling of the structure of
oxazolidinone drug in the ribosome-bound state. Crosslinking
results are in excellent agreement with mutational analysis: all
the well-characterized oxazolidinone-resistance mutations are
clustered in 23S rRNA at or near the ribosomal peptidyl
transferase centre. However, ribosomes of different species
show remarkable idiosyncrasy in the type and position of
oxazolidinone resistance mutations, suggesting that mutations
may have different cost of ﬁtness in ribosomes of different
organisms. Oxazolidinone resistance mutations in rRNA are
co-dominant and confer resistance even in the presence of wild
type ribosomes in the cell. The extent of resistance correlates
with the number of ribosomal RNA operons carrying the
mutation.
S131
Macrolide-lincosamide-streptogramin resistance
by ribosome methylation
R. Leclercq (Caen, F)
Cross resistance to macrolides, lincosamides and streptogra-
mins B (the MLSB phenotype) is spread in a variety of
micro-organisms and is due to ribosomal modiﬁcation by
methylation. Nearly forty different erm gene classes responsible
for ribosomal modiﬁcation are distinguished. According to the
class of erm gene, the Erm methylases can monomethylate or
dimethylate adenine at position 2048 (E. coli numbering) in the
23S rRNA. Generally, each class of erm gene is found in a
limited number of bacterial genera. This is the case for
staphylococci where three erm genes, erm(A), erm(B), and
erm(C) account for nearly all the isolates with the MLSB
phenotype and for streptococci where the erm(B) and erm(TR)
[a subset of the erm(A) class] genes are widely distributed.
Resistance may be expressed constitutively or inducibly regard-
less the erm determinant. The inducible phenotype is related to
translational regulation of resistance and is characterized by
dissociated resistance to MLSB antibiotics due to differences in
inducing capacity of the antibiotics. In staphylococci, the strains
are resistant to 14- and 15-membered ring macrolides which are
inducers whereas clindamycin which is not inducer remains
active. The use of clindamycin for the treatment of an infection
due to an inducibly resistant strain of S. aureus may lead to the
selection of constitutive mutants and therefore should be
discouraged particularly in the case of infections with heavy
inoculum. For the erm(B) gene, when present in streptococci,
the spectrum of inducer antibiotics is broader and includes
clindamycin and 16-membered macrolides. The MLSB resist-
ance phenotype results from both the type of ribosomal
methylation (mono or dimethylation) and of the type of
expression of methylase (inducible or constitutive).
S132
Resistance to aminoglycosides in Gram-negative
bacteria by 16S rRNA methylation
P. Courvalin (Paris, F)
Despite the development of new b-lactams and ﬂuoroquino-
lones, aminoglycosides are still used for the treatment of
severe infections caused by Gram-negative organisms. There
are three known mechanisms of resistance to aminoglycosides
in bacterial human pathogens: (i) decreased intracellular
accumulation of the antibiotic by alteration of the outer
membrane permeability, diminished inner membrane trans-
port, or active efﬂux; (ii) modiﬁcation of the target by
mutation in ribosomal proteins or 16S RNA; and (iii) enzy-
matic modiﬁcation of the drug. Micro-organisms that produce
aminoglycosides have developed an additional pathway to
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avoid suicide: posttranscriptional methylation of rRNA by use
of S-adenosyl-methionine as a cofactor. The armA (aminogly-
coside resistance methylase) gene was initially found on
conjugative Inc L/M plasmid pIP1204 in Klebsiella pneumoniae
BM4536. Cloning of the gene in Escherichia coli conferred to
the new host high-level resistance to 4,6-disubstituted deoxy-
streptamines (amikacin, isepamicin, gentamicin, netilmicin,
sisomicin, and tobramycin) and to fortimicin by conversion
of G1405 N-7 to 7-methylguanosine within 16S rRNA. Plasmid
conduction experiments indicated that the armA gene was
part of composite transposon Tn1548 together with genes
ant3’9, sulI, and dfrXII for resistance to streptomycin-spec-
tinomycin, sulfonamides, and trimethroprim, respectively. The
16.6-kb genetic element is ﬂanked by two copies of IS6 and
migrates by replicative transposition. This observation
accounts for the presence of armA on self-transferable plas-
mids of various incompatibility groups and its already
worldwide dissemination in members of the family Entero-
bacteriaceae from human or animal origin and in Acinetobacter
baumanni. The deduced sequence of ArmA displayed from 37
to 47% similarity to those of 16S rRNA m7G methyltransf-
erases from various actinomycetes, which confer resistance to
aminoglycoside-producing strains. However, the low GC
content of armA (30%) does not favor an actinomycete
origin for the gene. Two other closely related 16S rRNA
methylases, RmtA and RmtB, have been recently reported. It
therefore appears that post-transcriptional modiﬁcation of 16S
rRNA can confer high-level resistance to all the clinically
available aminoglycosides, except streptomycin, in Gram-
negative human pathogens.
Patterns of antibiotic stewardship, use and resistance in European
hospitals (Joint symposium arranged with ARPAC and ESAC)
S134
Medical antibiotic use surveillance networks
in Germany
W.V. Kern (Freiburg, D)
In Germany, a large country with over 80 million inhabitants
and more than 2,000 hospitals in 16 federal states, there have
been national surveys of antimicrobial drug prescriptions in
ambulatory care published on a yearly basis while hospital
antibiotic use databases outside private, economic and market
research surveys have not been available until recently. Two
antibiotic use surveillance networks, both supported by gov-
ernmental funds and coordinated by physician–scientists from
the University of Freiburg, are now operating in this country.
One is, project SARI (Surveillance of Antibiotic Use and
Resistance in Intensive Care, http://www.sari-antibiotika.de),
an intensive care oriented surveillance programme similar to
ICARE. The second is the MABUSE network (Medical Anti-
biotic Use Surveillance and Evaluation, http://www.if-frei-
burg.de) that aims at integrating ambulatory and hospital care
antibiotic use, and resistance surveillance and research at
regional levels. MABUSE projects initially included interhos-
pital comparisons of antibiotic use and expenditures at
university hospitals, and ambulatory care antibiotic use
surveillance at regional level. The network has now estab-
lished a hospital antibiotic use database designed for pros-
pective data entry from selected convenience regional hospital
samples. ATC/WHO DDDs are used in addition to prescribed
daily doses deﬁned according to current practice. Recent
MABUSE projects include systemic antifungal use, overall
(hospital and ambulatory) antibacterial drug use in selected
regions, and linking drug use and resistance surveillance
databases. Provided that further funds are available, projects
will address a comparison of SARI/MABUSE databases
with IMS databases and the deﬁnition of a suitable and
representative national and regional hospital sample for drug
use surveillance via quarterly online data exchange and
retrieval. We will discuss our experience with the DDD
versus PDD issue, appropriate drug classiﬁcations, and rea-
sonable departmental data aggregation.
S136
ARPAC consensus recommendations on
antimicrobial stewardship and control of
resistance
I.M. Gould (Aberdeen, UK)
ARPAC (Antibiotic Resistance Prevention and Control) is a DG
Research Concerted Action funded under the ﬁfth framework. It
involved collecting data on antibiotic policies, antibiotic con-
sumption, resistance and infection control policies from over 200
European hospitals. Marked geographic differences were appar-
ent in all but antibiotic policies. There were strong association
between both infection control policies and antibiotic consump-
tion versus resistance prevalence and weaker association
between resistance and the presence of a hospital antibiotic
formulary, drugs and therapeutic committee and educational
programmes. The data were presented at a Consensus Confer-
ence held in Amsterdam in November 2003 at which expert
opinion was synthesised with ARPAC data to draft guidelines
for harmonization of policy in these areas at hospital, national
and European level. These draft guidelines will be ﬁnalised at a
meeting at the European Commission in Brussels in February
2005 and will be summarised for presentation at ECCMID. The
proceedings of the Consensus Conferences and the draft
recommendations are currently available at www.abdn.ac.uk/
arpac/.
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Combination antifungal therapy (Symposium arranged with
EFISG)
S138
Neonatal Candidiasis
F.-M. Mu¨ller (Heidelberg, D)
Invasive Candida infections have not only emerged in the adult
population, but also in children and especially in neonates (birth
weight < 1500 g). Even a fullterm newborn is not immunocom-
petent and due to a high Candida colonisation rate of the mother
during pregnancy, it may develop oropharyngeal candidiasis
and diaper dermatitis or congenital cutaneous candidiasis.
Candidaemia and disseminated candidiasis is inversely corre-
lated with the gestational age and birth weight: Extremely low
birth weight infants (ELBW) have a risk of up to 20% for
developing neonatal candidiasis during their stay in the
neonatal intensive care unit (NICU). From a recent epidemio-
logical study conducted in Germany, 50% of ELBW infants are
colonised with fungi, and from those that develop disseminated
infection, the mortality rate is 30%. C. albicans is the most
common isolated pathogen (70%), but 23% were non-albicans
Candida spp. with C. parapsilosis the leading one. Others so far
rare yeasts, such as Trichosporon and Rhodotorula spp. are as well
as rare moulds emerging in neonatology. Unfortunately, in
general almost 60% of the children and 90% of the newborns
receive treatment with unlicensed drugs in Europe, so it’s the
paediatrician’s choice either to prescribe a drug with high
efﬁcacy in adults that has not been tested in children or a drug
with less efﬁcacy that has been tested in children. Antifungals
that are commonly used in paediatrics are conventional and
liposomal amphotericin B as well as the azoles ﬂuconazole and
itraconazole due to their oral bioavailability. The new antifun-
gals of the next generation triazoles (voriconazole, posaconazole
and ravuconazole) as well as the echinocandins (caspofungin,
micafungin, anidulafungin) have potentials for the paediatric
population due to their broader spectrum, oral bioavailability
for the azoles as well as their tolerability and excellent safety
proﬁles. Before these drugs can be recommended in paediatrics
clinical trials including pharmacokinetic and pharmacodynamic
studies for the different age groups are warranted. In this
interactive symposium, clinical cases of neonatal candidiasis
will be discussed with special regard to management, potential
combinations of new and old antifungals as well as strategies for
prophylaxis and empirical treatment.
S140
Combined therapy for central nervous system
invasive fungal infections
L. Pagano (Rome, I)
CNS fungal infections are rare but fatal complications,
particularly in immunocompromised hosts. The most frequent
CNS manifestations, excluding cryptococcosis, are aspergillosis
and zygomycosis. These infections typically present with a
CNS mass, while candidiasis primarily involves the meninges.
The major causes of CNS aspergillosis are acute leukemia and
AHSCT. Diagnosis is usually difﬁcult because signs and
symptoms are frequently aspeciﬁc, and the diagnosis can be
often performed only using aggressive procedures, which are
impaired by the bad clinical conditions, particularly in
patients with acute leukaemia. Treatment includes surgery
(removal of abscesses or stereotactic drainage) and the use of
antifungal agents. The majority of old and new antifungal
drugs do not reach therapeutic levels in brain tissue. Amph-
otericin B (AmB), also administered at the highest tolerable
doses, showed very low efﬁcacy. The efﬁcacy of AmB lipid
compounds is higher. In particular, liposomal AmB presents a
high diffusion in CNS reaching high therapeutic peak.
Furthermore recent published data show that voriconazole
may be highly effective for the treatment of CNS aspergillosis.
Few data have been reported on combined therapy of this
complication and are only based on anedoctal reports.
Zygomycetes are the second frequent cause of brain abscesses.
They are observed not only in patients with acute leukaemia,
but also in the course of other diseases, in particular during
ketoacidotic diabetes. CNS involvement is more frequent that
in invasive aspergillosis, it is characterized as well by a high
mortality rate. In vitro and in vivo studies demonstrated that
only posaconazole and L-AmB present some chances of
success in the treatment of zygomycosis, but the pharmaco-
logical approach should always be associated to surgery.
Considering the high mortality rate and the action of these
antifungal drugs, the combination of L-AmB and posaconaz-
ole may represent in the future the best therapy for this
complication
New diagnostic methods for the laboratory
O141
A novel and rapid method for determination of
rubella virus immunoglobulin G avidity
M. Eggers, M. Enders, S. Strobel, J. Piche, I. Diz,
G. Enders (Stuttgart, D; Marcy l’Etoile, F)
Objectives: Although rare in many industrialised countries,
because of the success of vaccination programmes, rubella
infection in pregnancy continues to occur where uptake of the
vaccine is low and in immigrants of countries with no
vaccination programme. As the clinical diagnosis of rubella is
unreliable, serological tests are needed for a diagnosis,
especially in pregnancy. Diagnosis is usually made by
detection of rubella speciﬁc immunoglobulin M (IgM).
However, in about 2.2% of clinical normal pregnant women
investigated by us in prenatal care long persisting IgM
antibodies following previous infection or vaccination are
detected. Therefore an easy, rapid, and reproducible test to
distinguish between long-persisting rubella virus IgM
antibodies from IgM antibody response due to a primary
infection in early pregnancy is of great importance. The
measurement of the avidity of immunoglobulin G (IgG)
antibodies has been shown by several investigators to be
helpful in identifying or excluding primary rubella infections
in pregnant women.
Method: In this study, we adapted this serological technique
to the VIDAS system (bioMerieux) using 6 M urea as the
dissociating agent. A total of 301 serum specimens were
Clinical Microbiology and Infection, Volume 11, Supplement 2, 2005
33
tested: 35 control sera, 50 specimens from women with acute
infection, 51 serum samples from women with recent
vaccination, 100 serum samples with long persisting IgM, 5
sequential sera from a woman with preconceptional
vaccination, 10 sera from women with reinfection in
pregnancy after vaccination, and 50 serum samples without
IgM from women with past infection or vaccination. To
evaluate the performance of this novel VIDAS Rubella IgG
avidity test we compared it with the diethylamine
denaturation (DEA) procedure used in an in-house version
of the laboratory Enders since 1998.
Results: Our results show that the bioMerieux test is easy to
use, and that an avidity index higher than 40% allows the
exclusion of a recent infection or vaccination: <20% indicates
acute infection or recent vaccination during the last 2 months,
20–40% is considered borderline, and >40% indicates past
infection or previous vaccination.
Conclusion: This new VIDAS rubella IgG avidity assay is a
rapid (50 min), reproducible test with very good performance
and is of considerable practical value for decision on the need of
prenatal diagnosis, to avoid requesting too many follow up sera
and, most important, in preventing unnecessary termination of
pregnancy.
O142
Quantitation of cytomegalovirus DNA by real-
time polymerase chain reaction in the blood of
solid organ transplanted patients: comparison
with end-point PCR and pp65-antigen assay
T. Allice, M. Enrietto, F. Pittaluga, S. Varetto, V. Ghisetti
(Turin, I)
Background: Cytomegalovirus (CMV) infection is an important
cause of morbidity in solid organ recipients. Early markers to
identify infection progress are required in order to apply a
strategy of pre-emptive therapy whose efﬁcacy relies on
accurate laboratory tests to monitor CMV infection. The pp65-
antigen test (antigenaemia) is the gold standard for the early
identiﬁcation of CMV infection but the technique is time-
consuming with some pitfalls like long hands-on time and the
need of a strong experience for the interpretation of the result.
The evaluation of CMV DNA by quantitative Polymerase Chain
Reaction (PCR) has been introduced for monitoring CMV
infection but standardization of the techniques is essential for
the clinical interpretation of its results. The recently introduced
real-time PCR (RT-PCR) is aimed to offer a more reliable and
standardized method than the end-point PCR (EP-PCR) for
evaluating CMV dynamic.
Speciﬁc aim: The aim of the study was to compare the pp65-
antigenaemia with two PCR systems working on peripheral
blood leukocytes (PBL): the EP Cobas Amplicor Monitor (Roche,
Brachburg, NY, US, detection limit: 100 copies/1 milion PBL)
and the RT-PCR CMV (Amplimedical, Buttigliera, To, I,
detection limit 100 copies/500,000 PBL). PCR results were
referred as Log10/genome/500,000 cells. PBL (n = 158) from
32 solid organ transplanted patients (pts) with CMV infection
(20/32 pre-emptive treated with ganciclovir and 12/32 not on
therapy due level of pp65 < 30/200,000 PBL) were studied. A
pannel of 58 negative specimens by a reference nested-PCR test
(10 copies/500,000 PBL) was used to establish the speciﬁcity of
the EP-and RT-PCRs.
Results: A good correlation was found between pp65 test and
both EP-PCR (R2 = 0.88) and RT-PCR (R2 = 0.87) as well as
between the two PCR methods (R2 = 0.76). A signiﬁcantly
higher DNA level was shown in pre-emptive treated pts (RT-
PCR median value 3.8 Logs, EP-PCR 3.9 Logs) than in pts not
on therapy (RT-PCR: 2.9 Logs, EP-PCR: 2.1 Logs: p < 0.0001
for both the two PCRs). Speciﬁcity was 98.3% for RT-PCR and
91.5% for the EP-PCR. Sensitivity of RT-PCR and EP-PCR
were 100% and 29%, respectively, as tested with 10 copies of
a known amount of the reference AD169 strain. In conclusion,
our study shows that RT-PCR for CMV DNA quantitation is a
highly sensitive and speciﬁc tool with a much lower
turnaround time (3 hours) than EP-PCR (7 hours) allowing a
rapid and early diagnosis of CMV infection in transplanted
pts.
O143
Diagnosis of dengue infection by reverse
transcription-nested polymerase chain reaction
and enzyme linked immunosorbent assay using
whole blood stored on ﬁlter paper
N. Jaimchariyatam, J. Pupaibool, S. Krajiw,
K. Arunyingmongkol, P. Suandork, O. Prommalikit, R. Sittichai,
A. Nisalak, C. Pancharoen, U. Thisyakorn,
W. Kulwichit (Bangkok, TH)
Objectives: Dengue infection has emerged as a global public
health problem. PCR and ELISA are used for diagnosis. We
evaluated utilities of PCR and ELISA performed on dried blood
spots on ﬁlter paper for dengue diagnosis in acute febrile
patients.
Methods: A descriptive observational study was conducted in
acute febrile pediatric and adult patients at King
Chulalongkorn Memorial Hospital, between June 2003 to
April 2004. Diagnosis of dengue infection was based on
standard serum ELISA assay. Patients tested negative by
serum ELISA served as controls. Whole blood (WB) was
collected on the ﬁrst day of admission and again 1–2 weeks
after discharge. Dried blood spots were stored on ﬁlter paper
which was kept at 4 degrees for at least 10 days before
testing. Reverse transcription-nested polymerase chain
reaction (RT-nested PCR) and ELISA were performed on
extracts from the spots. Blood spots with IgM over 40 units
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and IgM/IgG ratio over 1.8 were considered primary infection
cases. Spots with IgG over 100 units were considered
secondary cases.
Results: We enrolled 102 patients with dengue infection
(6 primary and 96 secondary cases) and 33 patients with
other infectious diseases. Dried blood spots from 134 patients
(101 cases and 33 controls) were tested by ELISA, and from
80 patients (65 cases and 15 controls) for RT-nested PCR.
Positive RT-nested PCR was found in 43 of 65 dengue cases
(4 in 5 of primary cases and 39 in 60 of secondary cases) and
one of 15 control cases (sensitivity 80% and 65%, speciﬁcity
93.33% and 93.33%, positive predictive value (PPV) 97.5%
and 97.73%, negative predictive value (NPV) 93.33% and
40% for primary and secondary cases, respectively). Positive
ELISA was detected in all dengue and none of control cases
(Table).
Conclusions: RT-nested PCR and ELISA using dried blood
spots on ﬁlter paper appear to be of diagnostic value for dengue
infections. This would prove especially useful in certain areas
where immediate laboratory testing is not available. In addition,
molecular epidemiologic studies could also be performed in
positive-PCR specimens.
O144
Shorter time to identiﬁcation of pathogens in
positive blood cultures by FISH in routine
practice
R.P.H. Peters, P.H.M. Savelkoul, A.M. Simoons-Smit,
S.A. Danner, C.M.J.E. Vandenbroucke-Grauls, M.A. van
Agtmael (Amsterdam, NL)
Objectives: Evaluation of the effects on turnaround time and
clinical management of routine implementation of ﬂuorescent in
situ hybridisation (FISH) for identiﬁcation of pathogens from
positive blood cultures.
Methods: FISH was performed on growth-positive blood
culture ﬂuids simultaneously to conventional identiﬁcation.
A selection of probes was used that should identify >95% of
pathogens most commonly found in blood cultures. To
determine the clinical impact of FISH identiﬁcation, results
and time points were compared between conventional
identiﬁcation and FISH.
Results: One-hundred and ﬁfty blood cultures were included.
FISH allowed identiﬁcation of 117 pathogens (78%) at the species
level (table 1). For pathogens identiﬁed at the genus level or with
eubacterial probes no species speciﬁc probes are available,
including Enterobacter cloacae and Proteus mirabilis. Identi-
ﬁcation was suboptimal in 3 cases: 2 with Staphylococcus aureus
that were identiﬁed as Staphylococcus species and 1 with
Escherichia coli that was identiﬁed as a lactose fermenting rod.
In 8 cases no micro-organisms were found with Gram-stain and
FISH. Average time to identiﬁcation with FISHwas 3.5 hours for
gram-negative and 4 hours for gram-positive organisms.
Compared to preliminary identiﬁcation (coagulase, optochine,
oxidase) FISH results were available 70 minutes earlier
(p < 0.001); for deﬁnite conventional identiﬁcation time gain
was approximately 16 hours (p < 0.001).
Conclusion: Identiﬁcation by FISH correlates well with
conventional culture identiﬁcation. In three cases identiﬁcation
with FISH was suboptimal because of difﬁcult interpretation of
ﬂuorescence due to the presence of large amounts of protein and
cells. The panel of probes should be extended to permit
identiﬁcation of >95% of pathogens; based on the results from
our study probes for Enterobacter cloacae and Proteus mirabilis
wouldbeof interest. FISHallows faster identiﬁcation compared to
conventional methods in a routine setting. This can be especially
useful for bloodcultures that are growth-positive in the afternoon.
For these, FISH results will be available the same day with
treatment beneﬁts for the patient, whereas conventional iden-
tiﬁcation will require overnight incubation. If the turnaround
time of the FISH procedure could be further decreased and the
panel of probes extended, FISH would provide a valuable
diagnostic improvement to the microbiological laboratory.
O145
Detection of Salmonella antibodies by ﬂagella-
based ELISA has potential for diagnosis of acute
gastroenteritis
T. Dalby, M. Strid, K.A. Krogfelt (Copenhagen, DK)
Objectives: Diagnosis of human gastrointestinal salmonellosis
is traditionally done by fecal culturing and agglutination assays.
An automatized ELISA is an obvious candidate for a more
reliable, fast and easy method of diagnosis. An indirect ELISA
employing repolymerized ﬂagella antigens was developed and
evaluated.
Methods: Two automatized indirect ELISAs employing
re-polymerized Salmonella ﬂagella were developed; H:[g,m]
ﬂagella respectively H:[i:1,2] ﬂagella were used. Both IgA, IgM
and IgG antibodies were detected. Sera from 153 Danish patients
diagnosed with infection by Salmonella enteritidis (SE) and from
150 Danish patients diagnosed with infection by Salmonella
typhimurium (ST) were obtained and analysed. Most patients
delivered blood-samples at approximately one, three and six
months after onset of salmonellosis. Cut-off values were
determined as the 90 percentile when analysing sera from
more than 100 healthy, Danish blood-donors.
Results: The developed ELISAs proved reliable, and at approx.
one month after onset of salmonellosis, anti-ﬂagella antibodies
were detected with 70% of the SE-patients and 77% of the
ST-patients; in comparison, a combined O- and H-agglutination
assay detected only 44% of the SE-patients and 8% of the
ST-patients. Three months after onset of salmonellosis, just 46%
Primary cases
+ve/total (%)
Secondary cases
+ve/total (%)
Controls
+ve/total (%)
Blood spot ELISA 6/6 (100) 95/95 (100) 0/33 (0)
Blood spot PCR 4/5 (80) 39/60 (65) 1/15 (6.7)
Table 1. Maximum level of identiﬁcation of pathogens identiﬁed
in culture (n = 148)
Pathogen in culture Total Species Genus Eubacterial
Gram-positive
Coagulase negative staphylococci 71 71 - -
Staphylococcus aureus 14 12 2 -
Streptococcus pneumoniae 2 2 - -
Streptococcus pyogenes 1 1 - -
Enterococcus faecalis 2 2 - -
Enterococcus faecum 1 1 - -
Other 11 - 8 3
Gram-negative
Escherichia coli 14 13 - 1
Klebsiella pneumoniae 5 5 - -
Pseudomonas aeruginosa 5 5 - -
Enterobacter cloacae 6 - - 6
Proteus mirabilis 4 - - 4
Other 8 - - 8
Yeast
Candida albicans 3 3 - -
Candida tropicalis 1 1 - -
Total 148 116 10 22
NB. Two pathogens were identiﬁed in 6 blood cultures
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of the SE-patients were detected as were 40% of the ST-patients.
Six months after onset, these detection-rates had decreased to
34% and 38%. Crossreactions between H:[g,m] and H:[i:1,2] anti-
ﬂagella antibodies were found. Similarly, crossreactions to
antibodies against other gastrointestinal ﬂagellated bacteria
were observed.
Conclusion: An indirect ﬂagella-based ELISA was found to be
superior to the standard O- and H-agglutination assay in
identifying patients suffering from gastrointestinal
salmonellosis. Moreover, the found sensitivities of 70% and
77%, respectively, will most likely improve if acute-phase sera
are analysed; as will be the case if the ELISA is to be employed
for diagnosis. The ELISA was not able to discriminate between
infections caused by Salmonella enteritidis and Salmonella
typhimurium, and crossreactions to other bacteria were
observed as well. An improvement of the speciﬁcity could
possibly be achieved by changing the antigen from
re-polymerized ﬂagella to monoclonal ﬂagellin fragments. The
level of anti-ﬂagella antibodies was found to decrease rapidly
succeeding a case of gastrointestinal salmonellosis.
O146
Exploring a pathogen’s gut feelings: molecular
characterisation of the mechanisms of
gastrointestinal persistence of the foodborne
pathogen Listeria monocytogenes
R. Sleator, C. Hill (Cork, IRL)
In 1999, the US Centres for Disease Control and Prevention
estimated that ~2500 cases of human listeriosis, including 500
deaths, occur annually in the United States. Given that the
majority of human listeriosis cases are associated with con-
sumption of contaminated food, the ability of Listeria monocy-
togenes to survive during gastrointestinal passage is
fundamental to disease transmission.
Objectives: To identify the molecular mechanisms
underpinning listerial growth and survival in the upper small
intestine.
Methods: Pre-genome mutational analysis, using transposon
(Tn917) and suicide plasmid (pORI19) approaches, based on
functionality, coupled with post-genomic in silico analysis of the
complete genome sequence, to identify potentially important
loci, based on homology.
Results: On entering the upper small intestine Listeria ﬁrst
encounter an osmotic challenge, equivalent to 0.3 M NaCl
(~twice the osmolarity of the blood). Further along the
intestinal tract the liver secretes up to a litre of the ‘biological
detergent’ bile into the duodenum each day, representing an
additional serious challenge to the pathogen. We identiﬁed three
gene systems in L. monocytogenes which contribute to
gastrointestinal persistence and virulence by allowing the
bacterium to evade these stresses. Firstly, OpuC, a membrane
transporter, facilitates the uptake of carnitine, an osmoprotective
compound which allows the bacterium to overcome the osmotic
challenge. Resistance to bile on the other hand is achieved
initially by excluding the detergent from the bacterial cell and
subsequently, if this defence is breached, by detoxifying
internalised bile. We identiﬁed two bile resistance
mechanisms; BilE which functions as a bile exclusion system,
and BSH a bile salt hydrolase which degrades internalised bile.
Furthermore we reveal that all three systems are co-ordinately
regulated by the alternative stress related transcriptional factor
SigB, and PrfA the master regulator of virulence potential in
L. monocytogenes.
Conclusions: The salt and bile resistance mechanisms: OpuC,
BilE and BSH, co-ordinately regulated by SigB and PrfA, play an
important role in listerial gut colonisation and virulence
potential.
O147
Epidemiological and microbiological
investigation of a gastroenteritis outbreak caused
by norovirus group II in a military unit
S.L.A. Tan, J.P.J. Loh, H.Y. Lo, B.H. Poon, C.W. Liaw,
B.H. Tan (Singapore, SGP)
Background: A gastroenteritis outbreak affecting a total of 92
military personnel who attended a dinner function was detected
in January 2004.
Objective: The objective of the investigation was to determine
the cause of the outbreak and to institute appropriate preventive
measures to prevent similar incidents from occurring in the
organization.
Methods: The investigation consisted of epidemiological,
laboratory and public health sanitation investigations.
Epidemiological investigation included case deﬁnition
formulation, case identiﬁcation, contact tracing, active case
surveillance, a case-control survey using a self-administered
structured questionnaire and statistical analysis of the survey
results. Laboratory investigation comprised of analysis for
enteric bacterial and viral pathogens using culture and
polymerase chain reaction (PCR) techniques. 9 stool samples
were obtained from amongst the affected patients. 4 of these
samples were sent for stool culture for Salmonella, Shigella and
Vibrio spp. 5 of the samples were sent for PCR analysis for Vibrio
cholerae, Vibrio parahemolyticus, Shigella spp and Norovirus.
Public health sanitation investigations involved environmental
inspection and hygiene practices auditing.
Results: 92 cases were identiﬁed out of approximately 500
participants (~18.4%) of the dinner function. The predominant
symptoms among the cases were diarrhoea (92%), vomiting
(80%) and fever (71%). The median onset of the symptoms was
28.5 hours from the time of the dinner function. Consumption
of raw oysters was found to be signiﬁcantly associated with
illness (p < 0.001). All the stool cultures were found to be
negative. PCR analysis of the 5 samples were negative for
Vibrio cholerae, Vibrio parahemolyticus, Shigella spp. 4 of the 5
PCR samples tested positive for Norovirus Group II. Water
samples were obtained from the venue and these were found
to be negative for coliforms. The public health sanitation
investigation showed that there was no lapse in the hygiene
practices.
Conclusion: The outbreak was most likely to be due to the
contamination of the raw oysters by Norovirus based on the
symptomatology of the affected cases, results of the food survey
and the positive results from the stool PCR analysis for
Norovirus.
O148
Rapid culture-independent monitoring of
gastrointestinal ﬂora changes by PCR-based
denaturing HPLC
O. Goldenberg, G. Marjoram, S. Herrmann, A. Fischer,
M. Noyer-Weidner, S. Bereswill, U. Go¨bel (Berlin, D)
Objectives: Antibiotic treatment causes drastic changes in the
gastrointestinal ﬂora leading to complications such as diarrhoea.
To acquire novel insights in the composition of the
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gastrointestinal microﬂora during antibiotic therapy, we
established a rapid culture-independent molecular approach,
allowing both global monitoring of the intestinal microﬂora, as
well as identiﬁcation of individual species.
Methods: Intestinal bacteria were detected in total DNA
isolated from stool samples by ampliﬁcation of the 16S rRNA
genes (variable regions V6 to V8). The amplicons were separated
by denaturing high-performance liquid chromatography
(DHPLC) with the WAVE system from Transgenomics Inc..
Results: The DHPLC peak-proﬁles of the PCR products were
representative for the dominant intestinal bacterial groups. The
applicability of the method was evaluated on 100 stool samples
taken from 45 patients at various points during antibiotic
therapy. The comparison of DHPLC proﬁles with band patterns
generated by denaturing gradient gel electrophoresis (DGGE)
revealed that both techniques reproducibly detected the
reduction in the bacterial diversity during antibiotic treatment.
Furthermore, DHPLC and DGGE allowed the identiﬁcation of
resistant bacterial species.
Conclusions: PCR-based DHPLC allows a rapid monitoring of
the intestinal microﬂora and the technique is superior to DGGE
for identiﬁcation of bacterial species by sequencing of DNA
from individual DHPLC fractions, as the DNA is easily sampled
and kept in solution. The technique is well-suited for the global
analysis of changes in complex microbial communities. The
identiﬁcation of bacterial species residing in patients receiving
antibiotic treatment will guide novel therapy regimens, reducing
the risk of complications.
O149
Supplementation of CHROMagar with Pal’s
medium for rapid identiﬁcation of Candida
dubliniensis
S. Ismail, M.D. Moragues , E. Eraso, M. Villar Vidal, G. Quindo´s,
J. Ponto´n (Bilbao, E)
Objective: To obtain a simple and rapid medium to identify
C. dubliniensis.
Methods: 142 strains of Candida species were studied (30
C. albicans, 100 C. dubliniensis, 3 C. krusei, 3 C. glabrata, 3
C. guilliermondii, 2 C. parapsilosis, and one C. tropicalis). Strains
were grown simultaneously on Pal’s agar (sunﬂower seed
agar) at 30C for 48–72 h, CHROMagar Candida (CHROMagar,
France) at 37C for 24–48 h, and CHROMagar Candida
supplemented with Pal’s medium (CH-P agar) at 30C for
24–48 h. Plates were examined visually by two investigators for
colour and colony morphology. Chlamydospores were
detected microscopically. The isolates were previously
identiﬁed by conventional mycological methods and
conﬁrmed by PCR.
Results: Ninety-six out of 100 C. dubliniensis isolates (96%)
formed rough colonies on Pal’s agar, 75% showed hyphal
fringe and 93% produced chlamydospores. All C. albicans
formed smooth colonies without hyphal fringe and failed to
produce chlamydospores. All C. parapsilosis and C. krusei
isolates formed rough colonies. The remaining Candida
species formed smooth colonies but none of them produced
chlamydospores. Fifty-eight out of 100 (58%) C. dubliniensis
isolates grew as smooth dark green colonies on CHROMagar
Candida and 42% as smooth light green colonies. Thirteen out
of 30 (43.3%) C. albicans isolates formed light green smooth
colonies and the remaining 56.6% formed green and dark
green smooth colonies. The other Candida species developed
different colours. Ninety-six out of 100 (96%) C. dubliniensis
isolates grew as rough colonies on CH-P agar. Seventy-ﬁve
formed hyphal fringe and 93 produced chlamydospores.
Ninety-four isolate gave a bluish green colour that was easy
to distinguish from C. albicans colony colour. All C. albicans
isolates formed smooth light green colonies failing to produce
neither hyphal fringe nor chlamydospores. Other Candida
species formed smooth or rough colonies but with a
distinguishable colour, and none of them was able to form
chlamydospores.
Conclusion: None of the individual media allowed a reliable
identiﬁcation of C. dubliniensis. However, the characteristic
colour and colony morphology, as well as the abun-
dant production of chlamydospores presented by most
C. dubliniensis isolates on CH-P allows the rapid and reliable
one step identiﬁcation of this species.
Acknowledgements: This work has been funded by projects
CO3/10 of FIS-Spain and IE019 of ETORTEK-Basque
Government.
O150
Evaluation of multiplex real-time PCR assay to
discriminate Staphylococcus aureus from
coagulase-negative staphylococci and determine
methicillin resistance from culture and human
sera
S.A.H. Awad, M. Guiver, J.P. Burnie, I. Alshami,
M. Upton (Manchester, UK)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA)
is a major cause of Nosocomial infection with a worldwide
prevalence. Early detection of MRSA is important in both
patient management and the prompt implementation of
infection control procedures. Molecular methods can be used
to detect the presence of the mec A gene and hence methicillin
resistance in both S. aureus and coagulase negative
staphylococci (CNS). Furthermore, detection of a second
target, fem A, which is speciﬁc for S. aureus and absent in
CNS allows detection of both species and methicillin resistance.
In the present study, a multiplex RT-PCR assay was
established and evaluated to detect MRSA in culture and
human sera seeded with MRSA using both of these gene
targets and a Qiagen extraction kit. The new assay measures, in
real-time, PCR product accumulation by means of dual labelled
ﬂuorogenic probes FAM and VIC.
Methods: Strains representing EMRSA types 1–17 were
examined for mecA and fem B. In addition, 83 strains of
MRSA collected from Manchester Royal Inﬁrmary (MRI) were
tested. 35 isolates of a number of different species, including
Methicillin-sensitive Staphylococcus aureus (MSSA), Methicillin
resistant Staphylococcus epidermidis (MRSE), Methicillin- sensitive
Staphylococcus epidermidis (MSSE), Streptococcus pyogenes,
Campylobacter and Escherichia coli from MRI and an in house
culture collection, were tested to determine the speciﬁcity of the
assay.
Results: Ampliﬁcation of mecA and fem B was correct for all
staphylococcal isolates with the exception of two strains. The
ﬁrst was mec A negative. The second was negative fem B, but
after further investigations it was CNS. These two isolates were
phenotypically methicillin resistant. Serial dilutions were done
to determine the sensitivity of this method, which was able to
detect as few as 1.5 · 102 cells per ml.
Conclusion: This multiplex RT-PCR assay represents a rapid,
sensitive (% 99), speciﬁc (% 100) and accurate assay for the
detection of MRSA with potential for direct detection of MRSA
from clinical specimens.
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Should doctors wear ties?
I. Ditchburn, P. Willson, A.P. Gibb (Edinburgh, UK)
Objectives: To assess the risks and beneﬁts of doctors wearing
ties.
Methods: Subjects were randomly selected at the New Royal
Inﬁrmary of Edinburgh. Samples from 40 doctors’ ties were
incubated, bacterial colonies were counted, and Staphylococcus
aureus and methicillin-resistant Staphylococcus aureus (MRSA)
colonies were identiﬁed. Doctors were asked when the tie had
last been cleaned. 100 participants were asked a questionnaire
regarding attitudes to doctors not wearing ties. Previous related
literature was reviewed.
Results: The mean bacterial colony count on a doctor’s tie was
68 and the distribution of colony counts was broad (s.d: 94). 20%
of doctors’ ties carried S. aureus. 2.5% carried MRSA. 70% of
doctors had never cleaned their tie. 93% of respondents did not
object to doctors not wearing ties. Factors that were considered
to be more important were: wearing a shirt; being clean and
tidy; being smart; wearing clear identiﬁcation; and wearing
trousers not jeans.
Conclusions: MRSA can be found on ties. Current research
suggests that doctors’ ties can carry dangerous pathogens, that
these pathogens can survive on ties for lengths of time long
enough to allow cross-infection, that bacteria may be transferred
to doctors’ hands, that bacteria may be transferred directly from
dangling tie-to-patient and that ties are a potential source of
cross-infection. A large majority of people do not object to
doctors not wearing ties. The tie may be taken away without
damaging a doctor’s professional integrity or the doctor-patient
relationship, provided other desirable attire remains. Ties are
associated with a risk of transferring pathogens, and are of little
obvious beneﬁt.
O152
A hospital-wide outbreak of Pseudomonas
aeruginosa infections associated with the use of
bottled mineral water
T. Eckmanns, M. Martin, K. Weist, H. Ru¨den (Berlin, D)
Objectives: Mineral water (MW) should be free of P. aeruginosa
according to the legal force of the mineral and table water act in
Germany. We investigated an outbreak of P. aeruginosa where
the pathogen was introduced into the hospital by MW in bottles.
Methods: One medical intensive care unit (ICU) noticed an
increase of pneumonias with P. aeruginosa. Environmental
samples (tap water samples, siphons, surfaces, equipment for
oropharyngeal hygiene, MW bottle) from the unit were cultured
and typed. Clinical P. aeruginosa isolates were collected from ﬁve
further ICUs. Microbiologic results were reviewed to determine
the numbers of P. aeruginosa on a weekly time scale for the ICUs.
All isolates were genotyped by PFGE and an AFLP PCR–
method.
Results: Clinical specimens from ﬁve medical ICU patients
yielded the same P. aeruginosa strain. In 4 from 103
environmental samples (3 · siphon, 1 · MW) P. aeruginosa was
isolated. The isolates of the siphons were different to all patient
isolates. The MW isolate was genetically indistinguishable to the
5 ICU patient isolates. Later the same strain was isolated in 4
more MW bottles of the same batch and in clinical specimens
from 3 more medical ICU patients and seven patients of ﬁve
other ICUs, respectively. Ten of the total 15 patients with
P. aeruginosa developed pneumonia. After recognising the
outbreak and the potential source delivery of this mineral
water to the patients was stopped. The mean number of all ICU
patients with newly detection of P. aeruginosa was 3.8 per week
(Std. Dev. 1.6) in the 42 weeks prior to the outbreak. During the
6 weeks of the outbreak the weekly occurrence of new
P. aeruginosa was 6, 6, 10, 9, 3, and 9 respectively (mean 7.2).
In the four weeks after the outbreak on the ICUs the mean
weekly occurrence of new patient with P. aeruginosa was 3.3.
Conclusions: This hospital wide outbreak was related to
bottled MW contaminated with P. aeruginosa. The water was
drunken by patients with tracheostomy tubes and used for oral
(enteral tube) drug preparation. The outbreak ceased after
determining the delivery of MW of this brand to the patients.
Production control of MW needs to be improved and use of MW
for ICU patients, especially those with endotracheal ventilation
may increase the risk of nosocomial pneumonia.
O153
Aerobiocontamination of moulds: epidemiology
and inﬂuence of on invasive fungal infection in a
tertiary care hospital
A. Imhof, M. Spiess Pangrazzi, C. Ruef (Zurich, CH)
Objectives: Nosocomial aspergillosis, is thought to be caused
primarily by Aspergillus organisms in the air. We conducted
this study to asses the role of mold concentrations of ambient air
and the impact of various weather conditions on mold
concentration inside the hospital.
Methods: Air sampling was conducted in 18 areas (6 outdoors)
of our hospital (1000 beds, tertiary care) two times a week. The
weather conditions were monitored at the day of sampling.
Surveillance of Nosocomial Aspergillus infection was conducted
by reviewing the records of all hospitalised neutropenic patients
from 4/2004 to 10/2004.
Results: During the study period a total of 614 air samples were
available of which 514 (84%) revealed at least one fungal colony.
Aspergillus sp. (AS) were isolated most frequently (mean 12 cfu/
m3 of air), followed by Zygomycetes (zyg) (0.6 cfu/m3) and
other molds (3 cfu/m3). A. niger (mean 3 vs. 2 cfu/m3), A. ﬂavus
(1.5 vs. 0.3 cfu/m3) and A. terreus (0.2 vs. 0.01 cfu/m3) were
found more frequently inside the hospital, whereas A. fumigatus
was more common outdoors (10 vs. 7 cfu/m3). During a short
time of renovation activity, colony counts of AS (OR: 2.93, 95%
CI 1.58–5.43) and zyg (OR: 4.08, 95% CI 2.29–7.29) increased
signiﬁcantly. Fungal growth was highest at 19–22C (42% of
isolates), in particular AS (OR: 1.62, CI 1.04–2.54) and zyg (OR:
3.53, CI 1.54–8.09). On rainy days, there were signiﬁcantly
higher chances of growth of AS (17 vs. 8 cfu/m3, p = 0.003) and
zyg (0.5 vs. 1, p = 0.024) than during other weather conditions.
High risk patient with leukemia or bone marrow transplantation
were hospitalized during the study period. The number of
neutropenic days was 635 with a mean of 31.6 days. Invasive
mold infection was diagnosed In 10 patients (53%), and one of
them died due to this infection.
Conclusion: Our observations show relatively high
concentrations of A. fumigatus in all environments, with a
signiﬁcantly increased amount of AS spores on rainy days. Our
investigation suggests that exposure of high risk patients to high
concentration of spores is a continuous risk for invasive fungal
infections.
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Detection of occult blood as a marker for IC
practice
S. Mehtar, O. Shisana, T. Mosala, F. Gxamza (Cape Town, ZA)
Objectives: The purpose was to evaluate Infection Control (IC)
practice using occult blood (OB)on clinical and non items used
in dental and paediatric HCF as a marker for good IC practice.
Methods: In a South African province all dental and paediatric
facilities were surveyed for IC practice. The presence of OB in
the environment and on critical care items were tested just prior
to use on the next patient. on site sampling was carried out
using a rapid immuno-chromatographic method (OBTI) (used in
forensic analysis), capable of detecting 1:100000 Hb; a negative
result reﬂected adequate cleaning or heat sterilization.
Results: Overall, 31/110 (25%)and 15/41 (37%) of dental items
tested were positive for OB, mainly found on extractor forceps,
drill heads and probes. In the maternity & baby units, overall
25% o clinical equipment tested positive, particularly in the
labour and maternity wards. The ﬁndings reﬂect poor levels of
IC practice and training, but most importantly the cleaning &
sterilization of critical equipment was inadequate.
Conclusions: We found the OBTI test kit useful as a rapid test
method while investigating IC practice particularly in poorly
resourced settings. The test can be performed by on site, with
minimum training and is an effective tool in assisting with IC
evaluation. In countries with a national HIV prevalence of 20%,
the presence of visible or occult blood on critical items of clinical
equipment services, the possible risk of nosocomial transmission
cannot be ignored. It is therefore essential that a test which can
help to visualise probable risk of transmission will also serve as
an effective teaching tool in IC and hygiene.
O155
Nurse-to-patient-ratio as risk factor for
nosocomial primary bloodstream infection
in ICUs
T. Eckmanns, S. Ba¨rwolff, M. Behnke, H. Grundmann,
H. Ru¨den, P. Gastmeier (Berlin, D; Bilthoven, NL; Hannover, D)
Objectives: Nosocomial primary bloodstream infections (BSI)
cause signiﬁcant morbidity and mortality among hospitalized
patients and have an enormous economic impact. In several
studies understafﬁng was identiﬁed as a risk factor for
outbreaks of BSI. However, little is known about the inﬂuence
of nurse-to-patient-ratios on BSI in endemic situations on ICUs.
We investigated the nurse-to-patient-ratio as a possible risk
factor for BSI in an endemic situation.
Methods: A prospective cohort study was done to identify
exposures associated with cases of BSI. During an 18-month
period all patients who were in one of two ICUs (A = 12 and
B = 24 beds) for more than 3 days were included. Data collected
on admission and discharge: admission date, age, sex, SAPS II,
infections on admission, discharge date. Additional data
collected during hospital stay: days on ICU, intubation,
urinary tract catheter, central venous catheter, dialysis,
surgical procedure during the stay on the ICU, and SOFA.
Daily bed occupancy and nurse stafﬁng on the ICU were also
recorded. Nurse-to-patient ratio was determined by dividing
nurse stafﬁng by the patient density. Risk factor analysis
included univariable approach and Cox proportional hazards
regression analysis.
Results: In total 801 patients were treated in the two ICUs. There
was no difference between patients with BSI and patients without
BSI concerning mean of age, distribution of sex, average stay on
ICU of patients with no BSI and average duration between
admission and diagnosis of BSI of case patients, and numbers of
infections on admission in the two groups. Patientswith BSI had a
signiﬁcant higher SAPS II on admission as patients who
developed no BSI. 21 patients (2.6%) had a BSI. The nurse-to-
patient ratio of ICU A was 0.86 and of ICU B 0.91. The overall
nurse-to-patient ratio in patients without BSI was 0.90 and in
patients with BSI was 0.87. The Hazard ratio of nurse-to-patient
ratio in the Cox analysis was 0.61; p = 0.04, that means patients
with average higher nurse-to-patient ratio per day had less BSIs.
Conclusions: BSI is highly dependent on hygienic behaviour.
The result of the study underlines that stafﬁng is an important
point in patient safety in hospitals. To our knowledge is this the
ﬁrst studywhich investigated the inﬂuence of stafﬁngon endemic
BSI in one hospital where the patient was the unit of analysis.
O156
Efﬁcacy of nosocomial infection control
in urological patients: building benchmarking
through active surveillance
A. Agodi, M. Barchitta, A. Anzaldi, F. Marchese, A. Bonaccorsi,
P. Bellocchi, P. Cantaro, M. Motta (Catania, I)
Objectives: Many studies have suggested that disseminating
Nosocomial infections (NI) risk-adjusted reliable infection rates
obtained through surveillance to healthcare personnel (HCP)
and establishing a link with prevention efforts is essential for
successful control. Our study goals were: i) to evaluate the
efﬁcacy of feeding back NI surveillance data to HCP of a
Urologic Clinic and ii) to provide indicators useful for
benchmarking within and between surgical wards.
Methods: Active surveillance was performed at the Urologic
Clinic of an Italian University Hospital, in accordance with the
methods, protocols and deﬁnitions of the National Nosocomial
infections Surveillance (NNIS) System, USA. A ﬁrst 1 month-
surveillance survey was conducted in June-July 2002 and data
recorded and analyzed. Diagnosis was based on CDC
deﬁnitions for NI. Each suspected infection was discussed and
validated by the epidemiologists, infection control personnel
and surgeons. Indicators were calculated including site speciﬁc
NI incidence and incidence density rates. At the end of the study
a feedback session was held and results were communicated
and discussed with the staff. A second study was planned and
performed as a 4 months-surveillance survey from April to July
2004. Surveillance data were analyzed and compared.
Results: The cumulative incidence of NI decreased from 8.0%
patients in 2002 to 2.3% in 2004 and incidence density from
11.5& patient-days to 3.2& (p < 0.05, chi square test).
Symptomatic urinary tract infections were not detected in 2002
while in 2004 their incidence was 1.4& patient-days, 13.04&
catheterized patients and 3.04& patient-days of catheterization.
Surgical site infections (SSI) incidence and incidence density
decreased respectively from 5.4% patients to 1.3% and from
7.7& patient-days to 1.8& (p < 0.05). SSI rates by operative
procedure and NNIS risk index category decreased from values
above the 90th percentile of NNIS distribution to values between
the 75th and the 90th percentile.
Conclusions: Few surveillance data have been published on NI
rates in urological patients. Our study represents a contribution
to building speciﬁc benchmarking and an example of successful
control of NI in a urology ward. Several explanation may be
suggested to have prevented infections, but the role of feeding
back information to ‘those who need to know’, changing
personnel behaviour and improving the quality of patient care
is shown to have been critical.
Clinical Microbiology and Infection, Volume 11, Supplement 2, 2005
39
O157
Validation and improvement of an automated
surveillance system for nosocomial bacteraemia
C. Bellini, C. Petignat, P. Francioli, A. Wenger, J. Bille,
A. Klopotov, Y. Vallet, R. Patthey, G. Zanetti (Lausanne, CH)
Objectives: We developed a computerized automated
surveillance system (ASS) for bacteraemia in a 850-bed
university hospital. The aims of this study were to validate
ASS-generated results and to identify possible improvements.
Methods: TheASSwas basedon a computerizeddatawarehouse
that included laboratory data (date of all blood and catheter
cultures, and species identiﬁcation and antibiotic susceptibility
testing in positive cultures) and demographic data (patients’ ID,
ward, and date of admission). Algorithms distinguished true
bacteraemia from contamination (culture of a possible contam-
inant in one of several blood samples), nosocomial bacteraemia
(positive culture of blood drawn >48 hours after admission), and
catheter-related bacteraemia among the latter (same bacteriawith
the same antibiotic susceptibility in blood and on IV catheter
cultured simultaneously ±6 days). Bacteremias that occurred
more than 3 days apart were considered distinct episodes. We
reviewed all positive blood cultures classiﬁed by the ASS as
nosocomial bacteraemia not related to a catheter in adult patients
admitted over 2 years on the followingwards: surgery,medicine,
and medical and surgical ICUs. The gold standard for validation
of classiﬁcation by the ASS was a manual review of patients’
charts using the CDC criteria for nosocomial infections.
Results: The ASS identiﬁed 154 nosocomial bacteraemia not
related to a catheter. 106/154 (69%) were conﬁrmed by chart
review (77% in medicine, 60% in surgery, and 73% in ICU). There
were 3 reasons for misclassiﬁcation by the ASS: a late
documentation of community-acquired bacteremias in 3/154
(2%) cases; the absence of catheter culture in 25 (16%) cases of
bacteraemia clinically attributed to catheter infection; and
duplication of bacteraemia sustained over >3 days in 20 (13%)
cases (13 of which being fungaemia in surgical patients). We
explored 2 alternative uses of available data to improve ASS
performance: 1) attributing all coagulase-negative bacteremias to
catheter infections led to correct classiﬁcation of 8/154 (5%) more
cases at the price of 2 additional misclassiﬁcations; 2) expending
the time interval to 10 days for deﬁnition of duplicates in case of
fungaemia allowed correct classiﬁcation of 11/154 (7%) cases at
no cost. TheASS accurately classiﬁed nosocomial bacteraemia not
related to catheter in 78% of the cases by implementing both
strategies.
Conclusion: ASS is a promising alternative to manual
surveillance of nosocomial bacteraemia.
O158
Rise and fall of Acinetobacter baumannii
bloodstream infections: efﬁcacy of a multifaceted
intervention
M. Paul, B. Rubinovitch, R. Holinger, H. Konisberger, Z. Samra,
S.D. Pitlik, M. Weinberger (Petah Tikva, IL)
Background: During the years 1997–2001 a hospital-wide
sustained rise in the incidence of multi-drug resistant (MDR)
Acinetobacter baumannii (AB) bloodstream infections (BSI) was
observed in our centre, a 900-bed primary and tertiary care
university hospital catering an adult population. While control
of single source outbreaks has been reported, data on hospital-
wide endemic situations are scarce.
Methods: A prospective BSI surveillance system in on going in
the hospital since 1988. MDR AB was deﬁned by resistance to all
antimicrobials except carbapenems, ampicillin-sulbactam or
amikacin (excluding colistin). Blood cultures were processed
using Bactec 9240 (Becton Dickinson, USA) and antibiotic
susceptibilities were tested by disc diffusion. Intervention: In
2002 intensive staff education and multiple interventions were
initiated hospital-wide. Alcohol-based hand-rub solution was
distributed in patients’ rooms and on patients’ beds in intensive
care units (ICU). Hand hygiene guidelines were implemented
and reinforced. All cleansing protocols and housekeeping
procedures were reviewed and mended. A laboratory alert for
AB isolates was installed; patients colonised or infected with
MDR strains were placed in contact isolation for the duration of
their hospitalisation. Infection control personnel rigorously
surveyed isolation policy. Restriction of carbapenem use was
reinforced.
Results: Between 1997–1999 the overall incidence of AB BSIs
increased 3-fold from 0.8 to 2.4 per 1000 admissions and
from 4.3 to 36.9 in ICU (9-fold, ﬁgure). Incidence persisted
until 2002 and during this period AB was the primary
BSI acquired in hospital. From 2002 to 2003 the incidence
dropped by 42% overall (2.7 to 1.6 per 1000 admissions) and
by 70% in the ICU (45.9 to 14.3). Carbapenem consumption in
ICU decreased from 4.9 gram per admission in 2002 to 3.6 in
2003.
Crude mortality was 62.2%. The most common identiﬁed source
of BSIs was pneumonia (32%), followed by catheter-related
infection (6%). Source remained unknown in 36.8% of cases.
Resistance rates are shown in the table.
In the last study year, 2003, 45% of AB BSI isolates were resistant
to carbapenems and 25% to ampicillin-sulbactam.
Discussion: A multifaceted intervention emphasizing
environmental and hand hygiene, contact isolation and
restriction of carbapenem use has contained a sustained
epidemic of AB and reversed a dramatic increase in BSIs in
our centre.
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Resistance rates of AB BSI isolates %
Hospital stay prior to positive culture
<48 hours (n = 68) >48 hours (n = 464)
Ampicillin-sulbactam 5.4 14.4
Imipenem 10.7 48.3
Amikacin 43.3 65.4
Ceftaziclime 73.1 85.9
Ciproﬂoxacin 76.1 89.7
Colistin 0 0.9
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Emphasis on quality of hand disinfection and
catheter care increases quality of and compliance
with hand disinfection and reduces the incidence
of catheter-related bloodstream infections
W. Zingg, A. Imhof, E. Ehrenreich, C. Ruef (Zurich, CH)
Objective: To study the impact of teaching interventions on the
compliance of hand disinfection by healthcare workers (HCW)
in ICU and on the rate of central venous catheter-related
bloodstream infection (CR-BSI) in ICU patients.
Methods: Prospective surveillance of CR-BSI in 5 ICUs (cardiac
surgery, neurosurgery, general surgery, trauma surgery,
internal medicine) of a large teaching hospital using CDC
deﬁnitions and methods during two periods (baseline [period I,
September–December ’03, 501 patients, 6’648 catheter days],
postintervention [period II, March–July ’03, 501 patients, 7’382
catheter days]. Observation of compliance with hand
disinfection during both periods. Teaching of standards of
catheter care and proper technique of hand disinfection between
the two periods during multiple teaching sessions in small
groups.
Results: Compliance of HCW in ICU with hand disinfection
was signiﬁcantly higher during period II than during period I
(65% versus 59% overall). Overall compliance with hand
disinfection was higher after patient contact than before
patient contact. The proportion of technically correct hand
disinfection increased from 22.5 to 42.6% overall (before patient
contact from 26% to 45%, after patient contact from 21 to 56%).
The incidence density (infections/1000 catheter days) of CR-BSI
was 4.4 during period I and 1.4 during period II (p < 0.001).
CR-BSI was a highly signiﬁcant risk factor for a lethal outcome
(8.8% in both periods): odds ratio 2.7 [period I], 2.65 [period II].
Independent risk factors for the development of CR-BSI were:
catheter use >7 days, length of stay >10 days, Charlson index 3,
presence of a nosocomial infection at another anatomical site.
Gram positive bacteria were responsible for 81% of CR-BSI,
followed by Candida spp. (10.8%) and gram negative bacteria
(8.1%).
Conclusions: Teaching of standards of catheter care as well as
indications and proper technique for hand disinfection are
successful interventions to reduce the rate of CR-BSI. While
overall compliance with hand disinfection was relatively high
compared with published studies, disinfection was frequently
performed using inadequate technique. Monitoring of
compliance with hand disinfection should include some
parameters that allow to assess the quality of hand
disinfection as well. As many identiﬁed risk factors of CR-BSI
are not modiﬁable, strategies to reduce the risk of CR-BSI should
focus on the quality of catheter care and hand disinfection.
O160
Prevention of urinary tract infection in spinal
cord-injured patients: safety and efﬁcacy of a
weekly oral cyclic antibiotic programme
J. Salomon, P. Denys, C. Merle, J.L. Gaillard, C.M. Perronne,
L. Bernard (Garches, F)
Background: Spinal cord injury patients with a neurogenic
bladder have an increased risk for a UTI. Patients who have
recurrent UTI receive multiple courses of antibiotic therapy,
markedly increasing the incidence of antibiotic-resistant bacteria
(ARB) and health care costs.
Aim: To determine the safety and efﬁcacy of a weekly oral
cyclic antibiotic (WOCA) regimen to prevent UTI in a
prospective cohort study of paralyzed patients with
neurogenic bladder undergoing intermittent catheterization for
bladder drainage.
Method: We examined the impact of a WOCA programme
upon the number of cases of UTI, antibiotic tolerance, and the
occurrence of ARB (anal and urinary samples). The WOCA
prophylaxis consists in the alternant administration of a dose of
antibiotic (amoxicilline 3000 mg, ceﬁxime 600 mg, fosfomycin-
trometamol 6000 mg, nitrofurantoin 200 mg, or trimethoprim-
sulfamethoxazole 1600–320 mg) once weekly. During week A,
the patient takes a single antibiotic (antibiotic A), and the
following week (week B) the patient receives another antibiotic
(antibiotic B). Antibiotic was speciﬁcally adapted according to
the recent culture of a 6 week urine specimen.
Results: 32 patients (17 men, 15 women; mean age, 47 years)
with neurogenic bladder were included. Before starting the
WOCA program, patients had presented with 8.8 symptomatic
UTI/year (included 162 febrile UTI: 37 prostatitis, 5 orchitis, 120
acute pyelonephritis; 45 hospitalizations). Following antibiotic
prophylaxis (follow-up of 2 years), there were 2 symptomatic
UTI/year (included 18 febrile UTI: 12 acute pyelonephritis, 6
prostatitis; 7 hospitalizations). Greater than 90 % of the patients
were careful to take their prophylactic therapy as directed. No
severe adverse events were reported and no new case of
colonization with multi ARB was reported.
Conclusion: WOCA prophylaxis reduces the number of UTI in
patients with neurogenic bladder susceptible to recurrent
infection.
New antibacterials for the decade: strategies to deliver agents with
novel actions (Symposium arranged by GlaxoSmithKline)
S165
The medical need for new agents
P. Hawkey (Birmingham, UK)
Dramatic increases in the prevalence of antibacterial resistance
have occurred in recent years as an inevitable evolutionary
response to the extensive use of antibacterial agents. The
efﬁcacy of new and existing agents continues to be compro-
mised, both by the transmission of existing mechanisms via
clonal spread and by new, emergent mechanisms of
resistance. Antibacterial resistance occurs across all bacteria,
both Gram-positive and Gram-negative, and is widespread
amongst community-acquired and nosocomial infections. In
the community, instances of multi-drug-resistant Streptococcus
pneumoniae, in which strains are resistant to three or more
drug classes, are becoming common and increasingly include
resistance to ﬂuoroquinolones as well as beta-lactams, macro-
lides and other classes. Furthermore, community strains of
MRSA are beginning to arise independently of nosocomial
strains and can exhibit increased virulence. New surveillance
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data show that community strains of Enterobacteriaceae act as
reservoirs for extended-spectrum beta-lactamase (ESBL) resist-
ance, the extent and types of which are increasing. Fluoroqu-
inolone resistance in E. coli is also increasing and exceeds 50%
in much of S.E. Asia.
New patterns of resistance are being observed in hospital-
acquired infections. MRSA is frequently observed in this
environment and is becoming increasingly difﬁcult to treat as
strains become resistant to almost all available drug classes. In
the mid-1990s, the ﬁrst strains of MRSA with decreased
susceptibility to vancomycin were detected, and the vanA
gene has been identiﬁed in 3 independent strains of MRSA.
Severe hospital-acquired infections are frequently caused by
Gram-negative pathogens such as Pseudomonas aeruginosa,
Acinetobacter spp. and Stenotrophomonas maltophila. These path-
ogens are resistant to many beta-lactams, and although resist-
ance to many carbapenems remains rare, resistance to those of
the IMP, VIM and OXA family is increasing.
S166
Options for sustainable antibacterials
T. File (Rootstown, USA)
The last two decades have seen a decline in antibacterial
development productivity and, more recently, in the scale of
antibacterial R&D. During the same time, the level and preval-
ence of antibacterial resistance have increased to worrying
levels. The clinical impact of current resistance levels in hospital
infections is well established, and accumulating evidence
suggests that resistant bacteria are implicated in the clinical
failure of antibacterials in the community setting. Given the
current situation, it is vital to develop new, effective agents and
to sustain the clinical utility of these and existing therapies.
Many recent initiatives have recognized the importance of using
antibacterials appropriately in order to sustain antibacterial
efﬁcacy. This requires a multifaceted approach. Firstly, an
accurate clinical diagnosis and severity assessment is vital to
avoid the use of antibacterials when they are not warranted,
such as in viral infection. Secondly, agents with an appropriate
spectrum of activity and pharmacodynamic proﬁle should be
selected, to provide maximal reduction of bacterial load and
minimize the potential for selection and spread of resistance.
Consideration of local resistance patterns is essential when
selecting the type or dose of agent to address resistant isolates.
Development of improved diagnostic techniques to differentiate
aetiologies, and stratiﬁcation of patients according to predictors
of both bacterial resistance and outcome would further enable
clinicians to tailor therapy choices for individuals. High-dose
and shorter treatment may reduce risk factors for selection of
resistant strains. Vaccines may also play a role in sustaining
antibacterial efﬁcacy by reducing the incidence of bacterial
infections and their sequelae, but their effects on resistance may
be limited by replacement of vaccine serotypes with non-vaccine
serotypes that have emerging resistances.
Antibacterials from new classes are urgently required that will
combat existing resistance, minimize the emergence of
resistance and the risk of cross-resistance, provide high
bacteriological efﬁcacy against target organisms, possess a
well-deﬁned safety proﬁle and provide a convenient dosing
regimen. In the future, advanced techniques may enable the
development of antibacterials designed to target speciﬁc
indications or pathogens, while having a reduced ecological
impact. Some novel agents are reaching the late stages of
development and their appropriate use should be encouraged
from the outset.
S167
Targets: hits and misses
D. Payne (Collegeville, USA)
The genomic era of antibacterial drug discovery was triggered
by the completion of the H. inﬂuenzae genome in 1995. At that
time, it was thought that the antibacterial therapy area was the
ideal model to illustrate the ability of genomics to rapidly
deliver novel mechanism medicines. Consequently, many large
pharmaceutical and biotechnology companies set up genomic-
based antibacterial programmes. It was generally believed that
genomics would fuel a ﬂow of targets that could be screened to
rapidly identify new classes of antibiotics. This genomic
exploitation was spectacularly successful in delivering hun-
dreds of novel antibacterial strategies. A review of the
literature from the last 9 years reveals a fraction of the
substantial effort applied to this area, showing >35 different
companies ran >120 screens on >60 different antibacterial
targets. Clearly, investment in this area has been signiﬁcant,
but success based on the number of novel acting antibiotics in
the industry pipeline is alarmingly low and there are some key
scientiﬁc reasons for this poor success rate. First, screening
metrics illustrate that the success of antibacterial High
Throughput Screening (HTS) is signiﬁcantly less productive
than screening targets from other therapeutic areas. Second,
optimizing hits and leads from HTS to molecules with all the
requisite properties to be a safe and efﬁcacious antibacterial
can be exceptionally challenging compared to creating new
generations of antibacterials from established classes where
substantial background structure-activity relationships exist.
Third, the initial bioinformatic and genomic analysis used to
validate a target may not always extrapolate to a broader set of
strains from the species or a range of target species. Conse-
quently, a refocus of effort and resource is required to tackle
antibacterial discovery in the post genomic world. Investment
in new genomic technologies or novel target discovery is no
longer merited. Focusing signiﬁcant, consolidated medicinal
chemistry and microbiology resources on advanced leads is
essential for success rather than spreading effort across a large
portfolio of targets. Furthermore, approaches for enhancing
success at HTS and prioritizing effort on targets that are
validated ‘beyond the genome’ are required. This presentation
will illustrate some of the scientiﬁc challenges faced by
GlaxoSmithKline in exploiting genomics to deliver new anti-
bacterial agents and describe some of the strategies implemen-
ted in our ongoing efforts to seek new antibacterials in the post
genomic world.
S168
The future, beyond the horizon
R. Finch (Nottingham, UK)
Development of novel antibacterial molecules, particularly from
new drug classes, presents several challenges. The demonstra-
tion of utility against bacteria resistant to other antibacterial
classes is essential for registration, reimbursement and market-
ing, but presents issues related to clinical trial size, costs and
end-points. Furthermore, product labelling and use may be
restricted in the future, at least at initial introduction, by
regulators and policy makers. For some indications, such as self-
limiting infections or indications where the value of antibacte-
rials is debatable, paradigms for clinical trials are changing
towards patient-reported outcome measures and demonstration
of superiority over comparators. Additionally, antibacterial
molecules of new classes present unknown safety liabilities,
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requiring extensive evaluation and tracking throughout the
product’s lifespan. The commercial potential of new products
may be impacted by reduced use owing to continuing efforts to
control resistance and costs through guidelines and reimburse-
ment controls, as well as narrowed indications. Furthermore, a
product’s lifespan may be reduced by the development of
antibacterial resistance if use is expanded greatly or inappro-
priately. Positive solutions must be found to encourage the
development of new antibacterials. Strategies could include
lowering R&D costs by introducing measures such as guaran-
teed ‘fast-track’ regulatory review or by focusing on the quality
rather than the quantity of clinical trials. Regulatory agencies
could further assist by providing direction on regulatory
expectations and identifying areas of debate to be addressed
during the development process. Additionally, research costs
could be offset by partnerships between academia and industry,
or by provision of public or private funding, tax breaks, and
revision of patent terms. Given the delay between initial
research and ﬁnal approval, we must act now to improve
future antibacterial development and introduction of new
molecules. To achieve success, coordinated action by pharma-
ceutical companies, regulatory agencies, health organizations,
government bodies and the scientiﬁc community will be
required.
Staphylococcus aureus disease – from basic science to clinical practice
S182
Molecular basis of Staphylococcus aureus
adherence to sqamous epithelium
T. Foster, E. Walsh (Dublin, IRL)
Staphylococcus aureus permanently colonizes the moist squamous
epithelium of the anterior nares of ca 20% of the population, and
transiently colonizes another 60%. Given that this is a risk factor
for invasive infection, it is surprising that there has been so little
interest until recently in the bacterial and host factors that
determine colonization. To address this, a simple assay for
measuring bacterial adhesion to desquamated epithelial cells
from the nares of donors was developed. S. aureus strains
defective in the surface proteins clumping factor B and serine-
aspartate repeat proteins SdrC and SdrD showed reduced
adherence. Conversely, expression of these proteins, as well as
a novel surface protein SasG, in the surrogate host Lactococcus
lactis, promoted adherence to squamous epithelial cells. Puriﬁed
recombinant rClfB protein bound strongly in a dose-dependent
and saturable manner to puriﬁed recombinant human cytoker-
atin 10 (K10; KD 1.4–1.7 micromolar) and to recombinant human
loricrin, major proteins of the squamous cell interior and
corniﬁed surface layer, respectively. Also, bacteria expressing
ClfB adhered strongly to immobilized keratin 10 and loricrin. In
the case of K10 it was shown that rClfB bound to the C-terminal
‘tail’ region which is composed predominantly of unusual
peptide sequences called glycine loops. A synthetic peptide
mimicking a typical glycine loop YGGGSSGGGSSGGY inhibited
ClfB binding to K10. It is noteworthy that loricrin has three
glycine loop regions, any one of which could be involved in
promoting ClfB binding. This is currently being investigated.
Binding of ClfB to loricrin was inhibited by the K10 peptide.
S184
Molecular interactions with platelets – lessons for
endovascular infections
C. Heilmann, S. Niemann, M. Hermann, G. Peters,
B. Kehrel (Munster, Homburg/Saar, D)
Staphylococcus aureus has emerged as a predominant cause of
infective endocarditis (IE), which often is fatal with mortality
rates of 20–40%. The pathogenesis of IE is characterized by a
series of events: initial endocardial damage results in exposure
of the subendothelium and subsequent deposition of platelets
and ﬁbrin. The ﬁbrin-platelet matrix on the damaged valves
may serve as binding foci for adhering bacteria. The ability of
S. aureus to adhere to platelets and to induce platelet
aggregation is considered as a critical factor in S. aureus-
associated IE. To identify and characterize bacterial factors
involved in the S. aureus-platelet interaction, we generated a
phage display library of S. aureus genomic DNA and a
phagemid vector. The library was afﬁnity-panned against
gel-ﬁltered, immobilized platelets. Repeatedly isolated clones
contained either a portion of the C-terminal domain of the
S. aureus coagulase or the N-terminal domain of the extracel-
lular ﬁbrinogen (Fg)-binding protein Efb. The S. aureus
coagulase and Efb may interact with platelets via Fg as a
bridging molecule. In another approach, repeatedly isolated
clones contained overlapping DNA fragments encoding a
portion of the S. aureus ﬁbronectin-binding proteins (FnBPs).
In a ﬂow cytometric adherence assay, Staphylococcus carnosus
producing either FnBPA or FnBPB showed increased adher-
ence to activated, gel-ﬁltered platelets. Adherence was pro-
moted by the addition of Fn or Fg, which most probably act
as bridging molecules. Interestingly, promotion of adherence
mediated by Fn was in the same range with S. carnosus
producing either FnBPA or FnBPB, whereas promotion of
adherence mediated by Fg was signiﬁcantly more pronounced
with S. carnosus producing FnBPA than with S. carnosus
producing FnBPB. Furthermore, FnBPA, but not FnBPB
mediated platelet aggregation when present on S. carnosus
cells indicating a substantial functional difference between
both proteins. To identify platelet-binding sites involved in
that interaction, platelets from knockout mice and from
patients with selective inherited deﬁciency of membrane
proteins or of granules were used. CD36, GPIIb/IIIa, and
P-selectin were excluded as receptors for S. aureus and
the contents of alpha-granules, such as Fg, Fn, and
thrombospondin, have been shown to be essential for the
S. aureus-platelet interaction. Furthermore, we found that
soluble ﬁbrin, but not Fg is the main mediator of that
interaction.
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Benchmarking nosocomial infections (Symposium co-organised by
SHEA and ESGNI)
S192
Prevalence studies: what do they tell us, if
anything?
J.F.H. Humphreys ESGNI/SHEA
Prevalent studies of nosocomial infection outline the number of
cases of infection in a deﬁned patient population either during a
speciﬁc period or at a speciﬁed point in time. The major
shortcomings of such studies are that they give us merely a
‘snapshot’ and do not convey the fully impact of infection.
However, they are relatively easy to conduct, and if carried out
regularly, can indicate trends over time. Furthermore, when
done nationally with a common protocol, it is possible to assess
variations in infection rates that may subsequently be investi-
gated further. Issues that need to be addressed when carrying
out prevalent surveys include the comprehensiveness of the
database, the deﬁnitions used, and both the data recording and
analysis. Whilst it may not be possible to conduct frequent
prevalent studies covering all hospitalised patients in a large
institution, intermittent studies or repeated studies in speciﬁc
areas, where the infection rate is relatively high, e.g. the
intensive care unit, are of considerable use, but the results
must be fed back to the relevant health care personnel. Periodic
national prevalence surveys of nosocomial infection, such as
those conducted in many European countries over the last 15
years indicate areas requiring speciﬁc interventions. However,
prevalence studies are not a substitute for a comprehensive
incidence-based surveillance programme that captures all infec-
tions in a hospital or institution.
S193
The Dutch PREZIES network: national
surveillance systems-more than just data
collection
J. Kluytmans (Breda, NL)
Surgical Site Infections (SSI) are important complications of
surgery. Although many advances have been made in asepsis,
antisepsis and surgical technique over the last century, infec-
tions are still relatively frequent complications.The pathogenesis
of SSI is complex and not completely understood. Therefore,
prevention can only be partly achieved by control of the process
and outcome measurement remains essential for optimal
performance. Repeatedly it has been shown that measuring of
SSI-rates with active reporting of these rates to the surgeons
results in a reduction of the SSI-rate. Although this is generally
accepted there is no consensus how to do this. There are many
aspects that should be taken care of, to produce reliable and
reproducible SSI-rates. Things get even more critical when these
rates are used for comparisons. The following aspects are of
major importance: Deﬁnitions, case-ﬁnding methods and control
for confounding (risk factors should be taken into account).In
the last decade several large, multicentre, surveillance projects
have been performed and have shown that signiﬁcant variations
in the SSI-rates between different hospitals exist. However, these
variations were for an important part caused by differences in
the case-ﬁnding methods used or by differences in the popu-
lation of patients operated on. Therefore, they do not necessarily
reﬂect true differences in the performance of the participating
centres. Also, it has been shown that centres that participate in
such projects for several years achieve a signiﬁcant reduction of
the SSI-rates. It are true quality improvement projects. The
conclusion is that measuring SSI-rates in a standardised way
with reporting of the rates to those that can improve the
outcome, improves the quality of care. Now those rates have
been gathered, there is a demand from the public to know the
hospital speciﬁc rates. One of the main reasons for this must be
that patients should be able to make a more justiﬁed decision
were they want to be operated. The question is if this is a
justiﬁed assumption? There are several arguments against
publication of SSI-rates: 1) It is likely that the SSI-rates will be
less reliable (too low) when they are published in a way that the
centre or even surgeon involved can be identiﬁed. 2) The risk
factors involved are not known completely and therefore the
observed differences do not necessarily reﬂect true differences
in performance. In conclusion, although the public demand
seems reasonable at a ﬁrst glance it is not the way to go at this
time. The SSI-rates cannot be used to make a reliable decision
were to be operated most safely (apart from other aspects of the
surgical procedure that are of importance). Moreover, if it is
enforced to publish SSI-rates this will likely terminate one of the
most important methods to improve quality in surgery currently
available.
Exotic infections
O195
Vibrio cholerae O1 classical strains are facultative
intracellular bacteria, which survive and multiply
symbiotically inside the aquatic free-living
amoebae
H. Abd, A. Weintraub, G. Sandstro¨m (Stockholm, S)
Objectives: Cholera is a severe intestinal disease, caused by
different spices of Vibrio cholerae. While cholera affects many
millions of people around the world, the main reservoir of the
bacterium is not completely known. Since both free-living
amoeba and V. cholerae inhabit aquatic systems, an association
between themwould be possible. Our previous study has shown
that the seventh-pandemic V. cholerae O1 El Tor- Inaba strain
N16961 behaves as a facultative intracellular bacteriumduring its
survival in free-living amoebae. Here we address the question if
strains of V. cholerae O1 classical have the same ability as strain
N16961 to grow and survive inside Acanthamoeba castellanii.
Methods: V. cholerae O1 classical strains were co-cultivated with
A. castellanii for more than two weeks. The interaction between
these microorganisms was followed by viable counts of alone-
and co-cultivated microorganisms. Intra-amoebic growth and
localization of each bacterial strain was estimated by gentamicin
assay, viable count, microscopy, and PCR to detect cholera toxin
gene and amoebic 18 s RNA gene disclosing symbiont-host
association.
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Results: The results show that examined V. cholerae O1
classical strains multiply and survive inside trophozoites and
cysts of A. castellanii. The bacterial internalization was in
cytoplasmic compartment of the amoebae cells. The relation
between these microorganisms in co-cultures could be
listed as symbiosis since, presence of the amoebae enhanced
growth of bacteria, and the presence of the bacteria did
not affect amoebic growth. In addition, V. cholerae
strains could not survive without A. castellanii more than a
few days.
Conclusions: The symbiotic relation between these bacterial
strains and A. castellanii showing a new environmental host of
V. cholerae and a facultative intracellular behaviour of V. cholerae
O1 classical strains, which is in contrast to the general held view
of the bacterium.
O196
Regional-scale synchrony of cholera epidemics
in the Equatorial Atlantic Coast (Gulf of Guinea)
G. Constantin de Magny, B. Cazelles, M. Petit,
J.F. Gue´gan (Montpellier, Paris, F)
Cholera is an ancient disease which had disappeared from
most of the developed countries in the last 50 years, but it still
persists in many parts of the world with serious epidemics
most often localized in tropical areas. This highly contagious
disease is due to the bacteria Vibrio cholerae, after ingestion
of contaminated water or seafood. V. cholerae is naturally
present in the environment and is autochthonous to coastal
and estuarine ecosystems. The bacteria is closely associated
with many phyto- or zooplankton organisms. Thus any
environmental, ecological impact on V. cholerae reservoirs
density may have some incidences in bacterial population
density. In this context, climatic and/or environmental,
ecological changes inﬂuencing V. cholerae reservoirs density
may be particularly involved in the emergence of cholera in
human populations by increasing the probability of contacts
between bacterial populations in the ecosystem and riverine
human populations.
Objectives: The present work aims at determining and
quantifying the relationships between climatic/environmental
factors and cholera populations dynamics, i.e. the evolution of
case numbers with time, across several countries in the
Equatorial Atlantic Coast (Gulf of Guinea).
Methods: In a ﬁrst part, cholera population dynamics is
studied using wavelets analysis to characterize the observed
dynamics and to synchronism between the different countries.
Secondly, climatic indicators (e.g. S.O.I) and space
oceanography variables (e.g. Sea Surface Temperature) are
also analyzed with similar questions. Finally, results are
crossed between environmental variables and disease time-
series in order to detect the existence of correlations and
phase delays.
Results: We observed an important synchrony between cholera
epidemics for Benin, Ghana, Republic Demographic of Togo and
Nigeria for the period 1987 to 1994, and this was highly
synchronized with some climatic and/or oceanographic
parameters.
Conclusion: This comparative approach should allow a better
understanding and quantiﬁcation of the importance of climatic
and environmental ﬂuctuations on cholera epidemics in human
populations at both the global and regional scales. This work is
then a ﬁrst step toward the objective of building a predictive
model for the risk of environmental emergence of Vibrio
bacteria in human populations.
O197
Routes of transmission of cholera in Zahedan
district, Sistan and Baluchestan province
S. Izadi, S.M. Tabatabaei , M.R. Miradi,
K. Sheikhzadeh (Zahedan, IR)
Objectives: Within the past few years outbreaks of cholera has
occurred in different points of Sistan and Baluchestan province
of Iran, especially in the Zahedan district. The objective of this
study was deﬁnition of the most important routs of transmission
of cholera in the rural areas of Zahedan district involved in the
outbreak of summer 2003.
Methods: The outbreak lasted about 50 days. 20 consecutive
cholera cases positive for Vibrio cholera O1 in stool culture
were compared with 89 controls sampled from the
population. The cases have occurred during 28 July to 16
September 2003.
Results: Age, eating food in parties, absence of soap in hand-
washing place, household size, getting ice from street vendors
were signiﬁcantly associated with cholera.
Conclusion: Different transmission principles have been
mentioned in the literature for cholera, however every
outbreak has its own special patterns of transmission.
O198
Giardia lamblia: different genotypes, different
symptoms?
T.G. Mank, R. Jansen, L.M. Kortbeek, E.A.M. Andriessen,
A. Vries de, J. Giessen van der (Haarlem, Bilthoven, NL)
Objective: In a previously described study, human Giardia
Assemblage A isolates were associated with mild intermittent
diarrhoeal complaints whereas infections with isolates
belonging to the Assemblage B were associated with profound
diarrhoea with weight loss and fatigue (Homan & Mank). Since
the number of patients is that study was limited (N = 18) and
inclusion of cases only took place in the Haarlem area, we
expanded this study with a group (N = 100) patient suffering
from symptomatic giardiasis visiting their General Practitioner
in various areas in the Netherlands.
Methods: Besides stool collecion, patients were asked to ﬁll
out a comprehensive pre-coded questionnaire. From all
included (N =100) patients with microscopically proven
giardiasis, genotyping of the DNA isolated from the isolated
cysts was performed. Genotyping comprised PCR restriction
fragment length polymorﬁsm (RFLP) analysis of the
glutamate dehydrogenase (Gdh) locus and the A- and
B- assemblage speciﬁc loci as well as Gdh and 18-S-rDNA
sequence analysis.
Results: During this study, again, only a limited number of
different genotypes were found (40 isolates belonging to the
Assemblage A, predominantly A1, and 60 belonging to the
Assemblage B). Furthermore, the earlier reported correlation
between the severity of the diarrhoeal complaints and the
presence of the genotype was found during this expanded study
as well. Assemblage A isolates were predominantly found in
patients with intermittent diarrhoeal complaints, while
Assemblage B was strongly associated with persistent,
profound diarrhoea.
Conclusions: Our results indicate that Giardia lamblia isolates
infecting human consists of virulent and less virulent genotypes.
In our opinion it can be postulated that the Giardia lamblia
genotype contributes to the establishment of symptoms in
human infection.
Clinical Microbiology and Infection, Volume 11, Supplement 2, 2005
45
O199
Diagnostic possibilities in giardiasis
T.G. Mank, E.A.M. Andriessen, M. Ras (Haarlem, NL)
Microscopic examination of stool specimens is the cornerstone
of detection of intestinal parasites in parasitology laboratories
and is the best known and most frequently performed
laboratory procedure. Although process has been made in
non-morphologic diagnosis (e.g. ELISA- and PCR techniques)
microscopy is still considered to be the gold standard in the
diagnosis of intestinal protozoal infecions, including giardia-
sis. In the Netherlands, as in most other members of the
European Union, fresh, nonpreserved stool specimens are
generally used for examination. Specimens are initially
screened as direct wet preparations using either Lugol’s
iodine or eosine for detection of vegetative stages of protozoa
and are subsequently examined for protozoan cysts and
helminth eggs using an ether- or ethylacetate sedimentation
method or ﬂotation concentration technique. Because intestinal
parasites are shed intermittently, patients are asked to deliver
at least three stool specimens. The limitation of this diagnostic
approach is that detection of the vegetative stages of protozoa
may be missed because of delays in processing and/or low
compliance to the request to submit multiple stool samples.
To overcome this limitation, a diagnostic test that combines
multiple sampling (on 3 consecutive days), a ﬁxative (Sodium
Acetate Acedic Acid Formalin, SAF), a concentration method,
and an easy to use permanent stain was developed for use in
routine clinical practice. The results of the new test, called the
"Triple Faeces Test" (TFT), a Giardia lamblia speciﬁc ELISA
(Ridascreen Giardia, r-Biopharm), and ﬂuorescence techniques
were compared with those of the conventional diagnostic
methods used for Giardiasis in routine clinical practice. These
comparative studies ( which formed the basis of our newly
developed diagnostic ﬂow chart) showed that the sensitivity
of the diagnostic approach using TFT and the Ridascreen
Giardia test improved signiﬁcantly (p < 0.005) as compared to
the conventional methods using a fresh non preserved stool
specimen.
O200
Detection of Giardia cysts in waste water
O. Manso, M. Sousa, I. Machado (Oporto, P)
Objectives: The aim of this study was to evaluate the presence
of Giardia cysts in wastewater treatment plants.
Methods: Collection of samples from two wastewater treatment
plants in the north of Portugal, between March and July of 2002.
Sampling was made in the beginning and in the end of the
treatment process. The presence of the parasites was assessed by
immunoﬂuorescence with monoclonal antibodies. In addition,
in each sample, microscopic examination was done after
concentration techniques, to estimate contamination with other
parasites.Physical and chemical parameters of wastewater
samples were also analysed.
Results: Giardia cysts were detected in 57% of wastewater
samples analysed, 27% of them from afﬂuents, and 30% from
efﬂuents. Infectious forms of human pathogens were detected in
afﬂuent and efﬂuent wastewaters.
Conclusion: These results demonstrate the persistence of
protozoa even after the wastewater treatment process. The
concentration of Giardia cysts observed alerts to a potential
source of contamination for men, animals and the
environment.
O201
Impact of dengue viral infection on liver function
S. Bhoi, A. Khera, A. Goel (New Delhi, IND)
Objective: Recent years has seen changing and unusual
characteristics of dengue viral infection. This prompted us to
study the impact of dengue viral infection on liver functions.
Material and methods: All patients; who tested positive for
either IgM or IgG and IgM anti-dengue antibodies were included
in the study. Classical Dengue fever (DF), Dengue haemorrhagic
fever (DHF) and Dengue shock syndrome (DSS) were deﬁned as
per WHO criteria. Statistical analysis was done by Epi Info 2002.
Results: Out of 155 cases; 36 caseswere excluded from the study,
as they did not fulﬁll the inclusion criteria. Rest 119 cases were
deﬁned as DF in 58 (48.7%), DHF in 53 (44.5%) and DSS in 8
(6.75%) cases. The predominant presentations were fever (100%),
rash (24.3%), abdominal pain (16.8%), seizures (1.6%) and
retrorbital pain (0.8%). Bleeding manifestations were observed
in 56 (47%) cases. Petichae (13%), hemetemesis (10.9%), gum
bleeding (10.08%), subconjunctival hemorrhage (9.24%) and
multiple site bleeding (11.7%) were noted frequently. The mean
platelet count noticed in DF, DHF and DSS were [50 ± 27.4,
46 ± 31.05, 42 ± 26] · 103 respectively. The major unusual
feature observed was moderate (£ 5 fold) elevation of
transaminases, which started rising on the 3rd day, peaked on
the 9th day and returned to baseline over a period of three to
eight weeks. In DF, DHF and DSS; the mean serum bilirubin
[0.83 ± 0.27, 0.89 ± 0.3, 0.9 ± 0.48] mg/dl (p = 0.9), SGOT
[123 ± 88.5,120 ± 93, 112 ± 37] IU/L, SGPT [108 ± 48, 109 ± 70,
107 ± 36] IU/L (p = 0.01) and serum alkaline phosphatase (SAP)
[138 ± 53, 124 ± 52, 153 ± 26] IU/L (p = 1.7) were noticed. USG
revealed acalculous cholecystis in 17% (DF), 2.8% (DHF) and
2.5% (DSS) cases. All patients recovered except one (0.84%); who
succumbed due to intracranial hemorrhage.
Conclusion: Statistically signiﬁcant elevation of transaminases
along with normal serum bilirubin and SAP was observed in all
categories (DF, DHF, DSS); this is in contrast to previous reports
where elevated transaminases were observed more frequently in
DHF and DSS. These observations may suggest the changing
trend of Dengue virus infection, where impact on liver occurs
irrespective of severity of the disease.
O202
Human trichinellosis in Argentina
J. Bolpe, M. Ledesma, M. Benı´tez, D. Cecchini, S. Gonza´lez
Ayala (Azul, Buenos Aires, La Plata, RA)
Objective: To describe the epidemiologic, clinical and
laboratorial aspects of human trichinellosis.
Methods: Database of the Epidemiologic Surveillance System of
Buenos Aires State, Argentina, 1/2000–9/2004 was processed
with Excel and Statistics software. The outbreak investigation
was routinely performed by county and state health authorities.
Trichinosis case was suspected based on eosinophilia in
conjunction with compatible symptoms and a dietary history
(pork meat). Diagnosis was conﬁrmed by serologic test (indirect
immunoﬂuorescence, IFI), and/or identiﬁcation of larvae in the
suspect meat (digestion of muscle tissue in artiﬁcial gastric juice
followed by examination of the sediment for larvae).
Results: One thousand and one hundred twenty eight cases and
65 outbreaks were studied. The distribution by gender
was asymmetrical, male 58.2% (n = 656). The median age was
33 years (range 1–97). Ninety eight per cent of the cases (n = 1103)
occurred in the context of an outbreak. All cases were related to
the consumption of porkmeat, and 72.1% of the suspect foodwas
from animals slaughtered and sold without sanitary inspection.
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Ninety seven per cent of the cases (n = 1094) presented clinical
symptoms and/or signs. Themost frequentwere:myalgias 66.0%
(n = 745), headache 50.3% (n = 567), periorbital edema 48.9%
(n = 552), fever 45.2% (n = 510), diarrhoea 27.1% (n = 306), nau-
sea and vomiting 14.7% (n = 166). The median for symptoms/
signs was 3 (range 0–8). Eosinophilia over 6% was observed in
42.9% (n = 484). IFI was positive in 65.3% (n = 737). The suspect
foodwas available for identiﬁcationof larvae in 11.7% (n = 132) of
the cases. The amount of larvae per gram ranged from 1 to 150.
Conclusion: Trichinellosis is a zoonotic infection related to the
ingestion of undercooked pork meat. In our study most of the
cases occurred in the context of an outbreak. We found a high
percentage of cases related to the consumption of pigs and their
derivatives that escaped from sanitary inspection. This shows
the lack of adequate bromatological control in our environment.
The frequency distribution of symptoms and/or signs was
similar to other series. In an appropiate epidemiologic context,
characteristic clinical symptoms strongly suggest the diagnosis
of trichinellosis, which can be conﬁrmed with serologic tests
and/or identiﬁcation of larvae in the involved meat. Health
education for breeders, producers and consumers is very
important in order to prevent future outbreaks.
O203
Artesunate-clindamycin versus
quinine-clindamycin in the treatment of
Plasmodium falciparum malaria: a randomised
controlled trial
M. Ramharter, S. Oyakhirome, P. Klein Klouwenberg,
A.A. Adegnika, S.T. Agnandji, M.A. Missinou, S. Issifou,
W. Graninger, P.G. Kremsner (Vienna, A; Lambare´ne´, GAB)
Objective: Artemisinin based drug combinations are the
mainstay in the ﬁght against drug resistant malaria in Africa.
Currently available antimalarial drug combinations including
artemisinins are pharmacokinetically unmatched and are there-
forepotentially increasing the riskof selecting resistantmutants in
areas of highmalaria transmission.We aimed to test the potential
value of short half-life artemisinin based combination therapy for
uncomplicated falciparummalaria in sub-Saharan Africa.
Methods: We conducted an open label randomized controlled
clinical trial to evaluate the efﬁcacy and tolerability of 3 days twice
daily, oral artesunate-clindamycin therapy (2 mg/kg and 7 mg/kg
per dose) compared to a standard quinine-clindamycin regimen
(15 mg/kgand7 mg/kgperdose) in the treatmentofuncomplicated
falciparummalaria in 100 Gabonese children aged 3 to 12 years.
Results: Artesunate-clindamycin showed comparable activity to
quinine-clindamycin in the per-protocol analysis of day-28 cure rates
(87% versus 94%). No serious adverse events were reported and
tolerability was similar in both groups. Fever and parasite clearance
timeswere signiﬁcantly shorter in the artesunate clindamycingroup.
Conclusions: Artesunate-clindamycin and other matching
short plasma half-life combinations of artemisinins merit
further attention in regions with high malaria transmission.
O204
Microarray based analysis of gene expression in
drug resistant Leishmania donovani isolated from
Indian patients of Kala azar
P. Salotra, R. Singh, R. Duncan, H. Nakhasi (New Delhi, IND;
Bethesda, USA)
Objective: Visceral leishmaniasis or kala azar (KA), fatal if not
treated, is caused by protozoan parasites of Leishmania donovani
complex. The prevalence of drug resistance to the traditional
drug, sodium antimony gluconate (SAG), has reached alarming
proportions in Indian patients of KA. There is an urgent need to
identify novel targets to combat drug resistance.
Method: We developed a genomic microarray for L. donovani
comprising of 4224 PCR ampliﬁed inserts(1.0 to 1.5 kb), 24
positive and 12 negative controls, each printed in triplicate.
Two-color ﬂuorescent (Cy3 andCy5) hybridizations were used
to compare gene expression in drug resistant and sensitive
strains. Sensitivity of the parasite isolates from bone marrow
aspirates of KA patients (SAG responder and Non responders)
was evaluated in vitro. ED50 from SAG resistant and sensitive
isolates was 250 microgm/ml and 25 microgm/ml, respectively.
The hybridized arrays were scanned in a GenePix Pro 4100
scanner (Axon) followed by analysis using software Acuity 3.0.
Results: Scatter plot comparing the log ratios against log
products of ﬂuorescence intensities is shown in Fig. 1.
Approximately 2% (85) clones showed 31.5 fold abundant
expression either in resistant or sensitive isolates. Partial
nucleotide sequence of selected clones was determined and
analyzed by BLAST analysis (Table 1).
Table 1. Ratio of micro array signal intensity in Drug resistant vs
sensitive parasites of L. donovani from KA patients. The nu-
cleotide sequence was analysed by BLAST analysis inGenbank
(NCBI) and in Leishmania major sequence databases (Gene DB).
Clone ID Gene Identity Ratio E value
Upregulated in resistant parasite
28G11 Parasite surface antigen(PBA-2)
(LmjF12.0760)
2.8 7.0e–43
39B11 PSA-2 (AY36511.1) 3.0 e-117
42A11 PSA-2 (AY437087.1) 2.5 0
34H7 rRNA large sub unit
(Lmj F 2 7.rRNA.2 6)
2.63 3.1e-232
28B11 Tetracyclin Res protein (LmjF 35.2810) 1.6 1.9e-157
31E9 93% homology with proteasormne
regulatory ATPase subunit ,
putative(Lmj F22.0620)
2.36 4.5e-124
24E5 NucIeoside transporter (Lmj F15.1240) 1.8 1.1e-31
28C11 86% with hypothetical protein
(Lmj F22.0730)
2.15 6.5e-127
50F9 hypothetical protein with Zn
ﬁnger domain (LmjF22_0190)
1.8 1.3e-38
Upregulated in sensitive parasite
67C6 iron/zinc transporter protein-like
protein (LmjF31.3070)
2.36 2.5e-40
53F2 Thioredoxin family protein
(LmjF26.0670)
1.4 2.1e-21
62D5 Hypothetical protein (LmjF30.1680) 1.8 4.1e-24
18A6 conserved hypothetical protein
(LmjF 18.0100)
1.5 6.2e-94
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Conclusion: The study led to identiﬁcation of a number of
transcripts showing over-expression in drug resistant isolates,
some of which corresponded to known genes like PSA-2,
nucleoside transporter (NT), tetracycline resistant protein
homologue (TRH) and proteasome regulatory ATPases. Three
clones corresponded to the PSA-2, a glycoprotein with leucine
rich repeats that has a role in facilitating attachment and
internalization of parasites by macrophages, resisting
complement mediated cell lysis. NT and TRH may promote
resistance to drug by inhibiting the drug intake by the parasite.
Proteasome and associated ATPases help increased survival of
Mycobacterium inside macrophage by lending resistance to
nitric oxide. The over-expression of this protein in drug resistant
Leishmania may help the parasite to persist in host. The study
establishes the utility of genome-wide RNA expression proﬁling
in Leishmania and identiﬁes numerous genes with potential role
in drug resistance.
Emergence and molecular evolution of antibiotic resistance
O205
A multidimensional screening of non-clinical
isolates reveals metallo-beta-lactamases in the
environment
S. Quinteira, H. Ferreira, L.V. Peixe (Porto, P)
Objectives: Even though increasingly reported in many
countries, metallo-beta-lactamase (MBL)-producing Gram-
negative bacilli have been associated to the hospital setting,
suggesting a relative conﬁnement within this ecological niche. In
this study, the presence of MBLs and imipenem susceptibility in
Gram-negative bacilli were evaluated among non-clinical
sources in order to verify a possible spreading into new,
previously undescribed, environments.
Methods: Samples (24 from healthy human volunteer faeces,
30 from poultry skin, 4 from swine faeces, 13 from rivers and
29 from hospital wastewaters-receiving urban sewage) were
collected in Northern Portugal between 2001 and 2004. Sample
aliquots were platted, in MacConkey agar and/or Pyocyanosel
agar supplemented with imipenem (2 mg/L) and colonies with
different morphology were collected. Species identiﬁcation was
performed with the API 32GN. Imipenem susceptibility was
determined using the disk diffusion method. A bioassay
method was employed in order to detect MBL production
and positive results were later conﬁrmed by a multiplex PCR
assay designed to amplify both blaVIM and blaIMP genes.
Characterisation of MBL-type was possible through
sequencing.
Results: 190 Gram-negative bacilli (21 lactose-fermenters and
169 non lactose-fermenters) were isolated from different sources.
Decreased susceptibility to imipenem was observed in 64
isolates from sewage (n = 25), rivers (n = 17), swines (n = 12)
and healthy volunteers (n = 10). All poultry isolates showed
imipenem susceptibility. Positive bioassays were detected in 49
out of the 64 isolates with reduced susceptibility to imipenem.
blaVIM-2 gene was detected in three isolates: two Pseudomonas
aeruginosa (river and hospital sewage) and a P. alcaligenes
(hospital sewage). blaIMP was not detected in none of the
isolates.
Conclusions: Carbapenems are in many cases the last
therapeutic resort and the detection of carbapenem-
hydrolyzing MBL producers in the hospital setting is a
worrisome phenomenon. Although VIM and IMP-producing
strains were not observed in animals and human healthy
volunteers, these enzymes seem not to be restricted to the
hospital setting anymore. Disturbingly, the results emerging
from this study show that, even if in very low frequencies, the
presence of VIM-2 loose in the environment, namely in sewage
and rivers, may undermine the effectiveness of carbapenems,
largely depending on the eradication or conﬁnement of resistant
bacteria.
O206
CTX-M-producing Escherichia coli now the
dominant cephalosporin-resistant
Enterobacteriaceae in London and SE England
N. Potz, R. Hope, M. Warner, A.P. Johnson, D. Livermore on
behalf of the London & South East ESBL Project Group
Objectives: There is increasing concern about the spread of
Enterobacteriaceae, principally E. coli, producing CTX-M-type
extended-spectrum beta-lactamases (ESBLs) in the UK. This is
reﬂected in increasing surveillance reports and submissions to
the reference laboratories, with many isolates reportedly from
community patients. To better assess the situation, a prospective
survey of cephalosporin-resistance was undertaken for
Enterobacteriaceae across London and Southeast England.
Methods: Eighteen laboratories participated: 10 in London and
8 elsewhere in southeast England. These screened all
Enterobacteriaceae isolates using cefpodoxime or both
cefotaxime and ceftazidime. Isolates resistant to any of these 3
cephalosporins were submitted for centralised susceptibility
testing and identiﬁcation. Interpretive reading was performed,
allowing an inference of resistance mechanism(s).
Results: During a 12–week collection period, >1000
cephalosporin-resistant Enterobacteriaceae isolates were
collected, mostly submitted on the basis of their cefpodoxime
resistance. E. coliwas by far the most numerous species (>50% of
all isolates), with over 70% of these having an ESBL, usually
conferring a CTX-M phenotype. Klebsiella and Enterobacter spp.
were also well represented (each over 15% of resistant isolates).
The majority of the resistant Klebsiella isolates had phenotypes
indicative of ESBL production but two-thirds of enterobacters
had phenotypes implying derepression of AmpC. ESBLs were
detected in a few Citrobacter, Morganella and Serratia spp.
isolates, but not in P. mirabilis. Approximately 60% of all
cephalosporin-resistant Enterobacteriaceae were inferred to be
ESBL-producers, mostly with CTX-M phenotypes, whereas
isolates with AmpC phenotypes accounted for 20%. The
remaining 20% comprised of isolates inferred to have other
beta-lactamases, or non-enzymatic resistance.
Conclusion: Until 2000 CTX-M-beta-lactamases were unknown
in the UK and cephalosporin-resistant Enterobacteriaceae were
mostly enterobacters with AmpC or Klebsiella spp. with TEM or
SHV ESBLs. This survey shows a dramatic shift towards E. coli
as the main host for ESBLs and cephalosporin resistance, and
towards CTX-M phenotypes.
Abstracts
48
O207
Characterisation of blaBEL-1, a novel
integron-located extended-spectrum
beta-lactamase gene from a Pseudomonas
aeruginosa clinical isolate in Belgium
L. Poirel, L. Brinas, A. Verlinde, L. Ide, P. Nordmann
(Le Kremlin Bicetre, F; Roeselare, B)
Objectives: Characterisation of the expanded-spectrum beta-
lactamase resistance determinant of a Pseudomonas aeruginosa
isolate from a scrotal swab of a patient admitted with a
dissecting aneurism of the left arteria renalis, complicated with
renal insufﬁciency at the Heilig Hartziekenhuis Roeselare,
Belgium. This strain was resistant to ticarcillin, and of
intermediate susceptibility to piperacillin, ceftazidime and
aztreonam.
Methods: Screening for extended-spectrum beta-lactamase
(ESBL) genes was performed using double-disk synergy test
and PCR techniques. Shotgun cloning was performed with
Sau3AI-partially digested DNA of P. aeruginosa and pBK-CMV
cloning vector. Selection was performed on amoxicillin-
containing plates.
Results: E. coli DH10B (pBEL-1) recombinant strain with
reduced susceptibility to ceftazidime was analyzed. Sequence
analysis identiﬁed a novel Ambler class A beta-lactamase BEL-1
(pI 7.1) weakly related to any other ESBLs. BEL-1 shared 5 and
43% amino acid identity with the plasmid-mediated ESBLs
GES-1 and CTX-M-8, respectively. BEL-1 activity was inhibited
by clavulanic acid and tazobactam, and uncommonly also
by cefoxitin, moxalactam, and imipenem. It hydrolysed
signiﬁcantly expanded-spectrum cephalosporins and
aztreonam. The blaBEL-1 gene was as a form of a gene cassette
in a class 1 integron, located downstream of an aacA4 gene
cassette encoding an aminoglycoside acetyltransferase, and
upstream of i) an aadA gene cassette encoding an
adenylyltransferase and ii) the smr2 gene cassette similar to
sugE-type genes and encoding a putative membrane transporter
of cationic drugs. This integron was chromosome-located and
part of a transposon.
Conclusion: A novel ESBL gene was identiﬁed in P. aeruginosa
underlining i) the diversity of ESBL genes, ii) that P. aeruginosa
may be a reservoir of these genes and iii) that integrons are
common vehicles of these genes.
O208
Antimicrobial resistance and dissemination of
class 1 and class 2 integrons in Portuguese
Salmonella isolates from different sources
P. Antunes, J. Machado, L.V. Peixe (Porto, Lisbon, P)
Objectives: The purpose of this study was to determine the
antimicrobial resistance patterns and to characterise class 1 and
2 integrons in 1183 Portuguese Salmonella isolates collected
during 2002–2003 from different sources (human, food products
and environment).
Methods: The minimum inhibitory concentration for 10
antimicrobial agents was determined by the agar dilution
method. Sulphonamide resistant isolates were screened for
class 1 and 2 integrons by PCR assays. The characterisation of
resistance gene cassettes was investigated by PCR, PCR-RFLP
with TaqI and sequencing. Clonality was assessed by PFGE
following XbaI digestion.
Results: 46% of the isolates were susceptible to all tested
antimicrobial agents, 33% presented a single type of
resistance, and 21% were multiresistant. Resistance to
nalidixic acid (30%), tetracycline (19%), streptomycin (18%),
sulfamethoxazole (17%) and ampicillin (17%) were the most
common. Resistance to sulphonamides (n = 200) was always
associated with resistance to other antimicrobial agents, with
75% (n = 150) carrying one (1000 to 2000 bp) or two (1000 and
1200 bp) class 1 integrons and 3% (n = 5) simultaneously
carrying a class 1 and 2 integrons. 7 RFLP integron types
were found, with the aadA genes (aadA1, aadA2 and aadA5)
alone or downstream of a trimethoprim resistance gene
(dfrA1, dfrA12 and dfrA17) or of a beta-lactamase gene
(blaOXA-30), detected in the variable region of 149 integrons.
The spread of class 1 integrons occurred among several
Salmonella serotypes and PFGE clones. However, some
Typhimurium-speciﬁc integrons were found: 1000 (aadA2)
and 1200 bp (blaPSE-1) simultaneously, or one of 2000 bp
(blaOXA-30-aadA1). In contrast, the other proﬁles appeared in
several serotypes, with the integrons carrying dfrA1-aadA1 or
dfrA12-aadA2 the most disseminated. Interestingly, data did
not suggest any difference in the distribution of resistance
gene cassettes between human and foods of animal origin
isolates.
Conclusion: The present study with Portuguese isolates
indicates that antibiotic resistance mediated by integrons is
common among diverse Salmonella serotypes. All types of
integrons were shared among human and food isolates,
suggesting that resistance determinants present among
animals may contribute to the problem of multidrug resistant
Salmonella in humans.
O209
Sporadic and outbreak cases of plasmid-mediated
quinolone-resistance in German ICUs
D. Jonas, K. Biehler, D. Hartung, B. Spitzmu¨ller,
F.D. Daschner (Freiburg, D)
Objectives: The occurrence of a novel plasmid-mediated
quinolone resistance has been reported in a few cases
outside Europe. This transmissible quinolone resistance gene
(qnr) was detected in isolates from patients in the USA, China
and Egypt. Molecular analysis demonstrated the location of
the qnr-gene in class I integrons. The aim of this study was to
determine the prevalence of qnr-positve strains in German
ICUs.
Methods: Six hundred and forty-eight ﬂuoroquinolone or
cephalosporin-resistant Enterobacteriaceae and Acinetobacter
spp., obtained from 34 ICUs during the last three years were
screened for the presence of integrons. One hundred and thirty-
four strains containing integron cassettes as well as integrase
sequences were tested for the presence of the qnr gene-locus by
use of PCR.
Results: One isolate of Enterobacter spp. from a German ICU
patient turned out to be qnr-positive as well as ﬁve Citrobacter
freundii strains from three patients treated in a South-German
ICU during a one month period. All C. freundii strains were
indistinguishable by use of XbaI macrorestriction analysis.
Moreover, none of these quinolone-resistant strains were
susceptible to cefoxitin, ceftazidime or cefotaxime.
Conclusion: This is one of the ﬁrst reports of qnr-positive
strains obtained from patients in Europe. Molecular
epidemiology suggests that qnr-positve strains were involved
in an outbreak in one ICU. The spread of transmissible
quinolone-resistance might be underscored.
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O210
Clinical investigation of the new QNR-based
mechanism of quinolone resistance in French
teaching hospitals: dissemination among
enterobacterial species and strains producing
expanded spectrum beta-lactamase
E. Cambau, J. Robert, C. Lascols, W. Sougakoff, M. Renard,
C. Bebear, C. Branger, J. Cavallo, F. Denis, L. Gutmann,
R. Leclercq, J. Sirot, V. Jarlier, C. Soussy (Creteil, Paris, Bordeaux,
Clichy, Saint Mande´, Limoges, Caen, Clermont-Ferrand, F)
Objectives: To investigate the new QNR-based plasmid-
mediated mechanism of quinolone resistance in strains of
gram-negative bacilli resistant to quinolones isolated in France,
with regards to the production of extended spectrum
Blactamase (ESBL).
Methods: 986 nalidixic acid (Nal) resistant strains (646
Escherichia coli, 162 Klebsiella spp., 96 Enterobacter spp., 41
Citrobacter spp., 16 Serratia spp., 14 Proteus spp. and 11 other
gram negative bacilli) isolated between 2002 and 2004 from nine
University Hospitals in France were screened for qnr by PCR
amplifying an intragenic 543-bp fragment. Among them, 300
(30%) produced ESBL. Qnr sequencing and detection of
mutation in the QRDR of DNA gyrase (gyrA, gyrB) and
topoisomerase IV (parC and parE) were performed for qnr-
positive strains. Molecular typing was applied to qnr-positive
strains belonging to the same species.
Results: 20 strains were qnr-positive, distributed as 17
E. cloacae, 1 K. pneumoniae, 1 C. freundii and 1 P. mirabilis.
A new qnr allele was observed for the P. mirabilis strain with 29
nucleotide and 3 amino-acid differences referring to the original
sequence. For the other strains, the qnr sequence differed from
the original strain by the mutation 537A/G described in isolates
from USA and China. From the experiments performed on the
ﬁrst E. cloacae isolate, qnr was shown to be transferred by
conjugation to E. coli BM13 resulting in a low level quinolone
resistance (Cip MIC 0.1 lg/ml, levoﬂoxacin MIC of 0.25 mg/L).
All the qnr-positive strains were ESBL producers. Whereas
strains with MIC of ciproﬂoxacin (Cip) above 16 mg/L
harboured gyrA and parC mutations, the 3 strains with Cip
MIC below 1 mg/L showed wild-type sequences for QRDR in
gyrA, gyrB, parC and parE. RAPD and ERIC PCR analysis
showed that among the 17 E. cloacae strains, 10 strains
distributed into 3 clusters (6, 2 and 2 strains) and the other 7
were not genetically related.
Conclusion: We detected the qnr gene in strains from different
enterobacterial species with a prevalence of 7% of the
ESBL producers. Qnr-positive strains without additional
topoisomerase mutations showed a low level of quinolone
resistance that might be undetected by standard susceptibility
testing.
O211
Persistence of vancomycin-resistant Enterococcus
faecium isolates belonging to C1 lineage in a
healthy human volunteer during a 4 year period
C. Novais, J.C. Sousa, T.M. Coque, L.V. Peixe
(Porto, P; Madrid, E)
Objectives: To analyze the clonal relationship and antibiotic
resistance genetic elements of different VREF isolates from a
healthy human (HV) collected during a 4–y period.
Methods: Feces from a 53–y old Portuguese male, without
exposure to antibiotics or hospital in the 3 and 12 months
previous to the sample collection were analyzed (Feb2001- Jun-
2004). He had hospital exposure for 1 day for a colonoscopy
(Sep-2001) and 5 days for a shoulder surgery (Sep-2003).
Samples were pre-enriched in BHI plus 6 mg/L of
vancomycin and then plated in the same media Antibiotic
susceptibility was determined by the agar dilution method.
Species identiﬁcation, the presence of antibiotic resistance genes
and virulence traits, and the Tn1546 backbone structure, were
determined by a PCR. PurK was identiﬁed by PCR and
sequencing. Clonal relatedness was established by SmaI- and
ApaI- PFGE.
Results: Six VREF corresponding to 3 PFGE types were
recovered. They were also resistant to ampicillin,
tetracycline, erythromycin and HLRKm. All isolates
contained vanA and ermB, while (aac(6’)-Ie-aph(2’’)-Ia),
aph(3’)-IIIa and vatE were only found in some cases.
Isolates of each PFGE type contained purK-1 which is
associated to E. faecium clonal complex C1 that includes
VREF causing outbreaks worldwide. Three Tn1546 types were
detected: PP-5 and PP-6 contain an ISEf1 insertion between
vanX-vanY region (frequently found among Portuguese VRE
faecalis clinical isolates) and type D (frequent among animals).
No virulence factors were detected.
Conclusions: The persistence of VREF isolates belong to a C1
lineage carrying elements associated to both the hospital
setting (Tn1546 with ISEf1 and purK1) and animal sources
(Tn1546 type D) in community based humans is of concern
since it might serve as a reservoir of clinical relevant genes or
clones that can be spread to both hospital and environmental
settings.
O212
Characterisation of the epidemic European
fusidic acid-resistant impetigo clone of
Staphylococcus aureus
A.J. O’Neill, A.R. Larsen, R. Skov, A.S. Henriksen,
I. Chopra (Leeds, UK; Copenhagen, DK)
Objectives: The recent increase in fusidic acid resistance (fusR)
in S. aureus strains causing impetigo in Europe is primarily the
result of dissemination of a single successful fusR clone. We
have designated this strain the Epidemic European Fusidic
acid-resistant Impetigo Clone (EEFIC). To better understand
the emergence, spread and success of the EEFIC, we have
subjected it to detailed phenotypic and genotypic
characterization.
Methods: Strain typing was conducted by PFGE, MLST and
spa-typing procedures. Antibiotic susceptibility testing was
performed using disk diffusion. Reversed passive latex
agglutination kits were used to test for exfoliative toxin A
(ETA) and toxic shock syndrome toxin 1 (TSST-1), whilst PCR
was used to probe for the Panton-Valentine Leukocidin (PVL)
gene. Established techniques were employed for cloning,
shotgun DNA sequencing and bioinformatics.
Results: EEFIC was susceptible to the majority of antibiotics
tested, but resistant to fus, macrolides (mac) and penicillin (pen).
Shotgun sequencing of the single, large (40 Kb) plasmid carried
by this clone revealed that it was closely related to staphylococcal
plasmid pETB, and indicated the presence of exfoliative toxin B
(ETB), epidermal cell differentiation inhibitor C (EDIN-C), and a
cadmium resistance determinant. In addition, EEFIC tested
positive for ETA, but negative for TSST-1 and PVL toxins. The
fusR gene, fusB, was cloned from the chromosome on a HindIII
fragment, and found to lie upstream of the groEL gene, at the
hypervariable locus occupied in some strains by the SaPI1
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pathogenicity island. Furthermore, this analysis revealed that
fusB has been recruited to the chromosome as a fragment of the
archetypal fusR plasmid, pUB101.
Conclusions: Exfoliative toxins are frequently found in
S. aureus strains causing impetigo bullosa; EEFIC carries both
ETA and ETB. In addition, the presence of the ADP-
ribosylating exotoxin, EDIN-C, may contribute to this strain’s
ability to cause superﬁcial disease. In conjunction with genes
conferring resistance to antibiotics that are mainstays in the
treatment of dermatological infections (fus, mac), and in
particular the stable recruitment of fusB to the chromosome,
the success of the EEFIC as a cause of impetigo bullosa is not
surprising.
O213
Prevalence of non-typeable Streptococcus
pneumoniae in carriers and insights into its
population structure
R. Sa´-Lea˜o, A. Simoes, S. Nunes, N.G. Sousa, N. Frazao,
H. de Lencastre (Oeiras, P)
Objectives: The study of 2,204 drug-resistant (DR) pneumococci
(Pn) isolated from the nasopharynx of children in day-care
centres in Lisbon between 1997–2003, showed that 9.1% of the
DR isolates had been presumptively identiﬁed as non-typeable
pneumococci (NTPn). Since this prevalence was not negligible
and this group of atypical Pn is largely understudied, we aimed
to unequivocally identify these strains and obtain insights into
its population structure.
Methods: The presumptive identiﬁcation of the isolates as
NTPn was based on optochin susceptibility after incubation in
5% CO2 atmosphere, typical colony morphology, and non-
typeability by the Quellung reaction. Deﬁnitive identiﬁcation of
the strains as Pn included bile solubility and PCR detection of
lytA and psaA, genes ubiquitous in Pn. Capsular type
determination was re-assayed by multiplex PCR serotyping.
Antibiotic susceptibility testing was done according to the
NCCLS guidelines. Genetic diversity was determined by
pulsed-ﬁeld gel electrophoresis (PFGE).
Results: Between 1997 and 2003, 201 DR NTPn-like strains
were isolated. The majority (170 or 84.6%) were bile soluble
and positive for lytA and psaA. By multiplex PCR serotyping,
155 of the 170 conﬁrmed Pn yielded no result suggesting that
the capsular polysaccharide (cps) locus was absent. These
strains were considered to be true NTPn. The remaining 15
strains were positive by the multiplex serotyping PCR and
could be assigned a capsular type upon retesting them by the
Quellung reaction. Ninety-three per cent of the 155 true NTPn
were multidrug resistant. The most common antibiotype
was resistance to macrolides, lincosamides, tetracycline,
cotrimoxazole, and intermediate resistance to penicillin.
PFGE analysis of the true NTPn strains identiﬁed 29 clones.
One major clone accounted for 46.5% of the isolates, was
prevalent through time and was disseminated in several day-
care centres.
Conclusions: The isolation of presumptive NTPn requires
further conﬁrmation tests since these atypical strains are not
easily identiﬁed. The prevalence of true NTPn among carriers
ranged from 2.9 to 13.0% of the DR strains (average 7.0%).
These isolates are frequently multidrug resistant and appear
to lack the cps locus. The high number of clones found
suggests that NTPn have diverse evolutionary origins. Careful
monitorization of NTPn is important since these strains are
not targeted by any of the pneumococcal vaccines
commercially available.
O214
Persistence of sulphonamide resistance in the
community despite lack of selection
D.C. Bean, D.M. Livermore, L.M.C. Hall (London, UK)
Objectives: Strategies to limit spread or reduce the prevalence
of antibiotic resistance commonly assume that resistance will
decline in the absence of selective pressure. However
sulphonamide resistance in Escherichia coli persisted in the
UK from 1991 to 1999, despite a dramatic reduction in
prescribing. The goal of this study was to examine whether
this trend had continued in 2004, nine years since the
UK restriction in prescription, and to investigate the
mechanisms that have lead to the maintenance of
sulphonamide resistance.
Methods: Urinary E. coli isolates were obtained from the
diagnostic microbiology laboratory of the Royal London
Hospital. All consecutive isolates from urinary specimens
from January through to March 2004 were included.
Sulphonamide resistance genes, sul1, 2 and 3, were detected
by PCR.
Results: Of the 391 E. coli isolates recovered in 2004, 45.5% were
sulphonamide resistant compared to 46.0% in 1999, and 39.7% in
1991. The sul2 gene continued to be the most prevalent
resistance determinant, present in 81% of resistant isolates in
2004 (79% and 67% in 1999 and 1991 respectively); 28% of
resistant isolates carried both sul1 and sul2 genes. The sul3 gene
was not found.
Conclusion: Continued persistence of sulphonamide resistance
has been conﬁrmed in 2004. One explanation for the persistence
and spread of sul2-mediated sulphonamide resistance is that
sul2 could be stably linked to other factors that continue to be
under positive selection pressure. Thirty-eight sul2 plasmids
were therefore transferred to a fully susceptible E. coli host
strain. Sul2 was frequently found to be co-transferred with other
antibiotic resistance markers, most notably ampicillin (76%) and
streptomycin (74%) resistance. Location of sul2 adjacent to the
streptomycin resistance genes strA and strB has been noted
before and was conﬁrmed in most plasmids; however
streptomycin is now rarely used in clinical practice.
Preliminary results indicated that there was not a similar
physical linkage with an ampicillin resistance determinant.
DNA ﬁngerprinting and the pattern of resistance proﬁles
demonstrated that sul2 plasmids were extremely diverse. The
data suggest that sul2 (with strAB) is borne on a discrete genetic
element that is not stably linked to other selectively
advantageous determinants, but has been able to mobilise
and disseminate amongst a wide variety of plasmids in
clinical E. coli.
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Predictors of the clinical course of HIV infection and therapy
O216
HIV and non-HIV-related deaths and their
relationship to immunodeﬁciency; the D:A:D
study
N. Friis-Møller, R. Weber, C.A. Sabin, P. Reiss, A. D’Arminio
Monforte, F. Dabis, W. El-Sadr, S. De Wit, L. Morfeldt, M. Law,
C. Pradier, G. Calvo, C. Holkmann Olsen, A.N. Phillips,
J.D. Lundgren on behalf of the D:A:D Study Group
Objectives: Deaths in people with HIV infection are often
classiﬁed according to whether they are HIV-related or not. We
aimed to study whether deaths generally supposed to be
unrelated to HIV are in fact more likely to occur in people
with a low CD4 count.
Methods: D:A:D is a prospective study of 23,441 patients (pts)
from11 existing cohorts in Europe, Australia and theUS.Detailed
information on deaths occurring between the initiation of D:A:D
in 2000 and Feb 2004 was collected; causes of death were coded
centrally. Relative rates (RR) of factors associated with deaths
from each cause were calculated using Poisson regression.
Results: Of the 23,441 persons, 82% had used ART prior to
enrolment (median exposure 2.8 years). Over the study period,
1248 (5.3%) pts died (incidence: 1.6 deaths/100 person-years).
The leading cause of death was AIDS (30%) followed by liver-
related death (14% – of which 79% were associated with chronic
viral hepatitis), death from heart disease (incl. cardiovascular
disease; 9%), and death from non-AIDS malignancies (8%). The
proportion of deaths from these causes remained stable over
time. AIDS-related deaths were, as expected, strongly associated
with the latest CD4 cell count (RR of death from an AIDS-event
in pts with latest CD4 count <50 cells/L versus >500 cells/L
after adjustment for HIV RNA, age, cohort, race: 96.4 [95% CI:
61.6–150.7], p < 0.0001). Liver-related deaths (RR 26.6 [12.9–
54.7], p < 0.0001) and deaths from non-AIDS malignancies (23.5
[9.4–58.7], p < 0.0001) were similarly strongly associated with
latest CD4 count; the relationship with death from heart disease
was less strong but remained signiﬁcant (3.1 [1.2–8.2], p = 0.02).
The trends persisted after lagging the analyses to associations
with CD4 counts 3 and 6 months earlier.
Conclusions: Deaths fromcauses that are generally referred to as
non-HIV related are more likely to occur in persons with lower
rather than higher CD4 counts. Although residual confounding
cannot be ruledout, it seems that lowCD4cell numbers contribute
to a proportion of such deaths. It appears that deaths occurring in
persons with a very low CD4 count can only be categorized as
non-HIV-related if there is clear evidence that the patient’s
immunodeﬁciency did not contribute to the death.
O217
HIV-patients across Europe: regional differences
in patient characteristics and AIDS diagnoses
D. Podlekareva, W. Bannister, L. Viksna, A. Mocroft, B. Knysz,
P. Reiss, N. Chentsova, D. Duiculescu, J.D. Lundgren, O. Kirk
on behalf of the EuroSIDA study group
Background: The HIV epidemic shows major differences across
Europe, including marked differences in prevalence and
incidence of AIDS deﬁning disease (ADD). These data have
previously been reported from the EuroSIDA study. However,
results were based on HIV-patients (pts) not exposed to HAART
and were restricted to Western Europe. Since 1999, the
EuroSIDA study has expanded to Eastern Europe.
Objectives: To compare characteristics of pts within EuroSIDA
in European regions and to assess any regional differences in the
prevalence and pattern of ADD with special focus on Eastern
Europe.
Methods: Analysis of 7104 HIV-pts under active follow-up in
September 2003. ADD made more than 1 year prior to
recruitment were excluded to minimise potential biases. The
regions are: South (SE), West Central (WC), North (NE), East
Central (EC) and East (EE).
Results: Pts in EEwere younger and primarily intravenous drug
users (IDU); a high percentage of them were co-infected with
HCV. Data shows more a recent HIV epidemic in EC and EE
regions (Table 1). Signiﬁcantly fewer pts in EE were taking
HAART in late 2003 (Table 1), this remained signiﬁcant after
adjustment. 1181 pts had experienced at least one ADD by
September 2003. The regional differences observed include a
higher proportion of Kaposi’s sarcoma in SE, WC and NE (p <
0.001). EE is remarkable by a high prevalence of PCP, and HIV
wasting syndromewhilepulmonaryMycobacteriumtuberculosis
(TB) infections were more prevalent in EC (p = 0.002) (Figure 1).
Summary: These preliminary results reﬂect substantial regional
differences in demographic and clinical characteristics of HIV-pts
across Europe anddemonstrate amore recent epidemic in EC and
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Fig. 1. AIDS deﬁning diseases at September 2003 according to
regions
Table 1. Characteristics of patients followed in September 2003
in the EuroSIDA study
SE
(n = 1888)
WC
(n = 1911)
NE
(n = 1974)
EC
(n = 890)
EE
(n = 441) p-value
Age, yrs; median
(IQR)
41
(37–47)
43
(39–51)
44
(39–52)
36
(31–44)
30
(24–39)
<0.001
Female, % 28 23 18 30 31 <0.001
IDU, % 29 14 11 30 51 <0.001
AIDS diagnosis,
n (%)
509 (27) 588(31) 684 (35) 214(24) 117(26.5) <0.001
HCV, % 30 17.5 13 34 33 <0.001
CD4 count cells/
mm3; median (IQR)
459
(291–679)
429
(281–601)
449
(300–620)
484
(297–659)
337
(185–593)
<0.001
Nadir CD4 count
cells/mm3;
median (IQR)
150
(57–263)
131
(49–229)
113
(42–200)
144
(65–270)
270
(131–476)
<0.001
Time from HIV
diagnosis, mths;
median (IQR)
122
(78–164)
134
(96–177)
136
(96–186)
75
(39–119)
32
(18–53)
<0.001
On HAART, % 77 80 84 78 30 <0.001
SE: Spain, Portugal, Italy, Greece, Serbia and Montenegro, Israel, Argentina; WC: France,
Belgium, south Germany, Luxembourg, Switzerland, Austria; NE: United Kingdom, Ireland,
Netherlands, north Germany, Denmark, Sweden, Norway; EC: Poland, Czech Republic,
Slovakia, Hungary, Romania; EE: Estonia, Latvia, Lithuania, Belarus, Ukraine, Russia
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EE. There is low usage of HAART in EE compared with other
regions including EC, which requires further follow-up and
monitoring of pts in this region. In EuroSIDA a high proportion of
AIDS pts in EC have been diagnosed with pulmonary TB, and
with longer prospective follow-up the prevalence in EE may also
increase. A high prevalence of multi-resistant TB has been
reported in these regions, thus further research is needed. The
high prevalence of HIVwasting syndrome and low percentage of
other diseases in EE might at least in part be due to the lack of
complex diagnostic technologies, experience and resources.More
detailed analyses are in progress and as follow-up accumulates,
particularly in EC and EE, analyses can focus on prospectively
characterising ADD patterns.
O218
Detection of HIV sequences in colon bacteria of
AIDS positive patients
V. Zajac, M. Kovac, S. Ciernikova, M. Mego, P. Rauko,
V. Stevurkova, D. Stanekova, M. Mokras (Bratislava, SVK)
Objectives: The hypothesis whether bacteria from intestinal
tract of HIV-1 positive patients carry HIV-like sequences was
examined.
Material and methods: Bacteria and Patients. Intestinal bacteria
were isolated from 51 HIV positive patients from USA and
Slovakia and 10 healthy individuals. PCR ampliﬁcation.
Polymerase chain reaction speciﬁc for HIV sequences was
carried out using these primers: P38F: ATAATCCACCTA
TCCCAGTAGGAGAAT; P39R: TTTGGTCCTTGTCTTATGTC
CAGAATG; P1F: CATTTGGAAAGGACCAGCAAAACTACT;
E1R: TCATATGCTTTAGCATCTGATGCACAA; E68F: AGCA
GCAGGAAGCACTATGG; E69R: CCAGACTGTGAGTTGC
AACAG; G3F: TTGGACATAAGACAAGGGCCAAAA; G4R:
GTCGTTGCCAAAGAGTGATTTGAG; Hybridization. 32P-
labeled probes were following: 38–39; 68–69, P1-E1 and
G3-G4.DNA sequencing.The sequencing reaction was
performed using Big Dye Terminator kit and sequences were
resolved on 310 Genetic Analyzer.Gentamicin protection assay
(GPA) HL-60 cells and human lymphocytes were infected with
bacteria of HIV patients (number of cells: HL-60 5 · 106; bacteria:
1 · 108). FollowingGPAwas performed as previously published.
Results: Colony hybridization with HIV-speciﬁc probes was
found positive. In a control experiment, bacteria were diluted to
concentration 10-10 and plates with single colonies were
analyzed. Since at least 70% of these colonies were found
positive for any of previously tested HIV fragments,
contamination with human cell debris appears unlikely. DNA
of all positive isolates was ampliﬁed in PCR reaction with all
four sets of primers. Sequencing of these products revealed
more than 90% homology with the reference HIV sequence. HIV
sequences were not present in samples isolated from healthy
persons. GPA was used to evaluate the ability of HIV-positive
intestinal bacteria to enter HL–60 cells. As shown in the table 1,
bacteria carrying viral sequences showed approximately 15
times higher afﬁnity to HL–60 cells then bacteria isolated from
carcinomas. DNA extracted from HL-60 cells carrying an
intracellular bacteria showed a strong positivity in
hybridization with HIV probes. The same results were
obtained three weeks after the internalization, although, no
intracellular bacteria could be detected by GPA.
Conclusions: 1. Sequences resolved from intestinal bacteria of
AIDS patients revealed at least 92%homologywithHIV-1. 2. These
bacteria likely enterHL-60 cells and the viral content remains in the
host cells even when bacterial carriers are not detectable.
O219
CCR5 polymorphism as potent factor affecting
susceptibility to HIV-1 infection in Polish
population
E. Piasecki, K. Rybka, K. Zwolinska, B. Knysz, J. Gasiorowski,
A. Gladysz (Wroclaw, PL)
Objectives: CCR5 protein is one of the HIV coreceptors,
particularly important in early stages of the infection when R5
HIVstrainsarepredominant.Anallelic formofCCR5gene –CCR5-
delta32 encodes an inactive receptor. Individuals homozygous for
CCR5-delta32 are almost completely resistant toHIV infection. The
heterozygosity is generally thought to be connected with delayed
progression of the infection. However, there is no agreement
whether the possessing of CCR5-delta32 gene is signiﬁcant in
particular subgroups of patients. Since the distribution of CCR5-
delta32 gene is geographically-dependent, our analysis of Polish
population is limited to Lower Silesia Region.
Methods: The genotype was determined by polymerase chain
reaction method. Genomic DNA was extracted from peripheral
blood by digestion with proteinase K and puriﬁcation on
columns according to manufacturer’s protocol. The primers
pair ampliﬁed a 182 bp fragment from wild type gene and
150 bp from gene with delta32 deletion.
Results: In control group consisting of healthy, non-infected, non-
exposed to HIV individuals frequency of CCR5-delta32 allele was
found to be 10.3% (16 of 78 individuals were heterozygous for
CCR5). In HIV-1-infected patients signiﬁcantly lower frequency
was observed (6.3%; 34 heterozygotes among 268 tested patients).
On the contrary, analysis of exposed uninfected group (sexual
partners of HIV-1-infected patients) showed high frequency of the
gene (19.0%; 8 of 21 tested individuals were heterozygous).
Conclusion: Heterozygotic CCR5/CCR5-delta32 individuals
were signiﬁcantly less susceptible to HIV-1 infection. Gene
frequency of CCR5-delta32 was found to be three times higher
in exposed uninfected than in infected patients. Differences
observed in Polish population were bigger than that described
in papers based on American or Western European population
suggesting signiﬁcant clinical importance of CCR5-delta32 in
Polish population of HIV-1 exposed patients.
O220
Reduced antibody-mediated immunity to malaria
in Zimbabwean adults co-infected with HIV-1
L.S. Vestergaard, P. Kallestrup, R. Zyniama, B. Mudenge,
J. Gerstoft, L. Hviid, H. Ullum (Copenhagen, DK; Harare, ZW)
Objectives: In sub-Saharan Africa, co-infection with HIV-1 has
been shown to increase the susceptibility to Plasmodium
falciparum malaria, suggesting that HIV-1 compromises
acquired malarial immunity. As IgG antibodies speciﬁc for
Patient/bacterial clone Number of bacterial colonies
HIV positive patients
Colon cancer patients
P15/7
P1/4
P3/3
M1/6
M12/5
K1/1
725/5
2264
1340
1680
71
104
44
<5
TuSG/1
883S/3
MZRa/3
negative control
481
lysis of HL-60 cells
lysis of HL-60 cells
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parasite-encoded variant surface antigens (VSA) on the surface
of infected red blood cells are involved in naturally acquired
immunity to P. falciparum, we examined these antibodies as a
possible mechanism of the HIV-1 induced loss of protection.
Methods: VSA-speciﬁc plasma IgG was determined by ﬂow
cytometry in samples from 198 HIV-1-seropositive and 181 HIV-
1-seronegative men and non-pregnant women living in a rural
area in Zimbabwe with low-to-moderate malaria transmission.
Antibodies against another malaria antigen, the repetitive
R2-region of glutamate rich protein (GLURP-R2), and total IgG
were also measured.
Results: Levels and repertoires of anti-VSA IgG were reduced
among HIV-1-seropositive individuals, were positively
associated with CD4+ T cells and were negatively associated
with HIV-1 viral load. By contrast, anti-GLURP-R2 IgG levels
were not affected by HIV-1, while the levels of total IgG were
increased in HIV-1-seropositive individuals.
Conclusions: Our results point to a virus-induced reduction of
variant-speciﬁc humoral immunity as an important cause of
HIV–1 induced increased susceptibility to P. falciparum malaria.
O221
Risk of AIDS and death at given HIV-RNA and
CD4 count levels, according to speciﬁc
antiretroviral drugs in the CART regimen
C. Holkmann Olsen, J. Gatell, B. Ledergerber, C. Katlama,
N. Friis-Møller, J. Weber, A. Horban, S. Staszewski, J. Lundgren,
A.N. Phillips for the EuroSIDA Study Group
Objectives: It is unknown whether the relationship between
the HIV-RNA/CD4 count and risk of clinical disease
continues to hold true for newer antiretroviral drugs, as
drugs licensed after 1997 have been approved on the basis of
clinical trials only assessing short-term surrogate endpoints.
We hypothesised that virological and immunological markers
have the same meaning in terms of long-term clinical effect
according to different drug regimens, rather than, for
example, newer drugs having an additional effect leading to
a higher or lower risk of AIDS/death for given HIV-RNA/
CD4 levels when compared with others.
Methods: Analysis included patients taking combination-
antiretroviral-therapy (CART) regimens containing two non-
abacavir nucleosides plus a ‘third drug’ of a non-nucleoside
reverse transcriptase inhibitor, a (possibly ritonavir boosted)
protease inhibitor or abacavir. We compared rate ratios of AIDS
and death at given, latest HIV-RNA & CD4 counts levels
according to the nucleoside pair and speciﬁc third drugs
patients received as antiretroviral therapy. In multivariate
analysis we adjusted for latest CD4 count, HIV-RNA, age,
exposure group, prior AIDS, calendar year, time from starting
CART, time on current combination.
Results: Among a total of 9,802 patients, 6814 were included in
this analysis and contributed a total of 22,766.6 person-years of
follow-up. Over follow-up, median CD4 count was 353 cells/lL,
HIV-RNA 199 copies/mL. 889 events of new AIDS or death
occurred over follow-up of which 125 were deaths. AIDS/death
incidence rates for any given CD4 or HIV–RNA category were
similar regardless of speciﬁc drugs being used; see ﬁgure.
Adjusted rate ratios (RR) for individual drugs compared with
indinavir (for which clinical endpoint trials are available) were all
close to 1 andwith relatively narrow95%conﬁdence intervals (CI)
all overlapping 1; e.g. nelﬁnavir RR 0.99 (95% CI 0.76–1.28);
efavirenz RR 0.83 (0.57–1.20); abacavir RR 1.01 (0.64–1.60); see
table. Results were similar for different nucleoside pairs with
adjusted RRs overlapping 1 when compared with other.
Conclusions: The results indicate that AIDS/death rates for
given CD4 count andHIV-RNA categories are similar, regardless
of CART regimen being taken. This provides reassurance that
HIV–RNA-and CD4–values in individual patients receiving
newer drugs have the same meaning in terms of AIDS/death
risk, regardless of speciﬁc antiretroviral regimen.
O222
Variable prediction of clinical outcome of the
GART interpretation system Guidelines 6.0 and
Virtual Phenotype
F. Garcı´a, I. Viciana, M.C. Nogales, F. Ferna´ndez, J.C Palomares,
F. Lozano, M. Ma´rquez, P. Viciana, J. Herna´ndez-Quero,
A. Pinedo, M.C. Maroto on behalf of RAERA study group Red
Andaluza para el Estudio de las Resistencias a Antirretrovirales
Andalucia, E
Background: A variable prediction of clinical outcome in terms
of virologic response have been reported for genotypic
antiretroviral resistance testing (GART) interpretation systems.
In addition, serious discrepancies with Virtual Phenotype (vPh)
in the interpretation of certain drugs have been also reported.
Objective: To analyse the inﬂuence on clinical outcome, in
terms of indetectable viral load three months after changing
therapy, of two GART interpretation systems: Guidelines 6.0
(Bayer) and Virtual Phenotype (Virco).
Patients and Methods: Virological, clinical and immunological
data from 258 patients fromAndalucia (Spain) undergoingGART
Incidence rates (IR)
of AIDS / death
(per 100 person-years)
100
CD4 count groups (IR with 95% Confidence Intervals)
< 50/mm3 50-99/mm3 100-199/mm3
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Fig. 1. Rates of AIDS/death according to latest CD4 count and
speciﬁc drugs used
Table 1. Crude and adjusted rate ratios (RR) for occurence of
AIDS disease or death from a Poisson regression model
Rate ratio (95% Cl) P-value
Univariable Multivariable
Nucleoside pair
AZT/3TC 1.05 (0.84–1.34) P = 0.66 1.21 (0.93–1.58) P = 0.15
d4T/ddl 1.08 (0.86–1.36) P = 0.49 1.26 (0.97–1.62) P = 0.08
d4T/3TC 0.98 (0.72–1.32) P = 0.87 1.15 (0.84–1.58) P = 0.38
other 1.00 1.00
Third drug
indinavir 1.00 1.00
ritonavir 1.14 (0.84–1.54) P = 0.41 0.88 (0.66–1.17) P = 0.39
saquinavir 1.80 (1.36–2.41) P < 0.0001 1.04 (0.78–1.38) P = 0.80
nelﬁnavir 0.78 (0.59–1.02) P = 0.069 0.99 (0.76–1.28) P = 0.92
IDV/r of SQV/r 0.56 (0.41–0.77) P = 0.0004 0.79 (0.59–1.05) P = 0.10
Iopinavir/r 1.04 (0.69–1.57) P = 0.83 1.08 (0.65–1.82) P = 0.76
abacavir* 0.72 (0.49–1.05) P = 0.09 1.01 (0.64–1.60) P = 0.97
nevirapine 0.57 (0.42–0.78) P = 0.0004 0.91 (0.65–1.28) P = 0.59
efavirenz 0.62 (0.46–0.84) P = 0.002 0.83 (0.57–1.20) P = 0.31
NB. RR = rate ratio per extra year; # counted only when 3rd drug; Indinavir = IDV; Ritonavir = r;
Saquinavir = SQV; AZT = ZDV = zidovudine; 3TC = lamivudine; d4T = stavudine; ddl = didanosine.
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were collected. GART was interpreted with Guidelines and with
vPH andwas given to the clinician to change therapy. Virological
and immunological data 3 and 6 months after changing therapy
were also recorded, and a database with these data and with
Guidelines genotypic sensitivity score (GSS) and vPh sensitivity
score (vPhSS)was developed. Twoways of interpreting vPhwere
included: vPh1, based on the % of susceptible strains; and vPh2,
based on the fold change on IC50 and the vPh cutoff.
Results: 81% of the patients in this study had failed 2 or more
lines of therapy. Mean No. of mutations in the protease was
4 ± 2.87, and in the RT was 5 ± 2.45 (2.78 ± 1.77 NAMs);
adherence was greater than 80% for 78% of the patients and
median CD4 count and Log Viral Load (copies/ml) was 324.5
and 3.94 respectively. Undetectable VL was achieved for 39.6%
of the patients at 3 months and for 44.4% at 6 months; median
decrease in Log VL from baseline was 1.64 and 1.66 at 3 and 6
months respectively. Mean number of active drugs in the new
regimen was 1.78 using Guidelines 6.0 for interpretation and
2.08 and 2.4 for vPh1 and vPh2. Odds ratio for achieving
indetectable viral load at month 3 was 1.45 for Guidelines (1.06–
1.96), 1.53 for vPh1 (1.00–2.32) and 1.41 for vPh2 (1.00–1.98). In
the multivariate analysis with the GART interpretation systems
evaluated, only Guidelines was predictive of achieving
indetectable VL at 3 months (OR, 1.42; 95% CI, 1.05–1.94).
Conclusions: Guidelines 6.0 is a better predictor of undetectable
viral load at three months than Virtual Phenotype. Other
participants from RAERA group: M. Alvarez, S Carlos,
Martinez NM, Serrano MC, J Parra, MC Ga´lvez, J Pasquau, MA
Lo´pez-Ruz, V Gutierrez-Rave´, E Pujol, E Pe´rez Guzman,
C Ferna´ndez, A de la Iglesia, A Terro´n, A. Alle, D Pen˜a, A del
Arco, M Castan˜o.
O223
Clinical usefulness of the tonsillar HIV
genotyping-guided change of therapy in HIV-1
infected patients with immune discordant
response to HAART
J. Parra-Ruiz, M. Alan˜o´n, M. Martı´nez, L. Mun˜oz-Medina,
M.A. Martı´nez-Pe´rez, F. Garcı´a, M.A. Lo´pez-Ruz,
J. Herna´ndez-Quero (Granada, E)
Introduction: Approximately 10–20% of HIV-1-infected
patients receiving HAART show an immune discordant
response deﬁned as persistently low CD4 cell counts, despite a
signiﬁcant decrease in plasma virus load. Incidence of AIDS–
deﬁning events and deaths among patients with immune
discordant responses are higher than among patients with
complete response or virologic discordant response.
Interventions to improve CD4 T cell response are needed.
Objective: To investigate the existence of active viral replication
in tonsillar tissue of patients with complete pVL suppression
and, if present, to make a genotyping test.
Material and methods: Nucleic acid was extracted using
QIAamp DNA mini kit (Quiagen), with a subsequent HIV
viral load determination (Cobas AMplicor HIV-1 Monitor -
Roche). Resistance genotyping test was made using TruGeneTM
HIV–1 (Bayer).
Results: Tonsillar biopsy was made in 13 patients, 12 men
and 1 woman. Data are expressed for 11 patients (2 samples
are being processed at the moment of writing this abstract).
Ampliﬁcation was possible in 8 of them (72%), being the
genotype WT for the RT in 4 (50%) and for the protease gene
in 3 (38%). Medium CD4 T-cell nadir was 37 cells/lL (range
1–96). Eight patients (73%) were on C3 status of the CDC, 4 of
them because of visceral leishmaniasis (37%). Medium CD4 T
cell count at the moment of tonsillar biopsy was 178 cells/lL
(range 111–223), and all of them have HIV-1 pVL < 50 copies/
ml for a prolonged period of time (medium 22,5 months,
range 12–52). After genotyping, HAART was modiﬁed in 6
patients, with an increase of the CD4 T cell count >50 cells/lL
at 6 months in 2 of them. Three other patients started on IL-2
therapy plus optimized HAART, with an increase of the CD4
T cell count >50 cells/lL at 6 months in one after three cycles
of IL-2, being the other two waiting for the results of the 2nd
and the 1st IL-2 cycle respectively. The remaining patient was
lost to follow up. Of the other 6 patients that did not modify
HAART based on the data from tonsillar genotyping test, only
1 patient has shown an increase of CD4 > 50 cells/lL in the
next 6 months.
Conclusions: Despite prolonged complete viral suppression in
sera, many patients with immune discordant response maintain
viral replication in lymph nodes. Tonsillar HIV ampliﬁcation
and subsequent genotyping-guided change of therapy can be a
useful tool to decide the best HAART and to evaluate the need
IL–2 therapy.
Antimicrobial growth promoters in food animal production
K232
Antimicrobial growth promoters in food animal
production
C. Wegener (Søborg, DK)
Feeding antibiotics to animals in order to make them grow faster
has been common practice in intensive agricultural production
systems since the late ﬁfties. In December 2002 the European
Union member states banned the use of antimicrobials as
growth promoters from January 2006. What lies behind this
change in attitude? In 1997 the World Health Organization
recommended; that the use of antibiotics for growth promotion
should be terminated if they are also used for treatment in
animals or humans, and furthermore, that the use of other
classes of antimicrobials as growth promoters should be gradu-
ally phased out and substituted with safer non–antimicrobials
alternatives. In April 1998, the Danish poultry, cattle and
pig producers terminated the use of antimicrobials growth
promoters. The DANMAP programme monitors the impact of
the withdrawal of antimicrobial growth promoters on antimi-
crobial resistance and antimicrobial usage in Denmark. The total
volume of active antimicrobials used for food animals is reduced
by more than 50%. Resistance to the most commonly used
AGP’s tylosin, virginiamycin, avoparcin and avilamycin has
declined signiﬁcantly. In a number of European countries the
occurrence of VRE in humans in the community has declined.
The producers in Denmark were concerned about terminating
the use of AGP’s. We have analyzed the national poultry
productivity data. Productivity were not affected by the
termination, and mortality rates were likewise unaffected.
Feed efﬁciency has changed slightly however, the savings on
antibiotics for growth promotion offsets the extra cost of feed. In
ﬁnishing pigs no or only a very limited effect of the withdrawal
of AGP’s has been observed, however in weaned pigs, some
herds have experienced problems with post weaning diar-
rhoea. The overall productivity has been increasing after the
Clinical Microbiology and Infection, Volume 11, Supplement 2, 2005
55
termination.The prevalence of Salmonella in broiler ﬂocks and
chicken products as well as in swine herds and pork in Denmark
has continued to decline after the withdrawal of the growth
promoters. The European Union will terminate the continuous
feeding of antimicrobials to healthy animals for growth
promotion. Experiences from Denmark, as well as from other
countries, such as Switzerland, Finland and Sweden, show that
banning antimicrobial growth promoters has a minimal impact
on agricultural productivity, but leads to major reductions in
antimicrobial resistance.
Crosstalk between bacterial pathogens and their host cells
K233
Crosstalk between bacterial pathogens and their
host cells: the Listeria paradigm
P. Cossart (Paris, F)
To establish and maintain a successful infection, microbial
pathogens have evolved a variety of strategies to invade the
host, avoid or resist the innate immune response, damage the
cells and multiply in speciﬁc and normally sterile regions. Based
on their capacity to deal with these critical issues, bacteria can be
grouped in different categories. This talk will focus on the tactics
used by enteroinvasive bacteria (e.g. Listeria, Salmonella, Shig-
ella and Yersinia) to trigger their uptake by epithelial cells and
discuss their intracellular life-styles. During phagocytosis by
phagocytes, bacteria play a passive role. In contrast during
bacterial-induced phagocytosis, the bacterium is the key and
active player in the complex interplay between the invading
microbe and the host cell. Another critical element is the
cytoskeleton whose plasticity is maximally exploited. After
internalization, some bacteria remain in a vacuole, in which
they replicate. They prevent the normal maturation and trafﬁck-
ing of the phagosome and impair its normal bacteriolytic
activites. Other bacteria escape from the vacuole and replicate
in the cytosol. In some cases, they also move and disseminate by
means of an actin–basedmotility process. How the cell senses the
bacterial intruders and adjust its transcription and translation
programme to its new life with a parasite is an important issue.
Apoptosis and anti–apoptosis, as well as cell cycle and inﬂam-
mation related pathways, are reprogrammed after infection to
help the cell to survive the stress induced by the infection. The
success of an infection depends on the two messages that the two
players – the bacterium and the cell–send to each other. At each
step of the infectious process, the bacterium exploits the host
machinery to its own proﬁt. The two last decades have seen an
accumulation of information concerning the molecular mecha-
nisms underlying host–pathogens interactions during infection.
A major issue is now to validate in vivo the molecular and
cellular events analyzed in vitro. This raises the importance of
having a relevant animal model. In some cases (e.g. Shigella) it is
still lacking. In others, it is already existing or has been generated
by use of sophisticated transgenesis approaches (e.g. Listeria).
There is no doubt that progress should be done to provide clues
in the ongoing battle against bacterial diseases and for elabor-
ating new therapeutic strategies.
Infection control: challenges now and ahead
K235
Infection control: challenges now and ahead
W.H. Seto (Hong Kong, HK)
With the outbreak of Severe Acute Respiratory Syndrome
(SARS) and the Avian Flu, Infection Control is ﬁnally receiving
the priority it deserves. However it is important to ensure that
this is a genuine resurgence of the ﬁeld and not simply a
reaction. The Joint Commission of the United States, when
introducing their new Infection Control standards for 2005,
pointed out that it must not be a ‘knee jerk reaction’, relegating
hospital infection as merely the ‘problem of the month’ but
rather it ought to be a long-term commitment to ensure patient
safety. The challenge now is to use the opportunity for
establishing the proper infrastructure for Infection Control and
the essential ingredients would be discussed. Summary data of
the situation in various countries including Hong Kong would
be presented. The challenges ahead are for Infection Control to
focus on the relevant issues, which can generate worthwhile
long–term results. This would include a discussion on the
‘Seven Healthcare Safety Challenges’ for Infection Control
presently promoted by the Center for Disease Control (United
States) and the areas of focus for Infection Control by the World
Alliance for Patient Safety of the WHO. One must avoid the
tendency to over–react because of a severe outbreak like SARS.
It includes the over emphasis on intricate protocols for outbreak
management or the building of expensive isolation facilities.
A summary of the actions resulting from the SARS outbreak for
some hospitals in Hong Kong would be presented, with some
examples of possible over-reactions in response.
Burkholderia, Pseudomonas and emerging infections in cystic ﬁbrosis
S236
Diversity, ecology and identiﬁcation of
Burkholderia cepacia complex and other
non-fermenting Gram-negative bacilli in cystic
ﬁbrosis specimens
P. Vandamme (Ghent, B)
Pulmonary infection in cystic ﬁbrosis (CF) patients is typically
characterised by a narrow spectrum of micro-organisms and is
dominated in older patients by Pseudomonas aeruginosa.
Burkholderia cepacia complex, Stenotrophomonas maltophilia,
Achromobacter xylosoxidans and a growing number of non-
fermenting gram-negative bacilli (NFGNB) have emerged as
potential pathogens in CF lung disease. Several of these novel
bacteria are naturally multiply resistant to antibiotics, cause
chronic infection, and, although probably environmental in
origin, are capable of patient-to-patient spread in the CF
population. Several of the best known NFGNB in medical
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microbiology are considered ubiquitous. Organisms like
Pseudomonas aeruginosa, Burkholderia cepacia complex,
Stenotrophomonas, and Acinetobacter occur in a range of
environmental and clinical niches and are metabolically and
genetically versatile. In spite of their demonstrated potential
for genetic adaptation and evolution, several clones of
NFGNB are reported to occur in a very wide geographical
area for prolonged periods of time. The considerable genomic
versatility has allowed many of these NFGNB to occupy
different environmental niches and to interact with their
environment and hosts in several ways. The genus Burkholde-
ria will be used to exemplify different types of environments
and interactions. The accumulated evidence of reports of the
natural behavior of near to forty Burkholderia species suggests
that their ancestor was a soil bacterium that lived in close
association with plants. Many plants leak nutrients in the
rhizosphere environment to attract bacteria that protect them
from harmful soil organisms, which include other bacteria,
fungi, and nematodes. The Burkholderia ancestor and its
offspring have developed a chemical warfare arsenal to
compete for those nutrients present in the plant rhizosphere
and interact with the plants through – among others – their
nitrogen metabolism and the production of plant hormones.
In this interaction process, burkholderias invaded the fungi of
the plant mycorrhizal community, the root system, and the
plant shoot tissues, and managed to colonize several ecosys-
tems in the plant, thereby interacting mostly in a symbiotic
manner with their hosts. Although we may know many
isolation sites and sources for contamination of vulnerable
patients, it is obvious that we only start to learn about the
natural niche and the ecological role therein of many, if not
most, of these NFGNB. One underlying reason is the heavily
underestimated species richness in many of these groups of
bacteria. Our knowledge of the biological diversity of several
genera of NFGNB underwent dramatic changes during the
past decades due to the detection of a large number of novel
species, but also as a consequence of the criteria for bacterial
genus and species delineation as established in the 1980s.
Very often, this taxonomic complexity is associated with
diagnostic problems. Recording this diversity will allow to
design accurate identiﬁcation procedures for those species that
are of particular interest. Understanding the natural lifestyle
of such organisms may however be instrumental to under-
standing their behavior in humans. The lecture will focus on
the natural diversity of NFGNB which emerged as potential
pathogens in CF lung disease. It will address the ecological
role of these bacteria in the context of epidemiological
investigations and will give an overview of recently devel-
oped identiﬁcation tools.
S237
Stenotrophomonas, Achromobacter, Pandoraea
and other emerging environmental pathogens
N. Høiby (Copenhagen, DK)
Cystic ﬁbrosis patients suffer from recurrent and chronic lung
infections caused by bacteria from the normal ﬂora (S. aureus,
H. inﬂuenzae, S. pneumoniae, M. catarrhalis) as well as bacteria
from the environment, notably P. aeruginosa and the B. cepacia
complex. The increasing life expectancy of CF patients due to
the improved management of these infections, however, has
revealed an increasing number of new environmental bacterial
species, which have colonized CF patients, e.g. S. maltophilia,
A. xylosoxidans, Pandoraea apista, Mycobacteria other than
tuberculosis, and Nocardia. The clinical situation resembles
the time when it was not realized, whether P. aeruginosa was a
pathogen or merely an innocent colonizer of the respiratory
tract of CF patients. Since the number of colonized/infected
patients in each CF centre is restricted, and since co-infection
is frequently present, the clinical dilemma whether to treat or
not is difﬁcult to solve. Experience from P. aeruginosa infection
in CF patients, however, showed that it is possible to
distinguish between innocent colonization and tissue-dam-
aging chronic infection by measuring the speciﬁc antibody
response to the offending bacteria, and this approach has been
used successfully for several years in the Danish CF Center at
Rigshospitalet.
Climate and environment: impact on infectious diseases
S238
The environment as a reservoir for non-culturable
but infectious, antibiotic-resistant bacteria: a new
risk for human health?
M. Lleo, C. Pruzzo, C. Signoretto, P. Canepari (Verona, Genoa, I)
Human pathogens are frequently transmitted from person-to-
person, directly or via vectors/vehicles, thus perpetuating their
parasitic cycle. However, they are also released into the
environment, for example with faeces, where they encounter
adverse conditions (oligotrophy, direct sunlight, extreme tem-
peratures and salinity) which prevent cell division. Under
stressing conditions, human pathogens and components of the
normal microﬂora do not necessarily die but might persist even
for long periods of time (several months) in that they are capable
of activating a survival strategy known as the viable but
nonculturable (VBNC) state. When in this phase, bacteria lose
their ability to form colonies on culture media but are still viable
and capable of metabolic activity and gene expression and show
a speciﬁc protein proﬁle and cell wall modiﬁcations. Moreover,
VBNC cells, which are capable of maintaining their pathogenic
potential (adhesion to animal tissues, toxin synthesis), may be
able to resume division on returning to favourable environmen-
tal conditions such as those encountered in the human gut after
ingestion of contaminated water or foods. A signiﬁcant amount
of data on VBNC bacterial forms derives also from our studies
conducted on a waterborne pathogen such as Vibrio cholerae
whose role as a seawater reservoir involved in cholera epidem-
ics has been deﬁnitively demonstrated. Recently, using a
vancomycin resistant Enterococcus faecalis model, we have
demonstrated that bacteria are capable of maintaining and
expressing antibiotic resistance during the VBNC state and after
resuming their divisional capability when permissive conditions
are restored. On the basis of their characteristics, VBNC cells
could therefore represent a potential risk for human health in
that (i) they might constitute a reservoir of infectious and
antibiotic-resistant bacterial forms involved in disease transmis-
sion and persistence, and (ii) they are undetectable with the
standard culture methods. For this reason, for reliable evalua-
tion of the microbiological quality of the environment is now
mandatory to re-design the currently used procedures in order
also to detect nonculturable bacteria.
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S239
Remote sensing and epidemiology
A. Gu¨ell (Toulouse, F)
MacLehose et al., (Issues on Public Health, 15 March 2002),
warned us about the new European public health threat
associated with communicable diseases. They express concern
about European capacity to responding to such challenge. The
picture gets grimmer when we know that the Rift Valley Fever
(RVF), the dengue hemorragic fever, malaria, cholera, menin-
goccal meningitis, West Nile virus, are re-emerging worldwide.
Half of the world population becomes at risk, and about 4
millions humans die per year (half under 5-year old). Increased
migration, overuse of medicine in Europe, lack of medicine in
the developing world, inappropriate funding do not facilitate
proper responses to the challenge of control and prevention.
Nevertheless since 1999, a French effort and a multidisciplinary
consortium has been developing ’innovative international
space monitoring and surveillance schemes’. The French
space agency (CNES), along with experts on public health
i.e. Institut Pasteur, national institute for agronomic
research, institute for space medicine (MEDES), databases
and environmental factors in-situ and from space (MEDIAS-
France), have been implementing integrated on epidemiology
based upon new technologies such as ’tele-medicine’. Follow-
ing the Johannesburg Summit 2002, a new French project or
‘RED GEMS’ (Re-Emergent Diseases Global Environment
Monitoring from Space), is born. Its two pillars i.e., tele-
epidemiology, and tele-medicine will enable real-time
monitoring of human and animal data (epidemiology, clinical
data, …), socio-economical data (habitat, migration, turmoil,
…), biosphere (land cover, …), hydrosphere (rainfall, stagnant
waters, wind stress, sea surface temperature, altimetry, algae
blooms, …) and atmosphere (winds, convection, aerosols, …).
Products and databases accessible from a dedicated Website
will be delivered to Early Warning Systems (EWS) and Health
Information Systems (HIS) for effective disease control strategy.
The EMERCASE project monitoring the RVF in Senegal, and
the dengue fever project in French Guyana are already
building blocks of ‘RED GEMS’. Two other projects on cholera
and meningococcal meningitis (type C) are under way. It is
believed that this French initiative on space and public health
will contribute to solving the new health challenge, to capacity
building and multidisciplinary networking worldwide.
Crimean Congo haemorrhagic fever in south-eastern Europe
S240
The clinical and epidemiological characteristics
of CCHF and the impact of ribavirin therapy
O. Ergonul (Ankara, TR)
Crimean-Congo haemorrhagic fever (CCHF) is a fatal viral
infection described in parts of Africa, Asia, Eastern Europe,
and Middle East. CCHF was ﬁrst recognized during a large
outbreak among agricultural workers in the mid 1940s in the
Crimean peninsula, and a recent outbreak was reported from
Turkey. The virus belongs to the genus Nairovirus in the
Bunyaviridae family and causes severe diseases in humans,
with the reported mortality rate of 3–30%. The mortality rate of
CCHF virus (CCHFV) infection was lower in Turkey than the
previously reported epidemics. Genetic analysis of the virus
isolates from Turkey revealed a close relation with the isolates
from former Yugoslavia and southwestern Russia. Humans
become infected through the bites of ticks, by contact with a
patient with CCHF during the acute phase of infection, or by
contact with blood or tissues from viremic livestock. The
occurrence of CCHF closely approximates the known world
distribution of Hyalomma spp. ticks. After a short-incubation
period, CCHF is characterized by a sudden onset of high fever,
severe headache, dizziness, and myalgia. Additional symptoms
can include nausea, vomiting, diarrhoea, and somnolence. In
severe cases, haemorrhagic manifestations, ranging from
petechiae to large areas of ecchymosis, develop. The levels of
liver enzymes, creatinine phosphokinase, and lactate dehy-
drogenase are elevated, bleeding markers are elongated. In
diagnosis, enzyme linked immunoassay and real-time reverse
transcription-polymerase chain reaction (RT-PCR) are used.
Treatment options for CCHF are limited. Ribavirin was
suggested as an effective drug in recent studies, and it was
found to be beneﬁcial. No adverse event related to ribavirin
therapy was noted. Based on our experiences in Turkey,
ribavirin should be given to the patients suspected of CCHF
infection who have severe thrombocytopenia, elevated ALT,
AST, AST/ALT levels. The hospital health care workers
(HCW) are under serious risk of transmission of the infection,
particularly during the follow-up of the patient, with hemor-
rhages from the nose, mouth, gums, vagina, and injection sites.
Simple barrier precautions were reported to be effective, but
rigorously applied. Based on the results of our studies, we do
not encourage prophylactic ribavirin use among HCWs,
instead, in such cases, we suggest rigorous daily follow-up of
the individual, by checking complete blood count, and
biochemical tests if necessary.
S241
Crimean Congo haemorrhagic fever: laboratory
diagnosis and epidemiology in Europe
H. Zeller, M.C. Georges-Courbot (Lyon, F)
Crimean Congo haemorrhagic fever (CCHF) is a severe viral
disease with awidespread distribution in subsaharian Africa and
Madagascar, the Middle East, Pakistan, Iran, Turkey, Russia,
Western part of China and some countries in Southern Europe
(Kosovo, Albania, Bulgaria, Greece, …). The virus is able to
produce severe human disease with high mortality rates (up to
30% in hospitalized patients). Due to the occurrence of nosoco-
mial cases, CCHF virus is a major public health concern and is
classiﬁed among the class 4 agents. The virus belongs to the
family Bunyaviridae, genus Nairovirus. It is transmitted by hard
ticks (Hyalomma, Amblyomma, Dermacentor,… sp). The natural
cycle involves small rodents, birds and domestic ruminants.
Humans can be infected via tick bites which occur in during the
peak activity of the vectors (from March to October in Southern
Europe), or by direct contact with infectious blood products.
Usually the incubation period in humans ranges from 3 to 7 days
but can be shorter. Initial clinical symptoms are not speciﬁc:
fever, headache, abdominal pain, nausea, vomiting; they precede
the haemorrhagic phase. Laboratory ﬁndings show leucopenia
(particularly neutropenia), thrombocytopenia, liver enzyme
(AST/AST) and LDH elevations. The virological diagnosis
includes the detection of CCHF viral genome by RT-PCR
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(semi-nested or real-time PCR) and/or detection of CCHF
antigen, in association with serology (detection of CCHF IgM
and IgG antibodies using ELISA or IFA). The viraemia may last
up to 10–14 days, even in the presence of speciﬁc antibodies.
New tools using recombinant antigens for CCHF antibodies
detection are now available. Viral isolation attempts from blood
samples can be conducted under biosafety level 4 conditions on
VeroE6 cells. Phylogenic studies have shown a large diversity
among CCHF viruses. Seven major genetic groups have been
identiﬁed, based on analysis of a 260 bp of the S (small) segment
coding for the nucleoprotein. Recent viral strains from the
Balkans (Albania, Kosovo, Bulgaria) clustered in the same branch
with some strains from Southern of Russia and strains from
Turkey. A few studies were undertaken on the M (medium) and
L (large) segments which encode for the glycoprotein precursor
and the RNA-dependent RNA polymerase, respectively.
Computerised decision support for management of bacterial
infections
S247
Building TREAT – computerised decision
support for antibiotic treatment
L. Leibovici, M. Paul, S. Andreassen (Petah-Tiqva, IL;
Aalborg, DK)
The mortality rate associated with bacterial infections in the
hospital is signiﬁcant, and so are the related costs. Empirical
antibiotic treatment that matches the in-vitro susceptibility of the
pathogen (appropriate antibiotic treatment) and given early in
the course of infection increases chances for survival. However,
in only a small minority of patients the pathogen of infection or
its susceptibilities are known on initiation of antibiotic treatment.
For empirical treatment, the physician balances the antibacterial
spectrum and activity of the drugs against their costs, adverse
events, and their potential to induce resistance. Many times these
calculations are wrong: about a third of patients are given
inappropriate treatment, while about 20% are given superﬂuous
drugs. In the TREAT project we built a computerized decision
support system for prescription of antibiotic drugs. The TREAT
system uses data on signs and symptoms, underlying conditions
of the patient, laboratory and imaging results; and the distribu-
tion of pathogens and their susceptibility in the particular setting
in which the patient acquired the infection, to assign probabil-
ities to sites of infection, pathogens and their susceptibilities to
antibiotics. It then balances the beneﬁt associated with the
different drugs or combinations of drugs against their costs,
potential for side effects, and potential to induce resistance. A
few of the system’s features merit emphasis. First, it assigns a
speciﬁc cost to induction of future resistance. We used local data,
and data available from the literature, to draw a curve relating
consumption to rise in resistance for each drug. To assign a cost
to future resistance, we used a model similar to the one proposed
to deal with optimal use of non-renewable resources Secondly,
its core is a causal probabilistic network, which allowed us to
combine knowledge and data from different sources in the same
system. Last, it was built for easy calibration to new sites, by
differentiating between universal factors (e.g., sensitivity and
speciﬁcity of diagnostic tests); and local factors (e.g., distribution
of pathogens and susceptibilities) that have to be calibrated anew
at each site. The system was calibrated to three locations: Rabin
Medical Center, Petah-Tiqva, Israel (Petah-Tiqva); Freiburg
University Hospital, Freiburg, Germany (Freiburg); and
A. Gemelli University Hospital, Catholic University, Rome,
Italy (Rome); and tried in 2 phases, a non-interventional one; and
a randomized controlled trial.
Hepatitis C virus: new targets for drug and vaccine development
and markers for therapy
S248
Innate immunity, adoptive immunity and vaccine
development
S. Abrignani (Siena, I)
There is no vaccine for HCV and the only treatment which has
proven efﬁcacious is IFN- therapy. However, the success rate of
this treatment is not satisfactory, thus there is a pressing need to
develop prophylactic as well as therapeutic vaccines. HCV
copes very well with the host’s immune system. Once HCV
enters the body, it is cleared naturally in a minority of cases.
While most HCV infections do elicit immune responses,
evidence of immunity is controversial. Obviously, an ideal
vaccine should protect from infection in that it should elicit
sterilising immunity. However, in the case of HCV where
infection can only be assessed by PCR, a more realistic goal
might be to look for vaccines capable of protecting from chronic
infection. After all, HCV acute hepatitis is not a serious public
health problem and most of us would be satisﬁed with a vaccine
that allowed subclinical acute infection but which after a few
months would be cleared by the immune response. Overall, our
view is that a candidate HCV vaccine would be one that protects
from infection and/or progression to chronic infection by the
major genotypes. Our experience in chimpanzees demonstrates
that a subunit vaccine composed by a recombinant form of the
envelope glycoproteins can prime antibody and CD4+ T-cell
responses that protect from chronic infection by heterologous
HCV strains. Based on these results, we have now started
prophylactic as well as therapeutic clinical trials for such a
vaccine.
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Focus on Mycobacterium tuberculosis
O250
Isolation of Mycobacterium species from
respiratory specimens for the diagnosis of
tuberculosis using an automated sample
preparation system based on magnetic particles
J. Lyse´n, H.K. Høidal Berthelsen, M. Espelund,
U.H. Refseth (Oslo, N)
Objectives: The causative agent of tuberculosis (TB),
Mycobacterium tuberculosis, is today the single greatest cause
of mortality due to an infectious agents with 2 million people
dying every year and 8 million new cases. The rising incidence
of multi-resistance Mycobacterium tuberculosis (MDR-TB)
represent an additional problem to public health, with higher
death-rates and the requirement for much more extensive
antibiotic treatment. Routinely, mycobacterium infections are
diagnosed by microscopic examination for the presence of acid-
fast bacilli (AFB) and by conventional culture techniques.
Whereas AFB testing lack sensitivity, cultivation may take up
to 2–4 weeks to determine the presence of mycobacterium due
to the slow growth. Compared to culture, sensitivity using
various nucleic acid ampliﬁcation techniques (NAAT) available
is much lower. This may be due to either insufﬁcient sample
preparation from respiratory samples or incomplete lysis of the
mycobacterium cells. Thus, the requirement for both a rapid and
sensitive diagnostic system for TB is still largely unmet.
Method: Here we present a new automated system for sample
preparation of mycobacterium DNA from respiratory samples
utilizing magnetic particles. In this system (chlamCAP,
Genpoint, Norway), mycobacterium cells are initially adsorbed
to uniquely coated paramagnetic particles and magnetically
separated from the respiratory sample. A rapid lysis at RT
releases DNA, which is then adsorbed onto the same magnetic
particles. After washing, puriﬁed DNA is transferred micro-
wells for NAAT analysis.Mycobacterium bovis (BCG) of the MTC
group was spiked in growth medium and isolation was
performed using the chlamCAP system on a Tecan Miniprep
75 customized to this particular application. Following isolation
of mycobacterium DNA, the samples were analyzed by real-
time PCR using primers speciﬁc for species belonging to MTC .
Results: The sensitivity obtained was <103 CFU/ml (positive
PCR signal) as determined by plating. In addition, results
obtained from heat-inactivated sputum samples containing 50%
sputasol from patients suspected to be infected with
M. tuberculosis, were in agreement with data from cultivation,
demonstrating the robustness of the chlamCAP system.
Conclusion: Based on these results, we believe that the
automated chlamCAP system in the future can promote the
implementation of NAAT based methods in mycobacterium
diagnostics, complementing today’s enrichment systems.
O251
Prospective MIRU-VNTR typing of
Mycobacterium tuberculosis isolates in the
Midlands, UK: detection of a previously
unsuspected large cluster of cases
J. Evans, K. Boese, E. Smith, G. Hong, P. Hawkey
(Birmingham, UK; Omaha, USA)
Objectives: Effective control of TB depends on rapid detection
of links between patients with active disease. IS6110 RFLP
cannot provide rapid results to direct control measures in
outbreaks. MIRU-VNTR PCR typing of M. tuberculosis has
comparable sensitivity to IS6110 RFLP. In July 2003,
prospective MIRU-VNTR typing of all M. tuberculosis isolates
received at Birmingham Regional Centre for Mycobacterio-
logy was implemented to prospectively detect and
conﬁrm epidemiological links between patients with active
TB disease.
Methods: DNA was extracted from positive M. tuberculosis
MGIT cultures. Novel oligos were designed to amplify the 3 ETR
and the 12 MIRU-VNTR loci. 5 L of each PCR reaction was
loaded onto a WAVE DNA Fragment Analysis System using
the DNA Sizing programme. The gradient for separation was an
8.2-min gradient (20–900 bp) at a ﬂow rate of 0.9 ml/min at
50C. Using a Microsoft Excel spreadsheet the number of repeats
at each locus was determined. IS6110 RFLP was performed on
the largest MIRU-VNTR cluster using the standardised
methodology.
Results: 1374 isolates have been typed (July 2003 to October
2004). 533 possess a unique MIRU-VNTR proﬁle with 841
isolates belonging to 170 clusters containing >2 isolates (range
2–75 isolates, median 3), representing a clustering ratio of
61%. The median patient age was 36 years (range 0–98) in
both clustered and unique isolates. The most prevalent
MIRU-VNTR proﬁles were 32333-224325153314 (75 isolates,
5%), 42235-225425173533 (44 isolates, 3%), and 32433-
223125153322 (19 isolates, 1%). Each of these strains
exhibited distinct clusters of cases in three separate
geographical locations. The most diverse VNTR clade was
22433 with a HGDI of 0.975. VNTR clade 32333 was most
homogenous group with a HGDI of 0.816. The largest MIRU-
VNTR cluster contained isolates obtained from 17 different
laboratories. IS6110 RFLP has been performed on 50 isolates
so far. 49 of 50 isolates possess an indistinguishable 7-band
RFLP pattern. The other isolate has an extra band but can still
be considered part of this cluster. 69 of 75 (92%) of these
isolates are in the West Midlands with only 6 (8%) located in
the East Midlands.
Conclusion: The high transmission rate and low median
age in the Midlands, suggests newly acquired infection
and not reactivation. Prospective MIRU-VNTR typing has
detected a large previously unsuspected cluster and has
allowed us to start to describe the epidemiology of TB in
the Midlands.
O252
The identiﬁcation of mycobacteria from solid
media and directly from VersaTREK myco bottles
using the MIDI HPLC system
V. LaBombardi, R. Katariwala, G. Pipia (New York, USA)
Objective: To minimize the time required to identify
mycobacteria, the Sherlock MIDI HPLC system was used to
identify mycobacterial isolates growing on solid media and
directly from positive VersaTREK myco bottles.
Methods: The mycolic acids from mycobacterial isolates
growing on 7H11 agar plates and from positive VersaTREK
myco bottles were extracted, derivatized and subjected to
analysis by HPLC. The resulting chromatograms were
analyzed using the MIDI database library to obtain a species
identiﬁcation. The resulting identiﬁcations were compared to
those obtained by using nucleic acid probes and conventional
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biochemicals. Many of the isolates used in the investigation
were previously vetted as to species identiﬁcation.
Results: Sixty-seven per cent of isolates tested from solid
media were identiﬁed correctly to species. Twenty of 25
Mycobacterium avium complex isolates were identiﬁed correctly
whereas none of the M. scrofulaceum isolates were identiﬁed to
species owing to the absence of this organism from the
database. Only 42.1% of the isolates obtained directly from
positive VersaTREK myco bottles were identiﬁed correctly to
species. A re-engineering of the database and a creation of a
new library resulted in 90.1% of the isolates obtained from
solid media and 82.9% of the isolates obtained from
VersaTREK myco bottles being identiﬁed correctly. All 11
isolates of M. tuberculosis were identiﬁed correctly when
tested directly from positive VersaTREK bottles using either
library.
Conclusions: The use of the revised HPLC library with growth
obtained directly from positive VersaTREK myco bottles allows
for the identiﬁcation of the majority of isolates within clinically
relevant time frames.
O253
Mutator strains may contribute to the acquisition
of drug resistance in Mycobacterium tuberculosis
R.M. Anthony, A.R.J. Schuitema, I.L. Bergval, L. Oskam,
P.R. Klatser (Amsterdam, NL)
Spontaneous rifampicin resistant mutants of Mycobacterium
tuberculosis (strain ATCC35801) were selected in vitro and the
MIC of the resulting mutants measured for rifampicin and
rifabutin. Of 105 colonies screened only a single mutant was
isolated which was rifampicin resistant (MIC 32 lg/ml) but
sensitive to rifabutin. The rpoB gene of this isolate was
sequenced and found to contain a single C to T S522L mutation.
This mutant was subjected to a second round of selection in
parallel with the parent strain using rifabutin. The parent strain
generated rifabutin resistant mutants with a frequency of
1.25 · 10)7 colonies per CFU plated and the R190 (S522L)
mutant generated rifabutin resistant mutants with a frequency
of 1.93 · 10)6 per CFU plated. Thus, spontaneous rifabutin
mutants were generated by R190 with >15 times the frequency
of the parent strain. DNA was extracted and the rpoB mutation
hotspot region sequenced from twenty-six of these randomly
selected rifabutin second round mutants. Additional mutations
in the hot spot region of the rpoB gene were only detected in 12
of the 26 mutants studied; all isolates retained the original S522L
mutation. Four strains had a mutation in codon 531, two in
codon 526, four in codon 512 and two in codon 515. We did not
detect any nucleotide changes in the mutT2, mutT4, or ogt gene
regions previously suggested to be associated with a mutator
phenotype. Selection of a mutator phenotype is recognised as a
consequence of antibiotic challenge in many bacterial species, as
the selection of strains with increased mutation frequencies will
result in a greater chance of acquiring resistance to other drugs.
The increased mutation frequency observed after selection with
rifampicin suggests that mutator strains may also be relevant
for the acquisition of drug resistance in Mycobacterium tuber-
culosis and may have serious implications for tuberculosis
control.
O254
Epidemiology of Beijing strain family in Samara
region, Russia
Y. Balabanova, V. Nikolayevskyy, M. Ruddy, S. Kuznetzov,
S. Zakharova, A. Melentyev, I. Fedorin, F. Drobniewski
(Samara, RUS; London, UK)
Background: Tuberculosis (TB) continues to increase globally
and multidrug resistant TB (MDR TB) is a serious problem in
Russia. Many TB cases originate among prisoners where the
rates are the highest. Previous studies demonstrated the
dominance of Beijing strains in some parts of Russia and other
FSU countries and suggested its increased virulence and
associations with resistance.
Objective: To address: (1) the extent of ’Beijing strain’
transmission in the prison/civil sectors; (2) the association of
drug resistance, clinical and social factors with the Beijing
genotype.
Design: Prospectivepopulation-basedmolecular epidemiological
study.
Setting: All civilian and penitentiary TB facilities in Samara
Region, Russia
Patients: 880 consecutively recruited patients with tuberculosis.
Results: Beijing-family strains (comprised of two main MIRU
types) were highly prevalent: 568/880 (66.6%, 95% CI 63.4–
69.7%) with a signiﬁcantly higher prevalence in the prison
population (RR = 1.3 (95% CI 1.2–1.5) and those aged under 35
(RR = 1.2 (95% CI 1.0–1.3). It supports recent and active
transmission particularly among prisoners who are younger
than civil patients. Comparable proportions were co-infected
with HIV (~10%), hepatitis B/C (~one-ﬁfth), drank alcohol,
smoked and had a similar sexual history. Univariate
analysis demonstrated that male gender (OR 1.5, 95% CI
1.1–1.9), advanced pulmonary disease (OR 3.3, 95% CI 1.3–
8.4), homelessness (OR 5.6, 95%CI 1.1–6.3) and previous
imprisonment (OR 2.0, 95% CI 1.5–2.7) (but less association
with night sweats (OR 0.7, 95% CI 0.5–0.9) were strongly
associated with Beijing-strain family disease. Multivariate
analysis supported previous imprisonment to be a risk factor
(OR 2.0, 95% CI 1.4–3.3) (and night sweats to be less associated
(OR 0.7, 95% CI 0.5–1.0) with Beijing disease. Multidrug
resistance and resistance to isoniazid, rifampicin, streptomycin
and ethambutol were two-fold higher in prisoners than in
civilians (RR = 2.4 (95% CI 1.9–3.0); RR = 1.9 (95% CI 1.6–2.3);
RR = 2.2 (95% CI 1.7–2.7), RR = 1.9 (1.5–2.3), 2.2 (1.6–3.2) and
respectively.
Conclusions: Drug resistance and previous imprisonment, but
not HIV co-infection was signiﬁcantly associated with Beijing-
strain infection. There was limited evidence, that Beijing isolates
caused radiologically more advanced disease. Larger clinical
and immunopathological studies are needed to verify enhanced
virulence of the Beijing family strain.
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Diagnosis and management of sepsis in the critically-ill patient
(symposium arranged with ISF)
S259
Association of statin therapy with 30- and 180-day
mortality in patients with bacteraemia:
population-based cohort study
R.W. Thomsen, H.H. Hundborg, S.P. Johnsen, H.T. Sørensen,
H.C. Schønheyder, H.-H. Lervang (Aalborg, Aarhus, DK)
Objectives: Statins may decrease the risk of severe sepsis and
death among patients hospitalized with bacterial infections, due
to anti-inﬂammatory effects. We conducted this population-
based cohort study to examine the effect of statin therapy on
short- and long-term mortality in patients with bacteraemia.
Methods: We retrieved all patients hospitalized with
bacteraemia in North Jutland County, Denmark, from January
1997 to December 2002 from the County Bacteremia Registry.
Using civil registry numbers, patients treated with statins were
identiﬁed by record-linkage with the County Prescription
Database. Mortality within 180 days after the bacteraemia was
determined through the Central Population Registry. Mortality
rates were compared for patients with and without statin
therapy, adjusted for gender, age, comorbidity, use of antibiotic
or immunosuppressive drugs, and focus of infection.
Results: Among 5353 patients older than 15 years hospitalized
with bacteraemia, 176 received statin therapy before admission.
The 30-day mortality in statin users vs. non-users was similar
(20.0% vs. 21.6%, adjusted mortality rate ratio (MRR) 0.9, 95%
CI 0.7–1.3). Among survivors 30 days after the bacteraemia,
however, statin therapy was associated with a substantial
decrease in mortality during the subsequent period up till 180
days after the infection (8.4% vs. 17.5%, adjusted MRR 0.4, 95%
CI 0.2–0.8). The tendency towards similar short-term mortality
and decreased long-term mortality rates in statin users was
observed in both community-acquired and nosocomial
bacteraemia episodes, and for various microbiologic agents
and foci of infection. When analyses were restricted to patients
with a prior medical indication for statin use (ischemic heart
disease, stroke, peripheral atherosclerosis, or diabetes), the
adjusted 30-day MRR among statin users was 1.1 (95% CI 0.8–
1.6), and the adjusted MRR from 30 to 180 days was 0.5 (95%
CI 0.3–1.0).
Conclusions: By contrast with previous smaller reports, in this
population-based study statin use was not associated with a
better prognosis within 30 days after an episode of bacteraemia,
where most directly infection-related deaths may take place.
Statins, however, seem to be associated with a substantially
decreased long-term mortality after bacteraemia.
S263
Role of guidelines in the management of severe
sepsis and septic shock
J.-L. Vincent (Brussels, B)
Septic shock is a common condition on our ICUs associated with
considerable morbidity and high mortality. Until relatively
recently, management of the patient with septic shock has
relied on infection eradication with anti-microbial agents and
surgery where needed, adequate ﬂuid resuscitation, and organ
support. However, research into therapeutic strategies is intense
and advances in management are moving fast. Physicians are
confronted with a wealth of study data that they are expected to
apply to daily clinical practice. And in this age of evidence-based
medicine and quality-assurance, each decision has to be backed
by a sound rationale. Clinical Guidelines, deﬁned as "systemat-
ically developed statements to assist practitioner and patient
decisions about appropriate health care for speciﬁc clinical
circumstances",1 are designed to help clinicians achieve this goal,
to assist in making appropriate decisions regarding management
for individual patients. However, to be of any real value,
guidelines need to be implemented and need to be ﬂexible and
adaptable. Medical research moves at a rapid pace and guide-
lines need to be continually updated as new discoveries aremade
and found, in high quality trials, to have an impact on outcomes.
The Surviving Sepsis Campaign has recently published guide-
lines for the management of severe sepsis and septic shock,2
which include, among others, recommendations on appropriate
antibiotic therapy, endpoints of ﬂuid resuscitation, vasopressor
preference, stress-dose steroid therapy for septic shock, use of
recombinant activated protein C, and importance of blood
glucose levels. Importantly, though, and unlike previous guide-
lines, the Surviving Sepsis Campaign has combined the devel-
opment of the guidelines with a process to encourage their
implementation and to assess the impact of the guidelines on
mortality reduction. An annual update of the guidelines is also
promised. Such evolving guidelines will help clinicians to apply
results from the ever-increasing mass of literature and data to
provide quality standard of care for their patients.
1. Field MJ, Lohr KN (editors). Institute of Medicine Committee
to Advise the Public Health Service on Clinical Practice
Guidelines. Clinical Practice Guidelines: Directions for a New
Program. Washington DC: National Academy Press; 1990.
2. Dellinger RP, et al. Surviving Sepsis Campaign guidelines for
management of severe sepsis and septic shock. Crit Care Med
2004; 32: 858–873.
MRSA – new challenges in hospital and community settings
O264
National surveillance on methicillin resistant
Staphylococcus aureus in Denmark, 1999–2003
R. Skov, A.R. Larsen, S. Bo¨cher, M. Stegger, T. Klemmensen,
D. Monnet (Copenhagen, DK)
Objectives: To present national surveillance data on methicillin
resistant Staphylococcus aureus (MRSA) in Denmark from the
5-year period 1999–2003.
Methods: Since 1988 all methicillin resistant S. aureus (MRSA)
isolates, both from infection and colonization cases, has been
referred to and stored at the Staphylococcus Laboratory, Statens
Serum Institut for national surveillance and since 1999 hospital
discharge summaries or general practitioner records providing
clinical and epidemiological data has retrospectively been
obtained on all patients. Based on this information each case
has been categorized as infection or colonisation as well as the
probable source of acquisition giving the following catagories
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for infections: IMP: acquired outside Denmark; HA: Hospital
acquired infection; CO: Community onset MRSA infection;
CO-Health care associated (CO-HCA): patient has been
hospitalized within the last 12 months; CO-community risk
(CO-CR): close contact to another patient with a community
acquired MRSA infection; CO-No Risk (CO-NR): No Risk factor
has been identiﬁed. CA: Community acquired = CO-CR and
CO-NR patients. All isolates has been subjected to PFGE –
according to the harmony protocol, phagetyping and
resistogram for 12 antibiotics. Presence of the mecA gene was
conﬁrmed with the EVIGENE kit.
Results: A total of 618 MRSA was found in the period. 131 were
found by screening (will not be considered further) leaving 487
cases of infection. The number of infections increased from 54 in
1999 to 201 in 2003. In the same period the number of CO
isolates increased from 26 to 113 (56%) of infections. In 2003, 17
patients had a community risk whereas 47 did not have any
identiﬁed risk factors. Throughout the period ST80-IV
accounted for 49% of CO-MRSA infections. Skin and soft
tissue infections dominated CA-MRSA (82% vs 17% in HA
infections).
Conclusions: The prevalence of MRSA has been very low in
Denmark for more than 20 years. However, the number of
cases is now increasing and the epidemiology of MRSA is
changing towards primary acquisition within Denmark and
community-onset infections, most of them without identiﬁable
risk factors associated with previous health care. The ST80-IV
clone has successfully established itself in the Danish
community. However, the recent increase in MRSA
infections is not due to the ST80-IV clone, which may
indicate that new, well-adapted clones are now evolving in
Denmark.
O265
Characterisation of ST125-MRSA-IV, a clone
evolved in and spread from Norway?
A.E. Fossum, K. Alm-Kristiansen, G. Bukholm (Nordbyhagen, N)
Objectives: During the last few years several incidences of
methicillin-resistant Staphylococcus aureus outbreaks have
occurred in nursing homes in Norway. As residents in
nursing homes often are transferred between different health
care institutions, nursing homes can serve as a reservoir for
MRSA strains resulting in outbreaks in other health care
institutions. During the period 1999–2000 an outbreak was
discovered in a nursing home (no. I) in the South-Eastern part
of Norway. The outbreak was discovered by ampliﬁed
fragment length polymorphism (AFLP) typing, and thought
to be cleared after infection control interventions in June 2000.
In May 2003 another MRSA outbreak occurred at a second
nursing home (no. II) situated in the same county as nursing
home I. The two nursing homes have an exchange of residents
and transfer residents to the same hospital. Reanalysis of all
MRSA isolates from both outbreaks were done to investigate
the possibility of an ongoing MRSA outbreak having lasted for
4 years.
Methods: The isolates were reanalyzed using multilocus
sequencing analysis (MLST), staphylococcus cassette chromo-
some mec typing (SCCmec) and AFLP.
Results: All isolates were of the same sequence and SCCmec
type, the novel ST125-IV. The AFLP analysis revealed a
homology between the isolates of the ﬁrst period (1999–2000)
to be approximately 97%, and the homology between all isolates
to approximately 89%.
Conclusion: The MRSA clones have survived in one or both of
the nursing homes during a time period of 3–4 years, only
having evolved slightly. ST125-IV has also been discovered in
northern Norway and in a Spanish university hospital at
Tenerife. In the Spanish hospital ST125-IV was ﬁrst discovered
in 2001, increasing rapidly and represented 22.8% of the clones
in 2002. To our knowledge ST125-IV has not been discovered
elsewhere. The ST125-IV clones are nearly related to ST5-IV,
‘pediatric clone’, differing with only one basepair in the yqiL
allele. This might indicate that the strain has evolved from ST5-
IV in Norway and spread to Tenerife e.g. by tourism. Another
scenario is that the point mutation in the yqiL allele has occurred
in several ST5 clones. The MRSA clones with sequence type 125-
IV have shown the ability to establishment itself as an endemic
strain in health institution environments, both in Norway and
Spain.
O266
Genetic diversity among community isolates
of methicillin-resistant Staphylococcus aureus
in southern Stockholm
H. Fang, G. Hedin, A. Tammelin (Stockholm, S)
Objectives: Community-acquired methicillin-resistant Staphylo-
coccus aureus (CAMRSA) strains are being isolated with
increasing frequency around the world. The ﬁrst CAMRSA in
the southern Stockholm area was documented year 2000. The
present study is aimed at understanding the molecular
epidemiology of CAMRSA in the southern Stockholm area.
Methods: The CAMRSA isolates detected during 2000 and 2003
were investigated. The strains were genotyped by pulsed-ﬁeld
gel electrophoresis (PFGE), multi-locus sequence typing, and
staphylococcal chromosomal cassette mec (SCCmec) analysis.
The presence of the Panton–Valentine leukocidin (pvl) genes
was detected by PCR. The antibiograms of the isolates were
determined by disk diffusion method.
Results: 38 CAMRSA isolates were detected during 2000 and
2003, which accounted for 21% of the 181 new MRSA cases
under the period. These isolates presented 12 PFGE patterns
and belonged to 10 MRSA clones. Among these clones, ST80-
MRSA-IV was the only clone persistent through all the
4 years. Clone ST8-MRSA-IV emerged in 2001 and the
frequency went down afterwards. ST150 was a new MLST
type reported so far only from Sweden. In 2002, a cluster of
ﬁve CAMRSA isolates was found to be ST150, which could be
further divided into two clones, ST150-MRSA-IIIC and ST150-
MRSA-IIID. The year after, another two ST150-MRSA-IIIC
isolates were detected in the same area. ST154-MRSA-IV was
another new clone found in the study and so far only one
strain belonged to this clone. Type IV was the most common
SCCmec type in the study, which accounted for 63% of these
strains and was present in diverse genetic backgrounds. Three
new SCCmec types were observed in the study, i.e. SCCmec I
variant, IIIC and IIID. Twenty-three of the 38 CAMRSA
isolates (61%) harboured the pvl genes, while no pvl genes
were detected in hospital clones of MRSA under the period.
However, the percentage of pvl-positive isolates among these
community isolates of MRSA has declined by years, which
was 91%, 57% and 36% in 2001, 2002 and 2003, respectively.
In the present study, most CAMRSA strains (95%) were non-
multiresistant except clone ST59-MRSA-IIIC, which was co-
resistant to erythromycin, clindamycin, chloramphenicol and
tetracycline.
Conclusions: The present study reveals the genetic diversity of
CAMRSA strains in the southern Stockholm area and
emphasizes the importance of typing in tracing the origin of
isolates for controlling their spread in community.
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O267
Polyclonal emergence of community-acquired
methicillin-resistant Staphylococcus aureus
strains harbouring PantonValentine leukocidin
genes in Belgium
O. Denis, A. Deplano, H. De Beenhouwer, M. Hallin,
G. Huysmans, M.G. Garrino, Y. Glupczynski, X. Malaviolle,
A. Vergison, M.J. Struelens (Brussels, Aalst, Namur, Yvoir, B)
Background: Community-acquired (CA) methicillin-resistant
S. aureus (MRSA) infections have been reported worldwide.
Molecular studies suggest spread of a limited number of
Panton–Valentine Leukocidin (PVL) producing MRSA clones
that are genetically distinct from nosocomial strains. The
objective of this study was to describe the molecular
characteristics of the ﬁrst PVL-positive MRSA strains isolated
in Belgium.
Methods: Identiﬁcation and oxacillin resistance were conﬁrmed
by triplex PCR for 16S rRNA, nuc and mecA genes. PVL genes
(lukS-lukF) were tested by PCR. PVL-positive strains were
genotyped by pulsed ﬁeld gel electrophoresis (PFGE) after SmaI
macrorestriction, staphylococcal cassette chromosome mec
(SCCmec) typing, spa sequence typing and MLST. The
accessory gene regulator (agr) polymorphism was determined
by PCR. Susceptibility to 16 antimicrobials was determined by
disk diffusion method.
Results: Among 65 putative CA-MRSA strains collected from
2002 to 2004, 15 isolates harboured lukS-lukF genes encoding the
Panton–Valentine Leukocidin. By molecular typing, they
belonged to PFGE type X1 ST80-SCCmec IV (n = 6), X2 ST80-
SCCmec IV (n = 4), J4 ST30-SCCmecIV (n = 2), A23 ST8-
SCCmec IV (n = 2) and Y1 new ST-SCCmec IV (n = 1). Strains
had an agr type 3 (n = 13) or type 1 (n = 2) genotype. Strains
were resistant to tetracycline (64%), fusidic acid (57%) and
kanamycin (36%) and susceptible to other antimicrobial drugs
including the quinolones. The mean age of patients with PVL-
MRSA isolates was 26 years (range 1–70). All but one infections
were community-acquired. including with skin or soft tissue
infections (n = 13), bacteraemia (n = 1) and peritonitis (n = 1).
One patient had skin colonisation. Five patients had previous
beta-lactam therapy. Two cases were travel associated.
Conclusions: These results showed the emergence and
importation in Belgium of PVL-positive CA-MRSA strains
belonging to four MLST clones. CA-MRSA strains of genotype
ST8-SCCmec IV and ST30-SCCmec IV were closely related with
nosocomial PVL-negative strains. Strains were susceptible to
most non beta-lactam antimicrobials except tetracycline,
kanamycin and fusidic acid. PVL-positive strains caused skin
or soft-tissue infections and rarely systemic infections.
Surveillance should be intensiﬁed to monitor the incidence of
MRSA and control its spread in the community.
O268
Panton–Valentine leukocidin positive
methicillin-resistant Staphylococcus aureus in the
Netherlands
X.W. Huijsdens, M.E.O.C. Heck, G.N. Pluister, E. Spalburg,
M.G. van Santen, E. Tiemersma, H.A.J. de Neeling,
W.J.B. Wannet (Bilthoven, NL)
Objectives: The worldwide emergence of hypervirulent
methicillin-resistant Staphylococcus aureus (MRSA) strains
carrying the loci for Panton–Valentine leukocidin (PVL) is not
limited to the community, but might also be emerging in the
hospital environment. The National Institute of Public Health
and the Environment (RIVM) serves as the national reference
centre for the surveillance of MRSA in Dutch hospitals. Since the
discovery of PVL positive MRSA strains in the Netherlands, all
MRSA isolates of the national surveillance programme are
routinely tested for the presence of the PVL loci. Because of the
low (<1%) MRSA prevalence in the Netherlands, we are able to
study virtually all hospital-acquired MRSA, which provides an
accurate representation of the actual MRSA situation in our
country. This report summarizes the results of PVL positive
MRSA in the Netherlands in the period 2000 through 2003.
Methods: The PVL-MRSA isolates were obtained from clinics
(40%), outpatient clinics (35%), and patients visiting general
practitioners (25%). A multiplex PCR was used for the detection
of PVL positive MRSA strains. The PCR detects not only the PVL
loci, but also conﬁrms the presence of the mecA gene and a S.
aureus speciﬁc DNA fragment. Molecular typing also included
pulsed-ﬁeld gel electrophoresis (PFGE) and multilocus sequence
typing (MLST).
Results: In the period 2000 through 2003 approximately 10% of
all Dutch hospital MRSA isolates carried the PVL loci, and
molecular subtyping revealed two predominant PVL-MRSA
genotypes: NL-28 (by PFGE) or sequence type (ST) 80 (by MLST)
and NL-218 (PFGE type USA 300) or ST8. Molecular subtyping
showed that most Dutch PVL-MRSA genotypes corresponded to
well-documented global epidemic types. PVL-MRSA genotype
ST80 is predominant in other European countries as well.
Genotype ST8 has been found to be associated with outbreaks
among jail inmates and gay men in the USA. Approximately
70% of the PVL-MRSA isolates were assigned staphylococcal
cassette chromosome mec (SCCmec) type IV. Recent data have
indicated the presence of SCCmec type IV in community-
acquired MRSA.
Conclusion: Forty per cent of the Dutch isolates were obtained
from clinics. The data presented here for PVL-MRSA isolates
seem to conﬁrm the hypothesis that PVL-MRSA might spread in
the hospital environment and also might be (come) a hospital-
associated public health threat.
O269
An MRSA strain associated with a community
maternity hospital and carrying an exfoliative
toxin gene
G.F.S. Edwards, I.M. Gould, D. Morrison, E.K. Girvan,
B. Cosgrove, T.M.S. Reid, F.M. Mackenzie, L.A. McBeath,
R.A. Browning, C.G. Gemmell (Glasgow, Aberdeen, UK)
Objectives: To follow-up the identiﬁcation of MRSA isolates
carrying the exfoliative toxin A (ETA) gene in patients
associated with a community maternity hospital near Aberdeen.
Methods: We searched the SMRL database for isolates
phenotypically and genotypically similar to those identiﬁed,
characterised them further and looked at the clinical records of
the patients.
Results: The index isolates were from skin infections in 1 adult
and 7 babies. They had a characteristic PFGE pattern which
resembled that of the US Paediatric Clone; this association was
conﬁrmed by MLST (ST5) and SCCmec (IV) typing. Toxin PCR
showed that the isolates had the genes for ETA and enterotoxin
D (SED) but not exfoliative toxin B (ETB) or Panton–Valentine
leukocidin (PVL). Of the 55,000 isolates in the database, 110,
nearly all referred from the Aberdeen Laboratory, resembled the
index isolates. Of these, 60, mostly isolated in 2003 or 2004, were
available for further testing. Nearly all these isolates were
positive for the SED gene, about 60% were positive for the ETA
gene and all were negative for the ETB and PVL genes. All the
ETA positive isolates (and many of the SED positive, ETA
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negative ones) had closely related PFGE patterns but they were
not all identical. The earliest isolate with the ETA toxin gene had
been isolated from a wound swab taken in the community in
1998. The patients with the ETA positive isolates fell into three
groups: (1) associated with the maternity hospital; (2) injecting
drug users in the community; (3) hospital patients with clinical
histories typical of those with hospital acquired strains.
Conclusions: We have shown that a phenotypically distinct
group of ST5, SCCmec IV MRSA isolates carrying the ETA gene
has been present in the Grampian region of Scotland for more
than 5 years. Isolates have been present both in the community
and in hospital patients; very similar isolates without the ETA
gene have also been found. The ETA gene is usually carried on a
plasmid and it is possible that the ‘outbreak strain’ has been
generated on more than one occasion. As the strain is so
widespread, attempts to contain it have been limited to the
standard policy of decolonisation after treatment of any
infection.
O270
Hospital transmission of a methicillin-resistant
Staphylococcus aureus strain of increasing
prevalence in the Scandinavian community
C. Ahre´n, L. Larsson, C. Welinder-Olsson, B. Olsson-Liljequist,
S. Haeggman, R. Skov (Go¨teborg, Stockholm, S; Copenhagen, DK)
Objectives: World-wide an increasing number patients with
MRSA are found in the community. We report a smaller hospital
outbreak caused by a strain of increasing prevalence in the
community and most likely transmitted in the hospital by a
healthy carrier.
Methods: The Infection Control unit at Sahlgrenska University
hospital has been responsible for typing all MRSA strains
isolated in the region as well as investigating epidemiological
relationships of all possible outbreaks of MRSA since 1983.
Strains are designated according to phenotypic characteristics,
antibiograms and pulsed-ﬁeld gel electrophoresis (PFGE)-
patterns. To enable investigation of relationships between
strains at the national level MRSA strains are further typed at
SMI.
Results: Within a 2-month period in spring 2003 three women
cared for in one of our maternity clinics were infected with the
same MRSA strain, two developed febrile infection. Their
newborns were later found to be throat carriers with this
strain. No epidemiological relationship could be established
between the mothers at that point. Co-patients and ~90
employees were screened for carriage but none was found
positive. A year later one additional mother developed mastitis
with the same strain. Her baby was also found to be a throat
carrier. Among co-patients and 200 personnel cultured, this time
also including the staff at the neonatal unit, one doctor was
found to be heavily colonised with the MRSA strain in question.
The doctor was later found to have been involved in the care of
all four neonates. The strain is sequence type (ST) 45, SCCmec
IV, PVL-toxin negative MRSA strain with additional resistance
only to tetracycline. It belongs to a clone with Berlin IV-like
pattern on PFGE, widely spread both in Sweden and Denmark
and presently increasing particularly in the community in
Sweden.
Conclusion: It has not been possible to establish where and
when the doctor was infected. Apart from being health
personnel, no risk factors for MRSA carriage were
encountered. Transmission most likely occured from healthy
neonates to the breastfeeding mothers and not vice versa as
initially believed. The extremely low prevalence of MRSA in
Scandinavia, in Sweden <600 cases/year, makes it unlikely that
the mothers, babies and the doctor have separate routes of
transmission. The increase of MRSA in the community raises the
questions of who and when to screen patients and employees to
prevent spread of MRSA in hospitals.
O271
Comparison of genetic backgrounds of MRSA
and MSSA isolated in Portuguese hospitals and
in the community
M. Aires de Sousa, C. Simas, T. Conceic¸a˜o,
H. de Lencastre (Oeiras, P)
Objectives: The nosocomial prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) in Portugal was stable and
estimated around 50% during the last decade. During this
period there were successive waves of dominant MRSA clones
in Portuguese hospitals, namely the Iberian (ST247-SCCmec IA),
Brazilian (ST239-III) and EMRSA-15 (ST22-IV) clones. In order to
understand the origins of these nosocomial major MRSA clones,
we compared the genetic background of MRSA from three
hospitals with methicillin-susceptible S. aureus (MSSA) isolates
from those hospitals and from the community where they were
located.
Methods: A total of 238MSSA isolates, including 141 nosocomial
and 97 community isolates, were characterized by pulsed-ﬁeld
gel electrophoresis (PFGE). Representatives of each PFGE pattern
were studied by spa typing and multilocus sequence typing
(MLST). Nosocomial isolateswere recovered from three hospitals
and the community isolates were recovered from healthy
children attending day care centres and from draftees.
Results: The 238 MSSA isolates were grouped into 18 clones, of
which 13 were present in both nosocomial and community
settings. Half of the isolates belonged to three major clonal
types: clone A (PFGE type A, spa type 33 or related, ST30), clone
B (PFGE type B, spa type 295 or related, ST34) and clone C
(PFGE type C, spa type 2 or related, ST5). Clone A, corresponds
to a slight variation (MLST single locus variant) of the genetic
background of the international MRSA clone EMRSA-16 (ST36-
II) and clone C corresponds to the background of the New
York/Japan (ST5-II) and Pediatric (ST5-IV) clones. To the best of
our knowledge, the former two clones have never been detected
in Portugal. However, the Pediatric clone was ﬁrst described
in a pediatric Portuguese hospital. Interestingly, the genetic
backgrounds correspondent to the dominant MRSA clones in
Portuguese hospitals (Iberian, Brazilian and EMRSA-15) were
scarcely or not found among the present MSSA collection.
Conclusions: The Iberian, Brazilian and EMRSA-15 clones,
which are the three major MRSA clones detected in
Portuguese hospitals during the last decade, seem to have not
originated from the introduction of SCCmec into dominant
MSSA backgrounds present in the Portuguese nosocomial or
community environment suggesting they were imported from
abroad. In contrast, the MRSA Pediatric clone might have
originated in our country by the acquisition of SCCmec type IV
into MSSA clone C.
O272
Active MRSA surveillance decreases the
incidence of MRSA bacteraemia
P. Shitrit, B. Gottesman, M. Katzir, A. Kilman, M. Chowers (Kfar
Saba, IL)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA)
colonization and infection in hospitals has increased during the
last two decades worldwide. In May 2003 the society of hospital
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epidemiology of America presented new guidelines for
prevention of nosocomial transmission of MRSA, stressing the
need for increased surveillance. Therefore, the objectives of the
current study were to evaluate the inﬂuence of active
surveillance cultures for MRSA, on the incidence of
nosocomial MRSA bacteraemia cases in our hospital.
Methods: In June 2003 new guidelines for MRSA active
surveillance cultures were implemented in our hospital.
Surveillance cultures were recommended for all high risk
patients. Contact isolation was implemented for patients with
positive cultures. The total number of surveillance cultures, the
per cent of positive surveillance cultures and the number of
MRSA bacteraemia cases before and after the intervention were
compared (January 2002 to February 2003 – before intervention
and July 2003 to October 2004 – after intervention).
Results: The number of surveillance cultures increased from a
mean of 272 cultures per month before the intervention, to 836
cultures per month after the intervention. The per cent of positive
surveillance cultures increased from 2.4% before, to 5.9% after the
intervention. The number of positive MRSA bacteraemia cases
per month decreased from a mean of 3.6 before the intervention
to a mean of 1.9 cases after the intervention (p = 0.0003).
Moreover, the trend line for new bacteremic patients changed
from a slope indicating a constant increase (R2 = 0.2), to an
almost ﬂat trend line (R2 = 0.01) (Fig. 1).
Conclusions: Active surveillance cultures are important in
order to identify the hidden reservoir of MRSA cases. Contact
isolation can prevent new colonization and infection, thus
resulting in signiﬁcant reduction of morbidity and healthcare
costs.
O273
Methicillin-resistant Staphylococcus aureus
bacteraemia trends after control programme
A. Pan, G. Carnevale, P. Catenazzi, P. Mondello, L. Ferrari,
B. Cadeo, S. Testa, L. Soavi, S. Lorenzotti, S. Magri, L. Signorini,
G. Carosi (Brescia, Cremona, I)
Objectives: To evaluate trends in MRSA bacteraemia after the
introduction of a nosocomial MRSA control system.
Methods: The study was of the before – after type. It was
conducted at the hospital of Cremona – 850 bed community
hospital – with intensive care unit (ICU), vascular surgery,
neurosurgery, bone marrow transplant, and AIDS units. The
study was performed in a hyperendemic setting, with a
prevalence of methicillin resistance (MR) among nosocomial
Staphylococcus aureus above 50%. Among all the hospitalized
patients,MRSAbacteraemiawas identiﬁed, origin of bacteraemia
deﬁned, and incidence rate calculated as per ward (ICU, surgical,
or medical) and per origin (primary, central venous catheter –
CVC – surgery, etc.). The MRSA control programme imple-
mented, was based mainly on active identiﬁcation of colonized
patients through surveillance cultures, and isolation with contact
precautions for all MRSA positive patients.
Results: From January 1,1996 through December 31, 2001, 69
MRSA bacteraemia were identiﬁed. When comparing the pre-
intervention period, 1/1996 – 6/1997, with 1/2000 – 12/2001,
the incidence rate of MRSA bacteraemia was reduced from 0.62
to 0.32 per 1000 admissions (relative risk (RR) = 0.51; 95%
conﬁdence interval (CI) = 0.28–0.96; p = 0.03). The effects were
most striking in ICU, with an 89% reduction (RR = 0.11; 95%
CI = 0.01–0.98; p = 0.03) and in CVC-related bacteraemia with
an 82% decrease (RR = 0.17; 95% CI = 0.05–0.55; p = 0.002).
Methicillin resistance among blood isolates decreased from 46%
to 17% (RR = 0.37; 95% CI = 0.22–0.62; p = 0.0005).
Conclusions: A reduction in MRSA bacteraemia may be
achieved through control of MRSA transmission in hospitals
with very high MR prevalence. Patients in ICU and with a CVC
may beneﬁt the most from ‘search and isolates’ control
interventions.
Focus on extraction and ampliﬁcation controls in molecular
diagnostics
O275
Automated nucleic acid extraction using the
NucliSens easyMAG system for the recovery of
DNA from various clinical specimen types
A. van den Brule, V. van Melick, P. van Deursen, J. Mollink,
M. Jacobs, E. Boel, G. Onland (Veldhoven, Boxtel, NL)
Objective: Measure the efﬁciency of a new automated nucleic
acid extraction system (NucliSens easyMAG, bioMe´rieux) for
various clinical samples as compared to a reference extraction
system.
Methods: 140 individual clinical samples (including plasma,
serum, CSF, blood, stool, and sputum samples) were spiked with
Phocine herpesvirus-1 (PhHV). Extracted sampleswere subjected
to real time PCR to determine the extraction efﬁciency of the
NucliSens easyMAG and compare it to a manual magnetic silica
method (NucliSensminiMAG, bioMe´rieux).Next, serial dilutions
of M. bovis were prepared in sputum to compare the extraction
efﬁciency of both systems with a second model system. Run
controlswere included tomeasure the reproducibility. Carry over
was addressed by processing highly positive samples in between
negative samples. For the easyMAG method two different
workﬂows were tested, lysis on board and lysis off board.
Results: PhHV DNA was detected in 96% (easyMAG) and 97%
(miniMAG) of the samples when tested undiluted and was
detected in all samples when tested 5-fold diluted. In total 6/20
(easyMAG) and 4/20 (miniMAG) stool samples were not
detected when tested undiluted, for all other sample types
100% detection was measured. Mean Ct values were 27.7 ± 2.5
(easyMAG) and 27.6 ± 2.3 (miniMAG) for undiluted samples
and 29.4 ± 1.8 (easyMAG) and 29.5 ± 2.0 (miniMAG) for 5-fold
diluted samples. The calculated 50% hit rate obtained with
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M. bovis PCR was found at dilution 1:14,000 (easyMAG) and
1:17,000 (miniMAG). Both systems showed good reproducibility
on the run controls, and no carry over was detected. Ct values of
extracted control samples (easyMAG 25.6 ± 0.4, miniMAG
26.0 ± 0.6) were comparable to values obtained with PCR
controls not subjected to extraction (PCR 25.8 ± 0.3).
Regarding the two different workﬂows, Ct values measured
were comparable for, respectively, the off board and on board
lysis; undiluted 26.7 ± 1.6 and 26.9 ± 1.4, diluted 29.0 ± 1.4 and
29.3 ± 1.5.
Conclusions: In this study, for all samples tested, the new
extraction system NucliSens easyMAG performs equal as
compared to manual magnetic silica extraction (NucliSens
miniMAG) that was used as reference. This means that both
platforms are interchangeable. For both systems inhibition was
observed in some of the stool samples when tested undiluted,
but PhHV DNA was well detected when these samples were
tested diluted. No inhibition was observed in any of the other
sample types included in this study.
O276
Speciﬁc enrichment of prokaryotic DNA from
human samples
S. Sachse, K.-H. Schmidt, M. Lehmann, S. Russwurm,
E. Straube (Jena, D)
Objectives: Rapid identiﬁcation of bacterial pathogens is crucial
to manage efﬁcient pathogen-adapted antimicrobial therapy.
Current problems for pathogen detection in human samples with
low bacterial load are patients under antibiotic pretreatment,
non-cultivable microorganisms and a time-to-result delay of
more than 4 days. Previous studies with patients of intensive
care units showed that 80–90% of blood cultures fail to detect the
triggering pathogen. Therefore, culture independent detection
methods take a centre stage in scientiﬁc interest. However,
compared to bacterial culture techniques, the sensitivity
of molecular biological methods like PCR is inadequate.
Here, we developed a method for the speciﬁc separation and
concentration of prokaryotic DNA from eukaryotic environment,
to enable culture independent molecular biological methods
with signiﬁcant increased sensitivity.
Methods: A protein (P-181) was identiﬁed that has a speciﬁc
binding afﬁnity for pro-karyotic DNA. P-181 was expressed in
Escherichia coli. Validating the properties of P-181, we used
spiked blood samples. Total DNA, isolated by means of phenol/
chloroform extraction, was given to a column packed with P-181
immobilized to a special matrix. The separation of prokaryotic
DNA was monitored by measurement of optical density and
special PCR-techniques. After the enrichment of prokaryotic
DNA, a PCR was performed to detect bacterial DNA. The
amplicons were sequenced for identiﬁcation of the pathogen.
Results: We showed that prokaryotic DNA is speciﬁcally
retained by immobilised P-181. We successfully separated the
DNA of Streptococcus pyogenes, Staphylococcus aureus and
Escherichia coli in spiked blood samples. In a current clinical
pilot study, we were able to detect bacterial DNA with different
sequences in the 16SrRNA-gene in some whole blood samples
from septic patients despite the corresponding blood cultures
showed negative results.
Conclusion: The developed method offers a unique
opportunity for concentration of prokaryotic DNA from
human samples with low bacterial load, tissue or other clinical
samples. This preanalytic procedure leads to an increased
sensitivity of culture independent methods of bacteria
detection in usually sterile clinical samples by means of
common PCR protocols.
O277
Real-time PCR with an internal control detecting
all 51 known adenovirus serotypes
M. Damen, P. Glasius, R. Mang, R. Minnaar, P. Wertheim,
M. Beld (Amsterdam, NL)
Objectives: The gold standard for the diagnosis of adenovirus
(AV) infection is culture. However, results are available after
days to weeks and not all AV types grow in culture. Especially
in immune compromised patients severe infections with AV are
described and a rapid diagnosis would be important. Therefore,
an AV real-time PCR was developed, detecting all 51 known AV
serotypes.
Methods: Primers were chosen in the hexon region. In order to
cover all 51 serotypes the forward primer is degenerated at three
positions and the reverse primer at two positions. The internal
control (IC) DNA contains the same primer binding sites, but
has a shufﬂed probe region compared to WT virus. The IC DNA
was added to the clinical sample in order to monitor extraction
and PCR efﬁciency. Twelve (2-fold) serial dilutions were made
from AV DNA and IC DNA in a background of AV negative
throat ﬂuid in order to assess the detection limit of the AV PCR.
To investigate the linearity, 8 (ten-fold) serial dilutions from AV
DNA (with 1000 copies IC DNA in every dilution) in a
background of AV negative sputum were tested. A panel of
AV prototype strains of all 51 AV serotypes, kindly provided by
Dr J. de Jong, Erasmus University, Rotterdam, the Netherlands,
was tested. To establish the clinical utility of the assay, a
comparison of AV PCR and culture was performed in a panel of
157 clinical samples (90 faeces samples, 56 respiratory materials,
8 serum/plasma samples, three other materials).
Results: In the serial dilutions in throat ﬂuid the 50% detection
limit of AV DNA was 8 copies per PCR assay (400 copies/ml)
and of IC DNA 16 copies per PCR assay (800 copies/ml). The
real-time AV PCR was linear from 125 copies per PCR assay
(6250 copies/ml) until 1.25 E8 copies per PCR assay (6.25 E9
copies/ml). All 51 AV serotypes were detected in the panel of
AV prototype strains. Concordant results between culture or Ag
detection and PCR were found in 138/157 (87.9%). In 10 cases,
PCR was positive while culture or Ag was negative (6.4%). In
one case, PCR was negative while culture was positive (0.6%)
and in 8 cases PCR was negative without culture or Ag data
Conclusion: A sensitive AV real-time PCR assay was
developed, detecting all 51 AV serotypes. The assay can be
applied on different body ﬂuids, among which faeces and
respiratory materials. The assay has proven to be more rapid
and more sensitive than AV culture.
O278
Rapid detection of Salmonella and Campylobacter
jejuni DNA in faeces by real-time PCR without
prior culture enrichment
T. Schuurman, R.N. Patty, A.M.D. Kooistra-Smid,
A.A. van Zwet (Groningen, NL)
Objectives: Salmonella spp. and Campylobacter jejuni are the
major causes of bacterial gastro-enteritis in The Netherlands.
Conventional diagnosis is based on detection of both species in
feces and consists of enrichment, selective culture and
identiﬁcation, which can take several days. Introduction of a
PCR based screening of feces is cost-effective (ICAAC 2004
poster O-1626) and will decrease the turn around time
signiﬁcantly. However in this approach a sensitive PCR
method is mandatory. This study describes the development
of real-time PCR based methods for the direct detection of
Salmonella spp. and C. jejuni in feces.
Clinical Microbiology and Infection, Volume 11, Supplement 2, 2005
67
Methods: Real-time PCR assays for Salmonella spp. and C. jejuni
were developed, based on the invA and mapA genes
respectively, and combined with a very efﬁcient ‘in-house’
DNA extraction from feces. The DNA extraction was validated
in recovery experiments and the PCR assays were validated
with culture positive [n = 229 (Salmonella spp.), n = 172
(C. jejuni)] and culture negative [n = 191 (Salmonella spp.),
n = 224 (C. jejuni)] fecal specimens.
Results: In a panel of 136 fecal samples, the ‘in-house’ fecal
DNA extraction performed with a high average recovery (97%)
compared to miniMAG (70%) and MagNA Pure DNA III (64%).
No samples proved troublesome (i.e. recovery <50%), whereas
16% and 27% scored lower recoveries (0–38%) with the
commercial kits. However, ﬁnal PCR results were only slightly
inﬂuenced by low recoveries. Analytical sensitivities were
determined at 500 CFU and 100 CFU/g feces for Salmonella
spp. and C. jejuni respectively. In clinical fecal specimens
sensitivity and speciﬁcity were 92%, 99% for Salmonella spp.,
and 96%, 96% for C. jejuni respectively. PCR inhibition was only
observed in 0.15% of the samples.
Conclusion: Sensitive and cost effective molecular screening of
fecal specimens for Salmonella spp. and C. jejuni is feasible and
has great potential as a means of rapid detection of bacterial
gastro-enteritis.
O279
Rapid detection of Clostridium difﬁcile-associated
diarrhoea in a prospective multicentre study,
using a new immunoassay and real-time PCR
R.J. van den Berg, E.S. Bruijnesteijn, H.J. Gerritsen, H.P. Endtz,
E.R. van der Vorm, E.J. Kuijper (Leiden, Rotterdam, Amsterdam,
NL)
Objectives: Clostridium difﬁcile-associated diarrhoea (CDAD) is
usually diagnosed by the detection of enterotoxin A (TcdA)
and/or cytotoxin B (TcdB) in faecal samples, or by culture of a
toxinogenic strain. A recently introduced new rapid
immunoassay (immunocard toxins A and B, Meridian) and an
in-house developed real-time PCR were compared in a
prospective multicentre study with conventional diagnostics.
Methods: In a prospective study of 4 months, 3 university
hospitals participated and tested all faecal samples from patients
with diarrhoea admitted to the hospital for 3 days or longer for
CDAD, irrespective of the physicians request. A conventional
enzyme-linked ﬂuorescent assay (ELFA, Vidas CDA2) was used
for detection of TcdA and the cytotoxicity assay on Vero-cells
was applied as the gold standard. Additionally, the
immunocard toxins A and B (ICTAB) and a real-time PCR for
the detection of tcdB were included in the study (FICDS, abstr.
p. 22, 2004). The sensitivity of the real-time PCR was 1 colony
forming unit (CFU) in 0.9% saline and 2800 CFU/g faeces.
Results: Of 471 faecal samples from patients with diarrhoea,
102 (21.7%) were excluded due to a lack of sufﬁcient material for
all assays. Of 369 samples included, 75 (20.3%) showed a
positive test result in one or more assays. The cytotoxicity test
was positive for CDAD in 23 (6.2%) of 369 patients. Of 23
patients with a positive cytoxicity assay, the diagnosis CDAD
was not considered in 10 (43%) by the physician. Using the
cytotoxicity assay as the gold standard, sensitivity of ELFA,
ICTAB and real-time PCR were 69.6%, 91.3% and 87.0%,
respectively. The speciﬁcity of ELFA, ICTAB and real-time
PCR were 95.4%, 96.2% and 95.4%, respectively. The positive
predictive value and negative predictive value for ELFA,
ICTAB, real-time PCR were 50% and 97.9%, 61.8% and 99.4%,
and 55.6% and 99.1%, respectively. Culture of two discordant
samples only positive by real-time PCR showed the presence of
toxinogenic CD in both samples. Culture of ﬁve samples only
positive in ICTAB revealed no toxinogenic CD.
Conclusions: The newly introduced rapid immunoassay is a
very rapid and easy-to-perform test for the diagnosis of CDAD.
It may be useful for guiding appropriate treatment. The real-
time PCR is an excellent instrument to control nosocomial
spread of toxinogenic C. difﬁcile.
O280
Detection of norovirus in an outbreak of acute
gastroenteritis at a nursing home in south-east
Austria
I. Lederer, E. Schreier, A. Gra¨nz, S. Richter, C. Berghold,
F. Allerberger (Graz, A; Berlin, D; Vienna, A)
Objectives: In April 2004, residents and staff in a nursing home
in south-east Austria fell ill with vomiting and diarrhoea: The
index case was an 85-year-old man with clinical onset on April
27th. During the following days an increased number of cases
with diarrhoea and vomiting among residents and stuff was
observed. The outbreak peaked on May 7th. We describe the
outbreak and its epidemiological investigation.
Methods and Results: At the time of the outbreak 77 persons
aged 62–96 years lived in the nursing home and up to 44 staff
members worked there. To stop the spread of the disease, all
residents were invited taking their meals in their rooms instead
of in the common dining room. Common social activities were
restrained. Since all meals were prepared in the residential
kitchen, water and food were sampled for routine testing of
infectious agents (not including norovirus); all results were
negative. Testing of stool samples for salmonella, shigella,
campylobacter, enterohaemorrhagic Escherichia coli, rotavirus,
adenovirus and cryptosporidia was also negative. These
results raised the suspicion that norovirus was the causative
organism in this outbreak. No indication of norovirus as
causative agent could be found in the stool samples either by
electron microscopy, or with routine RT-PCR in the polymerase
gene of norovirus (ORF1). Finally, analysis with real time
RT-PCR in the capsid region (ORF2) of the virus genome could
identify norovirus of the genogroup II (GG II) as causative
agent; detection was possible using a TaqMan probe. Nursing
administration provided lists of residents and staff with
corresponding symptoms and days of sickness for
epidemiological evaluation; the attack rate (AR) was 52% for
the residents. Five of the 40 residents affected had 2 episodes of
illness and 2 residents had 3 episodes; the AR of personnel was
27.3% without any relapses. None of the kitchen staff became ill.
Conclusion: This outbreak demonstrates that in order to
evaluate an outbreak with suspected norovirus involvement,
molecular virus identiﬁcation of 2 different genomic regions
may occasionally be useful, especially when clinical symptoms
and epidemiological features of the disease indicate norovirus
infection as its cause.
O281
Detection of human metapneumovirus in
nasopharyngeal aspirates from young children by
real-time RT-PCR
W.A. Verstrepen, P. Bruynseels, A. Mertens (Antwerp, B)
Objectives: Human metapneumovirus (HMPV) was recently
discovered as a new paramyxovirus responsible for a substantial
proportion of acute respiratory tract infections. Our aim was to
retrospectively determine the prevalence of HMPV infections in
young children admitted to our hospital from December 2002
until April 2003.
Abstracts
68
Methods: Nasopharyngeal aspirates (NPA) from children with
symptomatic respiratory tract infections but negative for
common viral respiratory pathogens were stored at )80C until
analysis. Patient age ranged from 10 days to 12 years. NPA were
defrosted, washed and spiked with an exogenous RNA
transcript prior to RNA extraction. All extracts were tested in
duplicate, both by an in-house developed real-time RT-PCR
assay and by another recently described real-time RT-PCR assay.
The in-house assay is based on TaqMan MGB probes directed to
conserved sequences located in the nucleoprotein gene.
Results: All specimens tested were adequate as monitored by
detection of the spikedRNAtranscript.HMPVRNAwasdetected
in 13 of 93 specimens (14%) by both real-time RT-PCR assays.
Eleven of these children were admitted with a variety of
respiratory symptoms ranging from cough to pneumonia. One
child presented with fever, the other one was diagnosed with
rachitis. The majority of children with a positive HMPV assay
(10/13) was less than 2 years old, the oldest child with a positive
HMPV assay was twelve. Remarkably, 10 of these 13 HMPV-
positive specimens were clustered in a 2 weeks time period,
strongly suggesting the occurrence of an epidemic outbreak.
Whereas Ct values varied from less than 20 up to almost 40,
differences in Ct values between both assays were not signiﬁcant.
Two other specimens from children admitted with symptoms of
gastroenteritis were weakly positive with the previously
described assay alone, albeit in just one of the duplicate reactions.
Conclusions: Real-time RT-PCR may prove to be a rapid,
convenient and reliable method to detect the presence of HMPV
RNA in NPA from children with acute respiratory infections.
Further clinical validation in a prospective study is in progress.
O282
Parallel real-time PCR quantiﬁcation of six
human herpes viruses in patients with acute
neurological infections
O.E. Varnier, J.L. McDermott, I. Martini, F. Bertolotti, D. Ferrari,
C. Giacomazzi, L. Tagliaferro, E. Capello, G. Mancardi (Genoa, I)
Introduction: The onset of symptoms and clinical
manifestations of the central nervous system (CNS) infectious
diseases often makes a speciﬁc diagnosis difﬁcult. The
etiological agent and type of infection can determine potential
prognoses as well as optimal treatment for the patient.
Unfortunately, laboratory tests used for the diagnosis of CNS
infections have the disadvantage of being either nonsensitive or
nonspeciﬁc or giving results difﬁcult to distinguish from the
norm. With the advent of molecular diagnostic protocols, it is
now possible to diagnose viral pathogens speciﬁcally and with
high sensitivity and accuracy.
Materials and Methods: The LightCycler Real-time PCR
technology was used to analyse 70 cerebrospinal ﬂuid (CSF)
specimens collected from 61 patients with encephalitis and/or
meningitis and 9 patients with acute neurological symptoms.
DNA was extracted from the CSF samples (1000 ll) using the
MagNa Pure robot and eluted in a ﬁnal volume of 100 ll,
therefore achieving 10-fold DNA concentration. The DNA
samples were analysed using 5 Real-time PCR protocols in
a single LightCycler run (30 min) for the parallel detection of
6 herpes viruses (HSV-1, HSV-2, VZV, CMV, EBV and HHV-
6).
Results: Herpes-type speciﬁc plasmid dilutions were ampliﬁed
to produce external standard curves for accurate PCR product
quantiﬁcation. Following HSV ampliﬁcation, HSV-1 and HSV-2
differentiation was performed by LightCycler melting curve
analysis, which detects sequence differences between the PCR
product and hybridisation probe: this results in a shift in the
probe melting temperature (57C for HSV-1 and 67C for HSV-
2). Viral DNA was detected in 13 of the 70 CSF samples: 4 were
positive for HSV-1, 1 for HSV-2, 5 for VZV and 3 for HHV-6. The
levels of quantiﬁed DNA varied from 100 to 22,630 copies/ml.
In one case, 4800 VZV DNA copies per ml were detected in the
CSF of a young woman (18 years) suffering from Runsay–Hunt
syndrome: the patient was successfully treated with acyclovir.
The combined use of an automated extraction procedure and
rapid LightCycler PCR allowed a turn-around-time (TAT) of 90–
120 min to be achieved.
Conclusion: These results suggest that the LightCycler Real-
time PCR platform offers a fast, highly automated, sensitive
and reproducible tool for the accurate quantitation of six
herpes virus DNAs in CSF samples with a TAT of less than
2 h.
New developments in epidemiology of antibiotic resistance
O283
Rapid increase in development of multidrug
resistance among Klebsiella pneumoniae during
hospitalisation: surveillance of ﬁrst isolates
underestimates the resistance problem
M.A. Leverstein-van Hall, H.A.J. de Neeling (Utrecht, Bilthoven,
NL)
Objectives: The Dutch national surveillance on the prevalence
of resistance is based on ﬁrst isolates per patient and therefore
unable to detect resistance development during hospitalisation.
Our aim was to design an analysis of surveillance data that
reveals to what extent hospital stay contributes to the
development of resistance to single as well multiple
antimicrobial classes (AC) in pathogens isolated from patients
during hospitalisation.
Methods: Klebsiella pneumoniae (KP) isolates (blood, respiratory
tract, wound or pus) cultured from hospitalized patients and
processed in one of 8 regional laboratories covering 27% of the
Dutch population in the years 1996/1997 and 2001/2002 were
studied. The percentage of patients who had acquired an
(intermediate) resistant isolate was determined up to15 days,
starting the ﬁrst day (day 0) when a KP was isolated from a
patient. This percentage was calculated for day 0 and for each
subsequent 3-days interval. Per interval only 1 random isolate
per patient was included if available.
Results: In 1996/1997, resistance percentages during
hospitalization to amoxi-clav, third gen. cephalosporins and
gentamicin remained stable while non-susceptibility to
cotrimoxazole and ciproﬂoxacin rose 2.5-fold and 4-fold
respectively (Table). Multidrug resistance (MDR; I/R to at
least 2 AC) reached a maximum of 11% of isolates tested 4–6
days after the day 0 (Fig.). In 2001/2002, however, resistance to
any single AC increased 3- to 5-fold during hospitalization and
after one week 50% of isolates were resistant to two or more AC,
of which half were resistant to all 5 AC tested.
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Conclusions: Development of MDR among Klebsiella
pneumoniae isolates during hospitalization in 8 Dutch regional
hospitals has increased substantially in recent years. The
analysis used in this study provides better insight in the
resistance prevalence inside hospitals than an analysis based
solely on ﬁrst isolates and is a useful tool to monitor resistance
development during hospitalization.
O284
Multidrug resistance among Streptococcus
pneumoniae from Europe, Asia and South
America: current data from the GLOBAL
Surveillance initiative 1999–2004
M. Jones, R. Blosser, D.F. Sahm (Hilversum, NL; Herndon, USA)
Objectives: Worldwide increases in theprevalenceofmultidrug-
resistant (MDR)-SP demonstrate the importance of surveillance
initiatives such as the GLOBAL Surveillance to monitor changes
in the in vitro activity of important antimicrobial agents. The
USFDA has recognized the importance of MDR among
S. pneumoniae (SP) and approved an MDR-SP indication for
levoﬂoxacin and more recently, gemiﬂoxacin.
Methods: The GLOBAL Surveillance initiative includes 15,878
non-repeat SP strains collected from patients in fourteen
countries worldwide from 1999 through 2004. All isolated
were susceptibility tested in a central laboratory using NCCLS
standards. Data were used to investigate MDR [resistance (R) to
‡3 among penicillin (PEN), ceftriaxone (CTX), azithromycin
(AZI), trimethoprim-sulfamethoxazole (SXT), and levoﬂoxacin
(LFX)] trends and phenotypes
Results: From 1999 to 2004, the prevalence of MDR strains
ranged between 11.4% and 12.5%. Regardless of year or country,
the most prevalent MDR phenotype was R to PEN, AZI, and
SXT. Globally, LFX R was rarely associated with MDR with over
96% of MDR strains remaining susceptible. On a country basis
for 2003–2004, the highest MDR rates were observed in Thailand
(23.1%), South Korea (47.8%), and Hong Kong (44.0%); LFX R as
part of the MDR phenotype remained low in these countries
(1.6%, 1.0%, and 5.3%, respectively). The lowest MDR rates were
observed in Germany (0.9%), United Kingdom (1.2%), and
Belgium (1.6%). Overall among the MDR isolates collected,
92.6% were R to 3 agents, and 7.4% were R to 4 agents. No 5
drug-resistant MDR SP were encountered.
Conclusions: The MDR phenotype among SP is prevalent
worldwide and most frequently involves resistance to beta-
lactams, macrolides and SXT. Currently, and especially in EU
countries, ﬂuoroquinolone R is rarely associated with the MDR
phenotype. However, the potential for this to emerge
underscores the need for continued surveillance and new
agent development.
O285
Spatial analysis applied to bacterial diseases and
resistance transmission: early report from the
EUREQA Project – Brazil 2004
C.R. Kiffer, A.M. Monteiro, P.C. Koga, C. Oplustil, J.L. Sampaio,
G. Camara, C.M. Mendes on behalf of the EUREQA Project Team
(Sa˜o Paulo, BR)
Objectives: Understand the spatial dynamics of upper
respiratory tract bacterial infections or colonizations and their
resistance patterns within the city of Sa˜o Paulo, Brazil, as part of
the EUREQA Project.
Methods: Project EUREQA is a multi-phase study to interpret
bacterial disease dynamics and distributions and its correlations
with risk factors within the city of Sa˜o Paulo. The city is located
in southeastern Brazil and has around 10,000,000 inhabitants.
Routine outpatient culture results for bacterial pathogens
isolated from respiratory tract between 2002 and 2004 were
entered in the database and geocoded in a digital map
containing different information categories (layers). Spatial
analysis technique used was Kernel function method
(TerraView 3.01, INPE, Brazil) to analyse total sample and
cases distribution. Comparisons between both patterns were
done to explore possible cluster formations.
Results: Five thousand and fourteen (5014) respiratory tract
cultures (one patient per day) were performed during the
period, which yielded 725 isolates of H. inﬂuenzae and 295 of
S. pneumoniae. So far 1795 occurrences were geocoded, with 243
(13.5%) H. inﬂuenzae and 111 (6.2%) S. pneumoniae. Of those, 11
H. inﬂuenzae isolates were beta-lactamase producers and 7
S. pneumoniaewere intermediate or resistant to penicillin. A non-
random pattern of total sample, H. inﬂuenzae, and S. pneumoniae
distributions was observed, probably meaning higher
population density. Early evidence of independent clusters
was detected.
Conclusions: Kernel function is an easy-to-use and initial
exploratory technique for interpolating and smoothing point
events and it identiﬁes possible clusters. However, it only
considers the sampled population (biased samples inﬂuence
result). Independent clusters of H. inﬂuenzae and S. pneumoniae is
possible but needs further investigations. Geographical
information systems and spatial methods can be applied to
better understand epidemiological patterns and to discriminate
target areas for public health interventions.
O286
Antimicrobial use and Streptococcus pneumoniae
penicillin resistance: temporal relationship at the
population level
R. Mera, L. Miller (New Orleans, Upper Providence, USA)
Objectives: To investigate the nature of the temporal relation-
ship between antimicrobial consumption and Streptococcus
No. of days after ﬁrst day of isolation
Antimicrobial agent Years 0 1–3 4–6 7–9 10–12 13–15
Co-amoxiclav 1996–1997 5% 7% 7% 8% 6% 6%
2001–2002 9% 15% 24% 32% 35% 35%
Ceﬂazidime/Cefotaxime 1996–1997 3% 3% 2% 1% 5% 2%
2001–2002 7% 15% 20% 33% 36% 40%
Gentamicin 1996–1997 5% 6% 7% 8% 7% 3%
2001–2002 9% 21% 28% 37% 43% 41%
Co-trimoxazole 1996–1997 8% 12% 19% 14% 19% 21%
2001–2002 13% 22% 32% 45% 41% 48%
Ciproﬂoxacin 1996–1997 2% 3% 4% 1% 6% 8%
2001–2002 7% 14% 19% 31% 35% 35%
No of isolates (min-max) 1996–1997 1111–1535 140–196 94–134 66–111 46–63 35–58
2001–2002 1416–1567 212–252 133–161 99–128 80–101 67–82
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pneumoniae penicillin resistance using population level data
across time.
Methods: National outpatient antibiotic prescription data for
1998–2003 from France, Spain, Italy, Germany, the UK and the
US was obtained from published reports, provided by IMS
Health Global Services. Aggregate data for total use and several
antibiotic classes was used to express outpatient consumption in
deﬁned daily doses per 1000 inhabitants per day. Surveillance
data consists of S. pneumoniae isolates obtained from the TSN
surveillance database (Focus Technologies) in the same
geographic regions from 1996 to 2001. Additional data for
2002 and 2003 was obtained from published studies. A linear
mixed model for repeated measures was used in modelling the
association between resistance and several antibiotic classes
through time.
Results: A multivariate random effects model shows that there
is a strong linear relationship between overall levels of
antimicrobial consumption and penicillin resistance, that the
association of exposure and resistance is unique for every
country and that there is no direct relationship between the
year-to-year change in consumption and penicillin resistance.
Changes in penicillin resistance through time in any country are
better explained by the cumulative total antimicrobial
consumption with a 2-year lag. A hypothetical 10%
consumption reduction in all antibiotic classes would decrease
by 2.6% the peak penicillin resistance rate in 2–years. A 15%
reduction in macrolide consumption and broad to narrow
spectrum penicillin ratio would independently decrease by
5.4% and 1.6% the peak penicillin resistance rate respectively.
An increase of medium-narrow penicillins to mid-90s levels
would diminish by 1.8% the peak penicillin resistance rate.
Conclusions: Large reductions in consumption at the
population level are needed to affect resistance. There is a
peak level of penicillin resistance associated with cumulative
exposure to a combination of antibiotic classes. It may be
possible for countries with low levels of penicillin resistance
under a speciﬁc steady-state situation to retain that condition for
a long period of time. For other countries reduction of
consumption alone may not result in reversal of resistance and
so they would need to rely on the use of new agents active
against multi-resistant clones.
O287
Comparative impact of azithromycin and
clarithromycin therapy on pharyngeal carriage of
macrolide-resistant Streptococci among healthy
volunteers: a double-blind, placebo-controlled,
longitudinal study
S. Malhotra-Kumar, C. Lammens, C. Mallentjer, J. Piessens,
K. Van Herck, H. Goossens (Antwerp, B)
Objectives: The abilities of azithromycin and clarithromycin to
promote carriage of macrolide resistant oral streptococci and the
temporal persistence of the selected resistant commensals in
healthy volunteers was investigated.
Methods: Volunteers (n = 204) included were adult with no
sign of respiratory tract infection and had not been administered
any antibiotic in the past 3 months. Throat samples were taken
before antibiotic administration (d1) and the volunteers
randomly allocated into four groups to receive azithromycin
or placebo once daily for 3 days, or clarithromycin or placebo
twice daily for seven days. Further samplings were done on the
8th day after commencing the antibiotic/placebo course (d2), on
the 14th day (w1), 28th day (w3), 49th day (w6), and ﬁnally in
the 6th month (m6). Quantitation of the aerobic streptococcal
ﬂora was done on streptococcal agar with and without
erythromycin (2 lg/ml) using a spiral plater (Eddy Jet, The
Netherlands), and the percentage of macrolide-resistant
streptococci determined by colony counting. Mean resistance
proportions were compared between both macrolides and their
respective placebo groups as well as between the two macrolide
groups. For this, Student’s t-test and an analysis of variance with
Bonferroni’s post-hoc test were used.
Results: Comparative impact of the two macrolide regimens
on the prevalence of macrolide resistant streptococci over a
period of 6 months is presented in the graph. The mean
resistance proportions at each time point following
azithromycin or clarithromycin use when compared to their
respective placebos, showed a signiﬁcant increase (p £ 0.01
overall) in macrolide-resistant streptococci that persisted for
>6 months. Comparing the two macrolides, differences in
mean macrolide resistance were not signiﬁcant immediately
following azithromycin and clarithromycin use (p = 0.8),
decreased signiﬁcantly faster in the clarithromycin group
than the azithromycin group in w1 and w3 (p £ 0.001), and
became non-signiﬁcant in w6 and m6 (p = 0.07 and 0.6,
respectively).
Conclusions: This is the ﬁrst study analyzing the temporal
evolution of the oral streptococcal ﬂora over a prolonged period
following macrolide use. Both azithromycin and clarithromycin
have a marked effect on macrolide resistance in oral streptococci
and these effects persist for >6 months post-therapy.
O288
Colonisation and resistance dynamics of
enterococci during and after hospitalisation
P.M.G. Filius, I.C. Gyssens, A. Ott, A.G. Vulto, H.A. Verbrugh,
H.P. Endtz (Rotterdam, NL)
Objectives: Colonization and resistance dynamics of
enterococci in the intestinal microﬂora of patients admitted to
intensive care units (ICU) and general wards (GW) were
investigated during and after hospitalization.
Methods: Specimens were obtained on admission, once weekly
during hospitalization, at discharge from the ICU, at discharge
from the hospital and 1 and 3 months after discharge. Five
colonies per specimen were selected for identiﬁcation and
susceptibility testing by the VITEK 2 system.
Results: A total of 1669 specimens from 411 patients were
collected. In the ICU population the frequency of isolation of
E. faecium signiﬁcantly increased from 10.8% on admission to
23.7% at discharge from the hospital, whereas the frequency of
E. faecalis decreased from 76.7% to 56.3%. Upon discharge, no
signiﬁcant changes were observed during the ﬁrst 3 months.
Similar frequencies were found in the GW population. In both
populations no differences were measured in the percentage
of patients colonized with ampicillin-, high-level gentamicin-
(HLG) or vancomycin-resistant enterococci between subsequent
Comparative impact of azithromycin and clarithromycin on
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points-in-time. Ampicillin resistance was infrequent in
E. faecalis. Vancomycin resistance was not detected at all. The
percentage of patients colonized with HLG resistant E. faecalis at
discharge from the hospital was signiﬁcantly higher in the ICU
than in the GW population. During hospitalization the
prevalence of ampicillin resistant E. faecium and HLG resistant
E. faecalis signiﬁcantly increased with length of stay on the ICU
and GW. Changes in resistance at two subsequent points-in-time
were more often detected in ICU patients compared to patients
in GW. PFGE typing of these strains revealed that 70% of these
resistant enterococci appeared unrelated to the strain isolated at
the previous point-in-time.
Conclusions: The risk of dissemination of resistant enterococci
into the community appears to be low. However, changes in
resistance in patients during hospitalization are observed and
may complicate treatment of nosocomial enterococcal
infections.
O289
Contribution of nitrofurans illegal use to the
selection and persistence of Salmonella amongst
humans and foods of animal origin in Portugal
P. Antunes, J. Machado, L.V. Peixe (Porto, Lisbon, P)
Objectives: Salmonellosis is one of the most frequent food-
borne diseases, with poultry products a potential source of
infection. Salmonella is naturally susceptible to nitrofurans, an
agent authorised in EU until 90’s for food animal production. In
Portugal, during the last years, a widely illegal use of
nitrofurans was detected, affecting several types of
husbandries, especially poultry ones. In this study we
evaluated the susceptibility to nitrofurantoin of 1183 Salmonella
isolates (clinical humans, poultry products, other foods and
environment), in order to assess the contribution of nitrofurans
illegal use in the selection and persistence of Salmonella.
Methods: The minimum inhibitory concentration was
determined by the agar dilution method. The presence and
genetic content of class 1 integrons were investigated by PCR
and sequencing. Clonality was searched by PFGE following
XbaI digestion.
Results: Decreased susceptibility to nitrofurantoin
(MIC ‡ 64 mg/L) was the most common amongst our isolates
(n = 767/1183; 65%), although resistance to other antimicrobial
agents was also observed. A different resistance rate to
nitrofurantoin was observed in isolates from poultry (n =
62/84; 74%) and clinical humans (n = 618/870; 71%)
comparing to those from other food products (n = 76/173;
44%) and environment (n = 11/56; 20%). Decreased
susceptibility to nitrofurantoin was most common in isolates
from serogroup D, mainly S. Enteritidis of different phagetypes
(85% of poultry and 89% of human isolates). It is of note that
multiresistant isolates from serogroup B of clinical and food
sources also presented decreased susceptibility to nitrofurantoin:
S. Typhimurium clone carrying an 2000-bp integronwith blaOXA-
30 – aadA1 and S. Typhimurium DT104 clone carrying 1000
(aadA2) and 1200 bp (blaPSE-1) class 1 integrons.
Conclusion: This study points out for another perspective
related with antibiotic usage in food animal production: the
contribution of one antimicrobial agent on the emergence of a
particular bacteria implicated in human infections. In Portugal,
the widespread use of nitrofurans especially in the poultry
industry may have contributed to the prevalence of S. Enteritidis
in chickens and consequently in human infection. It is tempting
to speculate that the use of nitrofurans may also have been
implicated in the selection and persistence of the two
multiresistant national widespread S. Typhimurium clones.
O290
Risk factors for ciproﬂoxacin resistance among
E. coli strains isolated from community-acquired
urinary tract infections
H. Arslan, O¨. Kurt Azap, O¨. Ergonul on behalf of the Urinary
System Infection Study Group
Objective: To determine the risk factors for community
acquired ciproﬂoxacin resistant E.coli urinary tract infection.
Methods: The study was performed with isolates of community
acquired urinary tract infections collected from 15 centres
representing 6 different geographic regions of Turkey. All
microbiological procedures were carried out in the central
laboratory. Multivariate analysis was performed for detection of
risk factors. Use of quinolone more than once within the last
year, living in rural area, having urinary catheter, age > 50,
complicated infections were included to the model as variables,
and logistic regression was performed.
Results: A total number of 537 isolates from 537 patients with
community acquired urinary infections were studied. Eighty-
ﬁve per cent of the patients were female, the median age was
49 years (19–70). Ciproﬂoxacin resistance was detected in 33% of
the patients. Extended spectrum beta lactamase (ESBL) was
detected in 9% of the strains. Living in rural area (p = 0.039),
having urinary catheter (p < 0.001), complicated infections
(including male gender, urological operation, etc), age > 50
(p = 0.002), quinolone use in last 3 months (p = 0.002), receiving
quinolone more than once within a year (p < 0.001) were found
to be statistically signiﬁcant. Use of antibiotic regimen other than
quinolone was not associated with ciproﬂoxacin resistance
(p = 0.222). The Marmara region had the lowest rate of cipro
resistance (23%), although it was not signiﬁcant (p = 0.230). In
multivariate analysis, use of quinolone more than once within
the last year (OR, 2.7; CI,1.4–5.2; p = 0.003), age > 50 (OR, 1.6;
CI, 1.06–2.4; p = 0.023), having urinary catheter (OR, 5; CI, 1.6–
16.7; p = 0.007), and complicated infections (OR, 2; CI, 1.3–3.1;
p = 0.001) were found to be the risk factors of ciproﬂoxacin
resistance. Emergence of ESBL was found to be associated with
quinolone use (p = 0.008).
Conclusion: The high rate (33%) of ciproﬂoxacin resistance
among urinary E.coli isolates is an emerging problem.
Quinolone use, older age, urinary catheters and complicated
infections are important predisposing factors. Prescribing
quinolones for community acquired urinary tract infections
should be based on antimicrobial susceptibility results even for
the uncomplicated cases.
O291
Community-acquired bacteraemia due to
extended-spectrum beta-lactamase-producing
Escherichia coli: an emerging clinical challenge
J. Rodrı´guez-Ban˜o, M.D. Navarro, L. Romero, M.A. Muniain,
M. de Cueto, M.J. Rı´os, E.J. Perea, A. Pascual (Seville, E)
Objectives: To describe the emergence of extended-spectrum
beta-lactamase-producing Escherichia coli (ESBLEC) as a cause of
community-acquired bacteraemia and to investigate the
epidemiology, clinical features and risk factors for this infection.
Methods: All episodes of community-acquired bacteraemia
(according to CDC criteria) due to ESBLEC from January 2001
to October 2004 in our 950-bed hospital were included. ESBL
production and antimicrobial susceptibility were studied by
microdilution (NCCLS guidelines). ESBL were characterized by
isoelectric focusing, PCR, and sequencing. Clonal relationships
among the isolates were determined by Rep-PCR. Two control
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groups (2:1 in each group) were chosen: (A) randomly selected
episodes of community-acquired episodes of bacteraemia due to
non-ESBLEC, and (B) randomly selected patients admitted from
the emergency department. Univariate and multivariate analysis
(logistic regression) were performed.
Results: Sixteen cases were included. The features of the
patients were: median age, 71 years (range, 28–89); 62% were
male; 81% had some contact with health-care during last year;
44% had a structural disease of the urinary tract; 56%
had received antimicrobials during the last 2 months
(ﬂuorquinolones the most frequent, 31%); the origin of the
bacteraemia was the urinary tract in 56%, an intraabdominal
infection in 31% and unknown in 13%; 25% presented with
severe sepsis or septic shock; related mortality was 6% and
crude mortality 13%. All isolates were susceptible to
meropenem, piperacillin/tazobactam and amikacin, 58% to
amoxicillin/clavulanic acid and 25% to ciproﬂoxacin. By Rep-
PCR, the 12 isolates studied to date were clonally unrelated. The
most frequent ESBL produced was CTX-M-14 (75% of the 12
studied isolates). Independent risk factors associated with
ESBLEC bacteraemia were (multivariate analysis): for control
group A, previous antimicrobial use (OR = 8.6, p = 0.004), and
for control group B, age (OR = 1.05 per year, p = 0.07),
structural disease of the urinary tract (OR = 18.7. p = 0.03),
and previous antimicrobial use (OR = 10.3, p = 0.01). Previous
health care-relation was not a risk factor.
Conclusions: ESBLEC should be consider as a cause of
community-acquired bacteraemia from urinary or
intraabdominal origins in adult patients who had recently
received antimicrobials, and particularly ﬂuorquinolones.
O292
Excess mortality associated with inappropriate
treatment of patients with severe sepsis due to
antimicrobial-resistant pathogens in European
ICUs
S. Harbarth, Y. Carmeli, C. Brun-Buisson,
M.J.M. Bonten (Geneva, CH; Tel Aviv, IL; Paris, F; Utrecht, NL)
Objectives: Despite the increasing prevalence of antimicrobial-
resistant pathogens (AMR-P) and the ongoing controversy about
the most effective control strategies, surprisingly few studies
attempted to quantify the mortality burden of AMR-P in
Europe. In the belief that accurate data on the clinical impact
of AMR-P are necessary to allow informed policy-decisions, we
performed an exploratory ecologic analysis of the crude excess
mortality associated with inappropriate initial antimicrobial
treatment of patients with severe sepsis and septic shock due to
AMR-P in European ICUs.
Methods: Based on a comprehensive review of the published
literature, we examined population-based data from several
large cohort studies and clinical trials of critically ill
patients with severe sepsis and septic shock. We constructed a
conceptual model of a hypothetical cohort of an average
European ICU (1000 admissions/year) to determine the
number of premature excess deaths associated with AMR-P
and to extrapolate the overall mortality burden. The model was
reviewed by a 4-member expert panel consisting of 1 critical care
specialist, 1 epidemiologist and 2 infectious disease specialists
with extensive research experience in severe sepsis and AMR-P.
Results: The conceptual model is shown in the Figure. Our
review indicated that the average excess fraction of AMR-
P-related deaths was 24 fatal cases per 1000 cases of severe
sepsis, corresponding to an average of 3 excess deaths per 1000
ICU-admissions. The AMR-P-related mortality burden varied
greatly across European countries with more than 1000 excess
ICU-deaths in Germany and France and less than 100 ICU-
deaths in Denmark, Finland and Norway. The estimated total
number of AMR-P-related excess deaths in 15 European
countries was at least 5800.
Conclusions: AMR-P in critically ill patients appear to be an
important public health problem in Europe. This report presents
crude estimates rather than precise numbers due to the lack of
validated surveillance data. Nevertheless, our results are likely
to be conservative estimates and may allow further research to
assess the cost-beneﬁt of AMR-P control.
Bacterial bioﬁlms
S315
Bacterial bioﬁlms in nature and disease
B. Costerton (Los Angeles, USA)
Direct examinations of bacterial populations, growing in a very
wide variety of natural and pathogenic ecosystems, have shown
that the overwhelming majority of these organisms actually
grow in matrix-enclosed bioﬁlm communities. Single ﬂoating or
swimming (planktonic) cells are rarely seen in any ecosystems
except in nutrient-deprived systems, like the deep oceans, and
in the acute bacterial infections that characterized the pre-
antibiotic and pre-immunization eras. Between 65 and 80% of
Conceputal Model: Crude estimates of AMR burden in European ICUs
Average ICU: 1000 admissions per year
250 will have ≥ 1 infecion (either on admission or during ICU stay)
125 patients have severe infections with ≥ 1 organ dysfunction
(severe sepsis or septic shock)
20 patients have inappropriate initial antimicrobial treatment within
the first 24 hours after onset of severe sepsis
15 patients have inappropriate initial antimicrobial treatment due to antimicobial-
resistant pathogens or pathogens selected due to prior antibiotic therapy
(e.g., fungi, enterococci, Pseudomonas spp)
Mortality among appropriately
treated patients : 20%
Excess fraction of AMR-related deaths:
24 fatal cases per 1000 cases of severe sepsis
Excess deaths in Germany:
1200 cases due to AMR
Excess deaths in France:
1120 cases due to AMR
Excess deaths in UK:
890 cases due to AMR
Excess deaths in Spain:
580 cases due to AMR
Excess deaths in Italy:
840 cases due to AMR
Excess deaths in Netherlands:
200 cases due to AMR
Excess fraction of AMR-related deaths:
3 fatal cases per 1000 ICU-admissions
Mortality among patients with inappropriate treatement
within 24 hours after onset severe sepsis : 40%
25%
50%
16%
75%
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bacterial infections treated by physicians in the developed world
have been shown to be caused by bacteria growing in bioﬁlms,
and all device-related infections belong to this category. Bioﬁlm
infections are generally characterized by a slow onset, by low-
grade symptoms, and by their chonicity and their refractory
response to antibiotic therapy. This inherent resistance to
antibacterial agents, and to host defenses, has been demonstra-
ted in vitro and its mechanism(s)has been elucidated to some
extent. The extracellular matrix protects bioﬁlm cells from
antibodies and from phagocytes, and these sessile cells adopt a
special phenotype that differs profoundly from that of plank-
tonic cells, and mediates high levels of resistance to antibiotics
and sterilants. Now that many of the salient characteristics of
chronic bacterial infections have been attributed to the fact that
the causative organisms live in bioﬁlms, we can understand the
etiology of dozens of infections ranging from otitis media to
infections of native and mechanical heart valves. Bacteria
colonize an inert or a tissue surface, they develop into bioﬁlms,
resist clearance by host or therapeutic factors, and damage
surrounding tissues by stimulating inﬂammatory responses.
Now that the central problem of chronic infection is perceived to
be bioﬁlm persistence, several methods of bioﬁlm control can be
’’borrowed’’ from nature and from engineering strategies. Many
sessile plants and animals protect themselves from being buried
in bioﬁlms, by producing chemical blockers of bioﬁlm forma-
tion, and these agents are now being used to control bioﬁlms in
industry. Engineers have discovered that bioﬁlm bacteria can be
killed by conventional antibiotics, if the structure of these sessile
communities is disturbed by ultrasonic energy or by D.C.
electric ﬁelds. We will describe instances in which these novel
bioﬁlm control measures are being used in medical and dental
contexts.
S317
P. aeruginosa chromosomal beta-lactamase and
bioﬁlm resistance
O. Ciofu (Copenhagen, DK)
High-level expression of chromosomally encoded AmpC beta-
lactamase is the main resistance mechanism to beta-lactam
antibiotics of bioﬁlm-growing P. aeruginosa from patients with
cystic ﬁbrosis and chronic lung infection. The aim of our studies
was to establish the importance of this resistance mechanism for
the resistance of bioﬁlms to beta-lactam antibiotics. The AmpC
expression in P. aeruginosa bioﬁlms was studied in ceftazidime
or imipenem treated bioﬁlms (sub-MIC concentrations) of PAO1
with a reporter fusion of the ampC promoter to gfp (ASV)
encoding an unstable version of green ﬂuorescent protein. The
effect of high-level expression of chromosomally encoded
AmpC beta-lactamase on the survival of bacteria in a
ceftazidime treated bioﬁlm (10 times MIC) was studied in
bioﬁlms of Tn7gfp tagged clinical isolate stable derepressed for
the production of AmpC due to an insertion sequence in the
regulatory gene ampD and in the complemented strain expres-
sing low basal level of beta-lactamase. The sub-MIC levels of
ceftazidime and imipenem induced the monitor system, though
imipenem was a better inducer. Sub-MIC levels of imipenem
induced the monitor system in the periphery of the microcol-
onies while the centre remained uninduced, although the
bacteria in the centre were physiologically active. The stable-
derepressed expression of AmpC beta-lactamase played a
protective role during the treatment with 10 times MIC ceftaz-
idime. These results show that in bioﬁlms, besides tolerance of
P. aeruginosa to beta-lactam antibiotics due to low-growth rate,
oxygen and nutrient deprivation, classical resistance mecha-
nisms, like high-level expression of AmpC beta-lactamase have
an important role for the therapeutic failure of bioﬁlm eradica-
tion in the cystic ﬁbrosis lung.
S318
Bioﬁlm and virulence in staphylococci
P. Vaudaux (Geneva, CH)
The role of bioﬁlm in staphylococcal diseases was revealed by
the emergence of S. epidermidis clinical isolates producing an
extracellular polysaccharide matrix and responsible for medical
device infections and nosocomial bacteraemia. This discovery
assessed that hospital conditions could transform non-virulent
organisms into signiﬁcant pathogens. In the following decades,
numerous studies aimed to correlate qualitative or quantitative
in vitro bioﬁlm production with bacterial virulence in coagulase-
negative staphylococci (CNS). Thus, bioﬁlm production was
considered as the major or sole factor of CNS virulence.
Characterization of a major polysaccharide intercellular adhesin
(PIA) component of staphylococcal bioﬁlm and identiﬁcation of
the icaABDC operon opened the way to molecular studies of
bioﬁlm production in staphylococci. The prevalence of a highly
conserved icaABDC operon in both S. aureus and S. epidermidis
or some other CNS species represents a challenging observation
that should be interpreted with caution in view of the signiﬁcant
differences in PIA expression by S. aureus versus CNS isolates.
First, the extent of bioﬁlm formation and its environmental
regulation in vitro show signiﬁcant differences between S. aureus
and S. epidermidis. Second, S. aureus exhibits a much wider
spectrum of virulence factors than S. epidermidis, which contrib-
ute to its multiple, alternative modes of virulence and persist-
ence in human and animal hosts. Further work is needed to
more precisely deﬁne the involvement of bioﬁlm formation in
the various categories of S. aureus diseases or colonization in
humans.
Focus on new antibacterials
S319
The oxazolidinones
R. Moellering (Boston, USA)
The oxazolidinones represent the only unique class of anti-
microbials developed in the past 20 years. Originally synthes-
ized as monoamine oxidase inhibitors, molecular manipulation
has resulted in compounds with acceptable toxic : therapeutic
ratios and outstanding activity against resistant gram-positive
pathogens. Linezolid is the ﬁrst of these compounds to be
successfully developed for clinical use. The oxazolidinones have
a unique mechanism of action, inhibiting the formation of the
initiation complex in ribosomal protein synthesis. Resistance
develops via mutations in the 23S rRNA gene. Since most of the
important gram-positive pathogens have multiple copies of this
gene and it requires more than a single mutation to develop
clinical resistance, bacteria have been slow to develop immunity
to these compounds. The oxazolidinones also exhibit excellent
bioavailability and outstanding tissue penetration. They show
little or no interaction with the cytochrome P450 system and
they have been shown to be clinically effective. Nonetheless, the
currently available oxazolidinone, linezolid, does have certain
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disadvantages. The MICs are near the breakpoints for many
susceptible organisms (and above for H. inﬂuenzae and
M. pneumoniae). The drug is bacteriostatic or only slowly
bactericidal and failures in endocarditis have been reported.
Although toxicity has not been an issue in standard courses of
therapy, myelosuppression, peripheral neuropathy, and optic
neuritis have been seen in patients receiving the drug for long
periods of time. This has proven to be a disadvantage in its
application for infections such as Nocardia and tuberculosis
(both organisms of which are susceptible to linezolid) because of
the long duration of therapy involved. It has outstanding
penetration in the CSF, but formal studies evaluating it in
meningitis have not been performed. Because of its relatively
short half-life, it must be given twice a day. A number of new
oxazolidinones are being developed in an attempt to improve on
the valuable properties of linezolid. Although none of these has
yet reached the clinic, they will receive further discussion.
S320
New glycopeptides and lipopeptides
D. Livermore (London, UK)
Vancomycin and teicoplanin are treatment mainstays versus
severe gram-positive infections, used increasingly with the
spread of MRSA. They are however less-than-ideal-antibiotics,
being only slowly bactericidal. Moreover, vancomycin is inferior
to beta-lactams against infections due to methicillin-susceptible
S. aureus and vancomycin resistance has emerged in enterococci
and –rarely– staphylococci; teicoplanin resistance is common in
coagulase-negative staphylococci (CoNS) and occurs in entero-
cocci with VanA. Three new glycopeptides now in Phase III:
dalbavancin, oritavancin and telavancin. Dalbavancin resembles
teicoplanin in microbiological activity but is more active against
CoNS. Its unique feature us a serum t1/2 of c. 10 days, allowing
once-weekly regimens and facilitating outpatient therapy or
early discharge. By contrast, telavancin and oritavancin break
the microbiological mould of earlier glycopeptides, being
rapidly bactericidal and retaining activity against all vancomy-
cin-resistant enterococci, including VanA strains. These differ-
ences reﬂect a secondary mode of action, probably involving
membrane disorganisation. Daptomycin, the ﬁrst lipopeptide
antibiotic licensed, resembles glycopeptides in spectrum but has
a unique mechanism, disrupting membrane potential and
causing cell leakage. It is rapidly bactericidal and is unaffected
by established resistance mechanisms; nevertheless there are a
few reports of resistance emerging during therapy. The coming
challenge is determining how best to deploy these compounds
in relation to earlier glycopeptides and to other new anti-gram-
positive options. Is the rapid bactericidal activity of telavancin,
oritavancin and daptomycin a major advantage in endocarditis,
in immuno-compromised patients or even in surgical prophy-
laxis vs. MRSA? Will multiple modes of action of guard against
rapid accumulation of resistance? Will any impact be made on
the prevalence of MRSA infections?
S322
Structure-activity relationship analysis and
therapeutic potential of peptide deformylase
inhibitors
T. Meinnel, C. Giglione, A. Boularot, A. Serero (Gif/Yvette, F)
Peptide deformylation is the ﬁrst step of the N-terminal Met
excision (NME) pathway in bacteria, unmasking the N-Met,
making possible the action of Met aminopeptidase [1].
Deformylation is a crucial step in bacterial protein biosynthesis
and is essential for bacterial growth [2]. At least one PDF gene
has been found in all eubacterial genomes sequenced to date
[3]. Peptide deformylase inhibitors (PDFI) appear to be one of
the most exciting classes of antibacterial agents discovered to
date. Rapid progress in the development of PDFI has been
possible because (i) PDF is a metalloprotease, and this class of
enzymes shows a high degree of structure-function conserva-
tion and (ii) the most potent PDFI are hydroxamate derivatives,
a well known category of pharmacophores. The current
challenge in structure activity relationship analysis is obtaining
molecules with potent antibacterial activity in vivo against a
range of drug resistant pathogens [4]. The PDFI now in clinical
trials target community based bacterial infections, correspond-
ing to a major pharmaceutical market [5]. Nevertheless, a
transcribed gene encoding a homolog of bacterial PDF has been
identiﬁed in the human genome [6]; the encoded enzyme was
shown to be active as a PDF in vitro, located in the
mitochondria and one of the two components of mitochondrial
NME [7–9]. Although further studies are required to determine
the precise function of human mitochondrial NME, PDF
activity appears to be crucial for human cells growth [10]. In
this context, the precautionary principle imposes a new
schedule of conditions for the design of new PDFI that will
take into account the absence of inhibition of human PDF. As
PDF inhibitors seem to have only very low levels of toxicity in
human cells, PDF is however truly an exciting new target for
the design of novel antibiotics.
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Emerging infections in the immuno-compromised host
(Symposium arranged with EORTC/IDSG)
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Infectious complications of anti-TNF strategies
J.W.M. van der Meer (Nijmegen, NL)
More than a decade ago, animal experiments demonstrated that
treatment with antibodies against tumour necrosis factor (TNF)
was deleterious inmycobacterial infections, fungal infections and
abscesses Although the exact mechanisms by which interference
with TNF produced these results were not fully elucidated, it was
clear that the containment of microorganisms within granulomas
and abscesses was not achieved or maintained. From these
studies, it could be predicted that large-scale and prolonged anti-
TNF treatment in humanswould lead to infectious complications.
Indeed, such complications (especially mycobacterial infections)
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are being encountered. The occurrence of these infections has
implications for pretreatment assessment of patients, and guide-
lines are now appearing. The risk for opportunistic infections
seems to be greater withmonoclonal antibodies against TNF than
with the TNF receptor construct. From a theoretical point of view
one would assume differences between the types of anti-TNF
drugs, as they differ in their capacity to interact with TNF-alpha
and TNF-beta (lymphotoxin), and with membrane-bound TNF.
As stated, it is not entirely clear how inhibition of TNF impairs
host defence. Secondary inhibition of interferon-gammamayplay
a role, but more investigations are clearly needed.
S325
Empirical antifungal therapy in cancer patients
with persistent fever
M. Akova (Ankara, TR)
Invasive fungal infections remain an unsolved misery in
neutropenic cancer patients. It has long been accustomed to
apply empirical amphotericin B or its lipid derivatives to those
who did not respond to broad-spectrum antibacterial therapy
and in whom no clues of infection apart from fever are present.
However, such a practice is far from being ideal for decreasing
mortality and morbidity due to disseminated fungal infections,
since by this approach many patients are exposed unnecessarily
to toxic and expensive drugs for an undetermined period of
time. Recently, new improvements have signiﬁcantly changed
this picture. First, although conventional amphotericin B is still
one of the most effective and broadest-spectrum antifungal
agents, new less toxic and equally effective compounds have
become available. Second, newer diagnostic tools tempted
physicians to use these antifungal agents in a preemptive or
targeted manner rather than empirical. The remaining piece in
this puzzle is to develop a predictive model, as this has been a
successful case for bacterial infections, in order to identify who
will most beneﬁt from empirical/preemptive antifungal treat-
ment. Until then, the current approach to cancer patients with
persistent fever must address antifungal treatment issues of
effectiveness, safety and cost.
Community-acquired MRSA in Europe – evolution at work
S327
The evolution of community MRSA in
Australia – lessons for Europe?
T.V. Riley, G.W. Coombs, F. O’Brien, J.W. Pearman,
K. Christiansen, W.B. Grubb (Perth, AUS)
In the early 1980s, epidemic MRSA (EMRSA) appeared on the
east coast of Australia. EMRSA were multiply resistant and they
became endemic in many large hospitals throughout Australia,
except Western Australia (WA). A statewide screening and
control policy was implemented in WA following an outbreak of
EMRSA in a Perth hospital after the admission of an interstate
patient in 1982. This involved screening all patients admitted to
hospitals from interstate or overseas and all new staff that had
worked outside WA in the previous 12 months. Following
screening, patients infected or colonized with MRSA were
isolated and treated, while infected or colonized staff were
prohibited from contact with patients until the organism was
eradicated. In WA, MRSA infection or colonization has been a
notiﬁable condition since 1985. The WA Department of Health
electronically ﬂags cases of MRSA, allowing carriers to be
identiﬁed and isolated on admission to any WA public hospital.
In the late 1980s, non-multi-resistant community MRSA
emerged in the north of WA. MRSA isolated from patients
living in the remote Kimberley region were phenotypically and
genotypically different to EMRSA and became known as
WAMRSA. During the 1990s, WAMRSA spread to most regions
of WA and, by 1997, a signiﬁcant number of cases of infection
and colonization were occurring in the Perth metropolitan area
and other Australian states. WAMRSA have the community-
associated SCCmec types IV and V that lack transposons,
integrated plasmids and other antibiotic resistance genes. Since
the screening and control policy was introduced, all MRSA
clinical isolates, and those isolated through screening, have been
sent to a reference laboratory where their identity was con-
ﬁrmed by standard procedures (mec/nuc PCR), complete
antibiotic susceptibility was determined and the isolates typed,
using initially PFGE and now MLST. In the 1990s, a different
community MRSA was isolated in eastern Australia, frequently
from people of Paciﬁc Island decent. These were subsequently
identiﬁed as ‘Western Samoan Phage Pattern’ strains, ﬁrst
described in New Zealand, and they can produce PVL. Most
Australian community MRSA do not produce PVL, apart from
the ‘Queensland’ clone. Although most Australian community
MRSA do not spread when introduced into a hospital environ-
ment, some do have the capacity to cause outbreaks. Identifying
the reasons for this and ways of identifying outbreak strains
remains a challenge for us all.
S328
Clonal evolution and SCCmec in
community-acquired MRSA
D.C. Oliveira, H. de Lencastre (Oeiras, P)
Community-acquired (CA) MRSA have recently emerged in
several parts of the world suggesting a new trend on MRSA
epidemiology with major impact on public health. Several pieces
of evidence suggest that CA-MRSA may have evolved inde-
pendently from hospital-acquired (HA) counterparts: (i) most
CA-MRSA belong to speciﬁc genetic backgrounds (deﬁned
either by PFGE or MLST); (ii) they are less resistant to
antimicrobial agents (usually resistant to b-lactam antibiotics
only); (iii) they are more often positive for the Panton-Valentine
Leucocidin (PVL) toxin genes; and (iv) they carry predominantly
the smallest variant of the chromosomal cassette responsible for
the resistance to b-lactam antibiotics (SCCmec type IV). The
origin and dissemination of CA-MRSA is not clear but it seems
that it was due to the independent acquisition of virulence traits
(e.g. PVL gene) and resistant genes (e.g. SCCmec) by S. aureus
lineages previously well adapted to the open community
environment. This hypothesis explains the emergence of
CA-MRSA in remote communities not exposed to the nosoco-
mial milleu (e.g. Australia) and in countries where MRSA
prevalence in hospitals is extremely low (e.g. Denmark). The
SCCmec element carries the central element of methicillin-
resistance (the mecA gene), so that its aquisition deﬁnes the
evolutionary step from methicillin-susceptible S. aureus (MSSA)
to MRSA. Moreover, since SCCmec also carries the genes
responsible for its mobility (ccrAB locus) as well other acessory
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DNA sequences, it may be used as a marker for the origin and
evolution of MRSA lineages. So far, four major SCCmec types
have been described. HA-MRSA are mostly characterized by
SCCmec types I–III, whereas CA-MRSA are mostly character-
ized by SCCmec type IV. Interestingly, SCCmec type IV seems to
be the most mobile version since, besides being dominant
among CA-MRSA, it is present among several HA-MRSA
lineages and is also quite frequent among methicillin-resistant
coagulase-negative staphylococci. Perhaps as consequence of its
enhanced mobility, SCCmec type IV is highly variable and
several structural variants have been described, which makes its
proper identiﬁcation problematic and a challenge for any
SCCmec typing scheme. Nevertheless, it is now clear that
studies on the genetic organization(s) of SCCmec type IV strains
are a key strategy for a better understanding of the origin and
evolution of MRSA in general, and CA-MRSA, in particular.
S329
Update on current community-acquired MRSA
situation in Europe
W. Witte (Wernigerode, D)
Community acquired MRSA (cMRSA) are deﬁned as affecting
patients without the known risk factors for MRSA associated
with nosocomial infections. The majority of cMRSA contains the
lukS-lukF determinant (coding for Panton Valentine Leukocidin
and SCCmec elements of group IV (the latter are, however, also
in epidemic MRSA of multilocus sequence types (MLST) 22 and
45. cMRSA are often the cause of deep seated infections of skin
and soft tissue, also cases of necrotizing pneumonia became
known. cMRSA from Europe as well as fromworld wide sources
belong to different MLST types (table).
Some MLST-types suggest a wide dissemination of particular
strains. This needs to be conﬁrmed by further subtyping. Of
special concern is the emergence of until now epidemic
nosocomial MRSA which have acquired lukS-lukF and cause
infections in the community. The reservoirs and ways of
transmission of cMRSA in Europe are largely unknown.
Recent trends in severe fungal infections
O334
Semi-national surveillance of fungaemia in
Denmark: species distribution and anti-fungal
susceptibility
M.C. Arendrup, K. Fuursted, B. Gahrn-Hansen, I.M. Jensen,
J.D. Knudsen, B. Lundgren, M. Tvede, H.C. Schønheyder
(Copenhagen, A˚rhus, Odense, Herlev, Hvidovre, A˚lborg, DK)
Objective: The epidemiology of fungaemia in Denmark is not
systematically investigated. This study was undertaken to
characterize species distribution and susceptibility pattern in
different parts of the country.
Methods: Six departments of clinical microbiology in
Copenhagen, Copenhagen county, Funen county, Aarhus county
and Northern-Jutland county were included prospectively. The 6
departments serve a population of 2,870,000which is about half the
Danish population. From each episode of fungaemia, deﬁned as
isolation of the same fungus from blood culture with in a 21 day
period, one isolate was to be sent to the unit of mycology and
parasitology for veriﬁcation of species identiﬁcation and
susceptibility testing. Species identiﬁcation was done by use of
colony morphology on CHROMagar plates at 35C (CHROMagar
CO.,Paris,France),presenceorabsenceof chlamydoconidiaonRice
and Tween agar plates (SSI Diagnostica, Hilleroed, Denmark),
growth at 35 and 42C and by ID32C (bioMerieux, Marcy l’Etoile,
France). Susceptibility testing for amphotericin B, caspofungin,
ﬂuconazole and itraconazole was performed according to the
NCCLS document M27-A.
Results: A total of 298 episodes of fungaemia were registered.
Candida species accounted for 97.5% of the fungal pathogens.
Although C. albicans was the predominant species (64%) the
proportion was lower than previously described (85% in 1994–5).
However, the relative proportion varied considerably, i.e. from
57% at Hvidovre University Hospital to 72% at Herlev and
Odense University Hospitals. C. glabrata was the second most
frequently isolated fungus (over-all 20%) but again considerable
variation in frequency was demonstrated (8–32%). C. krusei was
rarely isolated (3%) and only detected at two of the six
microbiology laboratories. Amphotericin B and Caspofungin
MICs were in agreement with the typical patterns predicted by
species identiﬁcation, however, decreased azole susceptibility,
deﬁned as ﬂuconazole MIC >8 and/or itraconazole
MIC > 0.125 lg/ml was detected among 11 non-glabrata, non-
krusei Candida isolates (Table 1).
Conclusion: The species distribution of invasive fungal
infections is shifting with an increase in non-albicans species.
Reduced susceptibility to azoles was detected among 4% of non-
glabrata/krusei isolates and more frequent in departments with
a high proportion of C. glabrata isolates.
Table 1. Emergence and spread of MRSA with lukS-lukF in dif-
ferent geographical regions and countries.
MLST type Country where emerging
80* Australia, Belgium, France, Germany, Netherlands,
Sweden, Switzerland
30 Germany Latvia, Sweden, US, Southern Paciﬁc
1* Germany, Sweden, US
5 Netherlands, Slovenia
8* New Zealand, US
22 Germany, Scotland
59 Sweden, US, Taiwan
152 Sweden, Slovenia
154* Sweden, Mongolia
290 Australia
*also nosocomial spread known
Table 1. Candida isolates with either genuine or acquired re-
duced susceptibility to ﬂuconazole and / or itraconazole among
Danish blood pathogens.
Species Herlev Odense RH Arhus Albong Hvidovre All
Genuine
SDD or R
Candida
spp.*
3 (8%) 8 (17%) 13 (23%) 14 (25%) 18 (31%) 14 (32%) 70
(23%)
Aquired
SDD or
R Candida
spp.
C. albicans C. parap-
silosis
C. parapsi
losis
C. albicans
C. albicans**
C. albicans
C. albicans
C. guillie
rmondii
C. albica
ns
C. tropicals
C. guillier
mondii
(10/30
isolates
are tested)
11
(4%)
*C. glabrata and C. krusei
** C. albicans: Highly resistant isolates with MIC’s of itraconazole > 16 and ﬂuconazole
>64 l/ml.
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Changing patterns of candida infection
S. Thomas, F. Dale, S. Ghoneim (Dumfries, UK)
Although Candida albicans remains the most common candidal
fungaemia, treatment resistant, non-albicans species are becom-
ing increasingly prevalent. There is little data available on the
epidemiology of these non-albicans species
Aims: To examine the incidence of candida colonisation in ITU
patients with emphasis on prevalence and infection patterns of
non-albicans species.
Method: A retrospective analysis of patients admitted to the
ITU in Dumfries and Galloway Royal Inﬁrmary, over a 6 month
period.
Results: A positive sputum culture was isolated from 54
patients. All patients had routine sputum samples sent,
tracheal aspirates were sent from ventilated patients. 52% of
patients were colonised with C. albicans. 48% of patients were
colonised with non-albicans species, 74% of which were male
patients. 85% of the non-albicans species were C. glabrata.
C. tropicalis was isolated in 19% of patients (5 patients, 4 out of 5
of which was in combination with a second candida species).
24% of patients were colonised with both C. albicans and
C. glabrata . The average age of patients with C. glabrata was
75 years, much higher than for patients with C. albicans
(62 years). The mean APACHE II scores for patients with
C. glabrata was 28 (range 79 to15), signiﬁcantly higher than for
patients with C. albicans 18, (range 32 to 8). All patients with
C. glabrata had been treated with broad spectrum antibiotics,
78% with more than one type. Of the patients with non-albicans
species, 77% had been ventilated, 82% had intravascular or
urinary catheters in-situ. 26% had undergone abdominal
surgery and 26% had severe underlying respiratory problems.
Only 5 patients with initial C. albicans, who were treated with
triazoles, subsequently became colonised with C. glabrata. Over
the six month period, results suggest clustering of C. glabrata in
months 1, 5 and 6.
Discussion: Studies suggest an increasing trend of C. glabrata in
the acute clinical setting. Isolates are possible in the absence of
C. albicans. Frail, immunocompromised patients, in particular
those who have had interventional therapy, broad spectrum
antimicrobial or antifungal therapy seem to be at a highest risk.
Clustering may implicate contamination from health-care
workers in its transmission. This may be an understated risk
factor in the acquisition of C. glabrata infection and emphasizes
the need for strict infection control measures.
O336
Trends in incidence of invasive fungal infections
at a tertiary cancer centre over a 14-year period: an
autopsy study
G. Chamilos, G.P. Bodey, M. Luna, R.E. Lewis, K.V. Rolston,
R. Chemaly, A. Safdar, I. Raad, D.P. Kontoyiannis (Houston, USA)
Objectives: Autopsy series remain the most reliable way to
study epidemiology of invasive fungal infections (IFI). We
sought to identify trends in incidence of IFI and associated risk
factors in cancer patients in our institution over the last 2
decades.
Methods: Autopsies of cancer patients at MDACC were
analyzed over 3 study-periods (A: 1989–1993, B: 1994–1998,C:
1999–2002), each associated with the introduction of a new
antifungal (A: ﬂuconazole, B: lipid formulations of amphotericin
B, C: echinocandins).
Results: The median autopsy rate decreased signiﬁcantly over
the 3 study periods (219/year, 65/year, and 56/year
respectively), (p = 0.02). 336 IFIs were identiﬁed in 1449
autopsies (23%). Most (94%) IFIs occurred in patients with
haematological malignancies. The incidence of IFIs increased
from 20% (1989–1993) to 30.5% (1994–1998) and 36.4% (1999–
2002) in recent years (p < 0.0001). This trend was mainly
associated by a signiﬁcant increase in incidence of invasive
aspergillosis after period A (8.4%, 16.5%, 20.4% in each period
respectively, p < 0.0001). Non-fumigatus aspergilli were the
most common causes of aspergillosis in our institution
throughout all periods (65%, 56%, 63%, p = 0.28). In contrast,
the incidence of candidiasis remained stable (8.4%, 10.1% and
8.0% respectively), (p = 0.68) while a predominance of non-
albicans Candida strains occurred in period B and C (43%, 69%,
61%, p < 0.0001). A signiﬁcant increase in incidence of
zygomycosis (0.4%, 2.5%, 2.2%) (p = 0.002) and other non-
Aspergillus mould infections was noted after period A (1.4%,
1,1% 5.3%) (p = 0.0002). Finally, Candida spp caused the
majority of IFIs in patients with solid tumors (65% of all IFI),
while aspergillosis and non-Aspergillus mould infections
predominated in patients with hematologic malignancy and/
or bone marrow transplantation (64% of all IFI).
Conclusions: Although Aspergillus and Candida continue to
represent the majority of IFIs at autopsy, the epidemiology of
IFIs is changing, with the emergence of resistant yeasts and
moulds, especially among severely immunocompromissed
cancer patients. The declining autopsy rates represent a
challenge in the study of epidemiology of IFIs.
O337
Nosocomial candidaemia in a Brazilian paediatric
population: a 9-year study comparing risk factors
and the outcome of paediatric and adult
candidaemia
A.C. Pasqualotto, W.L. Nedel, T.S. Machado, L.C. Severo (Porto
Alegre, BR)
Objectives: To compare risk factors, etiology, therapy, and
outcome of nosocomial candidemia between pediatric and adult
patients with candidemia in a large Brazilian tertiary hospital.
Methods: A retrospective cohort study was performed in Santa
Casa Complexo Hospitalar, Brazil, during the period comprising
1995 and 2003. Patients were considered pediatric if their age
was <13 years-old. Medical charts were reviewed to record
clinical and demographic characteristics presented in the period
of 30 days before collection of the ﬁrst blood sample positive for
Candida.
Results: During this period, 78 pediatric and 113 adult patients
with nosocomial candidemia were studied. Species other than
C. albicans caused 78.2% of episodes of candidemia in pediatric
patients. Compared to adults, pediatric patients received
more frequently broad-spectrum antibiotics, H2 blockers,
vasopressors, blood transfusions, arterial catheter, gastrostomy,
chest tube, cardiothoracic surgery, mechanical ventilation, and
parenteral nutrition. Candidemia caused by C. parapsilosis was
more common in pediatric patients, as was the isolation of
Candida spp. from catheters. Amphotericin B treatment wasmore
common in pediatric patients. The 30-day mortality rate was
higher in adults.
Conclusions: C. parapsilosiswas themain etiology of candidemia
in this largeBrazilian retrospective cohort of pediatric patients.As
expected for pediatric patients, C. glabrata was an infrequent
species. The underlying diseases, predisposing conditions, and
antifungal treatment were different between pediatric and adult
patients, and Candida spp. were more commonly isolated from
catheters in pediatric patients. Treatment with amphotericin B
was more common in pediatric than adult patients. Although
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in-hospital crudemortalitywas similar between these groups, the
mortality rateswithin 48h, 7 days, 15 days and 30 days after blood
sample were all higher in adults. We reinforce the necessity of
continuous epidemiologic surveillance to follow the dynamics of
candidemia.
O338
Fluconazole susceptibility in Candida glabrata
varies with clade
A.R. Dodgson, C. Pujol, M.A. Pfaller, D.W. Denning,
D.R. Soll (Manchester, UK; Iowa City, USA)
Objectives: Candida glabrata is the second most prevalent
Candida species in cases of bloodstream infection in the US. It
is notable for its decreased susceptibility to the azole antifungal
agents. Recent studies have shown that C. glabrata has a
primarily clonal population structure. To date, seven major
clades have been described, however there is no description of
clinically relevant differences in the phenotypes exhibited by
isolates of different clades. This study aimed to examine the
relationship between ﬂuconazole susceptibility and clade.
Methods: A collection of 445 US C. glabrata isolates from the
SENTRY and ARTEMIS studies was used in this study. The
ﬂuconazole MIC of each isolate was determined using NCCLS
M27-A methodology. Clade was determined using a reduced
Multilocus Sequence Typing (MLST) method, whereby only 2 of
the loci found to be most variable in previous studies (NMT1
and FKS) were sequenced. This methodology, while slightly
reducing discrimination, allowed accurate determination of
clade while decreasing both the cost and time involved in
sequencing all 6 MLST loci.
Results: Of the 445 isolates typed in this study, 397 belonged to
one of 8 major clades (named Groups I to VIII). Seven of these
were previously described, the additional one being novel to this
study. The number of isolates within each clade ranged from 5
(Group VII) to 82 (Group III). For the total collection of 445
isolates, the numbers in each of the NCCLS susceptibility
categories were as follows: Susceptible (S, MIC < 16 lg/ml)
292 (66%); Susceptible Dose Dependent (S-DD, 16–32 lg/ml) 108
(24%); Resistant (R > 32 lg/ml) 45 (10%). For most clades the
percentage of isolates within these categories was broadly similar
to that seen for the whole collection. However, a number of
clades showed distributions markedly different to the collection
as a whole. For instance in Group I (49 isolates) only 53 %were S,
whereas in Group VI (78 isolates) this value was 74%.
Conclusions: This study demonstrates that clinically relevant
phenotypic differences exist between isolates from the major
clades of C. glabrata. This is the ﬁrst observation of the
phenomenon in C. glabrata, though clade-speciﬁc differences in
5-FC resistance and alleles of the ALS family of adhesions have
been described in C. albicans. Previous studies have shown
geographical differences in the MIC’s of C. glabrata, it remains to
be seen if this is due to the clade-speciﬁc differences noted in
this study.
O339
Aspergillus galactomannan antigen detection in
different batches of piperacillin-tazobactam
M. Machetti, E. Furfaro, L. Boni, C. Viscoli (Genoa, I)
Objectives: Invasive aspergillosis (IA) is a serious life-
threatening complication in patients with haematological
malignances. The detection of circulating galactomannan (GM)
in blood with the Platelia Aspergillus test (PA – Bio-Rad), is one
of the criteria deﬁning IA. In the last 2 years several authors
found GM in patients treated with Piperacillin-Tazobactam
(P/T) and in P/T vials (Maertens et al. NEJM 2003, Viscoli et al.
and Adam et al. CID 2004), while others did not (Penack et. al,
CID 2004). Therefore we decided to try to give an explanation to
these apparently controversial results, by evaluating both the
proportion of positive batches and vials and the extent of GM
contamination.
Methods: Ninety P/T vials from 30 randomly selected batches
were tested with the PA test (median vials per batch 3, range
1–4). The drug was diluted as for clinical use (4.5 mg/ml NaCl
0.9%) and the test was performedwith the samemethod used for
serum samples. NaCl 0.9% alone was tested as negative control.
Samples with a GM index > 0.7 was considered as positive.
Results: Twenty-six batches (86%) tested positive (all vials),
with a median GM index of 1.99 (range 0.77–6.98) among vials
with quantiﬁable levels, while 4 tested negative (median index
0.28, range 0.19–0.3) and 4 (12 vials) had an index >7. No further
quantiﬁcation was performed in these 12 samples. There is an
apparently bimodal distribution of GM levels in the 79 positive
vials (Fig. 1). Indeed 40 vials had GM indexes ranging from 0.77
to 2.87, while 39 vials had indexes ranging from 3.86 to 6.98.
Distinction of positive results into 2 groups was supported by
analysis of frequency distribution (data not shown).
Conclusion: The rate of P/T batches testing positive with the
PA test is in agreement with previous reports (75–100%). A
recent study indicates that the positivity of PA test with P/T is
likely due to a contamination of the drug with GM and not to a
cross-reaction with the antibiotic (Mennink-Kersten et al. ICAAC
2004). So, while the origin of this contamination could be due to
the use of Penicillium cultures for the production of P/T, it
remains unclear why GM content differ substantially by batch
and why some batches are negative. Our results show that not
all P/T batches contain GM, and that the extent of
contamination is highly variable.
O340
Prospective evaluation of sequential Aspergillus
galactomannan antigen detection and CT scan of
the chest for early diagnosis of invasive
pulmonary aspergillosis in recipients of
allogeneic stem cell transplantation
A. Busca, G. Limerutti, A. Mele, R. Serra, A. Barbui, L. Godio,
F. Locatelli, M. Falda (Turin, I)
Early diagnosis of invasive pulmonary aspergillosis (IPA) is
important as early treatment with antifungal drugs may increase
patient survival.
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Objectives: Our study investigated the efﬁciency for IPA
diagnosis of the Aspergillus galactomannan antigen (AGA)
detection routinely used in combination with chest CT scan.
Methods: From February 2002 to June 2004, we prospectively
measured serum AGA levels in a consecutive series of 74 adult
hemato-oncological patients who underwent allogeneic SCT
from matched sibling donors (n = 48), partially matched related
donors (n = 7) or matched unrelated donors (n = 19). Serum
samples were taken twice weekly, starting at the beginning of
conditioning regimen until the end of hospitalisation, while
outpatients were monitored once per week if received
immunosuppressive therapy. AGA positivity was deﬁned as
an OD index of galactomannan · 1.0 in 2 subsequent sera. High
resolution chest CT scans were performed when fever of
unknown origin had lasted 3 days of broad-spectrum
antibacterial therapy, or when chest radiographs showed
abnormalities.
Results: IPA was diagnosed in 9 of 74 patients (12%): according
to the EORTC/MSG criteria, 7 patients were classiﬁed with
probable IPA, 2 patients were classiﬁed with proven IPA,
whereas 65 patients did not fulﬁll criteria of IPA. Fourteen
patients showed positive results for AGA. Five patients (8%)
had a false-positive result, while no false-negative tests have
been observed in our series. The sensitivity and speciﬁcity of the
test were 100% and 93% respectively; the PPV and NPV were
64% and 100% respectively. All patients with probable or
proven IPA showed abnormal CT signs. In 4 cases imaging
signs followed AGA positivity (median 5 days;range 0–9),
whereas in 5 cases preceded the positive results of serological
tests (median 8 days;range 1–12). Based on the presence of
positive AGA combined with imaging signs suggestive of IPA,
antifungal therapy was promptly instituted including lipid
formulations of amphotericin B (n = 5) or caspofungin (n = 4).
In only 2 of the 9 patients (22%) with IPA, the primary cause of
death was the fungal infection; 4 patients (45%) died of
recurrent disease (in 2 cases fungal infection contributed to
death) and 3 patients (33%) are currently alive with no evidence
of infection.
Conclusions: The combination of AGA detection and early
chest CT scans might be considered useful tools to detect
minimal changes of IPA. Based upon these ﬁndings, aggressive
antifungal therapy should be initiated.
O341
Predisposing risk factors and outcome in ICU
patients with invasive aspergillosis
K. Vandewoude, S. Blot, P. Depuydt, D. Benoit, J. Decruyenaere,
J. De Waele, E. Hoste, F. Colardyn (Ghent, B)
Objective: To investigate outcome in ICU patients with
invasive aspergillosis (IA) and to evaluate whether patients
with predisposing risk factors have a worse outcome.
Methods: Retrospective cohort study (1997–2003). Deﬁnite IA
was deﬁned as: (1) positive microscopic examination with
septate hyphae and positive Aspergillus culture on tissue
biopsy, or (2) positive culture of a normally sterile site
obtained by aseptic invasive techniques. Probable IA is
deﬁned as (1) clinical symptoms of infection, (2) any positive
culture from a nonsterile site, (3) chest X-ray or CT of lungs
suggestive for IA and (4) either (a) positive results of
microscopic examination and culture of BAL ﬂuid or (b)
predisposing host risk factors for IA. Haematological/
oncological malignancy treated with cytotoxic agents,
neutropenia, glucocorticoid treatment, and congenital or
acquired immunodeﬁciency were considered as risk factors for
the acquisition of IA.
Results: During the study period 83 patients developed IA
whereof 50 with and 33 without risk factors. Deﬁnite IA was
diagnosed in 16 patients; 8 in each group (respectively 16% and
24.4%). Patients with risk factors had higher APACHE II scores
(32 ± 6.8 vs. 23 ± 9.2; p = 0.002). Patients with and without risk
factors had the same age (60 ± 14.0 vs. 55 ± 15.0 year; p = 0.060)
and there was no difference in the proportion of patients
needing mechanical ventilation (94% vs. 100%; p = 0.273), renal
replacement therapy (34% vs. 48%; p = 0.252) or vasoactive
therapy (86% vs. 94%; p = 0.306). Length of ICU stay (18 ± 18.4
vs. 28 ± 23.5 days; p = 0.027) and length of mechanical
ventilation (16 ± 14.9 vs. 25 ± 21.1; p = 0.041) were
signiﬁcantly longer in patients without risk factors. 86% of
patients with and 85% of patients without risk factors received
antifungal therapy (p = 0.999). There was no difference in delay
of administering antifungal therapy between patients with and
without risk factors was observed (respectively 2.3 ± 3.0 vs.
2.1 ± 1.9 days; p = 0.723). No difference was found between
patients with and without risk factors in 14-days mortality (70%
vs. 55%; p = 0.251), 28-days mortality (76% vs. 64%; p = 0.322)
and in-hospital mortality (82% vs. 70%; p = 0.285). A logistic
regression model could not identify independent risk factors for
mortality.
Conclusion: The hospital mortality in ICU patients with IA is
high (77%). No difference in mortality was found between
patients with (82%) and without risk factors (70%) for the
acquisition of IA.
O342
Results of a double-blind, placebo-controlled
trial in patients with culture-conﬁrmed invasive
candidiasis, treated with a human recombinant
antibody to hsp90 and liposomal amphotericin B
R.C. Matthews on behalf of the Mycograb Study Group
Objectives: To determine whether combination therapy with a
human recombinant antibody to hsp90 (Mycograb) plus a lipid
preparation of amphotericin B was superior to monotherapy
with liposomal amphotericin B.
Methods: This was a prospective, double-blind, randomised,
comparative study of the efﬁcacy and safety of a 5 day course of
Mycograb (1 mg/kg iv) plus liposomal amphotericin B versus
placebo (saline iv) plus liposomal amphotericin B in adult
hospitalised patients with culture-conﬁrmed deep-seated
candidiasis. Patients were stratiﬁed on the basis of their germ
tube test result. Efﬁcacy was assessed on the basis of clinical and
mycological response at Day 10, Candida-attributable mortality
(28 days after last dose of study drug) and speed of culture-
conﬁrmed resolution of the infection. The primary efﬁcacy
variable was overall response at Day 10 i.e. clinical and
mycological resolution of the infection. There were 137
patients in the modiﬁed ITT population, recruited from 10
European countries and 2 US Centres.
Results: A complete overall response was obtained in 48% (29/
61) of the placebo group compared to 84% (47/56) of the
Mycograb-treated group (p < 0.001). The following secondary
efﬁcacy criteria were also met: clinical response (52% versus
86%, p < 0.001), mycological response (54% versus 89%,
p < 0.001), Candida-attributable mortality (18% versus 4%,
P < 0.025), and rate of culture-conﬁrmed clearance of the
infection, being over twice as fast in the Mycograb-treated
group (P 0.001). Mycograb was well-tolerated.
Conclusion: Combining Mycograb with amphotericin B
produced a highly statistically signiﬁcant improvement in
outcome in patients with culture-conﬁrmed invasive
candidiasis, mirroring the synergy observed between these
Abstracts
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two drugs in pre-clinical studies. This is the ﬁrst time a double
blind, placebo controlled trial has shown synergy between two
antifungals in the treatment of invasive candidiasis.
O343
Efﬁcacy of high-dose caspofungin in 22 cancer
patients with invasive fungal infections
A. Safdar, G. Rodriguez, K.V. Rolston, H. Kantarjian,
R. Champlin, I. Raad, D. Kontoyiannis (Houston, USA)
Objective: Echinocandins exhibit concentration-dependent
efﬁcacy in animal models of mycosis (Winderhold et al,
ICAAC 2003; Andes et al, AAC 2003). We sought to determine
the safety and efﬁcacy of high-dose caspofungin (HD-
CAS) therapy in cancer patients with invasive fungal infections
(IFIs).
Methods: We retrospectively evaluated patients during 2002–
2004 who had received HD-CAS (100 mg daily) after obtaining
IRB approval. All values are given in median ± s.d.
Results: Agewas 46 ± 18 years, 9 (41%)weremen, 10 (45%)were
neutropenic and APACHE II score was 15 ± 5. All 22 patients
(100%) had hematologic malignancies; 15 had leukemia. In 7
(32%) hematopoietic stem cell transplant recipients, 6 patients
received allogeneic grafts and 3 (14%) had acute graft-versus-host
disease. Fifteen patients (68%) had refractory cancer. Six (27%)
were receiving substantial dose systemic corticosteroids
(> 600 mg equivalent prednisone dose) during antifungal
therapy. The range of cumulative CAS dose was 300–4400 mg
per patient and numbers of HD-CAS doses were 21 ± 17
(range, 3–60). Nine patients (41%) had deﬁnite IFIs, 6 (27%)
sino-pulmonary infections (5 Aspergillus; 1 Scedosporium
apiospermum) and 3 patients (14%) had disseminated disease (2
Fusarium and 1 Aspergillus fumigatus). In 13 patients (59%) with
probable IFIs, 10 (45%) had fungal pneumonia and 3 (14%) with
sino-pulmonary involvement. Twenty-one patients (95%)
received HD-CAS in combination with another antifungal
agent, 6 (27%) received HD-CAS upfront, whereas in 16 patients
(72%) initial therapy included AmBisome, voriconazole, and
conventional-dose CAS. The 12-week crude mortality was 41%
and IFI-attributable deaths were 32%. Overall, HD-CAS was
tolerated without serious adverse reactions; 2 patients (9%)
developed fatal liver failure, which was deemed unrelated to
HD-CAS.
Conclusions: In our high-risk patient population HD-CAS in
combination with other antifungals was well tolerated and
appears to have favorable impact on short-term mortality in
patients with invasive mycosis.
Antibiotic and antibiotic resistance mechanisms
O344
Long-term effects of antibiotic administration on
clonal stability and emergence and persistence of
resistance genes in the intestinal microﬂora
S. Lo¨fmark, C. Jernberg, C. Edlund (Stockholm, S)
Objectives: To study emergence and persistence of antibiotic
resistance genes in the intestinal ﬂora after antibiotic
administration over a two-year period, and to monitor the
stability of clonal selection and changes in the ﬁngerprint
patterns of the dominant members of the bacterial community.
The commensal ﬂora of the human intestine is a complex
ecological system involved in host beneﬁcial activities and
disturbances of the microﬂora by antibiotic administration can
lead to clinical implications. Exchange of resistance genes
among the intestinal bacteria and bacteria passing through the
colon might also be a serious threat to human health.
Methods: Four healthy subjects receiving clindamycin for seven
days and four non-treated subjects were included in the study.
Faecal samples collected at nine different time points prior to
and during a two-year period following the antibiotic treatment
were cultured for Bacteroides spp. strains. Twenty
representative colonies were collected and phenotyped and
tested for antimicrobial susceptibility to clindamycin,
tetracycline and ampicillin according to NCCLS. Screening of
speciﬁc resistance genes were performed by RealTime PCR.
Resistance to the different antibiotics has shown to be connected
and presence of tetQ, ermF, ermB, cepA and cfxA involved in
these resistances were investigated. Speciﬁcally ermF and tetQ
are common in the B. fragilis group and often reside on the same
conjugative transposons. rep-PCR was used for clonal
genotyping of the isolates and T-RFLP was used for
ﬁngerprinting of the total faecal bacterial community.
Results and Conclusion: Short-term administration of
clindamycin resulted in major long-term ecological disturbances
up to at least 24 months after administration. The trend showed a
decline in species diversity,which did not return to pre-treatment
levels for up to 18 months after administration. An increased
frequency of resistance to clindamycin and tetracycline and a
long-term enrichment of resistance genes (ermF and tetQ)
among Bacteroides spp. were seen in exposed subjects. A broad
baseline variation of clonal stability and antibiotic resistance
between subjects were observed in both groups. This
ﬁngerprinting pattern of the total bacterial community
challenges the common view of the intestinal microﬂora as a
stable environment.
O345
Prevalence of antibiotic resistance among
commensal Escherichia coli from farm animals in
the UK
V.I. Enne, M.D. Aguas, C. Cassar, K. Sprigings,
P.M. Bennett (Bristol, Weybridge, UK)
Objectives: To determine the incidence of antibiotic resistance
and expressed and silent resistance genes among commensal
Escherichia coli from healthy farm animals.
Methods: 1798 E. coli were isolated from rectal swabs taken
from pigs, sheep and cattle upon entry to the abattoir. Their
susceptibility proﬁles to a panel of 16 antibiotics were
determined by disc susceptibility testing. The prevalence of 11
resistance genes as well as the Class 1 integrase gene was
determined among 615 of these isolates by PCR. Both resistant
and susceptible isolates were screened to identify expressed as
well as unexpressed resistance genes.
Results: The prevalence of antibiotic resistance among these
isolates was low; only 9.1% of isolates were resistant to at least
one agent. Of these, 5.2% were multi-resistant (deﬁned as
resistance to three or more agents of different classes). In terms
of individual agents, resistance was 1.1% to apramycin, 2.4% to
ampicillin, 0.1% to co-amoxiclav, 0.1% to cefoperazone, 1.2% to
chloramphenicol, 3.5% to colistin, 1.6% to co-trimoxazole, 0.3%
to furazolidone, 0.2% to gentamicin, 0.1% to nalidixic acid, 3.6%
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to neomycin, 4.3% to streptomycin, 4.6% to sulfonamide and
7.4% to tetracycline. There was no resistance to ceftazidime or
amikacin. Of the ampicillin resistant isolates tested, 64.5%
produced TEM type beta-lactamases, 19.4% produced OXA-2
type beta-lactamases and 0% produced SHV type beta-
lactamases. Of the tetracycline resistant isolates tested 36.0%
carried tetA and 73.0% carried tetB. Of the co-trimoxazole
resistant isolates tested 12.5% carried dhfr17 or related genes
and 16.7% carried dhfr12 or related genes. Of the streptomycin
resistant isolates tested 62.0% carried the strAB gene pair and
53.5% carried aadA1 or related genes. Of the sulfonamide
resistant isolates tested 27.4% carried sul1 and 71.0% carried
sul2. 18.2% of isolates tested were positive for the for type1
integrase. We found ﬁve incidences of strains that were PCR
positive for a given resistance gene but susceptible to the
corresponding antibiotic. Further investigation by sequencing
revealed that in each case either the promoter was absent or the
gene was truncated.
Conclusion: The incidence of antibiotic resistance among
commensal E. coli isolated from healthy farm animals is low.
The resistance that does exist is due to a wide variety of
resistance genes. The incidence of unexpressed resistance genes
is low and generally due to lack of promoter activity.
O346
Growth of Pseudomonas aeruginosa in bioﬁlms
results in elevated mutation frequencies
K.L. Drifﬁeld, K. Miller, J.M. Bostock, I. Chopra (Leeds, UK)
Objectives: Pseudomonas aeruginosa colonises the lungs of cystic
ﬁbrosis (CF) patients forming bioﬁlms that are difﬁcult to
eradicate due to intrinsic expression of resistance and rapid
development of acquired resistance. P. aeruginosa with elevated
mutation frequencies (MFs) have been isolated from the lungs of
CF patients, but have yet to be isolated from non-CF patients.
Hypermutators may arise during bioﬁlm growth as a
consequence of enhanced mutability in DNA repair genes
leading to permanent hypermutator strains. To address this
possibility we compared MFs of P. aeruginosa grown as
planktonic cells and as bioﬁlms. We also examined the effect
of a methyl-directed mismatch repair (MMR) deﬁciency on MF.
Methods: MFs of planktonic P. aeruginosa PAO1 and PAOdelta
mutS::Km, a MMR mutant, were determined by selecting
mutants at 4xMIC rifampicin (rif) after incubation at 37C for
48 h. Colony counts were expressed as a proportion of total
viable cell numbers after incubation at 37C for 24 h.
P. aeruginosa bioﬁlms were created using a modiﬁed Sorbarod
model. Sorbarod ﬁlters were inoculated, perfused with media
and maintained at 37C for 72 h. Bacteria were harvested from
the ﬁlter. MFs were determined as described.
Results: P. aeruginosa PAO1 and PAOdelta mutS::Km bioﬁlm
cultures showed signiﬁcantly elevated MFs when compared to
planktonic cells. RifR PAO1 were recovered from the bioﬁlm at a
frequency of 3.42 ± 2.02 · 10)8, and from planktonic cultures at
2.63 ± 1.76 · 10)9. PAOdelta mutS::Km showed an elevated MF
when compared with PAO1. PAOdelta mutS::Km rifR mutants
were recovered from the bioﬁlm at a frequency of
1.00 ± 0.88 · 10)5 and from planktonic cultures at
3.54 ± 1.66 · 10)6.
Conculsion: P. aeruginosa may beneﬁt from an increased
mutation rate when confronted with the stressful situation of
bioﬁlm growth in the CF lung. The elevated MF of cells grown in
the bioﬁlm may give insight into the high occurrence of
antibiotic resistant P. aeruginosa leading to treatment failure in
CF patients. Increased mutability in bioﬁlms may enhance the
opportunity to derive permanent hypermutators through
mutation in DNA repair genes. MF observed in planktonic
culture of PAOdelta mutS::Km was further elevated in the
bioﬁlm suggesting that in addition to mutS activity, expression
of other mut genes may also inﬂuence mutability in the bioﬁlm.
O347
Horizontal gene transfer as a cause of
ﬂuoroquinolone resistance in an invasive
Streptococcus pyogenes isolate
M.W.R. Pletz, L. McGee, C. van Beneden, S. Petit, M. Barlow,
K.P. Klugman (Atlanta, Hartford, USA)
Objectives: To date ﬂuoroquinolone (FQ) resistance has been
described only anecdotally in Streptococcus pyogenes. Similar to
other streptococci, efﬂux and/or mutations in the topoisomerase
type II enzymes seem to account for ﬂuoroquinolone resistance
in this species. Mutations can arise spontaneously or be
transferred by intraspecies or interspecies recombination. We
analyzed an invasive ciproﬂoxacin-resistant (MIC 8 mg/l)
S. pyogenes isolate (emm-type 83) collected by the CDC’s
Active Bacterial Core surveillance programme to determine
the mechanism through which it had become resistant.
Methods: Efﬂux was tested for by comparing ciproﬂoxacin
MICs in the presence and absence of reserpine (10 mg/l). The
quinolone resistance-determining regions (QRDR) of gyrA and
parC were sequenced. For parC, phylogeny was constructed by
the Bayesian method. Recombination was statistically conﬁrmed
by using the maximum chi-squared test.
Results: MICs were 8 mg/l for ciproﬂoxacin and 4 mg/l for
levoﬂoxacin. There was no evidence for an efﬂux pump. There
was nomutation in gyrA and a S79Fmutation was found in parC
that is known to confer ﬂuoroquinolone resistance. The parC
nucleotide sequence of the isolate showed an increased diversity
compared to the S. pyogenes reference strain, and there was a
region of repeat nucleotide mismatches on both sides of the S79F
mutation. Phylogenetic analysis of the parC sequence revealed
homologies to the parC of S. dysgalactiae. Statistical analysis for
recombination suggests interspecies recombination of at least
90bp sequence containing the S79F mutation with S. dysgalactiae.
Conclusion: Interspecies recombination as cause of FQ
resistance has to date not been described for S. pyogenes. We
have found an invasive isolate with evidence for the acquisition
of FQ resistance from S. dysgalactiae.
O348
Evidence of allelic variants of MEF carried on
Tn1207.3-like genetic elements in Streptococcus
pyogenes
S. Malhotra-Kumar, F. Iannelli, C. Lammens, G. Pozzi,
H. Goossens (Antwerp, B; Siena, I)
Background: The M phenotype in macrolide-resistant
Streptococcus pyogenes is mediated by an efﬂux transport
system of the ATP-binding cassette (ABC) superfamily, in
which mef(A) encodes the transmembrane domains, and
msr(D) (previously called mat(A)) the ATP-binding domains.
Both genes are carried on the Tn1207.3 element that integrates at
a speciﬁc site, the comEC coding region, in the S. pyogenes
chromosome.
Methods: Two S. pyogenes (SP1 and SP2) isolated from wound
and respiratory tract infections in Belgium were identiﬁed as
macrolide-resistant and exhibited the M phenotype by the
conventional disc-diffusion test. Primers consensus for mef(A)/
(E) were developed. RFLP analysis was done using BamH1,
HindIII, and NheI followed by double-strand sequencing to
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distinguish mef(A) from mef(E). Moreover, primers to detect the
left and right junctions of Tn1207.3 in comEC were used. A DNA
microarray containing oligonucleotides designed to target each
of the 58 Orfs of Tn1207.3 was used to detect presence of
Tn1207.3. Emm types and clonality were investigated by reverse
line blotting and PFGE, respectively.
Results: The mef gene in SP1 and SP2 could be successfully
detected by the consensus mef(A)/(E) primers. RFLP analysis
proved inconclusive; a restriction pattern similar to mef(E) with
BamH1 and HindIII, and one similar to mef(A) with NheI was
observed for both isolates. Emm and PFGE typing found SP1 to
belong to the emm4 serotype and SP2 to emm12 and both were
clonally unrelated. Microarray analysis showed that only 19 out
of 58 probes had reactivity with SP1 DNA. No reactivity was
detected with SP2 DNA. DNA sequence analysis showed that
the mef gene from SP1 and SP2 were different (91% homology at
the nucleotide level), and were also different from the canonical
mef(A) and mef(E) genes. Mef from SP1 showed 88% homology
to mef(A) and 89% to mef(E). Mef from SP2 showed 90%
homology to mef(A) and 95% to mef(E). In SP1, the Tn1207.3-
like element was integrated in comEC.
Conclusions: We present here evidence of novel Tn1207.3-like
genetic elements that carry allelic variants of mef in S. pyogenes.
The complete sequence of these elements and their integration
sites in S. pyogenes are currently under investigation.
O349
Antipneumococcal activity of telithromycin in
comparison with other drugs in relation to the
presence of different resistance genes
S. Stefani, M. Santagati, M. Mezzatesta, C. Cascone,
G. Nicoletti (Catania, I)
Objectives: The antistreptococcal activity of telithromycin and
11 different comparators was evaluated in 26 multi-drug
resistant Streptococcus pneumoniae collected during 2002–2003
as part of the ongoing PROTEKT (Prospective Resistant
Organism Tracking and Epidemiology for the Ketolide
Telithromycin) Italian Surveillance Program. The strains were
characterized for their susceptibility to antibiotics both at the
phenotypic and genotypic levels; furthermore, the association of
resistance genes and the mobile genetic elements that carry them
was also evaluated.
Methods: MICs of antibacterials were performed by following
NCCLS guidelines. The presence of erm(B), erm(A), mef(A) and
tet(M) genes, as well as the mobile elements carrying them was
determined using previously published methods1, 2, 3.
Results: The strains in this study were resistant to penicillin
(MIC > 2 mg/l) in 19.2% of cases, resistant to tetracycline in
88.5%, to cotrimoxazole, cefuroxime and amoxicillin in 23.1%
while only telithromycin retained 100% activity against all
microorganisms. A total of 88.5% of isolates were co-resistant to
all macrolides and to tetracycline, 23% were co-resistant to all
macrolides, to tetracycline and to cotrimoxazole and 19.2% to
macrolides, to tetracycline and to penicillin. All isolates showing
MLSB phenotype of resistance possessed the erm(B) genes and
in 71.9% of cases this gene was associated with tet(M). In these
strains the resistance determinants were carried by the Tn-1545-
type element. Isolates showing the M phenotype generally
possessed mef(A) genes alone, carried by Tn-1207.1 and only in
one isolate the class mef(A) was associated with tet(M) and
carried by Tn-2009. Although genotypically diverse, strains
included in the study carried erm(B) associated with tet(M) in
the same ApaI fragment of different sizes.
Conclusion: Telithromycin is highly active against multi-drug
resistant Streptococcus pneumoniae carrying many genes
responsible for resistance to different classes of antibiotics.
Our study shows that erm(B) is the most frequent gene
responsible for macrolide-resistance found in S. pneumoniae
and this was always associated with tet(M) on the same Tn-
1545–like element, while the association between mef(A) and
tet(M) is carried by Tn-2009.
1. Cascone et al – MDR 2002; 8:129.
2. Doherty et al – AAC 2000; 44:2979.
3. Santagati et al – AAC 2000; 44:2585.
O350
Activity of cathelicidin peptides against
Chlamydia spp.
R. Cevenini, M. Donati, K. Di Leo, M. Benincasa, F. Cavrini,
S. Accardo, A. Moroni, R. Gennaro (Bologna, Trieste, I)
Objectives: To study the in vitro activity of six cathelicidin-
derived peptides (Bac7, BMAP-28, SMAP-29, LL-37, PG-1,
BMAP-27) against puriﬁed elementary bodies (EBs) of 25
Chlamydia strains.
Methods: Chlamydial strains were grown in LLC-KM2 cells
and EBs puriﬁed by sucrose gradients. The cathelicidin peptides
were synthesized by the solid phase method using Fmoc
chemistry. After puriﬁcation by reversed-phase HPLC the
peptides were lyophilized and stored at 4C. Peptides were
twofold diluted in test tubes containing PBS and a total volume
of 0.15 ml of a suspension of puriﬁed EBs in SPG medium was
added to the tube. The suspensions were incubated at room
temperature for 2 hours and inoculated onto LLC-MK2 cells.
After incubation cell cultures were ﬁxed and stained with
ﬂuorescein-conjugated monoclonal antibody reactive with the
chlamydial speciﬁc genus antigen.
Results: A different sensitivity of chlamydiae to cathelicidin
peptides was observed. C. trachomatis was the most sensitive of
chlamydiae and SMAP-29 was the most active peptide. The
treatment of C. trachomatis EBs with SMAP-29 reduced by over
50% the inclusion number of all the 10 strains tested, at a
concentration of 10 lg/ml. BMAP-27, BMAP-28 and Bac7
displayed a similar activity at a concentration of 80 lg/ml. In
contrast, LL-37 did not exert any inhibitory activity and PG-1was
only active against serotypesD,HandLGV2.C. pneumoniae strains
( n tested = 5) were sensitive only to SMAP-29 at a concentration
of 10 lg/ml. Chlamydia strains of animal origin ( n tested = 10)
were not susceptible to cathelicidins, with the exception of four
strains of C. felis. Electron microscopy analysis of C. pneumoniae
EBs treated with SMAP-29 showed striking morphological
changes of EBs with the loss of their integrity, the appearance of
amorphous and membranous material and empty vescicles.
Conclusions: Previous studies and the present one suggest that
cathelicidin peptides have substantial in vitro activity against
several microorganisms. Much remains to be done to evaluate
their in vivo efﬁcacy and safety, in particular with respect to
their interaction with constituents of biological ﬂuids. Therefore,
studies in animal models of chlamydial infection are needed to
prove whether they will parallel in vitro results.
O351
Evolution of the primate cathelicidin: effect of
structural variations on modulating antimicrobial
and cytotoxic activities
I. Zelezetsky, A. Pontillo, N. Antcheva, M. Boniotto, S. Crovella,
A. Tossi (Trieste, I)
The growing number of antibiotic-resistant microbial strains
and the appearance of new human pathogens require the
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development of novel antibiotics with different mechanism of
action. Antimicrobial peptides (AMPs) are very promising
candidates in this direction, as they kill target microbes rapidly,
have broad activity spectra that can cover bacteria, fungi and
some enveloped viruses, including the more serious antibiotic-
resistant pathogens, while it is relatively difﬁcult to select
resistance against them in vitro. AMPs are an important
component of the innate immune system, an ancient form of
host defence, which is shared by effectively all multicellular
organisms and provides a rapid ﬁrst line of antimicrobial host
defence.
Objectives: To determine the mechanisms of natural selection
underlying variations in one of these peptides, the amphipathic,
alpha-helical cathelicidin-derived LL-37 and its variants in
numerous primates and to relate these variations to functional
properties.
Methods: We have cloned, sequenced and investigated the
evolutionary relationship of the genes for 22 LL-37 primate
variants. Selected peptides have been synthesised using
optimised solid phase peptide synthesis. We have then
analysed and compared the capacity of the peptides to assume
a helical structure in different salt and membrane mimicking
conditions by circular dichroism spectroscopy. This structural
data has then been correlated to biological activity in vitro.
Results: The tested peptides showed broad but differing
medium- and salt-sensitive spectra of activity against Gram-
positive and Gram-negative bacteria as well as fungi. Killing
kinetics and membrane permeabilisation kinetics of reference
Gram-positive and Gram-negative bacteria indicated that the
mode of action may vary in a manner dependent on both
structure and charge. Unlike other AMPs that act selectively on
bacterial cells, LL-37 and its variants also exhibit structure
dependent cytotoxic effects against mammalian cells.
Conclusion: The results suggest that the evolution of these
peptides works to vary the charge, while conserving the
amphipathic structure in a manner that markedly affects the
capacity to aggregate under physiological conditions. This
process appears to be subjected to positive selection, possibly
caused by direct interaction of the peptides with speciﬁc
pathogens or biotas, although the added role of the immune
functions, such as signalling and chemotaxis, remains to be
determined.
O352
GES-5, a novel variant of the extended-spectrum
beta-lactamase GES-1 with an increased
hydrolysis of aztreonam identiﬁed in a
Pseudomonas aeruginosa clinical isolate in France
L. Poirel, L. Brinas, N. Fortineau, P. Nordmann (Le Kremlin
Bicetre, F)
Objectives: Characterization of the expanded-spectrum beta-
lactamase resistance determinant of a Pseudomonas aeruginosa
clinical isolate recovered from a rectal swab of a patient
hospitalized at the Biceˆtre hospital, K.-Biceˆtre (France) in
March 2004. This strain was resistant to most beta-lactams
except to imipenem.
Methods: Double disk synergy test performed with clavulanic
acid-containing disks was used for detection of the extended-
spectrum beta lactamase (ESBL). PCR experiments and
cloning were used for identiﬁcation of the corresponding
gene.
Results: A blaGES-like gene was identiﬁed by PCR that was
cloned in Escherichia coli. The beta-lactam susceptibility pattern
of E. coli DH10B harboring recombinant plasmid (pDEJ/GES)
showed resistance to expanded-spectrum cephalosporins and
aztreonam. Amino acid sequence analysis revealed a novel GES
variant, GES-5, that had a single amino acid change as compared
to ESBL GES-1, differing by a Gly to Ser substitution in position
Ambler 242. Kinetic measurements revealed that GES-5
hydrolyzed penicillins and cephalosporins at a higher level
than GES-1. In addition, GES-5 hydrolyzed aztreonam at a
higher level than the other GES-type enzymes. GES-5 activity
was inhibited by clavulanic acid and tazobactam but also by
imipenem. The blaGES-5 gene was located in a class 1 integron
together with an aacA4 gene cassette, both cassettes being
separated by an ISPa21 insertion sequence element.
O353
Comparative minimal inhibitory concentration
and mutant prevention concentration of
moxiﬂoxacin against clinical isolates of penicillin
susceptible, intermediate and resistant
Streptococcus pneumoniae
J. Blondeau, S. Borsos (Saskatoon, CAN)
Objective: Mxf is amongst the most potent of newer
ﬂuoroquinolones (FQ) against SP. Previous MIC testing has
shown an MIC90 of 0.25 lg/ml and an MPC90 of 1 lg/ml.
Concern over the possible escalation of FQ resistant SP
prompted us to evaluate MIC and MPC values for Mxf on a
large number of SP isolates collected prior to and after the
introduction of the drug into clinical use.
Methods: A total of 454 clinical isolates collected between 1994–
2003 were used: 365 PS, 76 PI, 13 PR. MIC testing was by
microbroth dilution in accordance with NCCLS guidelines. For
MPC testing, 10 billion organisms were applied to agar plates
containing drug and incubated for 24 and 48 hours. The lowest
drug concentration preventing growth was the MPC.
Results: Against PSSP isolates (susceptibility lg/ml), MIC50/
90, range and MPC50/90, range were as follows: 0.125/0.25,
0.031–4 and 0.5/1, 0.05–8; PI 0.125/0.25, £0.031–4 and 0.5/1,
0.25–‡8; PR 0.031/0.05, 0.31–0.5 and 0.5/1, 0.05–1. Only 1/454
(0.2%) strains had an MIC ‡2 lg/ml and 8/454 (1.7% had
MPC > 2 lg/ml). No difference in the MIC or MPC drug
inhibition distributions were seen against PS, PI or PR strains
nor were there any changes in these distributions over time.
Modal MIC and MPC values were constant. Greater than 99% of
strains by MIC were inhibited by £1 lg/ml compared to 95% by
MPC and 98% by £2 lg/ml.
Conclusion: Mxf has enhanced in vitro activity against SP by
both MIC and MPC measurements. Penicillin susceptibility of
SP does not effect Mxf activity. No change in MIC nor MPC
values of SP isolates collected prior to after release of the drug
were seen. These studies conﬁrmMxf to be highly active in vitro
and use of this compound does not appear to select for FQ
resistance. This observation has long term implications for the
use of FQs for treating SP infections.
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O354
Evaluation of 4 serological tests for the detection
of Mycoplasma pneumoniae in patients with
lower respiratory tract infections
K. Loens, D. Ursi, L. Danie¨ls, H. Goossens, M. Ieven (Edegem, B)
Objectives: Serology and PCR are widely used for diagnosis of
M. pneumoniae (MP) in respiratory tract infections, but studies
comparing the different methods are rare. The aim of this study
was to evaluate PCR, NASBA and 4 different IgM and IgG EIA
assays for the detection of MP in patients with lower respiratory
tract infections.
Methods: 205 paired sera from 224 patients with CAP and 10
paired sera from 20 MP PCR positive patients without CAP
were available. From 29 patients only an acute phase serum
sample was available. Four different EIA’s were evaluated:
ImmunoWell IgG and IgM EIA (Genbio); Medac IgM, and IgG
EIA (Medac); AniLabsystems IgM and IgG EIA (Biomedical
Diagnostics); and Euroimmun IgM, and IgG EIA (Biognost).
PCR and NASBA were applied to respiratory specimens. An
expanded gold standard was used to calculate the sensitivities
and speciﬁcities of all tests: 1) positive by PCR and NASBA or 2)
positive by 1 ampliﬁcation test and at least one serological test
(either IgM or a seroconversion or signiﬁcant rise of IgG
antibodies), or 3) a seroconversion or a signiﬁcant rise of IgG
antibodies in at least two different EIA’s.
Results: 39 patients met the criteria of the expanded gold
standard. The sensitivities of the EIA’s ranged from 10%–31%
for IgM in the acute phase serum and from 19%–42% for IgM in
the convalescent serum. IgG seroconversion or a signiﬁcant rise
in titre ranged from 41%–68%. Higher sensitivities were
obtained for PCR and NASBA: 82% and 72%, respectively. The
speciﬁcities ranged from 81%–99% for IgM in the acute phase
serum, from 82%–99.5% for IgM in the convalescent phase
serum, and from 95%–99% for IgG. The calculated speciﬁcities of
PCR and NASBA were 98% and 97%, respectively. The MP IgM
assay with the best combined values for sensitivity and
speciﬁcity was the AniLabsystems EIA. The best MP IgG assay
was the Medac EIA. MP PCR and NASBA positive patients had
usually higher rises in IgG titre than MP PCR and NASBA
negative patients. False positive IgM results occurred most
frequently with the Immunowell assay.
Conclusion: Evaluation of the 4 EIA’s and 2 independent
ampliﬁcation tests for MP showed substantial differences
between the performances of the assays. Ampliﬁcation
methods are the most sensitive tests to diagnose an acute MP
infection. IgM antibodies are of limited value. IgG serology has
usually a moderate sensitivity but results in late diagnosis.
O355
Comparison of real-time PCR and conventional
methods to determine aetiology of community-
acquired pneumonia
K.E. Templeton, S.A. Scheltina, W.C.J.F.M. van den Eeden ,
A.W. Graffelman, P.H. van den Broek , E.C.J. Claas (Leiden, NL)
Objectives: To compare conventional microbiological methods,
including serology and culture, with real-time PCR for diagnosis
of 12 respiratory viruses and Mycoplasma pneumonia, Legionella
Spp and Chlamydophila Spp (atypical bacteria) in patients with
community-acquired pneumonia (CAP) and to assess the use of
real-time PCR formicrobiological diagnosis in patientswithCAP.
Methods: Conventional techniques andmultiplex real-time PCR
for atypical bacteria and respiratory viruses were performed and
compared on samples collected from 105 adults enrolled in a
prospective study in a deﬁned geographical area. All patients
had an inﬁltrate on chest radiograph and a pneumoniae severity
index (PSI) score was obtained at admission.
Results: Microbiological diagnosiswas obtained in 52/105 (50%)
patients by conventional techniques and in 80/105 (76%) by real-
timePCR.Resultscouldbeobtainedinoneworkingdayusingreal-
time PCR whereas 2–3 weeks was required for serological
diagnosis. Respiratory viral infections were detected in 15/105
(14.2%) of the infections by conventional methods but in 59/105
(56.2%) by real-time PCR methodology. Mixed infections were
seen in 28/105 (26.6%) when real-time PCR was performed
compared to 3/105 (2.8%) with conventional methods. The
presence of a mixed infection by real-time PCR was signiﬁcantly
associated with severe pneumoniae (p = 0.002). Human
rhinoviruses and coronaviruses, OC43 and 229E were frequently
identiﬁedpathogens inmixedinfectionsbutwerealso identiﬁedin
4 cases of severepneumoniaas theonlymicrobiological pathogen.
Conclusions: The real-time PCR assays enabled sensitive
diagnosis for the main viral and atypical bacteria in comparison
to conventional methods in a way that clinically relevant results
can be obtained. The presence of mixed infections may be
important in the severity of pneumonia.
O356
Comparative study of Legionella pneumophila
pneumonia according to sporadic and outbreak
presentation
N. Sopena, L. Force, M.L. Pedro-Botet, P. Barrufet, G. Sauca,
M. Garcı´a-Nun˜ez, G. Tolchinsky, J.A. Capdevila,
M. Sabria` (Badalona, Mataro´, E)
Objective: To compare the risk factors, the clinical presentation
and the outcome of community acquired pneumonia (CAP)
caused by Legionella pneumophila (LP), according to sporadic and
outbreak presentation.
Methods: We included 138 patients with sporadic LP
pneumonia diagnosed from 1996 to 2004 and 113 patients
from an outbreak occurring in 2002, attended in two hospitals in
Catalonia (Spain). Data about epidemiological and clinical
features, blood chemistry values, radiological ﬁndings and
outcome were analyzed by univariate analysis.
Results: The following variables achieved signiﬁcance on
univariate analysis (p < 0.05). Sporadic cases were more
frequently male (81.8 vs. 64.6%), had a higher frequency of
chronic lung disease (19.6% vs. 9.7%), HIV infection (11.6% vs.
1.8%) and corticoid therapy (5.8% vs. 0%), and had also more
frequently cough (70.3% vs. 51.8%), expectoration (39.1% vs.
14%), thoracic pain (23,2% vs. 12,6%), dyspnea (45.3% vs. 28.6%)
and confusion (16.7% vs. 7.5%) on presentation, while headache
(56.5% vs.23.6%) prevailed in outbreak cases. Concerning blood
chemistry, Na < 130/mm3 (21.3% vs. 6.7%), AST (48.8%
vs.31.3%) elevation, BUN · 13 mmol/l (14.6% vs. 2%) and pO2
<60 mmHg were more frequently observed in sporadic cases.
FINE severity index III (56.4% vs. 41%), ICU admission (16.1%
vs. 4.4%) and complications (54.3% vs.32.7%), mainly respiratory
failure, were more frequent in sporadic cases. There were no
differences in the delay and the rate of appropriate treatment.
The mortality related to LP pneumonia was higher in sporadic
cases (6.3% vs. 1.8%), although this variable did not achieve
statistical signiﬁcance on univariate analysis.
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Conclusion: Sporadic cases had a higher frequency of some
underlying diseases, such as chronic pulmonary diseases and
HIV infection, and corticoid therapy. Respiratory symptoms at
clinical presentation, confusion and blood chemistry alterations,
such as hyponatremia, AST and BUN elevation were more
frequent in sporadic cases, while headache prevailed in
outbreak cases. Sporadic cases were more severe and had a
worse outcome than outbreak cases.
O357
CURB65 outperforms generic severity assessment
tools in stratifying and predicting 30-day
mortality in community-acquired pneumonia
G.D. Barlow, D. Nathwani, P.G. Davey (Hull, Dundee, UK)
Objectives: Severity assessment is the key determinant of
management strategy in community-acquired pneumonia
(CAP). Lim et al recently developed CURB65, which divides
patients into 3 groups based on 5 prognostic indicators. There is
evidence that hospital medical staff, however, have sub-optimal
knowledge about assessing severity in CAP. Potentially this
could be improved by using a generic rather than the disease
speciﬁc tools currently used in acute medicine. This study
assessed the performance of two generic tools, the Scottish Early
Warning System (SEWS) and the Systemic Inﬂammatory
Response Syndrome (SIRS), with CURB65 in CAP.
Methods: As part of a quality improvement programme, data
were collected prospectively over two winters (November–April
2001 and 2002). Prognostic indicators were recorded at admission
and a severity score assigned for each of the tools. Mortality was
assessed at 30 days. For each tool, sensitivity, speciﬁcity, positive
predictive value (PPV) and negative predictive value were
calculated and a receiver-operating curve (ROC) produced.
Results: Full prognostic data were available on 435 (CURB65),
426 (SEWS) and 439 (SIRS) patients. 30-daymortality for CURB65
scores of 0–1 (home therapy), 2 (non-severe, but manage in
hospital) and 3 or more (severe) was 2%, 16% and 35%. Mortality
for SEWS scores of 0–1 (routine observations), 2–3 (hourly
observations) and 4 or more (doctor review within 30 mins.) was
9%, 17% and 27%. Mortality for patients with 0–4 SIRS criteria
was 0 = 13%, 1 = 20%, 2 = 20%, 3 = 21% and 4 = 6%. Adding a
severe sepsis stratiﬁcation to the SIRS criteria was not useful as
some patients without sepsis (SIRS 0–1) appear to have organ
dysfunction/hypoperfusion; these patients have high mortality.
Sensitivity and speciﬁcity for severe versus non-severe illness
(deﬁned as a CURB65 score of 3 or more, a SEWS score of 4 or
more and two or more SIRS criteria) for each of the rules were
71% and 70% (CURB65), 52% and 67% (SEWS), and 74% and 31%
(SIRS). The ROC is shown below.
Conclusion: SIRS criteria on admission did not adequately
stratify mortality in CAP. SEWS did stratify mortality (from 9%
to 27%), but failed to identify a low risk group; it may be useful
in guiding management in hospitalised patients. CURB65
outperformed SIRS and SEWS and had higher sensitivity/
speciﬁcity when delineating severe from non-severe illness. It
would be interesting to investigate the performance of CURB65
as a generic severity tool.
O358
Molecular and clinical characteristics of invasive
Group A streptococcal infections in Sweden
J. Darenberg, B. Luca, C. Schalen, A. Jasir, V. Romaus,
A. Norrby-Teglund, B. Henriques Normark (Solna, Lund,
Stockholm, S)
Objectives: To investigate the epidemiology, molecular
epidemiology and clinical characteristics of invasive Group A
Streptococcal (GAS) disease, and to compare invasive and non-
invasive isolates.
Methods: Invasive GAS isolates were sent to SMI from the
Swedish microbiological laboratories between April 2002 and
December 2004. Also, during 18 months 10 non-invasive
isolates were collected each month at 6 of the laboratories.
Questionnaires for clinical and epidemiological data were sent
to the responsible MD for each patient with invasive disease. All
isolates were characterized with respect to T-type, emm-
sequence type, gene detection for 9 superantigens and
antibiotic susceptibility. The clonal relationship within sub-
groups of isolates was investigated with PFGE and MLST.
Results and Conclusions: Until November 2004 we received
675 invasive isolates and 548 (81%) returned questionnaires. So
far 70% of the patients had underlying chronic diseases,
predisposing factors or drug abuse. 60% of patients were
reported to have skin as site of entry of infection, 16% the
respiratory tract, and 7% had a puerperal or genital infection.
12% of patients had no identiﬁed focus. Further, 13% of patients
developed streptococcal toxic shock syndrome (STSS) and 40%
of these patients died. The over all mortality was 14%. When
looking at the outcome of STSS patients receiving IVIG as
compared to those who did not, a signiﬁcant difference was seen
in survival in favour of the treatment (p = 0.0122), which is in
agreement with our previous studies. The most common T-type
in Sweden during this period was the T3/13/B3264 cluster that
accounted for about 34% of invasive isolates and 20% of controls
(isolated from patients with skin- or throat infections).
Resistance to MLS antibiotics was rare (0.2%) whereas a high
rate of tetracycline resistance (33%) was observed.
Acknowledgement: The study was supported by the European
Commission.
O359
Modiﬁcation of basic epidemiological
characteristics of hepatitis A, from a food- and
water-borne disease to a predominant sexually-
transmitted disorder. An emerging matter of
public health
R. Manfredi, L. Calza, F. Chiodo (Bologna, I)
Introduction: Hepatitis A virus is transmitted through oral-
fecal contact, including exposure to water or food contaminated
with stools of infected patients (p). Recent outbreaks of hepatitis
A were observed worldwide, with special attention on
homosexual men, but also illicit drug users.
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Patients and Methods: An prospective observational survey of
all admissions due to hepatitis A occurred in our metropolitan
area and was carried out from 1999 to October, 2004.
Results: 132 consecutive p were hospitalized in the examined
period. Since October 2002, acute hepatitis A largely prevailed
over acute HBV,HCVand HEV hepatitis. Adult female p and
children represented only 19 cumulative patients out of 132
(14.4%). The temporal trend of male adults admitted for
hepatitis A showed a signiﬁcant increase from 1999 to the ﬁrst
10 months of 2004: a ~300% increase vs 1999, leading to a crude
rate of 7.8 per 100.000 residents per year). Among the 132 p
diagnosed with hepatitis A, the prevalence of immigrants had a
temporal increase from 1–3 cases/year from 1999 to 2001, up to
20 cases in the 22 months from 2003 to June 2004 (p < 0.03).
Even 113 p of 132 (85.6%) were represented by male adults aged
22–44 years, who recognized unprotected homo-bisexuals
contacts in the 2 months preceding the onset of hepatitis A in
89 cases (78.8%). Nobody reported contacts with p with a
recently diagnosed hepatitis A and nobody underwent speciﬁc
anti-HAV vaccination. Among the 113 adult males with HAV,
concurrent STD were seen in 35 p (p < 0.004) including chronic
hepatitis B in 6 cases, hepatitis C in 14, syphilis in 7 and HIV in
12 patients.
Discussion: Despite the availability of anti-HAV vaccination
and information campaigns aimed against the spread of
HIV and STD in general, the continued spread of hepatitis
A clearly recognize an increased prevalence of homo-bisexual
transmission. Our experience shows a strict link between novel
diagnoses of acute HAV infection and homo-bisexual behavior
which remained unchanged in proportion since 1999,
but showed a signiﬁcant increase of absolute number of
detected cases from late 2002 until now. A careful report and
monitoring, speciﬁcal educational campaigns, and enforced
public health measures (such as recommendation of anti-HAV
immunoprophylaxis for p at risk), are expected to contain the
rising outbreak of hepatitis A among homo-bisexual men in our
community and concurrently stop the spread of other common
and potentially severe STD such as HIV, hepatitis B and C, and
syphilis.
O360
Candidaemia in the elderly
P. Sandven, L. Bevanger, A. Digranes, H.H. Haukland,
T. Mannsa˚ker, P. Gaustad (Oslo, Trondheim, Bergen, Tromsø, N)
Objectives: A prospective nationwide candidemia study has
been ongoing in Norway since 1991. Population-based
surveillance studies makes comparisons of incidence and
species distribution in various age groups possible. This report
provides a description of the epidemiological characteristics of
candidemia in the elderly.
Methods: Yeast blood culture isolates in all microbiological
laboratories in Norway (population 4.5 mill) have been recorded
prospectively. Isolates have been sent to the national mycology
reference laboratory for identiﬁcation and susceptibility testing.
Results: For the period 1991–2003 a total of 1400 candidemia
episodes were diagnosed in Norway. The total number of yeast
strains recovered were 1421 (21 patients with 2 species). The
overall candidemia incidence was 2.5 per 100000 inhabitants.
The annual incidence in patients aged ‡80 years is especially
high and has increased markedly the last 3 years compared to
patients in younger age groups (Table 1). The species
distribution is also different in the old age group. The
percentage of C. glabrata isolates was 5% the age group
<50 years, 13% in patients aged 50–79 years and 31% in
patients ‡80 years.
Table 1. Annual incidence of candidenia in patients aged ¼>
50 years. Norway 1991–2003
Conclusion: In Norway both the candidemia incidence and
species distribution is markedly different in old patients
(‡80 years) compared to younger aged groups. This ﬁnding
has important therapeutic implications.
O361
Infections in nonagenarians
M. Hemmersbach-Miller, A. Conde Martel, J. Ruiz Herna´ndez,
J. Arencibia Borrego, M.A. Ca´rdenes Santana, P. Betancor
Leo´n (Las Palmas de Gran Canaria, E)
Objective: Perform a study of infections in nonagenarians in an
Internal Medicine Department of a third level hospital, focusing
on prior conditions, speciﬁc laboratory abnormalities, mean stay
and mortality in the hospital.
Methods: 400 consecutive nonagenarians admitted during a 5
year period in an Internal Medicine Department were
included. Speciﬁc prior conditions, laboratory values (WBC,
lymphocytes, hemoglobin, creatinine, glycaemia, albumin and
lipids), site of infection, Charlsons comorbidity index and
outcome (mean hospital stay, intra-hospital mortality, place of
discharge) were recorded. The variables of the group with an
infectious condition were compared with the group that was
hospitalised for any other reason. Chi Square test, Student’s
t-test and the Mann-Whitney U test were used for statistical
analysis.
Results: Out of the 400 nonagenarians (148 males, 252 females),
with a mean age of 92.5 years, 245 (61.3%) presented with some
kind of infection. Prior conditions related to infections were
exclusively dementia (p = 0.001) and cognitive impairment
(p < 0.001). Hemoglobin, creatinine and glycaemia did not
differ between both groups. Total WBC was signiﬁcantly higher
(12,917 vs 10,019; p < 0.001), albumin signiﬁcantly lower (2.7 vs
3.4 g/dl; p = 0.003) as well as total cholesterol (151.3 vs
162.6 mg/dl; p = 0.012). Sites of infection: urinary tract
(24.5%;98), pneumonia (22%;88), respiratory tract infection
(18.5%;74), sepsis (4.8%;19), abdominal infection (2%;8),
gastroenteritis (1.5%;6), meningitis (0.8%;3). No relation with
Charlsons comorbidity index was observed. Mean hospital stay
did not differ between both groups (10.6d vs 11.3d in
infections; p = 0.7). Intra-hospital mortality was signiﬁcantly
higher in patients with an infectious condition (27.9% vs
15.6%:p = 0.005). Those who survived were discharged more
frequently to other hospital facilities than back home (14.3% vs
7.1%; p = 0.028).
Conclusion: Dementia and cognitive impairment are conditions
related to a higher incidence of infections in nonagenarians. The
most frequent site of infection in hospitalized nonagenarians is
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the urinary tract (24.5%), followed by pneumonia (22%) and
respiratory tract infection (18.5%). Laboratory values do not
differ from those already known to be acute phase reactants,
such as elevated WBC and a low albumin level. Intra-hospital
mortality is signiﬁcantly higher in nonagenarians presenting
with an infectious condition.
O362
High incidence of intravascular infection in
zoonotic nontyphoid Salmonella bacteraemia in
elderly patients
H. Nielsen, K.O. Gradel, H.C. Schønheyder (Aalborg, DK)
Objectives: Bacteremia and invasive disease with zoonotic
nontyphoid Salmonella spp. are well known to occur in subjects
with co-morbidity. Especially, aortitis and endocarditis are
described in patients with arteriosclerosis and aortic aneurysms.
However, the incidence of these complications and the age-
dependency are not well established.
Methods: We recorded all cases of bacteremias with
nontyphoid Salmonella in North Jutland County, Denmark,
for a 10-year period, 1994–2003. Data sources were medical
records, the Bacteremia Research Database, the Hospital
Discharge Registry, and the Central Population Registry, all
linked by the unique Danish personal identiﬁcation number.
Cases with secondary intravascular focal infection were
analysed.
Results: A total of 109 patients with nontyphoid Salmonella
bacteraemia was identiﬁed, and 77 of these were > 50 years old.
In this age group, seven patients (9%) had an intravascular
Salmonella focus, ﬁve with mycotic aorta aneurysm, and two
patients had endocarditis. We detected S. enteritidis in 3 cases,
S. typhimurium in 2 cases, S. dublin in 1 case and S. sandiego in 1
case, which is not different from the overall bacteraemia species
distribution. As North Jutland County had a 10-year cumulated
population of 1,665,094 subjects >50 years, the population-
incidence was 0.04/100,000 person-years. Mortality was 1 out
of 7 within 30-days and 3 out of 7 within 180-days after
detection of bacteraemia. Four patients were long-term
survivors.
Conclusions: In elderly patients >50 years a high percentage of
zoonotic nontyphoid Salmonella bacteraemia cases has
secondary intravascular focal infections, which requires special
treatment. Clinical examinations for a secondary intravascular
focus are recommended in this age group.
O363
First pan-European epidemiological and
microbiological surveillance programme for
severe S. pyogenes disease
A. Jasir, C. Schalen on behalf of Strep-EURO study group
Objectives: The project Strep-EURO started by September 2002
to improve understanding of severe group A streptococcal
(GAS) disease in Europe and achieve an integrated picture of
these infections.
Methods: An European case deﬁnition was agreed upon
amongst participants and a clinical questionnaire containing
background identiﬁcation data was used. Enhanced surveillance
of GAS invasive disease commenced on 1 January 2003 for a two
years period. Collected isolates were characterized by both
serological T, OF and M typing and more advanced molecular
methods e.g. emm-sequencing, PFGE and MLST. Strains were
screened for antibiotic susceptibility and MIC was determined
by E-test. For standardization of methods and detection of
possible errors two sets of EQA strains for antibiotic
susceptibility and one set for typing were sent to all centres.
Data ﬁle speciﬁcation for collection of patient and
microbiological data was developed and each partner
submitted their results to a central database in Finland.
Results: By July 2004 over 5000 invasive GAS isolates were
collected. The population based incidence for year 2003 varied
between countries from 0.1 to 3.8 per 100,000 inh. The type
distribution of GAS also varied markedly. In a few countries
types 1, 3 and 28were predominant; however, an overall increase
of new invasive types was noticeable. A high level of MLS
antibiotic resistance in some countries (France, Italy) and very
frequent tetracycline resistance in almost all countries was noted.
Conclusion: The Strep-EURO project created a European
network for epidemiological analysis and surveillance of severe
streptococcal disease in ten EU and one Associated Countries.
We expected 1,000 cases/year to be found but after 18 mounts
over 5,000 were reported. The overall increase of invasive cases
partly depend on the role of Strep-EURO in establishment of a
new surveillance system and development of an European
network. Any deﬁned conclusion has to wait until the data are
carefully analysed. Report on increasing frequency of unusual
emm types is a concern. There is also a need of studying the
background of increasing tetracycline resistance despite lack of
use of this drug for treatment of streptococcal diseases.
Acknowledgment: The Strep-EURO project is funded by the
European Commission.
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Metallo-beta-lactamases: a last frontier for
beta-lactams?
G.M. Rossolini, J.D. Docquier (Siena, I)
Beta-lactams remain a cornerstone for antimicrobial chemother-
apy of a large number of bacterial infections, but their efﬁcacy has
been increasingly thwarted by dissemination of acquired resist-
ance determinants among pathogenic bacteria. Metallo-beta-
lactamases (MBLs) are a family of beta-lactam-degrading
enzymes present in some environmental species, that only
recently have emerged as resistance determinants of notable
clinical importance. Their overall impact is still lower than that of
serine-beta-lactamases, but during the last decade at least 4
different types of MBLs (IMP, VIM, SPM and GIM), encoded by
genes associated to mobile DNA, have been recruited from
unknown genomes into major gram-negative pathogens, inclu-
ding members of the family Enterobacteriaceae, Pseudomonas
aeruginosa, Acinetobacter spp. and other nonfastidious gram-
negative nonfermenters. These acquired MBLs, of which some
are already distributed on a worldwide scale, represent a
formidable challenge to antimicrobial chemotherapy due to
their extremely broad substrate speciﬁcity and mechanistic
uniqueness: most beta-lactams (including carbapenems and
expanded-spectrum cephalosporins) are efﬁciently degraded by
these enzymes, while conventional beta-lactamase inactivators,
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such as clavulanate, sulbactam and tazobactam, are useless
against them. MBLs exhibit a remarkable structural plasticity
and it remains unclear whether they share a common reaction
mechanism: this explains, at least in part, the difﬁculties encoun-
tered in ﬁnding broad-spectrum inhibitors and underlines the
importance of comparative studies aimed at the identiﬁcation of
relevantmolecular targets for inhibition. Several important issues
concerning MBLs remain open: epidemiological distribution/
magnitude of the problem, laboratory diagnosis, clinical
signiﬁcance in different settings, spreading mechanisms, ori-
ginal sources and evolutionary history, structure-function
relationships and catalytic mechanism. The scope of this presen-
tation will be to discuss over recent advances on open issues, and
how they are likely to contribute to combating resistance medi-
ated by MBLs, which are now considered among the most
worrysome emerging resistance determinants in gram-negative
pathogens.
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Social-political consequences of the HIV pandemic: are we turning
the tide?
K372
Social-political consequences of the HIV
pandemic: are we turning the tide?
L. Kallings (UN Secretary-General’s Special Envoy for AIDS)
The enormous size of the HIV/AIDS pandemic and its devas-
tating social and economic consequences have made it a
geopolitical threat of prime importance to the world and
placed it on the agenda of the UN Security Council and the
General Assembly. According to the Millennium Goal further
spread of HIV should be stopped by 2015. Is this a realistic goal?
The odds to succeed within such a limited period of time do not
seem favourable as we after 20 years still are in the beginning of
the pandemic which is in a dynamic phase spreading to
populous regions such as India, China and the former Soviet
Union. The pandemic is continuing unabated with some ﬁve
million new infections and three million fatal cases per year.
Forty million are currently living with HIV/AIDS in the world
and 30 million have already died. Another 45 million is
predicted to be HIV infected within the next ten years. It is
easy to be paralysed by the sheer numbers. However, mankind
can mobilise immense resources once the awareness and
political will are present. That has unfortunately not happened
yet on a scale which is commensurate to the threat. It is true that
more political leaders now are talking about AIDS than before
and that considerably more funding has been made available but
it is far from enough to make a difference. The ﬁght against AIDS
is hampered by many obstacles of social and cultural nature that
is embedded in human behaviour. Sexually transmitted infec-
tions are notoriously difﬁcult to control. Syphilis is still rampant
in many parts of the world after 500 years and in spite of efﬁcient
and inexpensive treatment since long. The subordinated status
of women, particularly in developing countries, is at the root of
the difﬁculties to control the spread of HIV. The inﬁdelity of
husbands and their refusal to use condoms are putting married
women at a particularly high risk. It will take long time to
inﬂuence male attitudes and to change laws, e.g. to empowering
women to inherit properties and to make independent decisions
in order to be economically emancipated and to be able to say no
to unwanted sex. The proportion of women among people
newly infected is increasing each year; ﬁfty per cent of all
infected persons in the world are women, in Africa it is sixty
percent. The nature of the causative agent makes the AIDS
epidemic uniquely difﬁcult to control. The retrovirus attacks and
resides in the immune system and hides in cellular sanctuaries.
It has an extreme ability to mutate to avoid immune control and
to develop resistance to antiretroviral drugs. Furthermore, HIV
is transmitted vertically. What can we do against this formidable
enemy? The introduction of efﬁcient antiretroviral treatment was
a revolutionary achievement but will not stop the HIV epidemic.
In 2004 about 35,000 new HIV infections occurred in Western
Europe and 45,000 occurred in North America in spite of the
wide use of antiretroviral treatment since many years. To which
extent antiretroviral treatment will be made available in a
sustained way in developing countries is still an open question.
Hopefully, prevention and treatment will work hand in hand.
A cure is not yet at sight. We do not know if it is possible to
develop an effective vaccine but we keep hoping so. However, in
spite of the long list of difﬁculties there are some progresses as in
several East African countries; the most heralded is the example
from Uganda with the decline of HIV prevalence in pregnant
women from 30 to 5 per cent (!) through sustained behaviour
change. Prevention of mother-to-child transmission is another
success – where it has been introduced.
Evolution and function of the haemagglutinin of the inﬂuenza
virus
K374
Evolution and function of haemagglutinins of
inﬂuenza viruses
J. Skehel (Mill Hill, UK)
Comparison of the structures of haemagglutinins representative
of the four inﬂuenza clades suggests that aspects of haemag-
glutinin stability and activation for membrane fusion may be
involved in clade formation. The structural details on which this
possibility is based will be described in relation to irreversible
changes in structure that are known to be required for
membrane fusion activity and that can result from thermal
inactivation.
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Streptococcus pneumoniae: a clonal war?
S375
The role of pneumococcal factors in virulence and
carriage
T.J. Mitchell (Glasgow, UK)
Streptococcus pneumoniae is a major pathogen of man, causing
diseases such as pneumonia and meningitis. The mechanisms by
which this organism causes disease are still unclear but certainly
involve over-activation of inﬂammatory pathways. The organ-
ism produces a range of factors that may be involved in the
pathogenesis of infection. These include a toxin (pneumolysin)
as well as a range of surface proteins and enzymes. The
polysaccharide capsule is essential for virulence of the organism.
The availability of genome sequences of several strains of
pneumococcus has allowed the identiﬁcation of putative viru-
lence factors and regulatory pathways. Use of this information
in conjunction with in vitro systems and animal models allows
the study of the role of these factors in disease. I will describe
data we have on the role of surface proteins, the toxin
pneumolysin and the heat shock protein HtrA in the virulence
of Streptococcus pneumoniae. Pneumolysin is a major virulence
factor of the organism and induces inﬂammation in the lung.
Very small amounts of the toxin are able to induce inﬂammatory
cytokine production. Surface proteins such as pneumococcal
surface protien C (PspC) play a role in both attachment and
interaction of the organism with the immune system. I will
describe the use of genetically deﬁned mutants of the pneum-
cooccus lacking PspC in animal models of infection. These
studies show that the role of PspC in the disease process is
different for different strains of the organism. HtrA is a heat
shock protein of the pneumococcus and is probably acts as both
a chaperone and protease to control protein folding and degrade
misfolded proteins. We have shown that deletion of the gene for
HtrA attenuates the pneumococcus in animal models of infec-
tion. This will allow us to investigate the possibility of using
HtrA mutants as live vaccination vehicles. Several strains of the
pneumococcus have have been subjected to total genome
sequencing. Availability of these genome sequence allows the
construction of microarrays and I will describe our use of these
chips to study regulatory pathways in the pneumococcus.
Analysis of gene expression in different serotypes of the
pneumococcus suggests that there may be serotype speciﬁc
regulatory pathways within the organism. This has implications
for treatment and vaccination.
S376
Impact of conjugate vaccine on the epidemiology
of Streptococcus pneumoniae
H. Peltola (Helsinki, FIN)
Pneumococci cause various diseases of which non-bacteremic
or bacteremic pneumonia, bacteraemia with unidentiﬁed focus,
true sepsis, meningitis, other focal infections, and otitis media
especially in small children are the most important manifes-
tations. There is no doubt that a functioning vaccination would
be of great individual and societal relevance. For 30 years, a 23-
valent vaccine has been available, but because of the inheritant
problems of polysaccharide antigens, this product – as such
good – left a room for a better immunogen. Hence, a 7-valent
conjugate vaccine (7CV) was highly welcomed, when it arrived
to the market a few years ago. The past few years have taught
us the most important pros and cons of this vaccine. So far,
data on the impact of 7CV have gathered only from vaccin-
ation of small children for whom a vaccine against acute otitis
would be mostly welcomed. Unfortunately, more than one
study has now showed that the effectiveness is, at most,
meagre. A slightly better effect is observed in endpoints
secondary to otitis (such as the need of tube insertion), but in
this respect, children have not gained much of 7CV overall.
Interestingly, the use of antimicrobials has sometimes declined
by ±20% in settings where conjugate vaccine was used. On the
other hand, replacement of the vaccine-type pneumococci by
other serotypes in children’s nasopharynx is documented. The
clinical relevance of this ﬁnding is unsettled. The positive side
of the coin is that 7CV indisputably prevents serious pneumo-
coccal diseases, meningitis being the gravest manifestation. In
developing countries, this information would be great news –
should they afford this extremely costly vaccine. In the
industrialized world these entities are, however, very rare. A
recent analysis of invasive pneumococcal infections in the
largest pediatric hospital of Finland (85 cases during 13 years)
showed only meningitis – 1–2 cases a year – to be a
meaningfully dangerous disease; all other manifestations
were rather benign in which a short course of penicillin led
to full recovery. Exceptions to this rule were rare. Because the
cases were caused by 24 different serotypes, wide-scale use of
7CV would potentially have protected 57% of the cases, at
maximum. Since the experience is similar in other industrial-
ized countries, one has to put various demands in scales before
7CV is taken among the society-paid vaccines. For well-deﬁned
risk groups, and in private practice, 7CV should be readily
available. The effect in the nasopharyngeal carriage of 7CV has
brought a surprising beneﬁt among elderly people in the USA
among whom pneumococcal disease has declined by ±20%.
This strong herd immunity effect is to be taken into account in
future strategies. Since 7CV’s high price is a critical issue, one
has sought for a solution in reduction of vaccine doses.
Australia has selected a 3-dose 7CV-schedule, and it is more
than likely it will work. Another solution might be to trigger
the T-cell response with 1–2 doses of 7CV, and to continue
with polysaccharide vaccine. In theory, this approach would
offer several major advantages.
Recent advances in chlamydiology
S379
Genomes of Chlamydiae
R.S. Stephens (Berkeley, USA)
The ﬁrst genome sequence for Chlamydia was released in 1997
and this information abruptly altered existing paradigms of
chlamydial biology. The wealth of information inferred from the
chlamydial genome sequence has had a large and broad impact
on the chlamydial research arena. There are now complete
genomes for more than six different chlamydial species/
biovariants and four genomes from different strains of C. pneu-
moniae. One of the conspicuous ﬁndings is that the three main
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phylogenetic groups, C. trachomatis, C. psittaci, and C. pneumo-
niae, have fundamentally identical gene content and gene order
(synteny), although orthologous genes have low nucleotide
identities. One point of reference is that genomes of different
strains of Escherichia coli share only 40% of their gene content.
The high level of genome identity for chlamydiae is even more
remarkable in that these organisms cause diseases in numerous
different host species and tissues. One can conclude that the
high genome synteny reﬂects the paucity of acquisition of
exogenous genes from other organisms and even a lack of
within-organism recombination. Although these species have
been separated for tens of millions of years and show their
divergence by accumulation of point mutations, their biological
relationships are extremely similar. All chlamydiae essentially
share the same gene set, the same metabolic pathways, the same
complex developmental cycle and the same mechanism for
causing disease. Thus, time alone has not resulted in meaningful
biological diversiﬁcation at the genus level and this data is not
consistent with proposals for a new genus separation for
Chlamydia such as Chlamydophila.
S380
Chlamydia proteomes
S. Birkelund, G. Christiansen (Aarhus, DK)
Chlamydia are obligate intracellular gram negative bacteria, with
an unique bi-phasic life cycle, in which extracellular infectious
elementary bodies (EB) of 300 nm in diameter alternate with the
intracellular replicating form, the reticulate bodies (RB), of
1000 nm in diameter. The extracellular EB attach to the cell
surface where it mediates its uptake in a phagosome. During the
intracellular stage Chlamydia grow inside the phagosome, the
chalmydial inclusion, within the host cell cytoplasm. EB trans-
form to RB that divide for 24–48 hours where after they
reorganize into EB. At the end of the cycle the host cell burst
and EB are liberated and can infect new cells. During the
intracellular phase the chlamydiae are surrounded by the
inclusion membrane. Chlamydia have small genomes of 1.04
mega basses (Mb) for C. trachomatis and 1.23 Mb for C. pneumo-
niae, and a coding capacity of 875 and 1073 proteins, respectively.
Such numbers of proteins are well separated by 2-dimentional
gel electrophoresis (2D-PAGE). Due to their bi-phasic life cycle
we puriﬁed EB and RB from infected cells and in addition we
puriﬁed the outer membrane complex of EB. These samples were
separated by 2D-PAGE, and protein spots were identiﬁed by
peptide mass ﬁngerprinting. These systematic proteome maps
have given an understanding of the protein composition in the
EB, RB and COMC, the metabolic possibilities of EB, and an
understanding of components that may be localized at the
chlamydial surface. Chlamydia have gene homologs for bacterial
type II, III, and IV secretion systems and can therefore secrete
proteins into the inclusion membrane and into the host cell
cytoplasm. Type II and IV secreted proteins do have a leader
sequence and type IV secreted proteins have characteristic
structural motifs, but not-secreted proteins can also show these
characteristics. Type III secreted proteins have no known motifs
so the onlyway to identify such proteins is by identifying them in
the host cell cytoplasm or in the chlamydial inclusion membrane.
We have used a proteomics approach to identify secreted
proteins, comparing the proteins from the cytoplasm, inclusion
membrane plus the RB/EB and ﬁnally comparing that to the
proteoms of RB/EB. This lead to identiﬁcation of proteins
secreted to the host cell cytoplasm by both type II and type IV
secretion. Our proteomics work have lead to an understanding of
both structural components of the microorganism and its
interaction with its host cell.
S381
Genital chlamydial infections are increasing:
what can we do?
B. Herrmann (Uppsala, S)
Rates of genital chlamydia have been increasing for several years
in Europe. In Sweden infection rates reached new record levels in
2004, with the sharpest rise in teenagers. This epidemic is
expected to grow further in coming years. The continuing
increase is not explained by the introduction of nucleic acid
ampliﬁcation tests. Increasing levels of sexual risk taking beha-
viour are amore likely explanation. Pioneering studies in Sweden
showed that chlamydia can lead to severe sequelae. In some
countries huge resources are being devoted to the opportunistic
detection and treatment to prevent salpingitis, ectopic pregnancy
and infertility, despite a lack of evidence of its effectiveness.
Annual screening in speciﬁc age groups has been widely
recommended, but this has not been accomplished in any
country. In Sweden free testing and treatment, and widespread
testing among women were introduced in the1980s. Concurrent
declines in rates of chlamydia-associated sequelae were widely
interpreted as being due to opportunistic screening. However,
recent analysis of a large Swedish cohort of women, followed for
up to 15 years, indicates that the efﬁciency of chlamydia
screening was low. In most years only 5–10% of 15–24 year old
women were screened and half of all women screened were only
ever tested once. This cohort study also showed that the risk of
reproductive complications was lower than previously thought.
Contact tracing can be used to detect chlamydia, especially in
asymptomatic men not reached by opportunistic screening.
However, its efﬁciency is suboptimal even in Sweden, where
contact tracing is mandatory. Improved outcomes have been
observed when home-sampling kits are offered to male partners
of infected women, and by designating professional contact
tracers in a central location for cases detected in primary care and
non-specialized clinics. In 2003 lymphogranuloma venereum
entered the European arena. Outbreaks amongst men having sex
with men, many of whom are HIV positive, have been reported
from the Netherlands and now several other countries. The
appearance of this neglected chlamydial infection highlights the
need for effective and integrated surveillance systems in Europe.
To conclude, current chlamydia control activities have not
controlled the spread of chlamydia. Large-scale randomised
trials to determine the most effective approach to chlamydia
screening in both men and women and to contact tracing are
urgently required, and the risk of sequelae must be better
determined.
S382
Development of a chlamydia vaccine
G. Christiansen, S. Birkelund (Aarhus, DK)
Chlamydia are obligate intracellular bacteria with a biphasic
developmental cycle. The two human pathogenic species are
C. trachomatis and C. pneumoniae, C. trachomatis is a leading cause
of sexually transmitted bacterial infections with severe sequelae
as tubal factor infertility and ectopic pregnancy and infections can
be asymptomatic. So far no vaccine has been developed but
studies that may lead to the development of a highly warranted
vaccine have been performed. The ﬁrst attempt to vaccinate
children with a whole cell vaccine resulted in initially protection
but the protection was short-lived. In animal models whole cell
vaccination resulted in hypersensitivity reactions and therefore
new strategieswere developed. Themost immunogenicmolecule
is the major outer membrane protein (MOMP) and therefore this
molecule has been studied in great details as a vaccine candidate
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in animal models. Even though complete protection was not
obtained reduced shedding was observed and vaccine trials
using naked DNA as a vaccine resulted in stimulation of both the
humoral and cellular immune response indicating progress in the
vaccine development.MOMP varies, however, between serovars
that are causing genital infections and therefore additional
components may be needed. C. pneumoniae is causing respiratory
tract infections and is associated to the development of coronary
heart disease. Antibodies to conformational surface exposed
epitopes are generated upon infections but MOMP is not the
major immunogen. A large family of proteins, the polymorphic
membrane proteins (Pmp) consisting of 21 members of which
most are expressedwere found tobe localized in theC. pneumoniae
outer membrane. As the Pmps are highly expressed in the outer
membranes of C. pneumoniae we investigated whether they are
recognized by a cell-mediated immune response. Amousemodel
for lung infections was developed. Following an experimental
lung infection the spleen was removed and spleen cells were
tested for production of interferon-gammaupon stimulationwith
C. pneumoniae elementary bodies (EB), recombinant MOMP and
recombinant Pmps in an EliSpot assay. Using C. pneumoniae EB,
recombinant MOMP and Pmp proteins as antigens it was found
that EB elicited a strong interferon-gamma response in the EliSpot
assay, MOMP did not respond but Pmp6,Pmp8, 20 and 21 were
found to stimulate spleen cells to secrete interferon-gamma. The
response was shown to be mediated by CD4+ T-cells. Pmp8
elicited the strongest response making it a good candidate for a
subcomponent vaccine.
Resistance to antifungal drugs
S384
The epidemiology of antifungal resistance
A. Pfaller (Iowa City, USA)
Invasive fungal infections are a signiﬁcant cause of morbidity
and mortality worldwide. They exert a growing clinical and
economic burden on healthcare systems and patients. The
increasing concern regarding antifungal resistance among both
common and uncommon fungal pathogens over the past 10–
15 years further drives this burden of disease. Typically species
such as Candida albicans, C. glabrata, C. krusei, Cryptococcus
neoformans and Aspergillus species exhibit different resistance
phenotypes. The impact of resistance has only recently been
fully appreciated with clinical failures due to both established
and recently introduced agents being reported. As both acquired
and intrinsic resistance continues to emerge it is recognized that
a successful clinical outcome depends on several factors inclu-
ding the patient, selection of the appropriate agent, and the local
epidemiology of the likely pathogen. Persistent drug pressure
may result in acquired resistance in normally susceptible species
or select for intrinsically resistant fungi from the patients
endogenous ﬂora or the extrinsic environment. In the hospital
setting nosocomial transmission coupled with drug pressure
may produce an endemic strain with progressively developing
resistance. It is now apparent that the antifungal susceptibility
proﬁles of Candida and Cryptococcus species may vary
considerably from region-to-region or even among different
hospital settings. Detection of speciﬁc DNA clades that are
enriched for antifungal resistance phenotypes is a recent ﬁnding
of great interest. Although new antifungal agents with novel
mechanisms of action may temporarily improve our ability to
treat certain fungal infections, the emergence of resistant fungi is
inevitable and deserves our constant attention.
S385
The importance of susceptibility testing
E.M. Johnson (Bristol, UK)
Whilst antifungal drug resistance has not proved to be as
problematic as that experienced with antibacterial agents, both
intrinsic and emergent resistance are encountered and antifungal
susceptibility testing can help in the guidance of prescribing
practices. The expanding armamentarium of antifungal agents
dictates that the clinician has some guidance in selecting themost
appropriate agent for a particular infection and relative suscep-
tibility of the infecting organism is an important factor in the
decision. There are many test parameters that can potentially
impact on the susceptibility test result and in the early years of
testing differences in test methods produced confusing and
conﬂicting results. In recent years standardized methods for
susceptibility testing of yeast and mould isolates have been
introduced and for some drugs it has been possible to deﬁne
breakpoints.Whilst there are still certain reservations over the test
methods and their application to certain organism-drug combi-
nations, their widespread adoption makes national and interna-
tional comparisons of susceptibility trends possible. Intrinsic
resistance, which is generally consistent and predictable, is
encountered in an increasing number of yeast and mould species
and highlights the need for accurate speciation of infecting
organisms. Susceptibility testing is of great importance in detect-
ing intrinsic resistance in a species and therefore establishing the
spectrum of activity of new and developmental agents. There is
the possibility that general use of an agent will lead to the
development of emergent resistance in a previously susceptible
organism. Currently there are few problems with emergent
resistance during a course of treatment which is potentially a
more serious scenario than themore predictable innate resistance.
Farmore likely to occur in yeast rather thanmould infections, this
has been encountered predominantly with ﬂucytosine and ﬂuc-
onazole mainly as a consequence of inappropriate prescribing
practices for speciﬁc infections in certain patient groups. It is
therefore important that testing mechanisms are introduced with
the capacity to identify potential problems as they occur.
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Emerging enteric pathogens: responding to the challenge
S392
Towards predicting cholera disease outbreaks
within the Mediterranean Basin
J.F. Gue´gan, G. Constantin de Magny (Montpellier, F)
New insights into population dynamics of infectious diseases
have shown the existence of regular cycles in the number of cases
over time, with alternance of periods of booms and busts. The
dynamics of infectious diseases is determined by a large number
of complex processes acting over a large range of spatio-temporal
scales. However, studies have been restricted so far to tiny
hierarchical scales, which cannot really capture what may still
happen at upper scales. Recent discoveries on both Vibrio
cholerae life-cycle and cholera cases dynamics started to disen-
tangle themany intrinsic and extrinsic environmental factors that
may be involved in the evolution of disease within communities.
Findings show that cholera cases may ﬂuctuate with periods of
outbreaks and quasi-extinction, depending on both local and
large-scale environmental conditions, which inﬂuence V. choler-
ae kinetics within the environment. Based on statistical analysis
and ecological modelling, we will show how we can model
cholera cases dynamics within the Mediterranean area in taking
account large-scale environmental conditions. Both studying the
evolution of cholera cases in countries of northern Africa (using
sophisticated wavelet analyses), and modelling the Vibrio life-
cycle (using differential equations systems) based on environ-
mental, ecological parameters obtained from remote-sensing and
oceanographic surveys, we here presentmodels that reallymimic
cholera disease patterns observed over time within the area.
Results on cholera time-series in the southern part of the basin
indicate that outbreaks aremainly associatedwith an elevation of
local sea surface. The ecological modelling of outbreaks, which
considers the many processes involved, shows that the existence
of an environmental reservoir may help to explain cholera
dynamics. This work constitutes one of the few studies on cholera
dynamics which clearly show the inﬂuence of large-scale envi-
ronmental factors on the evolution of cholera cases. More
speciﬁcally, it is the ﬁrst study which really demonstrates for
theMediterranean Sea that common processes to other regions of
the World are at work in producing more or less periodic cholera
outbreaks in the sub-southern region of the Basin. As climate
temperature should increase in the future, the consequences on
cholera outbreaks might be highly sensitive. Accordingly, this
study is then the ﬁrst step towards producing a predictive model
of Vibrio bacteria emergence within the Mediterranean basin
based on an integrated environmental surveillance.
Inﬂuenza vaccination
O395
Effectiveness of revaccination against inﬂuenza
in the Dutch inﬂuenza vaccination programme
E. Hak, E. Buskens, T.J.M. Verheij on behalf of the PRISMA Study
Group
Objectives: It has recently been suggested that a ﬁrst
vaccination against inﬂuenza is less effective than revaccination
among elderly persons (Voordouw B, et al. JAMA, 2004). This
might negatively inﬂuence ﬁrst starters, especially persons with
high-risk medical conditions younger than 65 years in whom
vaccine uptake is considerably lower. We therefore aimed to
assess the clinical effectiveness of inﬂuenza vaccination among
ﬁrst starters of any age in the Dutch inﬂuenza vaccination
programme in preventing morbidity and mortality.
Methods: We conducted a case-control study nested in a cohort
of 75,227 patients requiring vaccination. During the 1999–2000
inﬂuenza A(H3N2) epidemic, incident cases who died during the
inﬂuenzaepidemicorwho requiredprimaryor secondarycare for
inﬂuenza, pneumonia, acute lung disease, myocardial infarction,
stroke or heart failure were compared with controls regarding
vaccination status. Estimates of the effectiveness of vaccination in
reducing these endpoints were adjusted for confounding using
stratiﬁed multivariate logistic regression analysis.
Results: After adjustments, vaccination prevented 46% of GP
visits (95%conﬁdence interval [CI]:)6% to 72%,p = 0.068) among
ﬁrst starting high-risk children aged under 18 years. Among ﬁrst
starting high-risk persons aged between 18 and 64 years, 14%
(95%CI:)28% to 41%, p = 0.463) of GPvisits, 97% (95%CI: 27% to
99%, p = 0.030) of hospitalisations and 63% (95% CI: 1% to 84%,
p = 0.047) of deaths were prevented. Corresponding ﬁgures for
elderly persons were –32% (95% CI: )78 to 3%, p = 0.063), 32%
()44% to 68%, p = 0.308) and –60% ()177 to 7%, p = 0.097).
Conclusion: These data conﬁrm low effectiveness of inﬂuenza
vaccination among ﬁrst starting elderly persons. However,
younger adults and children with high-risk medical conditions
beneﬁt from the vaccine even when receiving the vaccine for the
ﬁrst time.
O396
Effectivity of inﬂuenza vaccination of employees
in reducing sick leave days, a meta-analysis
M. Damen, K. Wolthers, L. Spanjaard (Amsterdam, NL)
Objectives: Since the introduction of inﬂuenza vaccination
several studies have been performed on the effectivity of
vaccinating employees to reduce sick leave days. However,
results were conﬂicting, and the statistical power was often too
small. To overcome these problems a meta-analysis was
performed.
Methods: A PUBMED and EMBASE search was conducted
with the terms: ‘inﬂuenza’ AND ‘vaccine’ AND ‘sickness
absence OR employees OR personnel’. Thirty papers were
selected which were possibly suitable for the analysis. These
papers were scored by two independent investigators with the
help of a standardised form for methods and results. The most
important selection criteria were: the study should be a double
blind, randomised trial and the paper should contain data on the
number of sick leave days of vaccinees and non-vaccinees. The
meta-analysis was performed in Review Manager 4.2.
Results: Six papers were suitable for analysis. None of the
studies recorded whether sick employees were tested for
inﬂuenza. The total number of vaccinated persons was 4346
and of non-vaccinated persons (controls) 2881. The mean
difference of sick leave days between vaccinated and non-
vaccinated employees was 0.05 days in favour of vaccinated
employees (95% CI 0.01–0.08, p = 0.01).
Conclusion: Employees vaccinated for inﬂuenza have
signiﬁcantly less sick leave days, however the mean difference
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with non-vaccinated employees is very small. Therefore, the
cost-effectiveness of vaccinating employees in daily practice is
questionable.
O397
Inﬂuenza immunization of healthcare workers in
a paediatric hospital: getting to 73% vaccination
coverage
O. Engels, M. Doyen, N. Goldman, A. Vergison (Brussels, B)
Background: In winter 2002, inﬂuenza immunization was
offered to the healthcare workers (HCWs) of our hospital. Since
then, the infection control team performed vaccination
campaigns: seminars, posters, and face to face discussions.
These campaigns targeted mainly at patients protection. Two
problemswere faced : 1) the trade unions saw these campaigns as
a harassment of HCWs. 2) occupational medicine doctors were
not convinced of the need of inﬂuenza immunization for HCWs.
Objectives: Immunization rates reached 48 % in 2002 and 47% in
2003. In order to improve our next campaign, wewanted to know
why the HCWs were accepting or refusing the vaccine and to
evaluate the impact of infection control team interventions.
Methods: From June to August 2004 we addressed an
anonymous questionnaire to the HCWs of our 170-beds
pediatric hospital. The questionnaires were distributed in the
different departments via the responsible doctor, nurse,
paramedics and administrative staff.
Results: The answer rate was 44% (260/594). 48% of the
answering persons received the inﬂuenza vaccine in 2002 and
59% in 2003. The immunization rates during these two
vaccination campaigns were 84%, 60%, 44% and 18% for
doctors, nurses, paramedics and administrative staff
respectively. 32% of the HCWs had their decision inﬂuenced by
the infection control practitionners. The face to face discussions
were the most important for 48% of HCWs. Protection of both
themselves and the patients was the main reason of
immunization for 69% of HCWs. The main reasons for refusal
in 2003were feeling of good health (49%), not being convinced by
the vaccine efﬁcacy (35%), fear of adverse events evoked by the
media (17%) and reactions to previous vaccination (8%). After
getting the results of this audit, we targeted the next campaign
towards patients and self-protection, insisted on vaccine efﬁcacy
and safety and provided a feedback showing a reduction of
nosocomial inﬂuenza since vaccination. In 2004, the
immunization rate obtained was 73% in mid-november.
Conclusions: Infection control practitionners’ vaccination
campaigns allowed to reach a good immunization rate among
our HCWs. Most HCWs do get vaccinated for both self
protection and patients protection. Face to face discussions
were important to convince HCWs about vaccine efﬁcacy and
safety. Vaccination coverage was highest in doctors and lowest
in administrative staff.
O398
Reduction of the nosocomial inﬂuenza A burden
in a paediatric hospital by immunisation of the
healthcare workers
O. Engels, N. Goldman, M. Doyen, M. Duyse, D. Van Beers,
A. Vergison (Brussels, B)
Background: Before 2002, the immunization rate of the
healthcare workers (HCWs) of our hospital was negligeable.
Since then, inﬂuenza immunization has been offered to HCWs.
Vaccination coverage reached 48% in 2002 and 47% in 2003.
Current national vaccine recommendations do not include ﬂu
vaccine except for children with underlying conditions.
Objectives: To study nosocomial inﬂuenza A in our 170 beds
pediatric hospital and to evaluate the impact of vaccination of
HCWs on nosocomial inﬂuenza rate.
Methods: We retrospectively reviewed nosocomial inﬂuenza A
cases during 5 seasons from 1999 to 2004. We compared the ﬁrst
period of the study (3 seasons) with the second period (2 seasons
post implementation of vaccination). Nosocomial cases were
deﬁned as a positive culture from naso-pharyngeal aspirate
obtained 48 h after admission and prompted by newly appeared
symptoms compatible with inﬂuenza.
Results: Inﬂuenza A was recovered in 579 ﬂu episodes during
the 5 seasons. Out of 237 (146 for period 1 and 92 for period 2)
inﬂuenza A positive cultures recorded in in-patients, 62 (26%)
were hospital acquired. 18/62 patients with hospital acquired
inﬂuenza (29%) had a prolonged hospital stay (median = 2
days, range 1 to 5 days). For 8/62 (13%), an antibiotic treatment
was initiated. 22/62 (35%) had a chest x-ray performed.
Nosocomial inﬂuenza rate dropped from 34% (49/146) of
hospitalized inﬂuenza cases during period 1 to 14% (13/92)
during period 2 (p < 0.001). Among the 62 nosocomial
inﬂuenza patients, 26 (42%) were less than 24 months old
and 33 (53%) had an underlying disease. The rate of at risk
patients was unchanged during the 2 study periods (27/49
versus 6/13). The majority (15/33) of patients with underlying
disease were cardiac patients from Algeria (no inﬂuenza
immunization). Their nosocomial inﬂuenza rate decreased
from 9% (13/146) to 2 % (2/92) between the 2 periods
(p = 0.05). In children <2 years old without risk factor,
nosocomial ﬂu rate was reduced from 5% (7/146) to 0%
(0/92) (p < 0.05).
Conclusions: Inﬂuenza A disease was associated with a longer
length of stay in 29% of the nosocomial cases and chest x-ray
were performed in 35% of the patients. A signiﬁcant decrease in
nosocomial inﬂuenza A disease was observed in children after
immunization of nearly 50% of the HCWs in our pediatric
hospital. It was observed in children with underlying cardiac
disease but also in young children of less than 24 months
without risk factor.
New drugs to ﬁght the resistance challenge
O400
Development of novel antipathogenic drugs
T.B. Rasmussen, T. Bjarnsholt, M. Skindersoe, R.K. Phipps,
T.O. Larsen, J. Nielsen, L. Eberl, M. Givskov (Kgs. Lyngby,
Frederiksberg, DK; Zurich, CH)
Pseudomonas aeruginosa, a well known opportunistic pathogen
and bioﬁlm former, utilizes intercellular communication –
quorum sensing – to coordinate virulence expression during
invasion of and establishment in the hosts. Traditional treatment
of infectious diseases is based on compounds which kill or
inhibit growth of bacteria. A major concern with this approach is
the frequent development of resistance to antibiotics. Further-
more, traditional antibiotics have little or no effect on bacteria in
the bioﬁlm mode of growth. In recent years, we have put much
effort into the development of quorum sensing inhibitors in
order to establish a non-antibiotic chemotherapy for patients
infected with ‘quorum sensing’ bacteria such as Pseudomonas
aeruginosa. Our approach is based on natural signal antagonists
isolated from the environment. Fungi, plants, sponges and
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seaweeds are devoid of advanced immune systems but some
have evolved to rely, at least in part, on secondary metabolite
chemistry for protection against colonizing or competing
bacteria. Hence, the study of cross-kingdom signal interference
might turn out to be the source of new anti-microbial com-
pounds. We present the design and demonstrate the usefulness
of a novel tool for screening purposes the quorum sensing
inhibitor selector (QSI-selector). QSI activity in the extracts of
fungi, plants, sponges and seaweeds was veriﬁed by means of
transcriptome analysis using Pseudomonas aeruginosa DNAmicro
arrays. The inﬂuence on Pseudomonas aeruginosa bioﬁlm struc-
ture and antibiotic tolerance was established using the ﬂow cell
bioﬁlm system. Whether the selected extract had an effect on the
pathogenecity of Pseudomonas aeruginosa was evaluated using a
nematode, Caenorhabditis elegans and a mouse pulmonary
model. We have also assessed the molecular mechanism of
inhibition and assessed the probability of development of
resistance towards the QSI compounds. Our results demonstrate
that eukaryotic organisms produce compounds capable of
interfering with prokaryotic communication. Furthermore,
these organisms contain quorum sensing’ bacteria indicating
that the plants and fungi does not produce these compounds by
happenstance. Using DNA micro arrays we have identiﬁed
genes involved in interactions between bioﬁlms and neutrophils
and assessed the effect of QS and QSIs on these genes.
O401
Structural characterisation and susceptibility
testing of epilancin 15X, a novel antibiotic
M.B. Ekkelenkamp, D. Milatovic, M. Hanssen, A. de Jong,
S.D. Hsu, N.A.J. van Nuland, J. Verhoef (Utrecht, Bilthoven, NL)
Objectives: Epilancin 15X is a novel lantibiotic peptide,
produced by a clinical isolate of Staphylococcus epidermidis. The
objectives of this work are: 1. to determine the structure of this
peptide and 2. to test an array of Gram-positive bacteria,
including methicillin resistant Staphylococcus aureus (MRSA) and
vancomycin resistant enterococci (VRE), for their susceptibility
to epilancin 15X.
Methods: NMR-spectra of puriﬁed epilancin 15X were
recorded by total correlation spectroscopy (TOCSY), nuclear
Overhauser enhancement spectroscopy (NOESY), natural
abundance 1H-13C heteronuclear single quantum correlation
(HSQC) and 1H-13C heteronuclear multiple bond correlation
(HMBC). From these spectra a putative peptide structure was
derived, which was then conﬁrmed by nano-scale liquid
chromatography/tandem mass spectrometry. Minimal
inhibitory concentrations (MICs) for epilancin 15X were
determined for Staphylococcus aureus (10 methicillin susceptible
and 10 methicillin resistant strains), coagulase negative
staphylococci (10 strains) and enterococci (10 vancomycin
susceptible and 5 vancomycin resistant strains) in a microtiter
assay in accordance with NCCLS guidelines.
Results: Epilancin 15X contains 31 amino acids and has a
molecular weight of 3,173 Daltons. It contains ten post-
translationally modiﬁed amino acids, three lanthionine ring
structures and a hydroxy-propionyl N-terminal moiety. The
peptide was found to highly resemble the previously identiﬁed
lantibiotic epilancin K7, with 68% amino acid sequence identity
and three nearly identical lanthionine rings. The MIC for
Staphylococcus aureus strains (both methicillin susceptible and
methicillin resistant) ranged from 0.25 to 0.5 lg/ml, for
enterococci from <0.125 to 1.0 lg/ml and for coagulase
negative staphylococci from <0.125 to 0.25 lg /ml.
Conclusion: We here present the structure of epilancin 15X, a
novel lantibiotic peptide which exhibits a high activity against
Gram positive organisms; further studies will have to establish
whether it could be of clinical use.
O402
Oleuropein: a novel antioxidant agent for
treatment of experimental sepsis induced by
multidrug-resistant Pseudomonas aeruginosa
V. Koussoulas, T. Geladopoulos, J. Vassiliadis, P. Koutoukas,
L. Sabracos, H. Giamarellou, E.J. Giamarellos-Bourboulis
(Athens, GR)
Objective: To clarify the potential antioxidant properties of
oleuropein, a phenolic secoiridoid glucoside present in olive
trees and virgin olive oil, in experimental sepsis induced by
multidrug-resistant P. aeruginosa.
Methods: Sepsis was induced in 17 rabbits by a single injection
of a multidrug-resistant P. aeruginosa isolate into the right renal
pelvis following ureter ligation. Rabbits were divided into two
groups; A: controls, and B: treated with one single iv dose of
1 ml of oleuropein (20 mg) diluted to 30 ml with D/W 5% upon
signs of sepsis. Survival was recorded and blood was sampled
for the estimation of malondialdehyde (MDA), tumor necrosis
factor alpha (TNF) and total antioxidant status (TAS). MDA was
determined by the thiobarbiturate assay followed by HPLC
analysis; TNF by a bioassay on L929 ﬁbrosarcoma cell line; and
TAS by a colorimetric assay. Results: Survival curves are shown
in Figure 1. Mean concentration of MDA before and 1.5, 3.5, 24,
48 hours after bacterial challenge were 1.43, 1.68, 3.34, 3.42 and
1.70 ll for group A; and 6.85, 5.44, 7.63, 4.73 and 8.74 ll for
group B, respectively. Respective mean concentrations of TNF
for group A were 16.29, 21.77, 13.52, 17.84 and 7235 pg/ml; and
for group B 37.11, 9.07, 20.52, 19.56 and 40.13 pg/ml. Respective
mean concentrations of TAS for group A were 1.54, 1.16, 1.26,
1.45 and 1.59 mM (TROLOX units); and for group B 1.62, 1.53,
1.48, 1.51 and 1.43 mM. Comparison of TAS between groups
was found statistically signiﬁcant (P between group A and
group B 0.043). Negative correlation was found between MDA
and TAS for group A (p = 0.017), but not for group B. Signiﬁcant
differences in bacterial load of liver, kidney, spleen and lower
right lung lobe between two groups were not recorded.
Conclusion: Administration of oleuropein prolonged survival
in experimental sepsis induced by multidrug-resistant P.
aeruginosa. Its effect might be connected to enhancement of
TAS accompanied by decreases of TNF.
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O403
Garlic blocks the Pseudomonas aeruginosa
communication systems and promotes rapid
clearing of pulmonary Pseudomonas aeruginosa
infections
T. Bjarnsholt, P.Ø. Jensen, T.B. Rasmussen, L. Christophersen,
M. Hentzer, H. Hougen, J. Rygaard, C. Moser, L. Eberl,
N. Høiby, M. Givskov (Kgs. Lyngby, Copenhagen, Valby, DK;
Zurich, CH)
The opportunistic human pathogen Pseudomonas aeruginosa is the
predominant microorganism of chronic lung infections in cystic
ﬁbrosis patients. P. aeruginosa colonizes the lungs by forming
bioﬁlm microcolonies through out the lung. Quorum sensing
(QS) renders the bioﬁlm growing bacteria highly tolerant to
otherwise lethal doses of antibiotics, and protect from the
bactericidal activity of polymorphonuclear leukocytes (PMNs).
We have previously demonstrated that QS is inhibited by garlic
extract. In this study we have evaluated the effect of garlic for the
interaction between P. aeruginosa and tobramycin and the PMNs
and outcome of pulmonary infection. P. aeruginosawas grown in
vitro in continuous-culture once-through ﬂow chambers with
and without garlic extract. 3 day old bioﬁlms were treated with
340 lg/ml of tobramycin continuously for 48 hours or human
PMNs. The garlic treated bioﬁlm was susceptible to both
tobramycin and grazing of PMNs. The PMNs showed an
increased activation, when incubated on the garlic treated
bioﬁlm. The differences in sensitivity were observed by confocal
laser scanning microscopy of ‘live-dead’ stained bioﬁlms, and
the degradation of GFP tagged bioﬁlms. The activation of PMNs
was visualised by staining the PMNs with 123-dihydrorhod-
amine, which is oxidised to 123-rhodamine when H2O2 is
produced – respiratory burst. Mice were treated with garlic
extract or saline for 7 days, 2 day profylactic. P. aeruginosa was
instilled in the left lung of the mice for up to 5 days. Bacteriology,
mortality, histopathology, and cytokine production was used as
endpoints. The results indicate that a QS inhibitory extract of
garlic renders Pseudomonas aeruginosa sensitive to both tobramy-
cin and, phagocytosis, and respiratory burst of polymorphonu-
clear neutrophile leukocytes. Garlic treatment of a pulmonary
mouse model initially provokes a higher degree of inﬂammation
and improved clearing of the infecting bacteria.
O404
Oral Ipsat P1A is a novel product to prevent
antimicrobial resistance and antibiotic induced
disturbance in gastrointestinal tract in humans
T. Heinonen, M. Carson, R. Jo˜gi, A.-M. Tarkkanen, S. Mentula,
C.J. Donskey, C.E. Nord (Espoo, FIN; Tartu, EST; Helsinki, FIN;
Cleveland, USA; Stockholm, S)
Objectives: Antibiotic administration may disturb the
indigenous intestinal microﬂora and diminish colonization
resistance against pathogenic microorganisms. Ipsat’s novel
beta-lactamase product aims to prevent such disturbance due to
beta-lactam antibiotics by degrading the portion of antibiotic
excreted into the small intestine without affecting systemic
antibiotic levels. The aim of this Phase II study was to
administer Ipsat’s product, P1A, simultaneously with i.v.
ampicillin and investigate the preventive effects and safety.
Methods: The study included three parallel groups of 12
healthy volunteers (males and females) per group. For 5 days,
Group 1 received 1 g ampicillin qid, Group 2 received 8.2 mg
Ipsat P1A qid and Group 3 received both treatments
simultaneously. Stool samples were collected before, during
and 7 days after treatment. Changes in stool microﬂora were
measured using 16S rRNA ﬁngerprints of bacteria and
quantifying the major anaerobic and aerobic bacterial groups.
The emergence of resistance was assessed by quantifying
ampicillin-resistant coliforms and by measuring the changes
(increase) in ampicillin resistant marker genes (TEM-family).
Results: Ampicillin treatment caused greater than a 50% change
(p < 0.0001) in the microﬂora, greater than an 80% increase
(p < 0.0001) in ampicillin-resistant coliforms and a highly
signiﬁcant increase in ampicillin resistant marker genes,
whereas concurrent treatment with Ipsat P1A completely
prevented these changes. Ipsat P1A also prevented the selection
of multi-drug resistant species including Klebsiella. No side
effects or other safety concernswere notedwith the Ipsat product.
Conclusions: Oral administration of Ipsat P1A eliminated
ampicillin-induced alterations of the intestinal microﬂora of
healthy volunteers and prevented the ampicillin-induced
emergence of bacterial resistance. These results suggest a new
strategy for reducing antimicrobial resistance in humans.
O405
Efﬁcacy and safety of DB289, a new oral drug for
treatment of Pneumocystis jiroveci pneumonia in
AIDS patients
P. Yeramian, J. Leon, E. Huarcaya, L.A. Castagnini, J.L. Allen,
J. Longstreth, E. Gotuzzo (Chicago, USA; Lima, PE)
Objectives: Trimethoprim sulfamethoxazone (TMP-SMX)
remains the ﬁrst line agent for treatment of PCP, although
individuals with AIDS have a high rate of side effects during
treatment and SMX resistance has been reported. We have
evaluated the efﬁcacy, safety and pharmacokinetics of new oral
DB289 in an open-label, dose escalation, Phase II trial in patients
with AIDS and mild-moderate PCP, who were intolerant to or
failed prophylaxis or treatment with TMP-SMX. DB289 is the
orally bioavailable prodrug of DB75, a novel diphenylfuran
diamidine, that is active in vitro against P. carinii and in murine
models of PCP.
Methods: Patients were ‡18 year with weight ‡45 kg and had
documented PCP and HIV. Baseline PO2 was ‡60 mmHg. Two
dose regimens were tested sequentially, 50 mg and 100 mg
DB289 twice a day for 21 days. Patients were followed for 42
days with scoring of symptoms, ECG, chest X-ray, blood gases,
and laboratory safety evaluations. DB289/DB75 plasma kinetics
were evaluated on Days 7 and 14 throughout 12 hours, and pre-
dose levels were taken on Days 4, 7, 10, 14, and 21.
Results: 35 patients were enrolled; 8 in the 50 mg group and 27
in the 100 mg group. All patients responded to treatment.
Patients treated with 100 mg had a faster reduction of their
symptom scores and normalization of blood-gases parameters
compared to patients treated with 50 mg, with maximal effect
observed by Day 10. There were no treatment failures with
100 mg DB289. Tolerance with DB289 treatment was good.
Treatment was withdrawn for a patient after 12 days due to
progression of underlying renal insufﬁciency. Other signiﬁcant
adverse events included two cases of moderate muscle pain/
weakness. Treatment with DB289 resulted in sustained DB75
plasma levels throughout the dosing interval. Mean DB75
exposure after 100 mg was 6-times that observed after 50 mg.
Pre-dose trough levels indicated some DB75 accumulation,
consistent with the long terminal half-life observed for DB75 of
over 80 hours, with steady state achieved between Days 10–14.
At steady state, mean metabolite ratio (DB75/DB289) was 6 and
13 for the 50 mg and 100 mg doses, respectively, demonstrating
excellent bioconversion of DB289.
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Conclusion: Treatment with DB289 100 mg BID for 21 days
provided rapid symptom relief and normalization of lung
function in AIDS patients with PCP, Further trials are being
planned for evaluation of DB289 as ﬁrst line therapy of PCP.
O406
A comparative, investigator-blind study of topical
tea tree oil versus erythromycin gel in the
treatment of acne
R. Darabi, M.A. Hafezi, N. Akbarloo (Tehran, IR)
Background: Acne vulgaris is commonly treated with topical
antibacterial agents but unfortunately there are increasing
reports of bacterial resitance to most commonly used
antibiotics such as erythromycin. Tea tree oil (TTO) has
recently emerged as an effective topical antibacterial agent for
the treatment of local skin infections including acne.
Objectives: This study sought to evaluate TTO efﬁcacy in
comparison to topical erythromycin for the treatment of acne.
Patients/Methods: Sixty volunteer patients with mild to
moderate inﬂammatory acne lesions, aged between 15 to 25
years old were selected, randomly devided into two groups and
treated with topical 5% TTO or 2% erythromycin gel twice daily
for six weeks on an investigator-blinded protocol. Severity and
number of acne lesions were evaluated before and after the
study course.
Results: The average reduction of acne lesions was higher in the
TTO compared to erythromycin treated group (Fig. 1,
P < 0.001). Meanwhile, in the TTO group, 87.5% of cases had
more than 50% reduction in acne lesions, which was
signiﬁcantly higher as compared to 53.8% in erythromycin
group (Fig. 2, P < 0.01). The drop out rate due to severity of side
effects in erythromycin group was signiﬁcantly higher
compared to TTO (P < 0.01). There were not any signiﬁcant
differences between frequency of side effects and relapse rate
between two groups.
Conclusions: These results indicate that topical 5% tea tree
oil in gel base is an effective and safe topical antibacterial
agent for treatment of mild to moderate inﬂammatory acne
vulgaris.
O407
Efﬁcacy and safety of ertapenem compared with
piperacillin/tazobactam for diabetic foot
infections: The SIDESTEP Study
B. Lipsky, D. Armstrong, D. Citron, T. Erb, T. King,
D. Morgenstern, S. Rawlins, M. Abramson for the SIDESTEP
Study Group
Objectives: Diabetic foot infections (DFI) are a frequent cause of
hospitalization for diabetics and the most common non-
traumatic cause of lower extremity amputations world-wide.
Few randomized controlled trials have compared the efﬁcacy of
different antibiotic regimens for DFI. Most previous studies
were small and not blinded.
Methods: This double-blind randomized study was designed to
determine noninferiority of intravenous (IV) ertapenem (E) to
piperacillin/tazobactam (P/T) (3.375 g qid) for the treatment of
patients with moderate to severe DFI. IV antibiotic therapy was
required for a minimum of 5 days. Patients could be switched to
oral therapy (amoxicillin/clavulanate) for a maximum
cumulative treatment of 28 days. Baseline and follow-up visits
included evaluation of tissue wound cultures and quantitative
wound scores. Assessments were made at discontinuation of IV
therapy (DCIV) and at day 10 post-treatment (IV or IV and oral
if given) follow-up.
Results: 576 patients were randomized to treatment (E: 289; P/
T:287); 445 were clinically evaluable at the end of IV therapy (E:
226; P/T: 219). The mean duration of IV therapy was 11.1 d for E
and 11.3 d for P/T. Clinical success rates were similar between
the treatments at DCIV (E: 94.2%, P/T: 92.2%; between
treatment difference: 1.9; 95% CI: )2.9, 6.9). In the
microbiologically evaluable population, the overall rate of
eradication (presumed or documented) at the 10 d follow-up
was also comparable (E: 87.8%, P/T: 84.4%; between treatment
difference: 3.4%; 95% CI: )4.5, 11.9). Clinical response rates were
similar in both treatment groups across baseline wound scores
and the response rates generally decreased with increasing
baseline wound scores. There were no differences in drug-
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related adverse events during parenteral therapy (E: 15.2%, P/T:
19.9%; RR E/(P/T): 0.77; 95% CI: 0.54, 1.10; p = 0.147) or
discontinuations due to drug-related adverse events during
parenteral therapy (E: 1.0%, P/T: 2.1%; RR E/(P/T) 0.50; 95% CI:
0.15, 1.94; p = 0.341).
Conclusions: This study, the largest and most comprehensive
randomized controlled trial of antibiotics for DFI, found that
clinical and microbiological outcomes for patients treated with E
once daily were equivalent to that of patients treated with P/T
q6h. Both E and P/T were generally well-tolerated.
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